

Tornier B.V.  
Form S-1/A  
July 15, 2010

Table of Contents

As filed with the Securities and Exchange Commission on July 15, 2010

Registration No. 333-167370

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**AMENDMENT NO. 1  
TO  
FORM S-1**

**REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

---

**TORNIER B.V.\***

(Exact name of Registrant as specified in its charter)

**The Netherlands**  
(State or other jurisdiction of  
incorporation or organization)

**3842**  
(Primary Standard Industrial  
Classification Code Number)  
**Olivier van Noortstraat 4**  
**3124 LA Schiedam**  
**The Netherlands**  
**(+ 31) 20 577 1177**

**98-0509600**  
(I.R.S. Employer  
Identification Number)

(Address, including zip code and telephone number, including area code, of Registrant's principal executive offices)

**Fred. Roeskestraat 123**  
**1076 EE Amsterdam**  
**The Netherlands**  
**(+ 31) 20 577 1177**

(Name, address, including zip code and telephone number, including area code, of agent for service)

---

*Copies to:*

**Cristopher Greer, Esq.**  
Willkie Farr & Gallagher LLP  
787 Seventh Avenue  
New York, New York 10019  
(212) 728-8000

**Charles Ruck, Esq.**  
**Shayne Kennedy, Esq.**  
Latham & Watkins LLP  
650 Town Center Drive, 20th Floor  
Costa Mesa, CA 92626  
(714) 540-1235

---

# Edgar Filing: Tornier B.V. - Form S-1/A

**Approximate date of commencement of proposed sale to the public:  
as soon as practicable after the effective date of this registration statement.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b2 of the Exchange Act.

Large accelerated filer       Accelerated filer       Non-accelerated filer       Smaller reporting company   
(Do not check if a  
smaller reporting company)

---

## CALCULATION OF REGISTRATION FEE

Title of securities to be registered	Proposed maximum aggregate offering price(1)(2)	Amount of registration fee
Ordinary shares, par value €0.01 per share	\$205,000,000	\$14,617(3)

- (1) Estimated solely for the purpose of determining the amount of registration fee in accordance with Rule 457(o) under the Securities Act of 1933.
- (2) Includes ordinary shares that may be purchased by the underwriters pursuant to an overallotment option.
- (3) Previously paid.

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.**

\* The registrant will convert from a private company with limited liability (*besloten vennootschap met beperkte aansprakelijkheid*) to a public company with limited liability (*naamloze vennootschap*) prior to the effective date of this registration statement. Upon such conversion, the registrant will be known as Tornier N.V.

---

Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED \_\_\_\_\_, 2010

**Preliminary Prospectus**

Shares

Tornier N.V.

Ordinary Shares

Tornier N.V., a public limited liability company incorporated under the laws of The Netherlands, is selling \_\_\_\_\_ ordinary shares. This is an initial public offering of our ordinary shares. The estimated initial public offering price is between \$ \_\_\_\_\_ and \$ \_\_\_\_\_ per ordinary share.

Prior to this offering, there has been no public market for our ordinary shares. We have applied to have our ordinary shares listed on the NASDAQ Global Market under the symbol "TRNX."

**Investing in our ordinary shares involves a high degree of risk. See "Risk Factors" beginning on page 8.**

	Per Ordinary Share	Total
Initial public offering price		
Underwriting discount		
Proceeds to Tornier N.V., before expenses		
We have granted the underwriters an option for a period of 30 days to purchase up to _____ additional ordinary shares on the same terms and conditions set forth above to cover overallocments, if any.		

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

The underwriters expect to deliver the ordinary shares to investors on \_\_\_\_\_, 2010.

**BofA Merrill Lynch**

**J.P.Morgan**

**Piper Jaffray**

**Credit Suisse**

**Wells Fargo Securities**  
2010

**William Blair & Company**

---

## TABLE OF CONTENTS

	<b>Page</b>
<u>PROSPECTUS SUMMARY</u>	<u>1</u>
<u>THE OFFERING</u>	<u>5</u>
<u>RISK FACTORS</u>	<u>8</u>
<u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</u>	<u>39</u>
<u>USE OF PROCEEDS</u>	<u>40</u>
<u>DIVIDEND POLICY</u>	<u>42</u>
<u>CAPITALIZATION</u>	<u>42</u>
<u>DILUTION</u>	<u>44</u>
<u>SELECTED CONSOLIDATED FINANCIAL DATA</u>	<u>46</u>
<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	<u>49</u>
<u>BUSINESS</u>	<u>78</u>
<u>MANAGEMENT</u>	<u>104</u>
<u>COMPENSATION DISCUSSION AND ANALYSIS</u>	<u>115</u>
<u>PRINCIPAL SHAREHOLDERS</u>	<u>133</u>
<u>RELATED PARTY TRANSACTIONS</u>	<u>135</u>
<u>DESCRIPTION OF ORDINARY SHARES</u>	<u>140</u>
<u>SHARES ELIGIBLE FOR FUTURE SALE</u>	<u>154</u>
<u>TAXATION</u>	<u>156</u>
<u>UNDERWRITING</u>	<u>165</u>
<u>LEGAL MATTERS</u>	<u>171</u>
<u>EXPERTS</u>	<u>171</u>
<u>WHERE YOU CAN FIND ADDITIONAL INFORMATION</u>	<u>171</u>
<u>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</u>	<u>F-1</u>

---

You should rely only on the information contained in this prospectus and any free writing prospectus we may specifically authorize to be delivered or made available to you. We have not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, ordinary shares only in jurisdictions where offers and sales are permitted.

We have not taken any action to permit a public offering of the ordinary shares outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the ordinary shares and the distribution of the prospectus outside the United States.

Table of Contents







Table of Contents

**PROSPECTUS SUMMARY**

*This summary highlights information contained elsewhere in this prospectus. Because this section is only a summary, it does not contain all of the information that may be important to you or that you should consider before making an investment decision. For a more complete understanding of this offering, we encourage you to read this entire prospectus, including the information contained in the section entitled "Risk Factors." You should read the following summary together with the more detailed information and consolidated financial information and the notes thereto included in this prospectus.*

*Unless the context specifically indicates otherwise, references in this prospectus to "we," "us," "our," the "Company" and "Tornier" refer collectively to Tornier N.V., after giving effect to its conversion to a public limited liability company, and its consolidated subsidiaries.*

**Our Business**

We are a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. We refer to these surgeons as extremity specialists. We sell to this extremity specialist customer base a broad line of joint replacement, trauma, sports medicine and orthobiologic products to treat extremity joints. Our motto of "specialists serving specialists" encompasses this focus. In certain international markets, we also offer joint replacement products for the hip and knee. We currently sell over 70 product lines in approximately 35 countries.

We have had a tradition of innovation, intense focus on surgeon education and commitment to advancement of orthopaedic technology since our founding approximately 70 years ago in France by René Tornier. Our history includes the introduction of the porous orthopaedic hip implant, the application of the Morse taper, which is a reliable means of joining modular orthopaedic implants, and, more recently, the introduction of the reversed shoulder implant in the United States. This track record of innovation over the decades stems from our close collaboration with leading orthopaedic surgeons and thought leaders throughout the world.

We were acquired in 2006 by an investor group led by Warburg Pincus (Bermuda) Private Equity IX, L.P., or WP Bermuda, and medical device investors, including The Vertical Group, L.P., or The Vertical Group, Split Rock Partners, L.P., or Split Rock, and Douglas W. Kohrs, our Chief Executive Officer. We refer to this group of investors as the Investor Group. They recognized the potential to leverage our reputation for innovation and our strong extremity joint portfolio as a platform upon which they could build a global company focused on the rapidly evolving upper and lower extremity specialties. The Investor Group has contributed capital resources and a management team with a track record of success in the orthopaedic industry in an effort to expand our offering in extremities and accelerate our growth. Since the acquisition in 2006, we have:

created a single, extremity specialist sales channel in the United States primarily focused on our products;

enhanced and broadened our portfolio of shoulder joint implants and foot and ankle products;

entered the sports medicine and orthobiologics markets through acquisitions and licensing agreements;

improved our hip and knee product offerings, helping us gain market share internationally; and

significantly increased investment in research and development and expanded business development activities to build a pipeline of innovative new technologies.

---

Table of Contents

As a result of the foregoing actions, we believe our addressable worldwide market opportunity has increased from approximately \$2 billion in 2006 to approximately \$7 billion in 2009.

We believe we are differentiated by our full portfolio of upper and lower extremity products, our dedicated extremity-focused sales organization and our strategic focus on extremities. We further believe that we are well-positioned to benefit from the opportunities in the extremity products marketplace as we are already among the global leaders in the shoulder and ankle joint replacement markets with the #2 market position worldwide for sales of shoulder joint replacement products and the #1 market position in the United States in foot and ankle joint replacement systems in 2009 as measured by revenue. We more recently have expanded our technology base and product offering to include: new joint replacement products based on new materials; improved trauma products based on innovative designs; and proprietary orthobiologic materials for soft tissue repair. In the United States, which is the largest orthopaedic market, we believe that our single, "specialists serving specialists" distribution channel is strategically aligned with what we believe is an ongoing trend in orthopaedics for surgeons to specialize in certain parts of the anatomy or certain types of procedures.

Our principal products are organized in four major categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics, and large joints and other. Our upper extremity products include joint replacement and bone fixation devices for the shoulder, hand, wrist and elbow. Our lower extremity products include joint replacement and bone fixation devices for the foot and ankle. Our sports medicine and orthobiologics product category includes products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries, in the case of sports medicine, or to support or induce remodeling and regeneration of tendons, ligaments, bone and cartilage, in the case of orthobiologics. Our large joints and other products include hip and knee joint replacement implants and ancillary products.

Innovations in the orthopaedic industry have typically consisted of evolutions of product design in implant fixation, joint mechanics, and instruments and modifications of existing metal or plastic-based device designs rather than new products based on combinations of new designs and new materials. In contrast, the growth of our target markets has been driven by the development of products that respond to the particular mechanics of small joints and the importance of soft tissue to small joint stability and function. We are committed to the development of new designs utilizing both conventional materials and new tissue-friendly biomaterials that we expect will create new markets. We believe that we are a leader in researching and incorporating some of these new technologies across multiple product platforms.

In the United States, we sell products from our upper extremity joints and trauma, lower extremity joints and trauma, and sports medicine and orthobiologics product categories; we do not actively market large joints in the United States nor do we currently have plans to do so. While we market our products to extremity specialists, our revenue is generated from sales to healthcare institutions and distributors. We sell through a single sales channel consisting of a network of independent commission-based sales agencies. Internationally, where the trend among surgeons toward specialization is not as advanced as in the United States, we sell our full product portfolio, including upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics and large joints. We utilize several distribution approaches depending on the individual market requirements, including direct sales organizations in the largest European markets and independent distributors for most other international markets. In 2009, we generated revenue of \$201.5 million, 57% of which was in the United States and 43% of which was international.

Table of Contents

**Our Business Strategies**

Our goal is to strengthen our leadership position serving extremity specialists. The key elements of our strategy include:

*Leveraging our "specialists serving specialists" strategy:* We believe our focus on and dedication to extremity specialists enables us to better understand and address the clinical needs of these surgeons. We believe that extremity specialists, who have emerged as a significant constituency in orthopaedics only in the last 10 to 15 years, have been underserved in terms of new technology and also inefficiently served by the current marketplace. We offer a comprehensive portfolio of extremity products, and also serve our customers through a sales channel that is dedicated to extremities, which we believe provides us with a significant competitive advantage because our sales agencies and their representatives have both the knowledge and desire to comprehensively meet the needs of extremity specialists and their patients, without competing priorities.

*Advancing scientific and clinical education:* We believe our specialty focus, commitment to product innovation and culture of scientific advancement attract both thought leaders and up-and-coming surgeon specialists who share these values. We actively involve these specialists in the development of world-class training and education programs and encourage ongoing scientific study of our products. Specific initiatives include the Tornier Master's Courses in shoulder and ankle joint replacement, The Fellows and Chief Residents Courses and a number of clinical concepts courses. We also maintain a registry that many of our customers utilize to study and report on the outcomes of procedures in which our extremity products have been used. We believe our commitment to science and education also enables us to reach surgeons early in their careers and provide them access to a level of training in extremities that we believe is not easily accessible through traditional orthopaedic training.

*Introducing new products and technologies to address more of our extremity specialists' clinical needs:* Our goal is to continue to introduce new technologies for extremity joints that improve patient outcomes and thereby continue to expand our market opportunity and share. Our efforts have been focused on joint replacement, as well as sports medicine and orthobiologics, given the importance of these product categories to extremity surgeons. Since our acquisition by the Investor Group, we have significantly increased our investment in research and development to accelerate the pace of new product introduction. During 2009, we invested \$18.1 million in research and development and introduced 18 new products, and in 2008, we invested \$20.6 million and introduced nine new products, up from only \$13.3 million and four new products in 2007. We have also been active in gaining access to new technologies through external partnerships, licensing agreements and acquisitions. We believe that our reputation for effective collaboration with industry thought leaders as well as our track record of effective new product development and introductions will allow us to continue to gain access to new ideas and technologies early in their development.

*Expanding our international business:* We face a wide range of market dynamics that require our distribution channels to address both our local market positions and local market requirements. One is focused on products for upper extremities and the other on hip and knee replacements and products for lower extremities. In other European markets, we utilize a combination of direct and distributor strategies that have evolved to support our expanding extremity business and also to support our knee and hip market positions. In large international markets where the extremity market segment is relatively underdeveloped, such as Japan and China, the same sales channel sells our hip and knee product portfolios and extremity joint products, which provides these sales channels sufficient product breadth and economic scale. We plan on expanding our international business by continuing to adapt our distribution channels to the unique characteristics of individual markets.

Table of Contents

*Achieving and improving our profitability through operating leverage:* With the additional capital resources brought by the Investor Group, we have made significant investments over the last several years in our research and development, sales and marketing, and manufacturing operations to build what we believe is a world-class organization capable of driving sustainable global growth. For example, we grew our research and development organization from approximately 20 employees as of December 31, 2006, to 79 employees as of December 27, 2009. We created a new global sales and marketing leadership team by integrating key personnel from acquired organizations and recruiting additional experienced medical device sales and marketing professionals. We also expanded our manufacturing capacity with two new plants in Ireland and France. With these organizational and infrastructure investments in place, we believe we have the infrastructure to support our growth for the foreseeable future. As a result, we believe we can increase revenue and ultimately achieve and improve profitability.

**Risk Factors**

Investing in our company entails a high degree of risk, as more fully described in the "Risk Factors" section of this prospectus. You should carefully consider such risks before deciding to invest in our ordinary shares. Our principal risks include:

we have a history of operating losses and negative cash flow;

if we do not successfully develop and market new products and technologies and implement our business strategy, our business and results of operations will be adversely affected;

we rely on our independent sales agencies and their representatives to market and sell our products;

we may be unable to compete successfully against our existing or future competitors;

we derive a significant portion of our sales from operations in international markets that are subject to political, economic and social instability;

if we fail to maintain regulatory approvals and clearances, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future products or product enhancements, our ability to commercially distribute and market these products could suffer; and

your rights as a holder of ordinary shares will be governed by Dutch law and will differ from the rights of shareholders under U.S. law.

**Corporate Information**

Our principal executive offices are located at Olivier van Noortstraat 4, 3124 LA Schiedam, The Netherlands. Our telephone number at this address is (+ 31) 20 577 1177. Our agent for service of process in the United States is CT Corporation, 1209 Orange St., Wilmington, DE 19801. Our website is located at [www.tornier.com](http://www.tornier.com). The information contained on our website is not a part of this prospectus.

This prospectus contains references to our trademarks Aequalis®, Affiniti™, Ascend™, Biofiber®, CoverLoc™, Futura™, Insite®, Intrafocal™, HLS Kneetec®, Latitude®, Linea™, Meije Duo®, NexFix™, Noetos®, Oceane™, Osteocure®, Piton®, Pleos®, RFS™, Salto®, Salto Talaris®, Stayfuse™ and Tornier™ among others. All other trademarks or trade names referred to in this prospectus are the property of their respective owners.

Table of Contents

**THE OFFERING**

Ordinary shares offered	ordinary shares
Ordinary shares outstanding immediately after this offering	ordinary shares (or ordinary shares if the underwriters exercise their overallotment option in full)
Use of proceeds	We estimate that our net proceeds from this offering will be approximately \$ million. We plan to use the net proceeds we receive from this offering to repay all of the existing indebtedness under our notes payable of approximately €80.7 million, or \$108.7 million at the exchange rate as of April 4, 2010, and for general corporate purposes. See "Use of Proceeds" for additional information.
Overallotment option	We have granted the underwriters a 30-day option to purchase up to additional ordinary shares.
Proposed NASDAQ Symbol	TRNX
Directed share program	At our request, the underwriters have reserved for sale, at the initial public offering price, up to ordinary shares offered by this prospectus to our directors, officers, employees, business associates and related persons.
Risk factors	Investing in our ordinary shares involves a high degree of risk. See "Risk Factors" for a discussion of factors you should carefully consider before investing in our ordinary shares.

The number of ordinary shares to be outstanding after this offering is based on 88,703,258 ordinary shares outstanding as of July 4, 2010, and excludes:

10,551,479 ordinary shares issuable upon exercise of outstanding options to purchase ordinary shares as of July 4, 2010, at a weighted average exercise price of \$5.53 per ordinary share; and

4,291,592 ordinary shares reserved for future issuance under our stock option plan as of July 4, 2010.

Unless we specifically state otherwise, the information in this prospectus assumes:

an initial public offering price of \$ per ordinary share, the mid-point of the range set forth on the cover page of this prospectus;

a to reverse stock split of our ordinary shares, which we intend to effect prior to the closing of this offering;

our conversion from a private company with limited liability to a public company with limited liability, and the filing of the accompanying amended articles of association to reflect such conversion, immediately prior to the effectiveness of this offering; and

the underwriters do not exercise their overallotment option.

Table of Contents**SUMMARY CONSOLIDATED FINANCIAL AND OPERATING DATA**

The following table presents our summary historical consolidated financial data, as of the dates and for the periods indicated. The summary historical consolidated statement of operations data and other financial data for the years ended December 31, 2007, December 28, 2008 and December 27, 2009, and the summary historical consolidated balance sheet data as of December 28, 2008 and December 27, 2009, have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary historical consolidated balance sheet data as of December 31, 2007, have been derived from our audited consolidated financial statements not included in this prospectus. The consolidated financial statements referred to in the previous two sentences were audited by Ernst & Young LLP, an independent registered public accounting firm, and were prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP.

The summary historical consolidated statement of operations data and other financial data for the thirteen weeks ended March 29, 2009, and the fourteen weeks ended April 4, 2010, and the summary historical consolidated balance sheet data as of April 4, 2010, have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. The March 29, 2009, and April 4, 2010, unaudited consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the financial position and results of operations for the periods presented. The results of any interim period are not necessarily indicative of the results that may be expected for any other interim period or for the full fiscal year, and the historical results set forth below do not necessarily indicate results expected for any future period.

Our fiscal quarters are generally determined on a 13-week basis and always end on a Sunday. As a result, our fiscal year is generally 364 days. Our year-end periods end on the Sunday nearest to December 31. Every few years, it is necessary to add an extra week to a quarter to make it a 14-week period in order to have our year end fall on the Sunday nearest to December 31. The first quarter ended April 4, 2010 includes an extra week of operations compared to the first quarter ended March 29, 2009.

You should read the summary financial and other data set forth below along with the sections in this prospectus entitled "Use of Proceeds," "Selected Consolidated Financial Data," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this prospectus.

	December 31, 2007	Year ended December 28, 2008	December 27, 2009	First quarter ended March 29, 2009	April 4, 2010
	(\$ in thousands)			(\$ in thousands)	
				(unaudited)	(unaudited)
<b>Statement of Operations Data:</b>					
Revenue	\$ 145,369	\$ 177,370	\$ 201,462	\$ 50,855	\$ 61,843
Cost of goods sold	49,959	49,085	58,472	14,690	18,365
Gross profit	95,410	128,285	142,990	36,165	43,478
Sales and marketing	78,628	103,285	112,017	26,854	33,381
General and administrative	17,976	21,742	20,790	5,213	6,526
Research and development	13,305	20,635	18,120	4,725	4,813
Amortization of intangible assets	7,946	11,186	15,173	2,615	2,997
Special charges			1,864		224
In-process research and development	15,107				
Operating loss	(37,552)	(28,563)	(24,974)	(3,242)	(4,463)
Interest expense	(2,394)	(11,171)	(19,667)	(3,059)	(5,830)
Foreign currency transaction gain (loss)	(5,859)	1,701	3,003	4,063	(2,294)
Other non-operating (expense) income	(1,966)	(1,371)	(28,461)	(1,900)	214
Loss before income taxes	(47,771)	(39,404)	(70,099)	(4,138)	(12,373)
Income tax benefit	6,580	5,227	14,413	621	2,322
Consolidated net loss	(41,191)	(34,177)	(55,686)	(3,517)	(10,051)
Net loss attributable to noncontrolling interest		(1,173)	(1,067)	(420)	(695)

Edgar Filing: Tornier B.V. - Form S-1/A

Net loss attributable to Tornier	(41,191)	(33,004)	(54,619)	(3,097)	(9,356)
Accretion of noncontrolling interest		(3,761)	(1,127)	(420)	(679)
Net loss attributable to ordinary shareholders	\$ (41,191)	\$ (36,765)	\$ (55,746)	\$ (3,517)	\$ (10,035)

Edgar Filing: Tornier B.V. - Form S-1/A

Table of Contents

	Year ended			First quarter ended	
	December 31, 2007	December 28, 2008	December 27, 2009	March 29, 2009	April 4, 2010
	(\$ in thousands)			(\$ in thousands)	
				(unaudited)	(unaudited)
<b>Balance Sheet Data:</b>					
Cash and cash equivalents	\$ 17,347	\$ 21,348	\$ 37,969	\$ 17,409	\$ 38,311
Other current assets	117,760	137,128	147,274	135,524	148,753
Total assets	431,614	475,967	520,187	460,480	510,930
Total liabilities	181,738	212,442	277,140	230,257	281,438
Noncontrolling interest		23,200	23,259	23,200	
Total shareholders' equity	249,876	240,325	219,788	207,023	229,492
<b>Other Financial Data:</b>					
Net cash provided by (used in) operating activities	\$ (8,956)	\$ (25,272)	\$ 3,417	\$ 1,478	\$ 3,304
Net cash provided by (used in) investing activities	(105,397)	(37,524)	(32,230)	(5,789)	(8,357)
Net cash provided by (used in) financing activities	121,886	66,487	44,857	558	4,832
EBITDA(1)	(29,795)	(5,902)	(20,700)	4,580	266
Adjusted EBITDA(1)	12,667	(2,277)	10,608	3,117	4,723

(1)

EBITDA, for the periods presented, represents net loss before interest expense, income tax benefit, depreciation and amortization. Adjusted EBITDA gives further effect to, among other things, non-operating (expense) income related to the mark to market of the warrant liability, foreign currency gains and losses, special charges, share-based compensation, operating expenses from a consolidated variable interest entity in-process research and development charges, and the impact of selling acquired inventory. We believe that EBITDA and Adjusted EBITDA provide additional information for measuring our performance and are measures frequently used by securities analysts and investors and therefore management uses these metrics to evaluate our business. EBITDA and Adjusted EBITDA do not represent, and should not be used as a substitute for, net income or cash flows from operations as determined in accordance with generally accepted accounting principles, and neither EBITDA nor Adjusted EBITDA is necessarily an indication of whether cash flow will be sufficient to fund our cash requirements. Our definitions of EBITDA and Adjusted EBITDA may differ from that of other companies.

The following table reconciles net loss to EBITDA and Adjusted EBITDA on a historical basis:

	Year ended			First quarter ended	
	December 31, 2007	December 28, 2008	December 27, 2009	March 29, 2009	April 4, 2010
	(\$ in thousands)			(\$ in thousands)	
				(unaudited)	(unaudited)
Net loss	\$ (41,191)	\$ (34,177)	\$ (55,686)	\$ (3,517)	\$ (10,051)
Interest expense	2,394	11,171	19,667	3,059	5,830
Income tax benefit	(6,580)	(5,227)	(14,413)	(621)	(2,322)
Depreciation and amortization	15,582	22,331	29,732	5,659	6,809
EBITDA	\$ (29,795)	\$ (5,902)	\$ (20,700)	\$ 4,580	\$ 266
Non-operating (expense) income (mark to market of warrant liability)	1,966	1,371	28,461	1,900	(214)
Foreign currency transaction (gain)/loss	5,859	(1,701)	(3,003)	(4,063)	2,294
Share-based compensation	2,836	3,672	3,913	682	1,559
Special charges			1,864		224
Operating expenses from consolidated VIE		283	73	18	594
In-process research and development	15,107				
Sale of acquired inventory	16,694				
Adjusted EBITDA	\$ 12,667	\$ (2,277)	\$ 10,608	\$ 3,117	\$ 4,723



Table of Contents

**RISK FACTORS**

*An investment in our ordinary shares involves significant risks. You should carefully consider all of the information in this prospectus, including the risks and uncertainties described below, before making an investment in our ordinary shares. Any of the following risks could have a material adverse effect on our business, financial condition and results of operations. In any such case, the market price of our ordinary shares could decline, and you may lose all or part of your investment.*

**Risks Related to Our Business and Our Industry**

*We have a history of operating losses and negative cash flow.*

We have experienced operating losses since our acquisition by the Investor Group in July 2006 and at April 4, 2010, we had an accumulated deficit of \$154.1 million. Our ability to achieve cash flow positive operations will be influenced by many factors, including the extent and duration of our future operating losses, the level and timing of future sales and expenditures, market acceptance of new products, the results and scope of ongoing research and development projects, competing technologies and market and regulatory developments. Additionally, following this offering, we expect general and administrative expenses to increase due to the additional operational and reporting costs associated with being a public company. As a result, we may continue to incur operating losses for the foreseeable future. These losses will continue to have an adverse impact on shareholders' equity and we may never achieve or sustain profitability.

*If we do not successfully develop and market new products and technologies and implement our business strategy, our business and results of operations will be adversely affected.*

We may not be able to successfully implement our business strategy. To implement our business strategy we need to, among other things, develop and introduce new extremity joint products, find new applications for and improve our existing products, properly identify and anticipate our surgeons' and their patients' needs, obtain regulatory clearance or approval for new products and applications and educate surgeons about the clinical and cost benefits of our products.

We are continually engaged in product development and improvement programs, and we expect new products to account for a significant portion of our future growth. If we do not continue to introduce new products and technologies, or if those products and technologies are not accepted, we may not be successful. Moreover, research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material or innovation. Demand for our products could also change in ways we may not anticipate due to evolving customer needs, changing demographics, slow industry growth rates, evolving surgical philosophies and evolving industry standards, among others. Additionally, our competitors' new products and technologies may precede our products to market, may be more effective or less expensive than our products or may render our products obsolete.

Our targeted surgeons are in areas such as shoulder, upper extremities, lower extremities, sports medicine and reconstructive and general orthopaedics, and our strategy of focusing exclusively on these surgeons may not be successful. In addition, we are seeking to increase our international sales and will need to increase our worldwide direct sales force and enter into distribution agreements with third parties in order to do so. All of this may result in additional or different foreign regulatory requirements, with which we may not be able to comply. Moreover, even if we successfully implement our business strategy, our operating results may not improve. We may decide to alter or discontinue aspects of our business strategy and may adopt different strategies due to business or competitive factors.

Table of Contents

***We rely on our independent sales agencies and their representatives to market and sell our products.***

In the United States, we sell our products through a single sales channel primarily focused on our products and consisting of approximately 23 independent commission-based sales agencies, which in the aggregate utilized over 300 sales representatives as of April 4, 2010. Our sales agencies do not sell our products exclusively and may offer similar products from other orthopaedic companies. In fiscal 2009, no individual sales agency accounted for more than 3% of our global revenue. Our success depends largely upon our ability to motivate these sales agencies to sell our products. Additionally, we depend on their sales and service expertise and relationships with the surgeons in the marketplace. Our independent sales agencies may terminate their contracts with us at the end of each yearly term, may devote insufficient sales efforts to our products or may focus their sales efforts on other products that produce greater commissions for them. If our relationship with any of our sales agencies terminated, we could enter into agreements with existing sales agencies to take on the related sales, contract with new sales agencies or a combination of these options. A failure to maintain our existing relationships with our independent sales agencies and their representatives could have an adverse effect on our operations. We do not control our independent sales agencies and they may not be successful in implementing our marketing plans.

***We may be unable to compete successfully against our existing or potential competitors, our sales and operating results may be negatively affected and we may not grow.***

The market for orthopaedic devices is highly competitive and subject to rapid and profound technological change. Our success depends, in part, on our ability to maintain a competitive position in the development of technologies and products for use by our customers. We face competition from large diversified orthopaedic manufacturers, such as DePuy Orthopaedics, Inc., or DePuy, a Johnson & Johnson subsidiary, Zimmer Corporation, or Zimmer, and Stryker Corporation, or Stryker, and established mid-sized orthopaedic manufacturers, such as Arthrex, Inc., or Arthrex, Wright Medical Group, Inc., or Wright Medical, and ArthroCare Corporation, or ArthroCare. Many of the companies developing or marketing competitive orthopaedic products are publicly traded or are divisions of publicly traded companies and may enjoy several competitive advantages, including:

greater financial and human resources for product development and sales and marketing;

greater name recognition;

established relationships with surgeons, hospitals and third-party payors;

broader product lines and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage;

established sales and marketing and distribution networks; and

more experience in conducting research and development, manufacturing, preparing regulatory submissions and obtaining regulatory clearance or approval for products.

We also compete against smaller, entrepreneurial companies with niche product lines. Our competitors may develop and patent processes or products earlier than we can, obtain regulatory clearance or approvals for competing products more rapidly than we can and develop more effective or less expensive products or technologies that render our technology or products obsolete or non-competitive. We also compete with other organizations in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies and technology licenses complementary to our products or advantageous to our business. If our competitors are more successful than us in these matters, we may be unable to compete successfully against our existing or future competitors.

Table of Contents

*We derive a significant portion of our sales from operations in international markets that are subject to political, economic and social instability.*

We derive a significant portion of our sales from operations in international markets. Our international distribution system consists of nine direct sales offices and approximately 32 distribution partners, who sell in approximately 35 countries. Most of these countries are, to some degree, subject to political, economic and social instability. For the years ended December 27, 2009, and December 28, 2008, 43% and 48% of our revenue, respectively, was derived from our international operations. Our international sales operations expose us and our representatives, agents and distributors to risks inherent in operating in foreign jurisdictions. These risks include:

the imposition of additional U.S. and foreign governmental controls or regulations on orthopaedic implants and orthobiologics products;

the imposition of costly and lengthy new export license requirements;

the imposition of U.S. or international sanctions against a country, company, person or entity with whom we do business that would restrict or prohibit continued business with that country, company, person or entity;

economic instability, including currency risk between the U.S. dollar and foreign currencies, in our target markets;

the imposition of restrictions on the activities of foreign agents, representatives and distributors;

scrutiny of foreign tax authorities, which could result in significant fines, penalties and additional taxes being imposed upon us;

a shortage of high-quality international salespeople and distributors;

loss of any key personnel who possess proprietary knowledge or are otherwise important to our success in international markets;

changes in third-party reimbursement policies that may require some of the patients who receive our products to directly absorb medical costs or that may require us to sell our products at lower prices;

changes in tariffs and other trade restrictions;

work stoppages or strikes in the healthcare industry;

difficulties in enforcing and defending intellectual property rights; and

exposure to different legal and political standards.

Not only are we subject to the laws of other jurisdictions, we are also subject to U.S. laws governing our activities in foreign countries, including various import-export laws, customs and import laws, anti-boycott laws and embargoes. For example, the FDA Export Reform and Enhancement Act of 1996 requires that, when exporting medical devices from the United States for sale in a foreign country, depending on the type of product being exported, the regulatory status of the product and the country to which the device is exported, we must ensure, among

## Edgar Filing: Tornier B.V. - Form S-1/A

other things, that the device is produced in accordance with the specifications of the foreign purchaser; not in conflict with the laws of the country to which it is intended for export; labeled for export; and not offered for sale domestically. In addition, we must maintain records relevant to product export and, if requested by the foreign government, obtain a certificate of exportability. In some instances, prior notification to or approval from the FDA is required prior to export. The FDA can delay or deny export authorization if all applicable requirements are not satisfied. Imports of approved medical devices into the United States are also

Table of Contents

subject to requirements including registration of establishment, listing of devices, manufacturing in accordance with the quality system regulation, medical device reporting of adverse events, and Premarket Notification 510(k) clearance or premarket approval, or PMA, among others and if applicable. If our business activities were determined to violate these laws, regulations or rules, we could suffer serious consequences.

In addition, a portion of our international sales is made through distributors. As a result, we are dependent upon the financial health of our distributors. If a distributor were to go out of business it would take substantial time, cost and resources to find a suitable replacement and the products held by such distributor may not be returned to us or to a subsequent distributor in a timely manner or at all.

Any material decrease in our foreign sales may negatively affect our profitability. We generate our international sales primarily in Europe, where healthcare regulation and reimbursement for orthopaedic medical devices vary significantly from country to country. This changing environment could adversely affect our ability to sell our products in some European countries.

***Our business plan relies on assumptions about the market for our products, which, if incorrect, may adversely affect our sales.***

We believe that the aging of the general population and increasingly active lifestyles will continue and that these trends will increase the need for our products. The projected demand for our products could materially differ from actual demand if our assumptions regarding these trends and acceptance of our products by the medical community prove to be incorrect or do not materialize, or if non-surgical treatments gain more widespread acceptance as a viable alternative to our orthopaedic implants.

***We obtain some of our products through private-label distribution agreements that subject us to minimum performance and other criteria. Our failure to satisfy those criteria could cause us to lose those rights of distribution.***

We have entered into private-label distribution agreements with manufacturers of some of our products. These manufacturers brand their products according to our specifications, and we may have exclusive rights in certain fields of use and territories to sell these products subject to minimum purchase, sales or other performance criteria. Though these agreements do not individually or in the aggregate represent a material portion of our business, if we do not meet these performance criteria, or fail to renew these agreements, we may lose exclusivity in a field of use or territory or cease to have any rights to these products, which could have an adverse affect on our sales. Furthermore, some of these manufacturers may be smaller, undercapitalized companies that may not have sufficient resources to continue operations or to continue to supply us sufficient product without additional access to capital.

***If our private label manufacturers fail to provide us with sufficient supply of their products, or if their supply fails to meet appropriate quality requirements, our business could suffer.***

Our private-label manufacturers are sole source suppliers of the products we purchase from them. Given the specialized nature of the products they provide, we may not be able to locate or establish additional or replacement manufacturers of these products. Moreover, these private-label manufacturers typically own the intellectual property associated with their products, and even if we could find a replacement manufacturer for the product, we may not have sufficient rights to enable the replacement party to manufacture the product. While we have entered into agreements with our private-label manufacturers to provide us sufficient quantities of products, we cannot assure you that they will do so, or that any products they do provide us will not contain defects in quality. The

Table of Contents

agreements with our private-label manufacturers are for terms ranging from one to five years, are renewable either automatically or with the consent of the parties and are terminable by either party upon notice under certain circumstances, including either party's uncured material breach of the terms and conditions of the agreement or the insolvency of either party. We also rely on these private-label manufacturers to comply with the regulations of the U.S. Food and Drug Administration, or FDA, the competent authorities of the Member States of the European Economic Area, or EEA, or foreign regulatory authorities and their failure to comply with strictly enforced regulatory requirements could expose us to regulatory action including warning letters, product recalls, termination of distribution, product seizures or civil penalties. Any quality control problems that we experience with respect to products manufactured by our private-label manufacturers, any inability by us to provide our customers with sufficient supply of products or any investigations or enforcement actions by the FDA, the competent authorities of the Member States of the EEA or other foreign regulatory authorities could adversely affect our reputation or commercialization of our products and adversely and materially affect our business and operating results.

***Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to, among other things, penalties and legal expenses that could harm our reputation and have a material adverse effect on our business, financial condition and results of operations.***

Our U.S. operations, including those of our subsidiary, Tornier, Inc., are currently subject to the U.S. Foreign Corrupt Practices Act, or the FCPA. Upon the closing of this offering, we will be required to comply with the FCPA, which generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials for the purpose of obtaining or retaining business or other benefits. In addition, the FCPA imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of "off books" slush funds from which such improper payments can be made. We are also currently subject to similar anticorruption legislation implemented in Europe under the Organization for Economic Co-operation and Development's Convention on Combating Bribery of Foreign Public Officials in International Business Transactions. We operate in a number of jurisdictions that pose a high risk of potential violations of the FCPA and other anticorruption laws, such as Algeria, China and Oman, based on measurements such as Transparency International's Corruption Perception Index and we utilize a number of third-party sales representatives for whose actions we could be held liable under the FCPA. We inform our personnel and third-party sales representatives of the requirements of the FCPA and other anticorruption laws, including, but not limited to their reporting requirements. We have also developed and will continue to develop and implement systems for formalizing contracting processes, performing due diligence on agents and improving our recordkeeping and auditing practices regarding these regulations. However, there is no guarantee that our employees, third-party sales representatives or other agents have not or will not engage in conduct undetected by our processes and for which we might be held responsible under the FCPA or other anticorruption laws.

If our employees, third-party sales representatives or other agents are found to have engaged in such practices, we could suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures, including further changes or enhancements to our procedures, policies and controls, as well as potential personnel changes and disciplinary actions. The Securities and Exchange Commission, or SEC, is currently in the midst of conducting an informal investigation of numerous medical device companies over potential violations of the FCPA. Although we do not believe we are currently a target, any investigation of any potential violations of the FCPA or other anticorruption laws by U.S. or foreign authorities also could have an adverse impact on our business, financial condition and results of operations.

Table of Contents

Certain foreign companies, including some of our competitors, are not subject to prohibitions as strict as those under the FCPA or, even if subjected to strict prohibitions, such prohibitions may be laxly enforced in practice. If our competitors engage in corruption, extortion, bribery, pay-offs, theft or other fraudulent practices, they may receive preferential treatment from personnel of some companies, giving our competitors an advantage in securing business, or from government officials, who might give them priority in obtaining new licenses, which would put us at a disadvantage.

***Fluctuations in foreign currency rates could result in declines in our reported sales and earnings.***

A substantial portion of our foreign revenue is generated in Europe and other foreign countries in Latin America and Asia where the amounts are denominated in currencies other than the U.S. dollar. For purposes of preparing our financial statements, these amounts are converted into U.S. dollars, the value of which varies with currency exchange rate fluctuations. For sales not denominated in U.S. dollars, if there is an increase in the value of the U.S. dollar relative to the specified foreign currency, we will receive less in U.S. dollars than before the increase in the exchange rate, which could negatively impact our results of operations. Although we address currency risk management through regular operating and financing activities, those actions may not prove to be fully effective.

***If we lose one of our key suppliers, we may be unable to meet customer orders for our products in a timely manner or within our budget.***

We use a number of suppliers for raw materials and select components that we need to manufacture our products. These suppliers must provide the materials and components to our standards for us to meet our quality and regulatory requirements. We obtain some key raw materials and select components from a single source or a limited number of sources. For example, we rely on one supplier for raw materials and select components in several of our products, including Poco Graphite, Inc., which supplies graphite for pyrocarbon, CeramTec Group, which supplies ceramic for ceramic heads for hips, and Heymark Metals Ltd., which supplies CoCr used in certain of our hip, shoulder and elbow products. Establishing additional or replacement suppliers for these components, and obtaining regulatory clearance or approvals that may result from adding or replacing suppliers, could take a substantial amount of time, result in increased costs and impair our ability to produce our products, which would adversely impact our business and operating results. We do not have a contract with many of our sole source suppliers and instead rely on purchase orders. As a result, those suppliers may elect not to supply us with product or to supply us with less product than we need and we will have limited rights to cause them to do otherwise. For those suppliers with which we have contracts, the agreement terms range from one to five years and automatically renew unless terminated upon notice by either party. In addition, some of our products, which we acquire from third parties, are highly technical and are required to meet exacting specifications, and any quality control problems that we experience with respect to the products supplied by third parties could adversely and materially affect our reputation or commercialization of our products and adversely and materially affect our business, operating results and prospects. We may also have difficulty obtaining similar components from other suppliers that are acceptable to the FDA, the competent authorities or notified bodies of the Member States of the EEA, or foreign regulatory authorities and the failure of our suppliers to comply with strictly enforced regulatory requirements could expose us to regulatory action including warning letters, product recalls, termination of distribution, product seizures or civil penalties. Furthermore, since many of these suppliers are located outside of the United States, we are subject to foreign export laws and U.S. import and customs regulations, which complicate and could delay shipments of components to us. For example, all foreign importers of medical devices are required to meet applicable FDA requirements, including registration of establishment, listing of devices, manufacturing in accordance with the quality system regulation, medical device reporting of adverse events, and Premarket Notification 510(k) clearance or PMA, if applicable. In addition, all imported medical devices must also meet Bureau of Customs and Border Protection requirements. While it is

Table of Contents

our policy to maintain sufficient inventory of materials and components so that our production will not be significantly disrupted even if a particular component or material is not available for a period of time, we remain at risk that we will not be able to qualify new components or materials quickly enough to prevent a disruption if one or more of our suppliers ceases production of important components or materials.

***Sales volumes may fluctuate depending on the season and our operating results may fluctuate over the course of the year.***

Our business is seasonal in nature. Historically, demand for our products has been the lowest in our third quarter as a result of the European holiday schedule during the summer months. We have experienced and expect to continue to experience meaningful variability in our revenue and gross profit among quarters, as well as within each quarter, as a result of a number of factors, including, among other things:

- the number and mix of products sold in the quarter;
- the demand for, and pricing of, our products and the products of our competitors;
- the timing of or failure to obtain regulatory clearances or approvals for products;
- costs, benefits and timing of new product introductions;
- increased competition;
- the timing and extent of promotional pricing or volume discounts;
- the availability and cost of components and materials;
- the number of selling days;
- fluctuations in foreign currency exchange rates; and
- impairment and other special charges.

***If product liability lawsuits are brought against us, our business may be harmed.***

The manufacture and sale of orthopaedic medical devices exposes us to significant risk of product liability claims. In the past, we have had a small number of product liability claims relating to our products, none of which either individually, or in the aggregate, have resulted in a material negative impact on our business. In the future, we may be subject to additional product liability claims, some of which may have a negative impact on our business. Such claims could divert our management from pursuing our business strategy and may be costly to defend. Regardless of the merit or eventual outcome, product liability claims may result in:

- decreased demand for our products;
- injury to our reputation;



significant litigation costs;

substantial monetary awards to or costly settlements with patients;

product recalls;

loss of revenue; and

the inability to commercialize new products or product candidates.

Our existing product liability insurance coverage may be inadequate to protect us from any liabilities we might incur. If a product liability claim or series of claims is brought against us for

Table of Contents

uninsured liabilities or in excess of our insurance coverage, our business could suffer. In addition, a recall of some of our products, whether or not the result of a product liability claim, could result in significant costs and loss of customers.

In addition, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts or scope to protect us against losses. Any claims against us, regardless of their merit, could severely harm our financial condition, strain our management and other resources and adversely affect or eliminate the prospects for commercialization or sales of a product or product candidate which is the subject of any such claim.

***If our patents and other intellectual property rights do not adequately protect our products, we may lose market share to our competitors.***

We rely on patents, trade secrets, copyrights, know-how, trademarks, license agreements and contractual provisions to establish our intellectual property rights and protect our products. These legal means, however, afford only limited protection and may not adequately protect our rights. The patents we own may not be of sufficient scope or strength to provide us with any meaningful protection or commercial advantage, and competitors may be able to design around our patents or develop products that provide outcomes that are similar to ours. In addition, we cannot be certain that any of our pending patent applications will be issued. The United States Patent and Trademark Office, or USPTO, may deny or require a significant narrowing of the claims in our pending patent applications and the patents issuing from such applications. Any patents issuing from the pending patent applications may not provide us with significant commercial protection. We could incur substantial costs in proceedings before the USPTO and the proceedings can be time-consuming, which may cause significant diversion of effort by our technical and management personnel. These proceedings could result in adverse decisions as to the priority of our inventions and the narrowing or invalidation of claims in issued patents. In addition, the laws of some of the countries in which our products are or may be sold may not protect our intellectual property to the same extent as U.S. laws or at all. We also may be unable to protect our rights in trade secrets and unpatented proprietary technology in these countries.

In the event a competitor infringes upon our patent or other intellectual property rights, enforcing those rights may be costly, difficult and time-consuming. Even if successful, litigation to enforce our intellectual property rights or to defend our patents against challenge could be expensive and time-consuming and could divert our management's attention. We may not have sufficient resources to enforce our intellectual property rights or to defend our patents or other intellectual property rights against a challenge. If we are unsuccessful in enforcing and protecting our intellectual property rights and protecting our products, it could harm our business and results of operations.

We rely on our trademarks, trade names and brand names to distinguish our products from the products of our competitors, and have registered or applied to register many of these trademarks. However, our trademark applications may not be approved. Third parties may also oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing these new brands. Further, our competitors may infringe our trademarks, or we may not have adequate resources to enforce our trademarks.

In addition, we hold licenses from third parties that are necessary to the design and manufacturing of some of our products. The loss of such licenses would prevent us from manufacturing, marketing and selling these products, which could harm our business.

In addition to patents, we seek to protect our trade secrets, know-how and other unpatented technology, in part, with confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information. We cannot be certain, however, that these agreements

Table of Contents

will not be breached, adequate remedies for any breach would be available or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors.

***If we are subject to any future intellectual property lawsuits, a court could require us to pay significant damages or prevent us from selling our products.***

The orthopaedic medical device industry is litigious with respect to patents and other intellectual property rights. Companies in the orthopaedic medical device industry have used intellectual property litigation to gain a competitive advantage. In the future, we may become a party to lawsuits involving patents or other intellectual property. A legal proceeding, regardless of outcome, could drain our financial resources and divert the time and effort of our management. A patent infringement suit or other infringement or misappropriation claim brought against us or any of our licensees may force us or any of our licensees to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party's intellectual property, unless that party grants us or any licensees rights to use its intellectual property. In such cases, we may be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if we or our licensees were able to obtain rights to the third party's intellectual property, these rights may be nonexclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.

In any infringement lawsuit, a third party could seek to enjoin, or prevent, us from commercializing our existing or future products, or may seek damages from us, and any such lawsuit would likely be expensive for us to defend against. If we lose one of these proceedings, a court or a similar foreign governing body could require us to pay significant damages to third parties, seek licenses from third parties, pay ongoing royalties, redesign our products so that they do not infringe or prevent us from manufacturing, using or selling our products. In addition to being costly, protracted litigation to defend or prosecute our intellectual property rights could result in our customers or potential customers deferring or limiting their purchase or use of the affected products until resolution of the litigation.

We have received, and we may receive in the future, notifications of potential conflicts of existing patents, pending patent applications and challenges to the validity of existing patents. For example, we corresponded with DePuy in 2006 regarding a possible license granted by DePuy to us under a French patent in connection with one of our shoulder products. We did not come to any agreement with DePuy and last corresponded on this matter in early 2007. We were contacted by an individual in June 2010 regarding his French patent and his request that we explain our position regarding this patent with respect to our hip product Meije Duo. We analyzed the patent and our product and responded to the individual stating our belief the product falls outside the scope of his patent. The individual has not responded. We have searched and found that the individual has no corresponding patent outside of France. In addition, we have become aware of, and may become aware of in the future, patent applications and issued patents that relate to our products or the surgical applications using our products and, in some cases, have obtained internal or external opinions of counsel regarding the relevance of certain issued patents to our products.

Table of Contents

***Our inability to maintain adequate working relationships with external research and development consultants and surgeons could have a negative impact on our ability to market and sell new products.***

We maintain professional working relationships with external research and development consultants and leading surgeons and medical personnel in hospitals and universities who assist in product research and development. We continue to emphasize the development of proprietary products and product improvements to complement and expand our existing product lines. If we are unable to maintain these relationships, our ability to market and sell new and improved products could decrease, and future operating results could be unfavorably affected.

***We are required to incur significant expenditures of resources to maintain relatively high levels of inventory, which can reduce our cash flows.***

As a result of the need to maintain substantial levels of inventory, we are subject to the risk of inventory obsolescence. The nature of our business requires us to maintain a substantial level of inventory. For example, our total consolidated inventory balances were \$75.0 million, \$82.7 million and \$83.0 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively. In order to market effectively we often must maintain and bring our customers instrument kits, back-up products and products of different sizes. In the event that a substantial portion of our inventory becomes obsolete, it could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.

***Recent acquisitions and efforts to acquire and integrate other companies or product lines could adversely affect our operations and financial results.***

We may pursue acquisitions of other companies or product lines. A successful acquisition depends on our ability to identify, negotiate, complete and integrate such acquisition and to obtain any necessary financing. With respect to future acquisitions, we may experience:

difficulties in integrating any acquired companies, personnel and products into our existing business;

delays in realizing the benefits of the acquired company or products;

diversion of our management's time and attention from other business concerns;

challenges due to limited or no direct prior experience in new markets or countries we may enter;

higher costs of integration than we anticipated; or

difficulties in retaining key employees of the acquired business who are necessary to manage these acquisitions.

In addition, any future acquisitions could materially impair our operating results by causing us to incur debt or requiring us to amortize acquired assets.

***If we cannot retain our key personnel, we will not be able to manage and operate successfully, and we may not be able to meet our strategic objectives.***

Our success depends, in part, upon key managerial, scientific, sales and technical personnel, as well as our ability to continue to attract and retain additional highly qualified personnel. We compete for such personnel with other companies, academic institutions, governmental entities and other organizations. There is no guarantee that we will be successful in retaining our current personnel or in hiring or retaining qualified personnel in the future. Loss of key personnel or the inability to hire or

Table of Contents

retain qualified personnel in the future could have a material adverse effect on our ability to operate successfully. Further, any inability on our part to enforce non-compete arrangements related to key personnel who have left the business could have a material adverse effect on our business.

***Fluctuations in insurance cost and availability could adversely affect our profitability or our risk management profile.***

We hold a number of insurance policies, including product liability insurance, directors' and officers' liability insurance, property insurance and workers' compensation insurance. If the costs of maintaining adequate insurance coverage should increase significantly in the future, our operating results could be materially adversely affected. Likewise, if any of our current insurance coverage should become unavailable to us or become economically impractical, we would be required to operate our business without indemnity from commercial insurance providers.

***If a natural or man-made disaster, including as a result of climate change or weather, strikes our manufacturing facilities or distribution channels, we could be unable to manufacture or distribute our products for a substantial amount of time and our sales could decline.***

We principally rely on five manufacturing facilities, three of which are in France and two of which are in Ireland. The facilities and the manufacturing equipment we use to produce our products would be difficult to replace and could require substantial lead-time to repair or replace. For example, the machinery associated with our manufacturing of pyrocarbon in one of our French facilities is highly specialized and would take substantial lead-time and resources to replace. We also maintain warehouses in Stafford, Texas and Montbonnot, France, containing large amounts of our inventory. Our facilities, warehouses or distribution channels may be affected by natural or man-made disasters. Further, such may be exacerbated by climate change, as some scientists have concluded that climate change could result in the increased severity of and perhaps more frequent occurrence of extreme weather patterns. For example, in the event of a hurricane in Stafford, Texas, we may lose substantial amounts of inventory that would be difficult to replace. In the event our facilities, warehouses or distribution channels are affected by a disaster, we would be forced to rely on, among others, third-party manufacturers and alternative warehouse space and distribution channels, which may or may not be available, and our sales could decline. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms or at all.

***Recent turmoil in the credit markets and the financial services industry may negatively affect our business.***

Recently, the credit markets and the financial services industry have been experiencing a period of unprecedented turmoil and upheaval characterized by the bankruptcy, failure, collapse or sale of various financial institutions and an unprecedented level of intervention from U.S. and foreign governments. While the ultimate outcome of these events cannot be predicted, they may have an adverse effect on our customers' ability to borrow money from their existing lenders or to obtain credit from other sources to purchase our products. In addition, the recent economic crises could also adversely affect our suppliers' ability to provide us with materials and components, either of which may negatively impact our business.

Table of Contents

***We may need substantial additional funding beyond the proceeds of this offering and may be unable to raise capital when needed, which would force us to delay, reduce, eliminate or abandon our commercialization efforts or product development programs.***

There is no guarantee that our anticipated cash flow from operations will be sufficient to meet all of our cash requirements. We intend to continue to make investments to support our business growth and may require additional funds to:

expand the commercialization of our products;

fund our operations and clinical trials;

continue our research and development;

defend, in litigation or otherwise, any claims that we infringe third-party patents or other intellectual property rights;

commercialize our new products, if any such products receive regulatory clearance or approval for commercial sale; and

acquire companies and in-license products or intellectual property.

We believe that the net proceeds from this offering, together with our existing cash and cash equivalent balances and cash receipts generated from sales of our products, will be sufficient to meet our anticipated cash requirements for the foreseeable future. However, our future funding requirements will depend on many factors, including:

market acceptance of our products;

the scope, rate of progress and cost of our clinical trials;

the cost of our research and development activities;

the cost of filing and prosecuting patent applications and defending and enforcing our patent and other intellectual property rights;

the cost of defending, in litigation or otherwise, any claims that we infringe third-party patent or other intellectual property rights;

the cost and timing of additional regulatory clearances or approvals;

the cost and timing of expanding our sales, marketing and distribution capabilities;

the effect of competing technological and market developments; and

## Edgar Filing: Tornier B.V. - Form S-1/A

the extent to which we acquire or invest in businesses, products and technologies, although we currently have no commitments or agreements relating to any of these types of transactions.

If we raise additional funds by issuing equity securities, our shareholders may experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our shareholders. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support or other resources devoted to our products or cease operations.

Table of Contents

***Our operating results could be negatively impacted by future changes in the allocation of income to each of the entities through which we operate and to each of the income tax jurisdictions in which we operate.***

We operate through multiple entities and in multiple income tax jurisdictions with different income tax rates both inside and outside the United States. Accordingly, our management must determine the appropriate allocation of income to each such entity and each of these jurisdictions. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing and product royalty arrangements, may require an extended period of time to resolve and may result in income tax adjustments if changes to the income allocation are required. Since income tax adjustments in certain jurisdictions can be significant, our future operating results could be negatively impacted by settlement of these matters.

***Future changes in technology or market conditions could result in adjustments to our recorded asset balance for intangible assets, including goodwill, resulting in additional charges that could significantly impact our operating results.***

Our balance sheet includes significant intangible assets, including goodwill and other acquired intangible assets. The determination of related estimated useful lives and whether these assets are impaired involves significant judgments. Our ability to accurately predict future cash flows related to these intangible assets may be adversely affected by unforeseen and uncontrollable events. In the highly competitive medical device industry, new technologies could impair the value of our intangible assets if they create market conditions that adversely affect the competitiveness of our products. We test our goodwill for impairment in the fourth quarter of each year, but we also test goodwill and other intangible assets for impairment at any time when there is a change in circumstances that indicates that the carrying value of these assets may be impaired. Any future determination that these assets are carried at greater than their fair value could result in substantial non-cash impairment charges, which could significantly impact our reported operating results.

***Our outstanding debt agreements contain restrictive covenants that may limit our operating flexibility.***

The agreements relating to our outstanding debt contain some financial covenants limiting our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. We therefore may not be able to engage in any of the foregoing transactions until our current debt obligations are paid in full or we obtain the consent of the lenders. There is no guarantee that we will be able to generate sufficient cash flow or revenue to meet the financial covenants or pay the principal and interest on our debt. Furthermore, there is no guarantee that future working capital, borrowings or equity financing will be available to repay or refinance any such debt.

***If reimbursement from third-party payors for our products becomes inadequate, surgeons and patients may be reluctant to use our products and our sales may decline.***

In the United States, healthcare providers who purchase our products generally rely on third-party payors, principally federal Medicare, state Medicaid and private health insurance plans, to pay for all or a portion of the cost of joint reconstructive procedures and products utilized in those procedures. We may be unable to sell our products on a profitable basis if third-party payors deny coverage or reduce their current levels of reimbursement. Our sales depend largely on governmental healthcare programs and private health insurers reimbursing patients' medical expenses. To contain costs of new technologies, third-party payors are increasingly scrutinizing new treatment modalities by requiring extensive evidence of clinical outcomes and cost effectiveness. Currently, we are aware of several private insurers who have issued policies that classify procedures using our Salto Talaris Prosthesis and Conical Subtalar Implants implants as experimental or investigational and denied coverage and



Table of Contents

reimbursement for such procedures. Surgeons, hospitals and other healthcare providers may not purchase our products if they do not receive satisfactory reimbursement from these third-party payors for the cost of the procedures using our products. Payors continue to review their coverage policies carefully for existing and new therapies and can, without notice, deny coverage for treatments that include the use of our products. If we are not successful in reversing existing non-coverage policies or other private insurers issue similar policies, this could have a material adverse effect on our business and operations.

In addition, some healthcare providers in the United States have adopted or are considering a managed care system in which the providers contract to provide comprehensive healthcare for a fixed cost per person. Healthcare providers may attempt to control costs by authorizing fewer elective surgical procedures, including joint reconstructive surgeries, or by requiring the use of the least expensive implant available. Additionally, there is a significant likelihood of reform of the U.S. healthcare system, and changes in reimbursement policies or healthcare cost containment initiatives that limit or restrict reimbursement for our products may cause our revenue to decline.

If adequate levels of reimbursement from third-party payors outside of the United States are not obtained, international sales of our products may decline. Outside of the United States, reimbursement systems vary significantly by country. Many foreign markets have government-managed healthcare systems that govern reimbursement for orthopaedic medical devices and procedures. Additionally, some foreign reimbursement systems provide for limited payments in a given period and therefore result in extended payment periods.

***Continuing weakness in the global economy is likely to adversely affect our business until an economic recovery is underway.***

Many of our products are used in procedures covered by private insurance, and some of these procedures may be considered elective. We believe the current global economic crisis is likely to reduce the availability or affordability of private insurance or may affect patient decisions to undergo elective procedures. If current economic conditions continue or worsen, we expect that increasing levels of unemployment and pressures to contain healthcare costs could adversely affect the global growth rate of procedure volume, which could have a material adverse effect on our sales and results of operations.

***Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, financial condition or results of operations.***

Because healthcare costs have risen significantly over the past decade, numerous initiatives and reforms initiated by legislators, regulators and third-party payors to curb these costs have resulted in a consolidation trend in the healthcare industry to create new companies with greater market power, including hospitals. As the healthcare industry consolidates, competition to provide products and services to industry participants has become and will continue to become more intense. This in turn has resulted and will likely continue to result in greater pricing pressures and the exclusion of certain suppliers from important market segments as group purchasing organizations, independent delivery networks and large single accounts continue to use their market power to consolidate purchasing decisions for some of our customers. We expect that market demand, government regulation, third-party reimbursement policies and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers, which may reduce competition, exert further downward pressure on the prices of our products and may adversely impact our business, financial condition or results of operations.

Table of Contents

*If we experience significant disruptions in our information technology systems, our business may be adversely affected.*

We depend on our information technology systems for the efficient functioning of our business, including accounting, data storage, purchasing and inventory management. Currently, we have a non-interconnected information technology system; however, we have undertaken the implementation of an upgrade of our systems. We expect that this upgrade will take two to three years to implement; however, when complete it should enable management to better and more efficiently conduct our operations and gather, analyze, and assess information across all of our business and geographic locations. We may experience difficulties in implementing this upgrade in our business operations, or difficulties in operating our business under this upgrade, either of which could disrupt our operations, including our ability to timely ship and track product orders, project inventory requirements, manage our supply chain, and otherwise adequately service our customers. In the event we experience significant disruptions as a result of the current implementation in our information technology system, we may not be able to fix our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our results of operations and cash flows.

**Risks Related to Regulatory Environment**

*The sale of our products is subject to regulatory clearances or approvals and our business is subject to extensive regulatory requirements. If we fail to maintain regulatory approvals and clearances, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals for our future products or product enhancements, our ability to commercially distribute and market these products could suffer.*

Our medical device products and operations are subject to extensive regulation by the FDA and various other federal, state and foreign governmental authorities, such as those of the European Union and the competent authorities of the Member States of the EEA. Government regulation of medical devices is meant to assure their safety and effectiveness, and includes regulation of, among other things:

design, development and manufacturing;

testing, labeling, packaging, content and language of instructions for use, and storage;

clinical trials;

product safety;

marketing, sales and distribution;

premarket clearance and approval;

recordkeeping procedures;

advertising and promotion;

recalls and field corrective actions;

post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; and

product import and export.

Before a new medical device, or a new use of, or claim for, an existing product can be marketed in the United States, it must first receive either premarket clearance under Section 510(k) of the Federal Food, Drug and Cosmetic Act, or FDCA, or PMA, from the FDA, unless an exemption

Table of Contents

applies. In the 510(k) clearance process, the FDA must determine that the proposed device is "substantially equivalent" to a device legally on the market, known as a "predicate" device, with respect to intended use, technology and safety and effectiveness to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device for its intended use based, in part, on extensive data including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. Products that are approved through a PMA application generally need FDA approval before they can be modified. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k). Both the 510(k) and PMA processes can be expensive and lengthy and entail significant user fees, unless exempt. The FDA's 510(k) clearance process usually takes from three to 12 months, but may take longer. The PMA pathway is much more costly and uncertain than the 510(k) clearance process and it generally takes from one to three years, or even longer, from the time the application is filed with the FDA until an approval is obtained. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.

Most of our currently commercialized products have received premarket clearance under Section 510(k) of the FDCA. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline. In addition, the FDA may determine that future products will require the more costly, lengthy and uncertain PMA process. Although we do not currently market any devices under PMA, we cannot assure you that the FDA will not demand that we obtain a PMA prior to marketing or that we will be able to obtain the 510(k) clearances with respect to future products.

The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:

we may not be able to demonstrate to the FDA's satisfaction that our products are safe and effective for their intended users;

the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;

the manufacturing process or facilities we use may not meet applicable requirements; and

changes in FDA clearance or approval policies or the adoption of new regulations may require additional data.

Any delay in, or failure to receive or maintain, clearance or approval for our products under development could prevent us from generating revenue from these products or achieving profitability. Additionally, the FDA and other governmental authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could lead governmental authorities or a court to take action against us, including:

issuing untitled letters or public warning letters to us;

imposing fines and penalties on us;

obtaining an injunction preventing us from manufacturing or selling our products;

bringing civil or criminal charges against us;

delaying the introduction of our products into the market;



Table of Contents

delaying pending requests for clearance or approval of new uses or modifications to our existing products;

recalling, detaining or seizing our products; or

withdrawing or denying approvals or clearances for our products.

If we fail to obtain and maintain regulatory approvals or clearances, our ability to sell our products and generate revenues will be materially harmed.

***Outside of the United States, our medical devices must comply with the laws and regulations of the foreign countries in which they are marketed, and compliance may be costly and time-consuming.***

To market and sell our products in other countries, we must seek and obtain regulatory approvals, certifications or registrations and comply with the laws and regulations of those countries. These laws and regulations, including the requirements for approvals, certifications or registrations and the time required for regulatory review, vary from country to country. Obtaining and maintaining foreign regulatory approvals, certifications or registrations are expensive, and we cannot be certain that we will receive regulatory approvals, certifications or registrations in any foreign country in which we plan to market our products. If we fail to obtain or maintain regulatory approvals, certifications or registrations in any foreign country in which we plan to market our products, our ability to generate revenue will be harmed.

In particular, in the EEA, which is composed of the 27 Member States of the EU plus Liechtenstein, Norway and Iceland, our medical devices must comply with the essential requirements of the EU Medical Devices Directives (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, as amended, and Council Directive 90/385/EEC of 20 June 2009 relating to active implantable medical devices, as amended). Compliance with these requirements entitles us to affix the CE conformity mark to our medical devices, without which they cannot be marketed in the EEA.

Further, the advertising and promotion of our products is subject to EEA Member States laws implementing Directive 93/42/EEC concerning Medical Devices, or the EU Medical Devices Directive, Directive 2006/114/EC concerning misleading and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other EEA Member State legislation governing the advertising and promotion of medical devices. These laws may limit or restrict the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare professionals.

***Modifications to our marketed products may require new 510(k) clearances or PMAs, or may require us to cease marketing or recall the modified products until clearances are obtained.***

Any modification to a 510(k)-cleared device that could significantly affect its safety or efficacy, or that would constitute a major change in its intended use, technology, materials, packaging and certain manufacturing processes, may require a new 510(k) clearance or, possibly, a PMA. The FDA requires every manufacturer to make the determination regarding the need for a new 510(k) clearance or PMA in the first instance, but the FDA may review the manufacturer's decision. The FDA may not agree with a manufacturer's decision regarding whether a new clearance or approval is necessary for a modification, and may retroactively require the manufacturer to submit a premarket notification requesting 510(k) clearance or an application for PMA. We have made modifications to our products in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. No assurance can be given that the FDA would agree with any of our decisions not to seek 510(k) clearance or PMA. If the FDA requires us to cease marketing and recall the modified device until we obtain a new 510(k) clearance or PMA, our business, financial condition, results of operations and future growth prospects could be materially adversely affected.

Table of Contents

Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective. Any recall or FDA requirement that we seek additional approvals or clearances could result in significant delays, fines, increased costs associated with modification of a product, loss of revenue and potential operating restrictions imposed by the FDA.

***Healthcare policy changes, including the recently enacted legislation to reform the U.S. healthcare system, may have a material adverse effect on us.***

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively, the PPACA, which substantially changes the way health care is financed by both governmental and private insurers, encourages improvements in the quality of healthcare items and services, and significantly impacts the medical device industry. The PPACA includes, among other things, the following measures:

an excise tax on any entity that manufactures or imports medical devices offered for sale in the United States;

a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research;

new reporting and disclosure requirements on device manufacturers for any "transfer of value" made or distributed to prescribers and other healthcare providers, effective March 30, 2013;

payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models, beginning on or before January 1, 2013;

an independent payment advisory board that will submit recommendations to reduce Medicare spending if projected Medicare spending exceeds a specified growth rate; and

a new licensure framework for follow-on biologic products.

These provisions could meaningfully change the way healthcare is delivered and financed, and may materially impact numerous aspects of our business.

In the future there may continue to be additional proposals relating to the reform of the U.S. healthcare system. Certain of these proposals could limit the prices we are able to charge for our products, or the amounts of reimbursement available for our products, and could limit the acceptance and availability of our products. The adoption of some or all of these proposals could have a material adverse effect on our financial position and results of operations.

Additionally, initiatives sponsored by government agencies, legislative bodies and the private sector to limit the growth of healthcare costs, including price regulation and competitive pricing, are ongoing in markets where we do business. We could experience a negative impact on our operating results due to increased pricing pressure in the United States and certain other markets. Governments, hospitals and other third-party payors could reduce the amount of approved reimbursements for our products. Reductions in reimbursement levels or coverage or other cost-containment measures could unfavorably affect our future operating results.

Table of Contents

***Our financial performance may be adversely affected by medical device tax provisions in the health care reform laws.***

The PPACA imposes a deductible excise tax equal to 2.3% of the price of a medical device on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, beginning in 2013. Under these provisions, the total cost to the medical device industry is estimated to be approximately \$20 billion over 10 years. These taxes would result in a significant increase in the tax burden on our industry, which could have a material, negative impact on our results of operations and our cash flows.

***The use, misuse or off-label use of our products may harm our image in the marketplace or result in injuries that lead to product liability suits, which could be costly to our business or result in FDA sanctions if we are deemed to have engaged in such promotion.***

Our currently marketed products have been cleared by the FDA's 510(k) clearance process for use under specific circumstances. Our promotional materials and training methods must comply with FDA and other applicable laws and regulations, including the prohibition on the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside of its cleared or approved indication is known as "off-label" use. We cannot, however, prevent a surgeon from using our products or procedure for off-label use, as the FDA does not restrict or regulate a physician's choice of treatment within the practice of medicine. However, if the FDA determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine and criminal penalties. Other federal, state or foreign governmental authorities might also take action if they consider our promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of the products would be impaired. Although we train our sales force not to promote our products for off-label uses, and our instructions for use in all markets specify that our products are not intended for use outside of those indications cleared for use, the FDA or another regulatory agency could conclude that we have engaged in off-label promotion.

In addition, there may be increased risk of injury if surgeons attempt to use our products off-label. Furthermore, the use of our products for indications other than those indications for which our products have been cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among surgeons and patients. Surgeons may also misuse our products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. Product liability claims are expensive to defend and could divert our management's attention and result in substantial damage awards against us. Any of these events could harm our business and results of operations.

***If our marketed medical devices are defective or otherwise pose safety risks, the FDA and similar foreign governmental authorities could require their recall, or we may initiate a recall of our products voluntarily.***

The FDA and similar foreign governmental authorities may require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. Manufacturers may, on their own initiative, recall a product if any material deficiency in a device is found. In the past we have initiated voluntary product recalls. For example, in 2008, we recalled a small number of medical devices due to a mislabeled product. We requested FDA closure of the recall in January 2010. A government-mandated or voluntary recall by us or one of our sales agencies could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects or other deficiencies and



Table of Contents

issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations. Any recall could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers' demands. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.

In the EEA we must comply with the EU Medical Device Vigilance System, the purpose of which is to improve the protection of health and safety of patients, users and others by reducing the likelihood of reoccurrence of incidents related to the use of a medical device. Under this system, incidents must be reported to the competent authorities of the Member States of the EEA. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. Incidents are evaluated by the EEA competent authorities to whom they have been reported, and where appropriate, information is disseminated between them in the form of a National Competent Authority Reports, or NCARs. The Medical Device Vigilance System is further intended to facilitate a direct, early and harmonized implementation of Field Safety Corrective Actions, or FSCAs across the Member States of the EEA where the device is in use. An FSCA is an action taken by a manufacturer to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices.

***If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.***

Under the FDA medical device reporting regulations, or MDR, we are required to report to the FDA any incident in which our product has or may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. If we fail to report these events to the FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Any adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.

***Our manufacturing operations require us to comply with the FDA's and other governmental authorities' laws and regulations regarding the manufacture and production of medical devices, which is costly and could subject us to enforcement action.***

We and certain of our third-party manufacturers are required to comply with the FDA's Quality System Regulation, or QSR, which covers the methods of documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our products. We and certain of our suppliers are also subject to the regulations of foreign jurisdictions

Table of Contents

regarding the manufacturing process for our products marketed outside of the United States. The FDA enforces the QSR through periodic announced and unannounced inspections of manufacturing facilities. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:

- untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
- customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;
- operating restrictions or partial suspension or total shutdown of production;
- refusing or delaying our requests for 510(k) clearance or PMA of new products or modified products;
- withdrawing 510(k) clearances or PMAs that have already been granted;
- refusal to grant export approval for our products; or
- criminal prosecution.

Any of these actions could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers' demands. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.

***We are subject to substantial post-market government regulation that could have a material adverse effect on our business.***

The production and marketing of our products are subject to extensive regulation and review by the FDA and numerous other governmental authorities both in the United States and abroad. For example, in addition to other state regulatory requirements, Massachusetts, California and Arizona require compliance with the standards in industry codes such as the Code of Ethics on Interactions with Health Care Professionals issued by the Advanced Medical Technology Association (commonly known as AdvaMed), the Code on Interactions with Healthcare Professionals issued by MEDEC, the national association of Canada's medical technology companies, and international equivalents. The failure by us or one of our suppliers to comply with applicable regulatory requirements could result in, among other things, the FDA or other governmental authorities:

- imposing fines and penalties on us;
- preventing us from manufacturing or selling our products;
- delaying the introduction of our new products into the market;
- recalling or seizing our products;

Edgar Filing: Tornier B.V. - Form S-1/A

withdrawing, delaying or denying approvals or clearances for our products;

issuing warning letters or untitled letters;

imposing operating restrictions;

imposing injunctions; and

commencing criminal prosecutions.

Table of Contents

Failure to comply with applicable regulatory requirements could also result in civil actions against us and other unanticipated expenditures. If any of these actions were to occur it would harm our reputation and cause our product sales to suffer and may prevent us from generating revenue.

***The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.***

Our ongoing research and development, pre-clinical testing and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting post-market clinical studies of some of our products to gather additional information about these products' safety, efficacy or optimal use. In the future we may conduct clinical trials to support approval of new products. Clinical studies must be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support market clearance for these products. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate's profile.

***If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products.***

We often must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.

***Federal regulatory reforms may adversely affect our ability to sell our products profitably.***

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of a medical device. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

Table of Contents

*We may be subject to or otherwise affected by federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, and could face substantial penalties if we are unable to fully comply with such laws.*

Although we do not provide healthcare services, submit claims for third-party reimbursement, or receive payments directly from Medicare, Medicaid or other third-party payors for our products or the procedures in which our products are used, healthcare regulation by federal and state governments could significantly impact our business. Healthcare fraud and abuse and health information privacy and security laws potentially applicable to our operations include:

the federal Anti-Kickback Law, which constrains our marketing practices and those of our independent sales agencies, educational programs, pricing policies and relationships with healthcare providers, by prohibiting, among other things, soliciting, receiving, offering or providing remuneration, intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare or Medicaid programs;

federal false claims laws which prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and its implementing regulations, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain regulatory and contractual requirements regarding the privacy, security and transmission of individually identifiable health information; and

state laws analogous to each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of certain health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

If our past or present operations, or those of our independent sales agencies, are found to be in violation of any of such laws or any other governmental regulations that may apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from federal healthcare programs and the curtailment or restructuring of our operations. Similarly, if the healthcare providers or entities with whom we do business are found to be non-compliant with applicable laws, they may be subject to sanctions, which could also have a negative impact on us. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Further, the recently enacted PPACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Any action against us for violation of these laws, even if we successfully defend against them, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business.

The PPACA also imposes new reporting and disclosure requirements on device and drug manufacturers for any "transfer of value" made or distributed to prescribers and other healthcare

Table of Contents

providers, effective March 30, 2013. Such information will be made publicly available in a searchable format beginning September 30, 2013. In addition, device and drug manufacturers will also be required to report and disclose any investment interests held by physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties of up to an aggregate of \$150,000 per year (and up to an aggregate of \$1 million per year for "knowing failures"), for all payments, transfers of value or ownership or investment interests not reported in an annual submission.

Governments and regulatory authorities have increased their enforcement of these health care fraud and abuse laws in recent years. For example, in 2007 five competitors in the orthopaedics industry settled a Department of Justice investigation into the financial relationships and consulting agreements between the companies and surgeons. The companies agreed to new corporate compliance procedures and federal monitoring. At issue were financial inducements designed to encourage physicians to use the payor company's products exclusively and the failure of physicians to disclose these relationships to hospitals and patients. Individual states may also be investigating the relationship between healthcare providers and companies in the orthopaedics industry. Many states have their own regulations governing the relationship between companies and health care providers. While we have not been the target of any investigations, we cannot guarantee that we will not be investigated in the future. If investigated we cannot assure that the costs of defending or resolving those investigations or proceedings would not have a material adverse effect on our financial condition, results of operations and cash flows.

***Failure to obtain and maintain regulatory approval in foreign jurisdictions will prevent us from marketing our products abroad.***

We currently market, and intend to continue to market, our products internationally. Outside the United States, we can market a product only if we receive a marketing authorization and, in some cases, pricing approval, from the appropriate regulatory authorities. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA clearance or approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA clearance or approval in addition to other risks. For example, in order to market our products in the Member States of the EEA, our devices are required to comply with the essential requirements of the EU Medical Devices Directives (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, as amended, and Council Directive 90/385/EEC of 20 June 2009 relating to active implantable medical devices, as amended). Compliance with these requirements entitles us to affix the CE conformity mark to our medical devices, without which they cannot be commercialized in the EEA. In order to demonstrate compliance with the essential requirements and obtain the right to affix the CE conformity mark we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low risk medical devices (Class I), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the Medical Devices Directives, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization accredited by a Member State of the EEA to conduct conformity assessments. The Notified Body would typically audit and examine the quality system for the manufacture, design and final inspection of our devices before issuing a certification demonstrating compliance with the essential requirements. Based on this certification we can draw up an EC Declaration of Conformity, which allows us to affix the CE mark to our products.

We may not obtain foreign regulatory approvals or certifications on a timely basis, if at all. Clearance or approval by the FDA does not ensure approval or certification by regulatory authorities or Notified Bodies in other countries, and approval or certification by one foreign regulatory authority or Notified Body does not ensure approval by regulatory authorities in other foreign countries or by

Table of Contents

the FDA. We may be required to perform additional pre-clinical or clinical studies even if FDA clearance or approval, or the right to bear the CE mark, has been obtained. If we fail to receive necessary approvals to commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, financial condition and results of operations could be adversely affected.

***Our existing xenograft-based orthobiologics business is and any future orthobiologics products we pursue would be subject to emerging governmental regulations that could materially affect our business.***

Some of our products are xenograft, or animal-based, tissue products. Our principal xenograft-based orthobiologics offering is Conexa reconstructive tissue matrix. All of our current xenograft tissue-based products are regulated as medical devices and are subject to the FDA's medical device regulations.

While we do not currently offer any products based on human tissue, in the future we may offer orthobiologics products based on human tissue. The FDA has statutory authority to regulate human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient, including allograft-based products. The FDA, EU and Health Canada have been working to establish more comprehensive regulatory frameworks for allograft-based, tissue-containing products, which are principally derived from cadaveric tissue.

Section 361 of the Public Health Service Act, or PHS Act, authorizes the FDA to issue regulations to prevent the introduction, transmission or spread of communicable disease. HCT/Ps regulated as 361 HCT/Ps are subject to requirements relating to: registering facilities and listing products with the FDA; screening and testing for tissue donor eligibility; Good Tissue Practice, or GTP, when processing, storing, labeling and distributing HCT/Ps, including required labeling information; stringent recordkeeping; and adverse event reporting. The FDA has also proposed extensive additional requirements that address sub-contracted tissue services, tracking to the recipient/patient, and donor records review. If a tissue-based product is considered human tissue, the FDA requirements focus on preventing the introduction, transmission and spread of communicable diseases to recipients. A product regulated solely as a 361 HCT/P is not required to undergo premarket clearance or approval.

The FDA may inspect facilities engaged in manufacturing 361 HCT/Ps and may issue untitled letters, warning letters, or otherwise authorize orders of retention, recall, destruction and cessation of manufacturing if the FDA has reasonable grounds to believe that an HCT/P or the facilities where it is manufactured are in violation of applicable regulations. There are also requirements relating to the import of HCT/Ps that allow the FDA to make a decision as to the HCT/Ps' admissibility into the United States.

An HCT/P is eligible for regulation solely as a 361 HCT/P if it is: minimally manipulated; intended for homologous use as determined by labeling, advertising or other indications of the manufacturer's objective intent for a homologous use; the manufacture does not involve combination with another article, except for water, crystalloids or a sterilizing, preserving, or storage agent (not raising new clinical safety concerns for the HCT/P); and it does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function or, if it has such an effect, it is intended for autologous use or allogeneic use in close relatives or for reproductive use. If any of these requirements are not met, then the HCT/P is also subject to applicable biologic, device, or drug regulation under the FDCA or the PHS Act. These biologic, device or drug HCT/Ps must comply both with the requirements exclusively applicable to 361 HCT/Ps and, in addition, with requirements applicable to biologics under the PHS Act, or devices or drugs under the FDCA, including premarket licensure, clearance or approval.

Title VII of the PPACA, the Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates a new licensure framework for follow-on biologic products, which could ultimately

Table of Contents

subject our orthobiologics business to competition to so-called "biosimilars." Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a referenced, branded biologic product. Previously, there had been no licensure pathway for such a follow-on product. While we do not anticipate that the FDA will license a follow-on biologic for several years, given the need to generate data sufficient to demonstrate "biosimilarity" to or "interchangeability" with the branded biologic according to criteria set forth in the BPCIA, as well as the need for the FDA to implement the BPCIA's provisions with respect to particular classes of biologic products, we cannot guarantee that our orthobiologics will not eventually become subject to direct competition by a licensed "biosimilar."

Procurement of certain human organs and tissue for transplantation, including allograft tissue we may use in future products, is subject to federal regulation under the National Organ Transplant Act, or NOTA. NOTA prohibits the acquisition, receipt, or other transfer of certain human organs, including bone and other human tissue, for valuable consideration within the meaning of NOTA. NOTA permits the payment of reasonable expenses associated with the removal, transportation, implantation, processing, preservation, quality control and storage of human organs. For any future products implicating NOTA's requirements, we would reimburse tissue banks for their expenses associated with the recovery, storage and transportation of donated human tissue that they would provide to us for processing. NOTA payment allowances may be interpreted to limit the amount of costs and expenses that we may recover in our pricing for our products, thereby negatively impacting our future revenue and profitability. If we were to be found to have violated NOTA's prohibition on the sale or transfer of human tissue for valuable consideration, we would potentially be subject to criminal enforcement sanctions, which could materially and adversely affect our results of operations. Further, in the future, if NOTA is amended or reinterpreted, we may not be able to pass these expenses on to our customers and, as a result, our business could be adversely affected.

***Our operations involve the use of hazardous materials, and we must comply with environmental health and safety laws and regulations, which can be expensive and may affect our business and operating results.***

We are subject to a variety of laws and regulations of the countries in which we operate and distribute products, such as the European Union, or EU, France, Ireland, other European nations and the United States, relating to the use, registration, handling, storage, disposal, recycling and human exposure to hazardous materials. Liability under environmental laws can be joint and several and without regard to comparative fault, and environmental, health and safety laws could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations, which could harm our business. In the EU, where our manufacturing facilities are located, we and our suppliers are subject to EU environmental requirements such as the Registration, Evaluation, Authorisation and Restriction of Chemicals, or REACH, regulation. In addition, we are subject to the environmental, health and safety requirements of individual European countries in which we operate such as France and Ireland. For example, in France, requirements known as the Installations Classée pour la Protection de l'Environnement regime provide for specific environmental standards related to industrial operations such as noise, water treatment, air quality and energy consumption. In Ireland, our manufacturing facilities are likewise subject to local environmental regulations, such as related to water pollution and water quality, that are administered by the Environmental Protection Agency. We believe that we are in material compliance with all applicable environmental, health and safety requirements in the countries in which we operate and do not have reason to believe that we are responsible for any cleanup liabilities. In addition, certain hazardous materials are present at some of our facilities, such as asbestos, that we believe are managed in compliance with all applicable laws. We are also subject to greenhouse gas regulations in the EU and elsewhere and we believe that we are in compliance based on present emissions levels at our facilities. Although we believe that our activities conform in all material respects with applicable environmental, health and safety laws, we cannot assure you that violations of such laws will not arise as a result of



Table of Contents

human error, accident, equipment failure, presently unknown conditions or other causes. The failure to comply with past, present or future laws, including potential laws relating to climate control initiatives, could result in the imposition of fines, third-party property damage and personal injury claims, investigation and remediation costs, the suspension of production or a cessation of operations. In particular, in relation to our manufacturing facility located in Saint-Ismier, France, we do not have a final agreement and/or authorization to discharge wastewater to the local community wastewater treatment system, which could notably lead to fines, civil liability, and/or reduced throughput. As has been standard practice for plants in the area, we believe that we obtained an informal authorization from local authorities to connect to the wastewater discharge network at the time we first made our connection in 2003. Since 2006, when formal authority over such matters was assumed by the *Syndicat Intercommunal de la Zone Vert* (SIZOV), we have been seeking a final agreement and/or authorization from SIZOV. As with the other plants in the area, we have not yet been able to obtain such final agreement and/or authorization because SIZOV is still in the process of developing its wastewater discharge standards for any plant that would fall within its jurisdiction. Recently, we have been able to engage in active discussions with SIZOV, and we anticipate obtaining a discharge agreement/authorization in the next year. We also expect that our operations will be affected by other new environmental and health and safety laws, including laws relating to climate control initiatives, on an ongoing basis. Although we cannot predict the ultimate impact of any such new laws, they could result in additional costs and may require us to change how we design, manufacture or distribute our products, which could have a material adverse effect on our business.

**Risks Relating to Our Ordinary Shares and this Offering**

*An active trading market for our ordinary shares may not develop and the trading price for our ordinary shares may fluctuate significantly.*

We applied to list our ordinary shares on the NASDAQ Global Market. Prior to the completion of this offering, there has been no public market for our ordinary shares, and there is no guarantee that a liquid public market for our ordinary shares will develop. If an active public market for our ordinary shares does not develop following the completion of this offering, the market price and liquidity of our ordinary shares may be materially and adversely affected. The initial public offering price for our ordinary shares will be determined by negotiation between us and the underwriters based upon several factors, and we can provide no assurance that the trading price of our ordinary shares after this offering will not decline below the initial public offering price. As a result, investors in our ordinary shares may experience a significant decrease in the value of their investment.

*The trading prices of our ordinary shares are likely to be volatile, which could result in substantial losses to investors.*

The trading prices of our ordinary shares are likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, like the performance and fluctuation of the market prices of other companies with business operations located mainly in Europe that have listed their securities in the United States. A number of European companies have listed or are in the process of listing their securities on U.S. stock markets. The securities of some of these companies have experienced significant volatility, including price declines in connection with their initial public offerings. The trading performances of these European companies' securities after their offerings may affect the attitudes of investors toward European companies listed in the United States in general and consequently may impact the trading performance of our ordinary shares, regardless of our actual operating performance.

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

In addition to market and industry factors, the price and trading volume for our ordinary shares may be highly volatile for factors specific to our own operations, including the following:

variations in our revenue, earnings and cash flow;

announcements of new investments, acquisitions, strategic partnerships or joint ventures;

announcements of new services and expansions by us or our competitors;

changes in financial estimates by securities analysts;

additions or departures of key personnel;

release of lock-up or other transfer restrictions on our outstanding equity securities or sales of additional equity securities;

potential litigation or regulatory investigations; and

fluctuations in market prices for our products.

Any of these factors may result in large and sudden changes in the volume and price at which our ordinary shares will trade. In the past, shareholders of a public company often brought securities class action suits against the company following periods of instability in the market price of that company's securities. If we were involved in a class action suit, it could divert a significant amount of our management's attention and other resources from our business and operations, which could harm our results of operations and require us to incur significant expenses to defend the suit. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.

***We have in the past and may in the future experience deficiencies, including material weaknesses, in our internal control over financial reporting. Our business and our share price may be adversely affected if we do not remediate these material weaknesses or if we have other weaknesses in our internal controls.***

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. A material weakness, as defined in the standards established by the Public Company Accounting Oversight Board, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. In connection with the audit of our financial statements for 2009, we identified a material weakness in our internal control over financial reporting relating to our audited financial statements for fiscal years 2007 and 2008. Specifically, in our case, management and our independent registered accounting firm have determined that internal controls over identifying, evaluating and documenting accounting analysis and conclusions over complex non-routine transactions, including related-party transactions, require strengthening. Although we implemented initiatives aimed at addressing this material weakness, these initiatives may not remediate the identified material weakness. Our management and independent registered public accounting firm did not perform an evaluation of our internal control over financial reporting during any period in accordance with the provisions of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act. Going forward, as a public company, absent an available exemption, we will be required to comply with Section 404 of the Sarbanes-Oxley Act by no later than December 31, 2011. Had we and our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional control deficiencies may have been identified by management or our independent registered public



Table of Contents

accounting firm, and those control deficiencies could have also represented one or more material weaknesses. We cannot be certain as to when we will be able to implement the requirements of Section 404 of the Sarbanes-Oxley Act. If we fail to implement the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory agencies such as the SEC. In addition, failure to comply with Section 404 or the report by us of a material weakness may cause investors to lose confidence in our financial statements, and the trading price of our ordinary shares may decline. If we fail to remedy any material weakness, our financial statements may be inaccurate, our access to the capital markets may be restricted and the trading price of our ordinary shares may decline.

***If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our ordinary shares, the market price for our ordinary shares and trading volume could decline.***

The trading market for our ordinary shares will be influenced by research or reports that industry or securities analysts publish about us or our business. If one or more analysts who cover us downgrade our ordinary shares, the market price for our ordinary shares would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our ordinary shares to decline.

***The sale or availability for sale of substantial amounts of our ordinary shares could adversely affect their market price.***

Sales of substantial amounts of our ordinary shares in the public market after the completion of this offering, or the perception that these sales could occur, could adversely affect the market price of our ordinary shares and could materially impair our ability to raise capital through equity offerings in the future. The ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, and shares held by our existing shareholders may also be sold in the public market in the future subject to the restrictions in Rule 144 and Rule 701 under the Securities Act and the applicable lock-up agreements. There will be \_\_\_\_\_ ordinary shares outstanding immediately after this offering, or \_\_\_\_\_ ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full. In connection with this offering, we and our officers, directors and certain of our shareholders have agreed not to sell any ordinary shares for 180 days after the date of this prospectus without the prior written consent of the underwriters. Upon expiration of these agreements with our officers, directors and certain of our shareholders, there will be an additional \_\_\_\_\_ ordinary shares that may be sold on the public market without restriction. However, the underwriters may release these securities from these restrictions at any time, subject to applicable regulations of the Financial Industry Regulatory Authority, Inc., or FINRA. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the availability of these securities for future sale will have on the market price of our ordinary shares.

***You will experience immediate and substantial dilution.***

The initial public offering price is substantially higher than the as adjusted net tangible book value of each outstanding ordinary share immediately after this offering. As a result, purchasers of our ordinary shares in this offering will suffer immediate and substantial dilution. Based on an assumed initial public offering price of \$ \_\_\_\_\_ per ordinary share, the midpoint of the range set forth on the cover page of this prospectus, and our as adjusted net tangible book value as of April 4, 2010, the dilution will be \$ \_\_\_\_\_ per share to new investors in this offering. If the underwriters sell additional

Table of Contents

shares following the exercise of their option to purchase additional shares or if option holders exercise outstanding options to purchase ordinary shares, further dilution could occur.

***We are a Netherlands company, and it may be difficult for you to obtain or enforce judgments against us or our executive officers, some of our directors and some of our named experts in the United States.***

We were formed under the laws of The Netherlands and, as such, the rights of holders of our ordinary shares and the civil liability of our directors will be governed by Dutch laws and our amended articles of association. The rights of shareholders under the laws of The Netherlands may differ from the rights of shareholders of companies incorporated in other jurisdictions. Some of the named experts referred to in this prospectus are not residents of the United States, and certain of our directors and our executive officers and most of our assets and some of the assets of our directors are located outside the United States. As a result, you may not be able to serve process on us or on such persons in the United States or obtain or enforce judgments from U.S. courts against them or us based on the civil liability provisions of the securities laws of the United States. There is doubt as to whether Dutch courts would enforce certain civil liabilities under U.S. securities laws in original actions or enforce claims for punitive damages.

Under our amended articles of association, we indemnify and hold our directors harmless against all claims and suits brought against them, subject to limited exceptions. Although there is doubt as to whether U.S. courts would enforce such provision in an action brought in the United States under U.S. securities laws, such provision could make enforcing judgments obtained outside of The Netherlands more difficult to enforce against our assets in The Netherlands or jurisdictions that would apply Dutch law.

***Your rights as a holder of ordinary shares will be governed by Dutch law and will differ from the rights of shareholders under U.S. law.***

We are a public limited liability company incorporated under Dutch law. The rights of holders of ordinary shares are governed by Dutch law and our amended articles of association. These rights differ from the typical rights of shareholders in U.S. corporations. For example, Dutch law significantly limits the circumstances under which shareholders of Dutch companies may bring an action on behalf of a company.

***We have not determined a specific use for a portion of the net proceeds from this offering, and we may use these proceeds in ways with which you may not agree.***

We have not determined a specific use for a portion of the net proceeds of this offering, and our management will have considerable discretion in deciding how to apply these proceeds. You will not have the opportunity to assess whether the proceeds are being used appropriately before you make your investment decision. You must rely on the judgment of our management regarding the application of the net proceeds of this offering. There is no guarantee that the net proceeds will be used in a manner that would improve our results of operations or increase the price of our ordinary shares, nor that these net proceeds will be placed only in investments that generate income or appreciate in value.

***We do not anticipate paying dividends on our ordinary shares.***

We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. Our board of directors has complete discretion as to whether to distribute dividends. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and

Table of Contents

other factors that the board of directors may deem relevant. Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars.

***We will incur increased costs as a result of being a public company.***

Upon completion of this offering, we will become a public company and expect to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and the NASDAQ Global Market, imposes various requirements on the corporate governance practices of public companies. We expect these rules and regulations to increase our legal and financial compliance costs and to make some corporate activities more time-consuming and costly. For example, as a result of becoming a public company, we will need to adopt policies regarding internal controls and disclosure controls and procedures. In addition, we will incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount of additional costs we may incur or the timing of such costs.

***WP Bermuda and its affiliates, our major shareholder, will control approximately % of our ordinary shares after this offering, and this concentration of ownership may deter a change in control or other transaction that is favorable to our shareholders.***

Upon completion of this offering, WP Bermuda and its affiliates, or Warburg Pincus, will, in the aggregate, beneficially own approximately % of our outstanding ordinary shares, or approximately % if the underwriters exercise their overallotment option in full. These shareholders could effectively control all matters requiring our shareholders' approval, including the election of directors. This concentration of ownership may also cause, delay, deter or prevent a change in control, and may make some transactions more difficult or impossible to complete without the support of these shareholders, regardless of the impact of this transaction on our other shareholders. In addition, our Securityholders' Agreement, as we currently contemplate amending prior to the consummation of the offering, will give Warburg Pincus and its affiliates the right to nominate three of the eight directors to our board of directors for so long as Warburg Pincus beneficially owns more than 25% of the outstanding shares, two of the eight directors for so long as Warburg Pincus beneficially owns more than 10% of the outstanding shares and one of the eight directors for so long as Warburg Pincus beneficially owns more than 5% of the outstanding shares. For more information regarding the Securityholders' Agreement please refer to the discussion under "Related Party Transactions."

***After this offering, we may be considered a "controlled company" within the meaning of the NASDAQ listing requirements and, as a result, would qualify for exemptions from certain corporate governance requirements.***

Warburg Pincus may own more than 50% of the voting power of our ordinary shares after this offering, and if so, we would be considered to be a "controlled company" for the purposes of the NASDAQ listing requirements. Under the NASDAQ listing requirements, a "controlled company" is permitted to opt out of the provisions that would otherwise require (i) our board of directors to be comprised of a majority of independent directors, (ii) compensation of our officers to be determined or recommended to the board of directors by a majority of its independent directors or by a compensation committee that is composed entirely of independent directors and (iii) director nominees to be selected or recommended for selection by a majority of the independent directors or by a nominating committee composed solely of independent directors. Although we intend to comply with these listing requirements whether or not we are a controlled company, there is no guarantee that we will not take advantage of these exemptions in the future. Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to all of the NASDAQ corporate governance requirements.

Table of Contents

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA**

This prospectus contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

You can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements about:

our growth strategies;

our future business development, results of operations and financial condition;

expected changes in our revenue and certain cost or expense items;

our ability to develop new products and attract customers;

our ability to protect our intellectual property rights;

our expectation regarding the use of proceeds from this offering; and

assumptions underlying or related to any of the foregoing.

You should read thoroughly this prospectus and the documents that we refer to in this prospectus with the understanding that our actual future results may be materially different from and worse than what we expect. Other sections of this prospectus include additional factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

You should not rely upon forward-looking statements as predictions of future events. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Unless otherwise indicated, information contained in this prospectus concerning the global orthopaedic medical device industry, the extremities sub-markets and geographic breakdown, and our and our competitors' market shares, is based on information from independent industry analysts and third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and markets, which we believe to be reasonable. Other than Millennium Research Group, which prepared a report at our request and expense, none of the sources cited in this prospectus have consented to the inclusion of any data from their reports, nor have we sought their consent. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed under the heading "Risk Factors."

Table of Contents**USE OF PROCEEDS**

We estimate that we will receive net proceeds from this offering of approximately \$ million after deducting underwriting discounts and the estimated offering expenses payable by us. If the underwriters exercise their overallotment option in full, we estimate that we will receive net proceeds of approximately \$ million. These estimates are based upon an assumed initial public offering price of \$ per share, the mid-point of the range shown on the front cover page of this prospectus. A \$1.00 increase or decrease in the assumed initial public offering price of \$ per ordinary share would increase or decrease, as applicable, the net proceeds of this offering by \$ million, assuming the sale of ordinary shares at \$ per share, the mid-point of the range shown on the front cover page of this prospectus and after deducting underwriting discounts and the estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0 million ordinary shares in the number of ordinary shares offered by us would increase or decrease the net proceeds to us from this offering by approximately \$ million, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting discounts and estimated offering expenses payable by us.

We intend to use the net proceeds received by us from this offering:

to repay all of the existing indebtedness under our notes payable, including accrued interest thereon, payable of approximately €80.7 million, or \$108.7 million at the exchange rate as of April 4, 2010; and

for general corporate purposes.

The notes payable we intend to repay are (i) the €37,000,000 promissory note due March 31, 2014, issued pursuant to a loan note instrument, dated April 3, 2009, between us and certain shareholders named therein; and (ii) the €34,500,000 promissory note due February 28, 2013, issued pursuant to a loan note instrument, dated February 29, 2008, between us and certain shareholders named therein. The notes carry a fixed interest rate of 8.0% per annum with interest payments accrued in kind semi-annually. The following table identifies our affiliates that hold notes and the amounts they own. We intend to repay these note amounts, plus any accrued interest thereon, with a portion of the proceeds from this offering:

Amounts held by our affiliates under the €37,000,000 promissory note due March 31, 2014:

Amounts held by our affiliates under the €34,500,000 promissory note due February 28, 2013:

Affiliate	Note amount	Affiliate	Note amount
Warburg Pincus (Bermuda) Private Equity IX, L.P	€ 11,204,000	Warburg Pincus (Bermuda) Private Equity IX, L.P	€ 24,700,000
KCH Stockholm AB	€ 2,400,000	KCH Stockholm AB	€ 3,500,000
Amy and Richard F. Wallman	€ 260,000	Vertical Fund I, L.P	€ 3,153,000
Douglas W. Kohrs	€ 258,000	Vertical Fund II, L.P	€ 929,000
Ralph E. Barisano, Jr.	€ 45,000	Douglas W. Kohrs	€ 562,000
Stephan Epinette	€ 30,000	Diane Doty	€ 166,000
Diane Doty	€ 18,000	Ralph E. Barisano	€ 26,000
		Jamal D. Rushdy	€ 26,000
		James C. Harber	€ 19,000
		James E. Kwan	€ 7,000

We may also use a portion of the net proceeds to acquire other businesses, products or technologies. Our management will have significant flexibility in applying the net proceeds of the offering. If an unforeseen event occurs or business conditions change, we may use the proceeds of this offering differently than as described in this prospectus.





Table of Contents

**DIVIDEND POLICY**

We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business.

Our board of directors has complete discretion as to whether to distribute dividends. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars.

Table of Contents**CAPITALIZATION**

The following table sets forth our cash and cash equivalents and our total capitalization as of April 4, 2010:

on an actual basis; and

on an as adjusted basis to reflect the sale of            ordinary shares by us in this offering at an assumed initial public offering price of \$            per ordinary share, the mid-point of the range set forth on the front cover of this prospectus, after deducting the underwriting discounts and estimated offering expenses payable by us.

You should read this table together with our consolidated financial statements and the related notes included elsewhere in this prospectus and the information under "Management's Discussion and Analysis of Financial Condition and Results of Operations."

	<b>As of April 4, 2010</b>	
	<b>Actual</b>	<b>As adjusted</b>
	<b>(in thousands, except share data)</b>	
	<b>(unaudited)</b>	
Cash and cash equivalents	\$ 38,311	
Long-term debt, including current maturities:		
Notes payable	70,095	
Other long-term debt	47,615	
Total debt	\$ 117,710	
Warrant liabilities	85,068	
Shareholders' equity:		
Ordinary shares, \$0.01 par value, 300,000,000 shares authorized; 77,186,382 shares issued and outstanding, actual;            shares issued and outstanding, as adjusted	1,012	
Additional paid-in capital	368,681	
Accumulated deficit	(154,074)	
Accumulated other comprehensive income	13,873	
Total shareholders' equity	229,492	
Total capitalization	\$ 432,270	

Each \$1.00 increase or decrease in the assumed initial public offering price of \$            per ordinary share, the mid-point of the price range set forth on the cover page of this prospectus, would increase or decrease each of the as adjusted cash and cash equivalents, additional paid-in-capital, total shareholders' equity and total capitalization by \$            million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0 million ordinary shares in the number of ordinary shares offered by us would increase or decrease each of the as adjusted cash and cash equivalents, additional paid-in-capital, total shareholders' equity and total capitalization by \$            million, assuming that the assumed public offering price remains the same, and after deducting the estimated underwriting discounts and estimated offering expenses payable by us.



## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

The number of ordinary shares to be outstanding after this offering is based on 88,703,258 ordinary shares outstanding as of July 4, 2010, and excludes:

10,551,479 ordinary shares issuable upon exercise of outstanding options to purchase ordinary shares as of July 4, 2010, at a weighted average exercise price of \$5.53 per ordinary share; and

4,291,592 ordinary shares reserved for future issuance under our stock option plan as of July 4, 2010.

Table of Contents**DILUTION**

If you invest in our ordinary shares, your interest will be diluted immediately to the extent of the difference between the public offering price per ordinary share you will pay in this offering and the as adjusted net tangible book value per ordinary share immediately after this offering.

Our net tangible book value as of July 4, 2010, was approximately \_\_\_\_\_ per ordinary share. Net tangible book value per ordinary share represents the amount of total tangible assets, minus the amount of total liabilities, divided by the total number of ordinary shares outstanding. Dilution is determined by subtracting net tangible book value per ordinary share from the assumed public offering price per ordinary share.

Without taking into account any other changes in such net tangible book value after July 4, 2010, our as adjusted net tangible book value at July 4, 2010, would have been \$ \_\_\_\_\_ per ordinary share, after giving effect to the sale of \_\_\_\_\_ ordinary shares in this offering at an assumed initial public offering price of \$ \_\_\_\_\_ per share, the mid-point of range set forth on the cover page of this prospectus, and after deducting underwriting discounts and estimated offering expenses payable by us. This represents an immediate increase in as adjusted net tangible book value of \$ \_\_\_\_\_ per ordinary share to existing shareholders and immediate dilution of \$ \_\_\_\_\_ per ordinary share to new investors in this offering.

The following table illustrates the dilution on a per ordinary share basis:

Assumed initial public offering price per ordinary share	\$ _____
Net tangible book value per ordinary share	\$ _____
Increase per ordinary share attributable to this offering	\$ _____

As adjusted net tangible book value per ordinary share after this offering

Dilution per ordinary share to new investors in the offering	\$ _____
--	----------

A \$1.00 increase or decrease in the assumed public offering price of \$ \_\_\_\_\_ per ordinary share would increase or decrease our as adjusted net tangible book value by approximately \$ \_\_\_\_\_ million, or \$ \_\_\_\_\_ per ordinary share, and the as adjusted dilution per share to investors in this offering by approximately \$ \_\_\_\_\_ per ordinary share, assuming no change to the number of ordinary shares offered by us as set forth on the cover page of this prospectus, and after deducting underwriting discounts and the estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase or decrease of 1.0 million ordinary shares in the number of ordinary shares offered by us would increase or decrease our as adjusted net tangible book value by approximately \$ \_\_\_\_\_ million, or \$ \_\_\_\_\_ per ordinary share, and the as adjusted dilution per share to investors in this offering by approximately \$ \_\_\_\_\_ per ordinary share assuming no change to the number of ordinary shares offered by us as set forth on the cover page of this prospectus, and after deducting underwriting discounts and the estimated offering expenses payable by us. The as adjusted information discussed above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based on the actual initial public offering price of our ordinary shares and other terms of this offering determined at pricing.

If the underwriters exercise their overallotment option in full, our as adjusted net tangible book value at July 4, 2010 would be \$ \_\_\_\_\_ million, or \$ \_\_\_\_\_ per ordinary share, representing an immediate increase to existing shareholders of \$ \_\_\_\_\_ per ordinary share and immediate dilution of \$ \_\_\_\_\_ per share to new investors in this offering.

The following table summarizes, on an as adjusted basis as of July 4, 2010, the differences between our existing shareholders as of July 4, 2010 and the new investors in this offering with respect to the number of ordinary shares purchased from us, the total consideration paid and the average price

Table of Contents

per ordinary share paid at an assumed initial public offering price of \$      per share, the mid-point of the range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and estimated offering expenses payable by us.

	Ordinary shares purchased		Total consideration		Average price per ordinary share
	Number	Percent	Amount	Percent	
Existing shareholders					
New investors					
<b>Total</b>					

A \$1.00 increase or decrease in the assumed public offering price of \$      per ordinary share would increase or decrease total consideration paid by new investors, total consideration paid by all shareholders and average price per ordinary share paid by all shareholders \$      , \$      and \$      , respectively, assuming the sale of      ordinary shares at \$      per share, the mid-point of the range set forth on the cover page of this prospectus, and after deducting underwriting discounts and estimated offering expenses payable by us.

If the underwriters exercise their option to purchase additional shares in full, the number of ordinary shares beneficially owned by existing shareholders would decrease to approximately      , or approximately      % of the total number of ordinary shares outstanding after this offering, and the number of shares held by new investors will be increased to      shares, or approximately      % of the total number of ordinary shares outstanding after this offering.

The tables and calculations above are based on 88,703,258 ordinary shares outstanding as of July 4, 2010, and excludes:

10,551,479 ordinary shares issuable upon exercise of outstanding options to purchase ordinary shares as of July 4, 2010, at a weighted average exercise price of \$5.53 per ordinary share; and

4,291,592 ordinary shares reserved for future issuance under our stock option plan as of July 4, 2010.

The table and calculations above excludes ordinary shares reserved for future issuance. To the extent the options are exercised and awards are granted under these plans, there may be dilution to our shareholders. We may also choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders.

Table of Contents

**SELECTED CONSOLIDATED FINANCIAL DATA**

The following table sets forth our selected historical consolidated financial information. The selected historical consolidated statements of operations data and other financial data for the years ended December 31, 2007, December 28, 2008, and December 27, 2009, and the selected historical balance sheet data as of December 28, 2008, and December 27, 2009, have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The summary historical consolidated balance sheet data as of December 31, 2007, have been derived from our audited consolidated financial statements not included in this prospectus. The selected historical consolidated statements of operations data and other financial data for the period from July 18, 2006, to December 31, 2006, and the selected historical balance sheet data as of December 31, 2006, were derived from the audited consolidated financial statements not included in this prospectus. The consolidated financial statements referred to in the previous three sentences have been audited by Ernst & Young LLP, an independent registered public accounting firm, and were prepared in accordance with U.S. GAAP. On July 18, 2006, we were acquired by the Investor Group. Selected financial data as of December 31, 2005, and for the periods January 1, 2005, to December 31, 2005, and January 1, 2006, to July 18, 2006, has not been presented because it is not available and cannot be created without unreasonable effort and expense. Furthermore, we believe that financial data for the periods January 1, 2005, to December 31, 2005, and January 1, 2006, to July 18, 2006, does not significantly contribute to an investor's understanding of our historical financial performance and financial condition because of our acquisition and adoption of uniform accounting standards on July 18, 2006.

Our selected historical consolidated statement of operations data and other financial data for the 13 weeks ended March 29, 2009, and 14 weeks ended April 4, 2010, and the selected historical balance sheet data as of April 4, 2010, have been derived from our unaudited consolidated financial statements included elsewhere in this prospectus. The March 29, 2009, and April 4, 2010, unaudited financial statements have been prepared on a basis consistent with our audited consolidated financial statements and reflect all adjustments, consisting of normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the financial position and results of operations for the periods presented. The results of any interim period are not necessarily indicative of the results that may be expected for any other interim period or for the full fiscal year, and the historical results set forth below do not necessarily indicate results expected for any future period.

Our fiscal quarters are generally determined on a 13-week basis and always end on a Sunday. As a result, our fiscal year is generally 364 days. Our year-end periods end on the Sunday nearest to December 31. Every few years, it is necessary to add an extra week to a quarter to make it a 14-week period in order to have our year end fall on the Sunday nearest to December 31. For example, the first quarter of 2010 includes an extra week of operations compared to the first quarter of 2009. For the purposes of this prospectus, references to:

2007 and our 2007 fiscal year refer to the fiscal year ended December 31, 2007;

2008 and our 2008 fiscal year refer to the fiscal year ended December 28, 2008;

2009 and our 2009 fiscal year refer to the fiscal year ended December 27, 2009;

The first quarter of 2009 refers to the 13-week period ended March 29, 2009; and

The first quarter of 2010 refers to the 14-week period ended April 4, 2010.



Edgar Filing: Tornier B.V. - Form S-1/A

Table of Contents

The information presented below should be read together with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and the notes thereto included elsewhere in this prospectus.

	Period from July 18, 2006 to December 31, 2006		Year ended December 31, December 28, 2007 2008		December 27, 2009		First quarter ended March 29, 2009		April 4, 2010			
	(in thousands, except per share data)						(unaudited) (unaudited) (in thousands, except per share data)					
<b>Statement of Operations Data:</b>												
Revenue	\$	46,158	\$	145,369	\$	177,370	\$	201,462	\$	50,855	\$	61,843
Cost of goods sold		20,959		49,959		49,085		58,472		14,690		18,365
Gross profit		25,199		95,410		128,285		142,990		36,165		43,478
Sales and marketing		20,497		78,628		103,285		112,017		26,854		33,381
General and administrative		9,118		17,976		21,742		20,790		5,213		6,526
Research and development		1,730		13,305		20,635		18,120		4,725		4,813
Amortization of intangible assets		2,272		7,946		11,186		15,173		2,615		2,997
Special charges								1,864				224
In-process research and development		9,649		15,107								
Operating loss		(18,067)		(37,552)		(28,563)		(24,974)		(3,242)		(4,463)
Interest expense		(828)		(2,394)		(11,171)		(19,667)		(3,059)		(5,830)
Foreign currency transaction gain (loss)		115		(5,859)		1,701		3,003		4,063		(2,294)
Other non-operating (expense) income				(1,966)		(1,371)		(28,461)		(1,900)		214
Loss before income taxes		(18,780)		(47,771)		(39,404)		(70,099)		(4,138)		(12,373)
Income tax benefit		2,279		6,580		5,227		14,413		621		2,322
Consolidated net loss		(16,501)		(41,191)		(34,177)		(55,686)		(3,517)		(10,051)
Net loss attributable to noncontrolling interest						(1,173)		(1,067)		(420)		(695)
Net loss attributable to Tornier		(16,501)		(41,191)		(33,004)		(54,619)		(3,097)		(9,356)
Accretion of noncontrolling interest						(3,761)		(1,127)		(420)		(679)
Net loss attributable to ordinary shareholders	\$	(16,501)	\$	(41,191)	\$	(36,765)	\$	(55,746)	\$	(3,517)	\$	(10,035)
Weighted-average ordinary shares outstanding: basic and diluted		44,000		66,666		71,791		73,224		72,928		74,293
Net loss per share: basic and diluted	\$	(0.38)	\$	(0.62)	\$	(0.51)	\$	(0.76)	\$	(0.05)	\$	(0.14)
<b>Balance Sheet Data:</b>												
Cash and cash equivalents	\$	8,734	\$	17,347	\$	21,348	\$	37,969	\$	17,409	\$	38,311
Other current assets		97,014		117,760		137,128		147,274		135,524		148,753
Total assets		291,124		431,614		475,967		520,187		460,480		510,930
Total liabilities		141,426		181,738		212,442		277,140		230,257		281,438
Noncontrolling interest						23,200		23,259		23,200		
Total shareholders' equity		149,698		249,876		240,325		219,788		207,023		229,492



Edgar Filing: Tornier B.V. - Form S-1/A

Table of Contents

	Period from July 18, 2006 to		Year ended		First quarter ended	
	December 31, 2006	December 31, 2007	December 28, 2008	December 27, 2009	March 29, 2009	April 4, 2010
	(in thousands)				(unaudited) (unaudited) (in thousands)	
<b>Other Financial Data:</b>						
Net cash provided by (used in) operating activities	\$ 6,273	\$ (8,956)	\$ (25,272)	\$ 3,417	\$ 1,478	\$ 3,304
Net cash provided by (used in) investing activities	(14,665)	(105,397)	(37,524)	(32,230)	(5,789)	(8,357)
Net cash provided by (used in) financing activities	(1,829)	121,886	66,487	44,857	558	4,832
Depreciation and amortization	4,919	15,582	22,331	29,732	5,659	6,809
Capital expenditures	(4,828)	(16,938)	(25,832)	(24,574)	(5,789)	(7,296)
Effect of exchange rate changes on cash and cash equivalents	699	1,080	310	577	(186)	563

48

Table of Contents

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL  
CONDITION AND RESULTS OF OPERATIONS**

You should read the following discussion of our financial condition and results of operations together with the selected consolidated financial data, consolidated financial statements and the notes thereto included elsewhere in this prospectus, and other financial information included in this prospectus. The following discussion may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under "Risk Factors" and elsewhere in this prospectus. These risks could cause our actual results to differ materially from any future performance suggested below.

**Overview**

We are a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. We refer to these surgeons as extremity specialists. We sell to this extremity specialist customer base a broad line of joint replacement, trauma, sports medicine and orthobiologic products to treat extremity joints. Our motto of "specialists serving specialists" encompasses this focus. In certain international markets, we also offer joint replacement products for the hip and knee. We currently sell over 70 product lines in approximately 35 countries.

We have had a tradition of innovation, intense focus on surgeon education and commitment to advancement of orthopaedic technology since our founding approximately 70 years ago in France by René Tornier. Our history includes the introduction of the porous orthopaedic hip implant, the application of the Morse taper, which is a reliable means of joining modular orthopaedic implants, and, more recently, the introduction of the reversed shoulder implant in the United States. This track record of innovation over the decades stems from our close collaboration with leading orthopaedic surgeons and thought leaders throughout the world.

We were acquired in 2006 by the Investor Group. They recognized the potential to leverage our reputation for innovation and our strong extremity joint portfolio as a platform upon which they could build a global company focused on the rapidly evolving upper and lower extremity specialties. The Investor Group has contributed capital resources and a management team with a track record of success in the orthopaedic industry in an effort to expand our offering in extremities and accelerate our growth. Since the acquisition in 2006, we have:

created a single, extremity specialist sales channel in the United States primarily focused on our products;

enhanced and broadened our portfolio of shoulder joint implants and foot and ankle products;

entered the sports medicine and orthobiologics markets through acquisitions and licensing agreements;

improved our hip and knee product offerings, helping us gain market share internationally; and

significantly increased investment in research and development and expanded business development activities to build a pipeline of innovative new technologies.

As a result of the foregoing actions, we believe our addressable worldwide market opportunity has increased from approximately \$2 billion in 2006 to approximately \$7 billion in 2009.

We believe we are differentiated by our full portfolio of upper and lower extremity products, our dedicated extremity-focused sales organization and our strategic focus on extremities. We further

Table of Contents

believe that we are well-positioned to benefit from the opportunities in the extremity products marketplace as we are already among the global leaders in the shoulder and ankle joint replacement markets with the #2 market position worldwide for sales of shoulder joint replacement products and the #1 market position in the United States in foot and ankle joint replacement systems in 2009 as measured by revenue. We more recently have expanded our technology base and product offering to include: new joint replacement products based on new materials; improved trauma products based on innovative designs; and proprietary orthobiologic materials for soft tissue repair. In the United States, which is the largest orthopaedic market, we believe that our single, "specialists serving specialists" distribution channel is strategically aligned with what we believe is an ongoing trend in orthopaedics for surgeons to specialize in certain parts of the anatomy or certain types of procedures.

Our principal products are organized in four major categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics, and large joints and other. Our upper extremity products include joint replacement and bone fixation devices for the shoulder, hand, wrist and elbow. Our lower extremity products include joint replacement and bone fixation devices for the foot and ankle. Our sports medicine and orthobiologics product category includes products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries, in the case of sports medicine, or to support or induce remodeling and regeneration of tendons, ligaments, bone and cartilage, in the case of orthobiologics. Our large joints and other products include hip and knee joint replacement implants and ancillary products.

Innovations in the orthopaedic industry have typically consisted of evolutions of product design in implant fixation, joint mechanics, and instruments and modifications of existing metal or plastic-based device designs rather than new products based on combinations of new designs and new materials. In contrast, the growth of our target markets has been driven by the development of products that respond to the particular mechanics of small joints and the importance of soft tissue to small joint stability and function. We are committed to the development of new designs utilizing both conventional materials and new tissue-friendly biomaterials that we expect will create new markets. We believe that we are a leader in researching and incorporating some of these new technologies across multiple product platforms.

In the United States, we sell products from our upper extremity joints and trauma, lower extremity joints and trauma, and sports medicine and orthobiologics product categories; we do not actively market large joints in the United States nor do we currently have plans to do so. While we market our products to extremity specialists, our revenue is generated from sales to healthcare institutions and distributors. We sell through a single sales channel consisting of a network of independent commission-based sales agencies. Internationally, where the trend among surgeons toward specialization is not as advanced as in the United States, we sell our full product portfolio, including upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics and large joints. We utilize several distribution approaches depending on the individual market requirements, including direct sales organizations in the largest European markets and independent distributors for most other international markets. In 2009, we generated revenue of \$201.5 million, 57% of which was in the United States and 43% of which was international.

We have significantly grown our business since our acquisition by the Investor Group in July 2006. Since then we have built an extremities focused business that offers a broad range of products to a focused group of specialty surgeons. We believe this strategy has been the primary factor in enabling our revenue growth from 2006 to 2009. During that time we also increased our operating expenses significantly. We have strategically invested with particular emphasis on product development, acquisition of strategic products and technologies and sales commissions to support both current and future growth. While we believe we will continue to experience operating losses during 2010, we also believe the investments made will allow us to grow our revenue at rates exceeding our expected growth in operating expenses in the future.

Table of Contents

**Foreign Currency Exchange Rates**

A substantial portion of our business is located outside the United States and as a result we generate revenue and incur expenses denominated in currencies other than the U.S. dollar. The majority of our operations denominated in currencies other than the U.S. dollar are denominated in Euros. In 2009 and 2008, approximately 43% and 48%, respectively, of our sales were denominated in foreign currencies. As a result, our revenue can be significantly impacted by fluctuations in foreign currency exchange rates. We expect that foreign currencies will continue to represent a similarly significant percentage of our sales in the future. Selling, marketing and administrative costs related to these sales are largely denominated in the same foreign currencies, thereby limiting our transaction risk exposure. We therefore believe that the risk of a significant impact on our revenue from foreign currency fluctuations is minimal. However, a substantial portion of the products we sell in the United States are manufactured in countries where costs are incurred in Euros. Fluctuations in the Euro to U.S. dollar exchange rate will have an impact on the cost of the products we manufacture in those countries, but we would not likely be able to change our U.S. dollar selling prices of those same products in the United States in response to those cost fluctuations. As a result, fluctuations in the Euro to U.S. dollar exchange rates could have a significant impact on our gross profit in the future.

**Basis of Presentation**

Our fiscal quarters are generally determined on a 13-week basis and always end on a Sunday. As a result, our fiscal year is generally 364 days. Our year-end periods end on the Sunday nearest to December 31. Every few years, it is necessary to add an extra week to a quarter to make it a 14-week period in order to have our year end fall on the Sunday nearest to December 31. For example, the first quarter ended April 4, 2010, includes an extra week of operations compared to the first quarter ended March 29, 2009. For purposes of this management's discussion and analysis of financial condition and results of operations, references to:

2007 and our 2007 fiscal year refer to the fiscal year ended December 31, 2007;

2008 and our 2008 fiscal year refer to the fiscal year ended December 28, 2008;

2009 and our 2009 fiscal year refer to the fiscal year ended December 27, 2009;

The first quarter of 2009 refers to the 13 week period ended March 29, 2009; and

The first quarter of 2010 refers to the 14 week period ended April 4, 2010.

**Corporate Transactions**

Since our acquisition by the Investor Group in 2006, we have engaged in a series of acquisitions and other transactions as we have sought to grow the business and broaden our product portfolio. Below is a summary of our recent acquisitions and other transactions:

***Relevant Acquisitions***

*Axya Holdings, Inc., or Axya.* On February 27, 2007, we acquired 100% of the stock of Axya. With the addition of Axya's sports medicine domain expertise and products, which included traditional and advanced suture anchors and arthroscopic instruments for soft tissue repair in the shoulder, we were positioned to enter the shoulder sports medicine market. Many surgeons who perform rotator cuff repair surgery also perform shoulder joint replacement surgery, and the Axya product portfolio provided us the ability to sell additional products to our existing customer base.

*Nexa Orthopedics, Inc., or Nexa.* On February 27, 2007, we acquired 100% of the stock of Nexa. Nexa, a private company based in San Diego, California, was an extremity-focused orthopaedic company with a strong portfolio of implants for the foot and ankle. Nexa's products complemented our

Table of Contents

Salto and Salto Talaris ankle implants and significantly broadened our lower extremity product portfolio. In addition, Nexa had proprietary capabilities to manufacture orthopaedic implants with pyrocarbon, a highly wear-resistant, biocompatible material with wide potential applicability to our entire existing product portfolio. Nexa also had a next-generation shoulder joint replacement implant in its development pipeline, which we currently market as our Ascend shoulder implant. We believe Nexa was the only orthopaedic company in the world with vertically integrated pyrocarbon design and manufacturing capabilities.

*DVO Extremity Solutions, LLC, or DVO.* On March 5, 2007, we acquired the assets of DVO. DVO was an orthopaedic company primarily focused on trauma products, including implants for the hand and wrist. In addition, DVO was developing a shoulder joint replacement that would complement our existing product offering. We commercially launched the shoulder joint replacement product in 2008 as the Affiniti.

*C2M Medical, Inc., or C2M Medical.* On March 26, 2010, we exercised our option to acquire 100% of the stock of C2M Medical, a medical device development company based in San Antonio, Texas, focused on the sports medicine market. C2M Medical developed the Piton Knotless Anchor, an advanced arthroscopic technology for rotator cuff repair. In 2008, we signed a license agreement with C2M Medical for exclusive worldwide rights to the Piton, along with an option to acquire the company. C2M Medical was determined to be a variable interest entity and was consolidated by us beginning in 2008 upon signing the initial license agreement. Refer to Note 16 of our consolidated financial statements for further information regarding the accounting for C2M Medical.

***Other Transactions***

*Tepha Inc., or Tepha.* On February 9, 2007, we signed an exclusive license and supply agreement with Tepha for its poly-4-hydroxybutyrate polymer for certain fields of use, which we have branded "Biofiber." Biofiber is a high-strength biodegradable polymer that we have used in suture applications and in several soft tissue repair development projects.

*Bioretec Ltd., or Bioretec.* On March 14, 2007, we signed a distribution agreement with Bioretec, a Finnish biomaterials company, for private label distribution rights in the United States for Bioretec's product lines marketed by us under the NexFix Resorbable Fixation System, or RFS, brand. The NexFix RFS system includes pin and screw fixation systems for use by extremity specialists to repair and treat a wide range of bone and joint disorders including fractures and arthritis.

*BioSurface Engineering Technologies, Inc., or BioSET.* On January 22, 2008, we signed an agreement with BioSET to develop, commercialize and distribute products incorporating BioSET's F2A synthetic growth factor technology in the field of orthopaedic soft tissue repair. The BioSET deal complemented earlier agreements that we signed with other orthobiologics companies, including Tepha Medical, providing us with a portfolio of innovative technologies to better address unmet soft tissue repair needs of orthopaedic surgeons and their patients.

*LifeCell Corporation, or LifeCell.* On March 28, 2008, we entered into an exclusive distribution agreement with LifeCell, a tissue engineering company, which is a division of Kinetic Concepts, Inc. Under the terms of the agreement, we gained certain exclusive rights to commercialize orthopaedic and podiatric applications, including repair of rotator cuff, tendons and cartilage, for LifeCell's xenograft reconstructive tissue matrix. We believe this new tissue matrix provides us with a differentiated, next-generation biologic graft product primarily focused on rotator cuff repair, Achilles tendon repair and several other extremities soft tissue applications. We market the LifeCell tissue matrix product for orthopaedic and podiatric applications under the Conexa brand, while LifeCell continues to market a version of this tissue matrix for other applications under the Stratrice brand.

Table of Contents

*T.A.G. Medical Products Corporation Ltd., or TAG.* On May 2, 2009, we signed a definitive agreement with TAG, a private Israeli-based medical device developer and contract manufacturer, to exclusively license TAG's ArthroTunneler™, an advanced suture-passing device, for orthopaedic applications of the extremities. The ArthroTunneler's primary application enables surgeons to repair rotator cuffs arthroscopically without using suture anchors. The ArthroTunneler complements our sports medicine portfolio of suture and anchor products and we believe is particularly compelling to surgery centers since the ArthroTunneler device may be less expensive to use than multiple anchors.

**Components of Results of Operations**

***Revenue***

We derive our revenue from the sale of medical devices that are used by surgeons who treat diseases and disorders of extremity joints including the shoulder, elbow, wrist, hand, ankle and foot. We report our sales in four primary product categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics, and larger joints and other. Our revenue is generated from sales to two types of customers: healthcare institutions and distributors, with healthcare institutions representing a majority of our revenue. We utilize a network of independent sales agencies for sales in the United States and a combination of employee sales representatives, independent sales agencies and distributors for sales outside the United States. Revenue from sales to healthcare institutions is recognized at the time of surgical implantation. We generally record revenue from sales to our distributors at the time the product is shipped to the distributor. Distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at the time of shipment. Our distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. We charge our customers for shipping and record shipping revenue as part of revenue.

***Cost of Goods Sold***

We manufacture a majority of the products that we sell. Our cost of goods sold consists primarily of direct labor, allocated manufacturing overhead, raw materials and components, and excludes amortization of intangible assets, which is presented as a separate component of operating expenses. A portion of the products we sell are manufactured by third parties, and our cost of goods sold for those products consists primarily of the price invoiced by our third-party vendors. Cost of goods sold also includes share-based compensation expenses related to individuals whose salaries are also included within this category. A majority of our current manufacturing facilities are located in Europe and the related manufacturing costs are incurred in Euro. As a result, the cost of goods sold for our products sold in the United States that were manufactured in Europe is subject to foreign currency exchange rate fluctuations.

***Sales and Marketing***

Our variable selling costs consist primarily of commissions paid to our independent sales agencies used in the United States and some other countries to generate sales, royalties based on certain product sales and freight expense we pay to ship our products to customers. Our non-variable sales and marketing costs consist primarily of salaries, personnel costs, including share-based compensation and other support costs related to the selling, marketing and support of our products as well as trade shows, promotions and physician training. Sales and marketing expenses also include the cost of distributing our products, which includes the operating costs and certain administrative costs related to our various worldwide sales and distribution operations. We provide surgical instrumentation to our customers for use during procedures involving our products. There are no contractual arrangements related to our customers' use of our surgical instrumentation and we do not charge a fee for providing access to the related instrumentation. We record surgical instrumentation on our balance



Table of Contents

sheet as a long-lived asset. The depreciation expense related to our surgical instrumentation is included in sales and marketing expenses.

***General and Administrative***

General and administrative expenses consist of expenses for our executive, finance, legal, compliance, administrative, information technology and human resource departments. General and administrative expenses also include share-based compensation expense related to individuals within these departments.

***Research and Development***

Research and development expenses include costs associated with the design, development, testing, deployment, enhancement and regulatory clearance or approval of our products. This category also includes costs associated with the design and execution of our clinical trials and regulatory submissions. Research and development expenses also include share-based compensation related to individuals within our research and development groups.

***Amortization of Intangible Assets***

Amortization expense for intangible assets includes purchased developed technology, customer relationships and intellectual property, including patents and license rights.

***In-Process Research and Development***

Acquired in-process research and development, or IPR&D, reflects amounts assigned to those projects acquired in business combinations prior to December 28, 2008, or the acquisition of assets for which the related products have not received regulatory clearance or approval and have no alternative future use. IPR&D acquired in business combinations subsequent to December 28, 2008, would be recorded as indefinite-lived intangible assets on consolidated balance sheets.

***Special Charges***

Special charges consist of certain severance, lease termination and moving costs related to the consolidation of our U.S. facilities during 2009. Special charges also include legal and consulting costs related to establishing new sales and distribution subsidiaries in the United Kingdom and Denmark.

***Interest Expense***

Interest expense reflects interest associated with both our notes payable and other long-term and short-term debt. Our notes payable accrue paid-in-kind interest at a rate of 8% annually. Our notes payable were also issued together with warrants to purchase our ordinary shares. The estimated fair value of the warrants at the date of issuance was recorded as a discount to the related notes payable. The debt discount is accreted as additional interest expense to the par value of the notes payable over the related term. We also incur interest expense at varying rates of interest on various revolving lines of credit, secured and unsecured term loans and other mortgage-related debt.

***Foreign Currency Transaction Gain (Loss)***

Foreign currency transaction gain (loss) consists primarily of foreign currency gains and losses on transactions denominated in a currency other than the functional currency of the related entity. Our foreign currency transactions primarily consist of foreign currency denominated cash, liabilities and intercompany receivables and payables.

Table of Contents**Other Non-operating (Expense) Income**

Other non-operating (expense) income primarily relates to losses incurred in the revaluation of our warrant liabilities to fair value as well as other expenses not related to the operations of the business.

**Income Tax Benefit**

Income tax benefit includes federal income taxes, income taxes in foreign jurisdictions, state income taxes and changes to our deferred taxes and deferred tax valuation allowance.

**Results of Operations****First Quarter of 2010 Compared to First Quarter of 2009**

Our year-end periods end on the Sunday nearest to December 31. Every few years, it is necessary to add an extra week to a quarter to make it a 14-week period in order to have our year end fall on the Sunday nearest to December 31. For example, the first quarter ended April 4, 2010, includes an extra week of operations compared to the first quarter ended March 29, 2009. The following table sets forth, for the periods indicated, our results of operations expressed as a percentage of revenue:

	<b>First quarter ended</b>	
	<b>March 29, 2009</b>	<b>April 4, 2010</b>
Revenue	100%	100%
Cost of goods sold	29	30
Gross profit	71	70
Operating expenses:		
Selling and marketing	53	54
General and administrative	10	11
Research and development	9	8
Amortization of intangible assets	5	5
Special charges	*	*
Operating loss	(6)%	(7)%

\*  
Not meaningful

The following tables set forth, for the periods indicated, our revenue by product category and geography expressed as dollar amounts and the changes in revenue between the specified periods expressed as percentages:

Revenue by Product Category	<b>First quarter ended</b>		<b>Percent change</b>
	<b>March 29, 2009</b>	<b>April 4, 2010</b>	
	(\$ in thousands)		
Upper extremity joints and trauma	\$ 31,540	\$ 36,647	16%
Lower extremity joints and trauma	5,171	6,256	21
Sports medicine and orthobiologics	1,142	3,441	201
Large joints and other	13,002	15,499	19
<b>Total</b>	<b>\$ 50,855</b>	<b>\$ 61,843</b>	<b>22%</b>

Table of Contents

Revenue by Geography	First quarter ended		Percent change
	March 29, 2009	April 4, 2010	
	(\$ in thousands)		
United States	\$ 28,809	\$ 34,182	19%
International	22,046	27,661	25
<b>Total</b>	<b>\$ 50,855</b>	<b>\$ 61,843</b>	<b>22%</b>

*Revenue.* Revenue increased by 22% to \$61.8 million for the first quarter of 2010 from \$50.9 million for the first quarter of 2009, as a result of increased sales in each of our product categories, with the most significant increase occurring in our upper extremity joints and trauma and large joints and other categories. We have also experienced an increase in sales in our sports medicine and orthobiologics categories as we continue to broaden our portfolio of offerings in this market. Our revenue was positively impacted by approximately \$1.9 million during the first quarter of 2010 as a result of foreign currency fluctuations. Revenue also increased over first quarter of 2009 due to the extra week of operations included in our 2010 first quarter.

*Revenue by product category.* Revenue in upper extremity joints and trauma increased by 16% to \$36.6 million for the first quarter of 2010 from \$31.5 million for the first quarter of 2009, primarily as a result of the continued increase in sales of our Aequalis shoulder and Affiniti products. We believe that increased sales of our Aequalis shoulder resulted from continued market growth in shoulder replacement procedures and further market acceptance of our reversed and standard Aequalis shoulder joint replacement products. We have seen an increase in sales in our Affiniti shoulder products, which were launched at the end of 2008. Revenue in our lower extremity joints and trauma increased by 21% to \$6.3 million for the first quarter of 2010 from \$5.2 million for the first quarter of 2009, primarily due to increased sales in our foot and ankle fixation products in both the United States and internationally. We continue to focus our U.S. distribution network on selling our full range of products and have increased the number of products available internationally. Revenue in sports medicine and orthobiologics increased by 201% to \$3.4 million for the first quarter of 2010 from \$1.1 million for the first quarter of 2009. This increase was attributable to an increase in sales of our Piton products, as well as an increase in sales of our Conexa product, which was in the beginning stages of initial launch during the first quarter of 2009. The first quarter of 2010 also included initial revenue from our ArthroTunneler, which was launched during the second half of 2009. Revenue from large joints and other increased by 19% to \$15.5 million for the first quarter of 2010 from \$13.0 million for the first quarter of 2009. Our large joint and other revenue increase was primarily due to the existence of an extra week in our first quarter of 2010, combined with approximately \$0.9 million of favorable impacts from changes in foreign currency exchange rates.

*Revenue by geography.* Revenue in the United States increased by 19% to \$34.2 million for the first quarter of 2010 from \$28.8 million for the first quarter of 2009, primarily driven by continued increase in sales in upper extremities joints and trauma products, together with a significant increase in sales in sports medicine and orthobiologics products as our focus on this category increased during 2009. Revenue from the first quarter of 2010 was also favorably impacted by the extra week compared to the first quarter of 2009. International revenue increased by 25% to \$27.7 million for the first quarter of 2010 from \$22.0 million for the first quarter of 2009. Our international revenue was positively impacted by approximately \$1.9 million during the first quarter of 2010 as a result of foreign currency fluctuations, principally due to the performance of the Euro against the U.S. dollar. Excluding the impact of the change in currency exchange rates, our international revenue increased by 17%, primarily due to the launch of our United Kingdom sales office in the first quarter of 2010, increased revenue in France, Australia, and the Netherlands and the existence of an extra week in the first quarter of 2010.

Table of Contents

*Cost of goods sold.* Our cost of goods sold increased by 25% to \$18.4 million for the first quarter of 2010 from \$14.7 million for the first quarter of 2009. As a percentage of revenue, cost of goods sold increased from 29% for the first quarter of 2009 to 30% for the first quarter of 2010, primarily due to the fact that our products currently being sold include a higher level of overhead costs than those sold in the first quarter of 2009. We have intentionally increased our manufacturing overhead costs in an effort to establish a sufficient level of capacity and manufacturing infrastructure to support our current and future growth plans. Our manufacturing overhead costs have grown at a rate faster than our factory output in recent years, causing an increase in the fully absorbed cost of our products. However, we believe this has allowed us to establish an infrastructure that will be able to sustain our sales growth plans and has increased our ability to obtain leverage on our costs in the future. Our cost of goods sold and corresponding gross profit as a percentage of revenue can be expected to fluctuate in future periods depending upon changes in our product sales mix and prices, distribution channels and geographies, manufacturing yields, period expenses, levels of production volume and currency exchange rates.

*Selling and marketing.* Our selling and marketing expenses increased by 24% to \$33.4 million for the first quarter of 2010 from \$26.9 million for the first quarter of 2009, primarily as a result of \$1.9 million of additional variable commissions and royalty expenses on higher revenue, \$0.7 million of increased instrument depreciation from a larger volume of instruments in the field, approximately \$0.8 million of increased expense due to changes in foreign currency exchange rates and approximately \$1.4 million of increased non-variable selling and marketing expenses related to the additional week of operations included in the first quarter of 2010. The remaining increase in selling and marketing expenses relates to general increases in our selling and distribution costs to support continued growth, including our expansion into the United Kingdom. Selling and marketing expense as a percentage of revenue increased from 53% for the first quarter of 2009 to 54% for the first quarter of 2010. The increase in our selling and marketing expenses as a percentage of revenue is due primarily to the increased operating expenses of our new sales office in the United Kingdom, which began operations in the first quarter of 2010.

*General and administrative.* Our general and administrative expenses increased by 25% to \$6.5 million for the first quarter of 2010 from \$5.2 million for the first quarter of 2009. As a percentage of revenue, general and administrative expenses increased to 11% for the first quarter of 2010 compared to 10% for the first quarter of 2009. The increase in expenses in the first quarter of 2010 is primarily due to severance-related expenses of approximately \$0.4 million accrued in the first quarter of 2010 from the departure of our CFO. General and administrative expenses also increased due to the existence of an extra week of expense in the first quarter of 2010. Excluding the impact of the severance-related expenses, our general and administrative expenses as a percentage of revenue would be 10%, which is consistent with the first quarter of 2009. While general and administrative expenses as a percentage of revenue increased by only one percentage point, given our preparation for an initial public offering of our ordinary shares, we may not be able to continue to maintain our general and administrative costs as a percentage of revenue in 2010.

*Research and development.* Research and development expenses increased by 2% to \$4.8 million for the first quarter of 2010 from \$4.7 million for the first quarter of 2009, primarily due to consolidated operating expenses from C2M Medical, including certain operating expenses related to the launch of our Piton product. C2M Medical was a variable interest entity which we consolidated in 2008 and holds the intellectual property related to our Piton products. The first quarter of 2010 included \$0.6 million of operating expenses related to C2M Medical compared to an immaterial amount for the first quarter of 2009. During the first quarter of 2010, we acquired C2M Medical and merged the entity into our existing U.S. operations. The acquisition of C2M was completed in order to purchase the intellectual property related to our Piton products, which we had previously been licensing from C2M, and therefore the C2M entity was no longer needed. As a percentage of revenue, research and

Table of Contents

development decreased from 9% for the first quarter of 2009 to 8% for the first quarter of 2010 due to a higher level of new product development work occurring the first quarter of 2009 compared to the first quarter of 2010. We expect our level of research and development to fluctuate depending on the timing of new product development projects.

*Amortization of intangible assets.* Amortization of intangible assets increased by 15% to \$3.0 million for the first quarter of 2010 from \$2.6 million for the first quarter of 2009, primarily as a result of additional amortization related to certain license intangibles acquired during 2009 as well as the impact of changes in foreign currency exchange rates on non-U.S. intangible assets.

*Special charges.* We recorded special charges totaling \$0.2 million for the first quarter of 2010, which were primarily related to the relocation of our U.S. headquarters and the establishment of our sales office in the United Kingdom.

*Interest expense.* Our interest expense increased by 91% to \$5.8 million for the first quarter of 2010 from \$3.1 million for the first quarter of 2009 due to the issuance of €37 million of 8% notes payable together with warrants to purchase 8.8 million ordinary shares in April of 2009. 2010 interest expense includes a full quarter of interest expense related to the 8% stated interest on the notes, together with additional interest expense related to the notes being issued at a discount because they were issued in conjunction with warrants. Refer to Note 8 of our consolidated financial statements for further discussion of the accounting treatment of our notes and warrants.

*Foreign currency transaction gain (loss).* Our foreign currency transaction loss was \$2.3 million for the first quarter of 2010 compared to a \$4.1 million foreign currency transaction gain for the first quarter of 2009. The primary driver of our foreign currency transaction loss in the first quarter of 2010 and gain in the first quarter of 2009 is related to the revaluation of our warrant liability, which is denominated in a currency other than our functional currency. We recorded a foreign currency loss of \$5.7 million and gain of \$1.4 million in the first quarters of 2010 and 2009, respectively, to revalue the warrant liability. The offsetting foreign currency gains and losses in each period relate to the impact of revaluing certain of our intercompany debt and payables between our U.S. and European subsidiaries as a result of changes in the Euro to U.S. dollar exchange rate.

*Other non-operating (expense) income.* Other non-operating income was \$0.2 million for the first quarter of 2010 compared to expense of \$1.9 million for the first quarter of 2009. Our non-operating income and expense primarily relates to the adjustment of our warrant liability to fair value at the end of each reporting period. We have subsequently settled our warrant liability in May of 2010 by exchanging all the outstanding warrants for our ordinary shares.

*Income tax benefit.* Our income tax benefit increased \$1.7 million to \$2.3 million for the first quarter of 2010 from \$0.6 million for the first quarter of 2009. Our effective tax rate for the first quarter of 2010 and 2009 was 19% and 15%, respectively. Given our history of operating losses, we do not generally record a provision for income taxes in the United States and certain of our European sales offices. Our income tax benefit in the first quarters of both 2010 and 2009 primarily relate to tax benefit recorded related to our French subsidiaries and the reversal of deferred tax liabilities recognized in the Netherlands related to the debt discount on the notes payable issued in 2008 and 2009. The change in our effective tax rate from the first quarter of 2009 to the first quarter of 2010 primarily relates to the relative percentage of our pre-tax loss made up by our French and Netherlands operations.

Table of Contents**Fiscal Year Comparisons**

The following table sets forth, for the periods indicated, our results of operations expressed as a percentage of revenue.

	December 31, 2007	Year ended December 28, 2008	December 27, 2009
Revenue	100%	100%	100%
Cost of goods sold	34	28	29
Gross profit	66	72	71
Operating expenses:			
Selling and marketing	54	58	56
General and administrative	12	12	10
Research and development	9	12	9
Amortization of intangible assets	5	6	8
In-process research and development	10		
Special charges			1
Operating loss	(26)%	(16)%	(12)%

The following tables set forth, for the periods indicated, our revenue by product category and geography expressed as dollar amounts and the changes in revenue between the specified periods expressed as percentages:

**Revenue by Product Category**

	December 31, 2007	Year ended December 28, 2008	December 27, 2009	Percent change	
				2008/2007	2009/2008
(\$ in thousands)					
Upper extremity joints and trauma	\$ 87,724	\$ 108,829	\$ 125,454	24%	15%
Lower extremity joints and trauma	13,729	18,167	20,417	32%	12%
Sports medicine and orthobiologics	2,082	2,513	6,593	21%	162%
Large joints and other	41,834	47,861	48,998	14%	2%
<b>Total</b>	<b>\$ 145,369</b>	<b>\$ 177,370</b>	<b>\$ 201,462</b>	<b>22%</b>	<b>14%</b>

**Revenue by Geography**

	December 31, 2007	Fiscal year ended December 28, 2008	December 27, 2009	Percent change	
				2008/2007	2009/2008
(\$ in thousands)					
United States	\$ 73,701	\$ 92,730	\$ 114,206	26%	23%
International	71,668	84,640	87,256	18%	3%

Edgar Filing: Tornier B.V. - Form S-1/A

Total	\$	145,369	\$	177,370	\$	201,462	22%	14%
-------	----	---------	----	---------	----	---------	-----	-----

***Fiscal Year Ended December 27, 2009, Compared to Fiscal Year Ended December 28, 2008***

*Revenue.* Revenue increased by 14% to \$201.5 million in 2009 from \$177.4 million in 2008, primarily as a result of growth in our target markets, new product launches and market share gains by our shoulder and ankle joint replacement products. During 2009, we launched 18 new products; six of

Table of Contents

these new products were introduced primarily in the United States. Our revenue was negatively impacted by approximately \$4.5 million during 2009 as a result of foreign currency fluctuations, principally due to the performance of the Euro against the U.S. dollar. Excluding the impact of the change in foreign currency exchange rates, our revenue increased by 16%.

*Revenue by product category.* Revenue in upper extremity joints and trauma product category increased by 15% to \$125.5 million in 2009 from \$108.8 million in 2008, primarily as a result of the continued increase in sales of our shoulder products, including our reversed shoulder and our Affiniti shoulder products, which launched at the end of 2008. We believe that increased sales of our reversed shoulder products resulted from continued market growth in shoulder replacement procedures and further market acceptance of our reversed and standard Acqualis shoulder joint replacement products. Our Affiniti shoulder products continued to grow in sales volume since their 2008 launch. Our upper extremity joints and trauma product category continues to represent the most significant group of products in our revenue, representing approximately 61% and 62% of revenue in 2008 and 2009, respectively. We expect our upper extremity joints and trauma product category will remain a significant portion of revenue in the immediate future and will be a primary driver of our anticipated 2010 revenue growth. Revenue in our lower extremity joints and trauma product category increased by 12% to \$20.4 million in 2009 from \$18.2 million in 2008, primarily due to high volume growth in our U.S. ankle products, which we believe was driven by our surgeon training and education efforts. Revenue in our sports medicine and orthobiologics product category increased by 162% to \$6.6 million in 2009 from \$2.5 million in 2008. This increase was attributable to the launch of our orthobiologics product, Conexa, as well as increasing market acceptance of our Piton anchors. We expect revenue in this product category to increase as we focus on further developing and broadening these products. Revenue in the large joint and other product category increased by 2% to \$49.0 million in 2009 from \$47.9 million in 2008. Our large joint products are primarily sold internationally and were negatively impacted by the strengthening of the U.S. dollar. Excluding the impact of currency fluctuations, our large joint sales increased by 9%, driven primarily by an increase in sales volumes of certain of our hip products during 2009. We also launched the HLS Kneetec, a new knee joint implant, during 2009 to continue to strengthen our knee product revenue. We have made the strategic decision to focus the sale of our large joint products only in select international markets.

*Revenue by geography.* Revenue in the United States increased by 23% to \$114.2 million in 2009 from \$92.7 million in 2008. Revenue internationally increased by 3% to \$87.3 million in 2009 from \$84.6 million in 2008. Our international revenue was negatively impacted by approximately \$4.5 million during 2009 as a result of foreign currency fluctuations, principally due to the performance of the Euro against the U.S. dollar. Excluding the impact of the change in currency exchange rates, our international revenues increased by 8%, driven primarily by increased sales in our French market as well as in Germany and Australia.

*Cost of goods sold.* Our cost of goods sold increased by 19% to \$58.5 million in 2009 from \$49.1 million in 2008, primarily attributable to increased manufacturing overhead costs to support increased production capacity, which grew at a rate higher than production during 2008, the period in which the majority of our 2009 product sales were manufactured. As a percentage of revenue, cost of goods sold increased to 29% in 2009 from 28% in 2008, as we increased our manufacturing overhead costs in an effort to establish a sufficient level of capacity and manufacturing infrastructure to support our current and future growth plans. During 2009, we leased and moved into a new manufacturing facility in Macroom, Ireland, which should enable us to expand our Irish manufacturing capacity. We also purchased a new facility in Grenoble, France in 2009, which expanded our manufacturing facilities in France. Our increases in manufacturing overhead costs have grown at a rate faster than our factory output in recent years, causing an increase in the fully absorbed cost of our products. However, this has allowed us to establish an infrastructure that we believe will be able to sustain our sales growth plans and has increased our ability to leverage our costs in the future. In addition, we experienced charges



Table of Contents

for excess and obsolete inventory of \$7.8 million during 2009 compared to \$4.3 million during 2008 as a result of higher levels of obsolete inventory from a higher level of new product launches during 2009 and an increase in estimated shrinkage of U.S. consigned inventory. We also incurred certain one-time charges for relocating our Ireland manufacturing facility during 2009. Our cost of goods sold and corresponding gross profit as a percentage of revenue can be expected to fluctuate in future periods depending on changes in our product sales mix and prices, distribution channels and geographies, manufacturing yields, period expenses, levels of production volume and foreign currency exchange rates.

*Selling and marketing.* Our selling and marketing expenses increased by 9% to \$112.0 million in 2009 from \$103.3 million in 2008, primarily as a result of \$5.2 million of higher variable commissions and royalty expenses related to higher revenue, \$3.0 million of increased instrumentation depreciation and \$3.1 million of increased selling expenses related to new product promotions and training offset by a positive impact of \$2.6 million due to changes in foreign currency exchange rates. Selling and marketing expense as a percentage of revenue decreased from 58% in 2008 to 56% in 2009, primarily as a result of our ability to increase revenue at a higher rate than the increases in our existing sales and distribution expenses. We believe this reflects the results of our having increased sales and marketing expenses in prior years to build a sales and distribution infrastructure capable of supporting the revenue growth we experienced in 2009. While we believe our existing infrastructure is sufficient to support our 2010 growth plans, we do not anticipate that our selling and marketing expenses will decrease as a percentage of revenue during 2010.

*General and administrative.* Our general and administrative expenses decreased by 4% to \$20.8 million in 2009 from \$21.7 million in 2008, primarily as a result of the consolidation of certain administrative functions in France related to a subsidiary acquired in the Nexa acquisition, combined with a reduction of certain French property taxes. As a percentage of revenue, general and administrative expenses decreased two percentage points from 12% in 2008 to 10% in 2009. We were able to decrease our general and administrative expenses as a percentage of revenue during 2009 through controlled expenditures on certain legal and administrative costs; however, given our preparation for an initial public offering of our ordinary shares, we expect that general and administrative expense could increase and we may not be able to continue to decrease our general and administrative costs as a percentage of revenue in 2010.

*Research and development.* Research and development expenses decreased by 12% to \$18.1 million in 2009 from \$20.6 million in 2008, primarily due to favorable foreign currency exchange rates and consolidation of certain research and development activities into our Warsaw, Indiana facility. Research and development expenses represented 9% and 12% of revenue in 2009 and 2008, respectively. We believe that continued investment in research and development is an important part of sustaining our growth strategy through new product development and anticipate that research and development expenses as a percentage of revenue in 2010 will remain at a level similar to 2009.

*Amortization of intangible assets.* Amortization of intangible assets increased by 36% to \$15.2 million in 2009 from \$11.2 million in 2008 primarily as a result of \$3.4 million of impairment charges recorded in 2009 from the abandonment of certain previously acquired developed technology and a full year of amortization related to the intangible asset recorded upon the consolidation of C2M Medical in 2008.

*Special charges.* In 2009, we recorded special charges totaling \$1.9 million related to the consolidation and restructuring of certain activities in our Boston, New Jersey and San Diego facilities, as well as the relocation of our U.S. headquarters.

*Interest expense.* Our interest expense increased by 76% to \$19.7 million in 2009 from \$11.2 million in 2008 due to the full year impact of interest related to €34.5 million of notes payable

Table of Contents

issued in February 2008 and €37.0 million of notes payable issued in April 2009. Of the \$19.7 million of interest expense in 2009, \$10.0 million relates to non-cash amortization of debt discount recorded on the notes payable issued in both 2008 and 2009 and \$7.3 million relates to paid-in-kind interest accrued as additional principal value of the notes payable issued in 2008 and 2009.

*Foreign currency transaction gain (loss).* Our foreign currency transaction gain increased by 77% to \$3.0 million in 2009 from \$1.7 million in 2008. During 2009, we recorded a \$3.9 million foreign currency gain related to the revaluation of our warrant liability, which is denominated in a currency other than our functional currency. The remaining foreign currency gains in 2009 and 2008 relate primarily to the impact of revaluing certain of our intercompany debt and payables between our U.S. and European subsidiaries as a result of changes in the Euro to U.S. dollar exchange rate.

*Other non-operating (expense) income.* Other non-operating expenses increased to \$28.5 million in 2009 from \$1.4 million in 2008 due to the charge recorded as a result of the change in the fair value of the warrant liability issued with the 2008 and 2009 notes payable. This increase in fair value primarily relates to our change in the estimated fair value of our ordinary shares from \$5.66 per share at the end of 2008 to \$7.50 per share at the end of 2009.

*Income tax benefit.* Our income tax benefit increased \$9.2 million to \$14.4 million in 2009 compared to \$5.2 million in 2008. Our effective tax rate for 2009 and 2008 was 21% and 13%, respectively. Given our history of operating losses, we do not generally record a provision for income taxes in the United States and certain of our European sales offices. During 2009, we recorded a \$3.2 million tax benefit related to losses incurred in France that we believe will be realizable in the future because of the existence of sufficient deferred tax liabilities that will reverse over time, creating future taxable income. We also recorded a \$2.8 million income tax benefit in the United States as a result of a law change allowing for a one-time ability to carry back our current year losses for five years. Finally, we recorded a \$9.2 million income tax benefit related to the reversal of deferred tax liabilities on the debt discount recorded on the notes payable issued in 2008 and 2009.

***Fiscal Year Ended December 28, 2008, Compared to Fiscal Year Ended December 31, 2007***

*Revenue.* Revenue increased by 22% to \$177.4 million in 2008 from \$145.4 million in 2007, primarily as a result of continued market penetration of our various shoulder joint replacement products together with strong international sales growth in our hip products due to several newly launched product offerings. Our revenue was positively impacted in 2008 by approximately \$5.6 million as a result of fluctuations in foreign currency exchange rates. Excluding the impact of foreign currency exchange rate changes, our revenue grew by approximately 18% during 2008.

*Revenue by product category.* Revenue in our upper extremity joints and trauma product category increased by 24% to \$108.8 million in 2008 from \$87.7 million in 2007 as a result of continued market penetration and increased sales of our standard and reversed shoulder products, as well as a 29% increase in sales of our hand, wrist and elbow products, which included the first full year of revenue from our CoverLoc Wrist Plate that was acquired through the DVO acquisition. Revenue in our lower extremity joints and trauma product category increased by 32% to \$18.2 million in 2008 from \$13.7 million in 2007, driven primarily from a 56% increase in our ankle joint replacement product sales. Our revenue in the sports medicine and orthobiologics product category increased by 21% to \$2.5 million in 2008 from \$2.1 million in 2007. This increase was primarily due to the inclusion of sales of products acquired in the Axya acquisition for the full year in 2008 compared to only ten months in 2007. In both 2007 and 2008, our primary sports medicine product sales consisted of bone anchors and related products that we manufactured on an original equipment manufacturer basis for a third-party orthopaedic company in 2007. Revenue of the large joint and other product category increased by 14% to \$47.9 million in 2008 from \$41.8 million in 2007. Sales in our large joint and other product category are primarily denominated in foreign currencies and were favorably impacted by the fluctuations of

Table of Contents

foreign currency exchange rates during 2008. Excluding the impact of foreign currency exchange rate changes, revenue in our large joint and other product category grew approximately 7%, primarily driven by increased sales of our hip products due to the launch of several new products.

*Revenue by geography.* Revenue in the United States increased by 26% to \$92.7 million in 2008 from \$73.7 million in 2007, primarily driven by sales of our standard and reversed shoulder products. Our international revenue was positively impacted in 2008 by approximately \$5.6 million as a result of fluctuations in foreign currency exchange rates. Excluding the impact of foreign currency exchange rate changes, our international revenue increased by approximately 10% which was a result of increased revenue in our French, German and Australian sales offices, as well as in our export division, which sells products to distributors in markets in which we have no direct distribution.

*Cost of goods sold.* Our cost of goods sold decreased by 2% to \$49.1 million in 2008 from \$50.0 million in 2007, which was primarily attributable to the recognition in cost of goods sold in 2007 of inventory acquired in business combinations that had been stepped up to fair value, resulting in lower realized margin upon sale, all of which was recognized in cost of goods sold in 2007. As a percentage of revenue, cost of goods sold decreased to 28% in 2008 from 34% in 2007. This decrease in our cost of goods sold as a percentage of revenue in 2007 included the reversal of \$16.7 million of this inventory step-up.

*Selling and marketing.* Our selling and marketing expenses increased by 31% to \$103.3 million in 2008 from \$78.6 million in 2007, primarily as a result of increased variable commissions, royalties and freight related to higher revenue, higher surgical instrument depreciation and increased selling and marketing expenses to support our expanding product categories and new product launches. Our selling and marketing expenses increased in 2008 as a result of the fluctuations in foreign currency exchange rates, as a significant portion of our selling and marketing expenses are incurred in currencies other than the U.S. dollar. Selling and marketing expense as a percentage of revenue increased from 54% in 2007 to 58% in 2008, primarily as a result of increased selling and marketing expenses to support the launch and marketing of new and acquired products.

*General and administrative.* Our general and administrative expenses increased by 21% to \$21.7 million in 2008 from \$18.0 million in 2007 due to increased legal, tax, accounting and other professional and administrative fees incurred as we began preparing ourselves to be a publicly traded company. Our general and administrative expenses also increased during 2008 as a result of fluctuations in foreign currency exchange rates. As a percentage of revenue, general and administrative expenses remained constant at 12% in both 2007 and 2008.

*Research and development.* Research and development expenses increased by 55% to \$20.6 million in 2008 from \$13.3 million in 2007 to support new product development. Research and development expenses as a percentage of revenue were 12% and 9% in 2008 and 2007, respectively. We increased research and development in 2008 in an effort to support our strategy of broadening our product portfolio as well as to complete development of certain new product launches.

*Amortization of intangible assets.* Amortization of intangible assets increased by 41% to \$11.2 million in 2008 from \$7.9 million in 2007, primarily as a result of a full year of amortization of intangible assets acquired in the DVO, Nexa and Axya acquisitions. Amortization of intangible assets also increased in 2008 as a result of the consolidation of C2M Medical, which was the holding company that purchased the intangible asset that became the basis of our Piton knotless fixation device. Please see Note 16 of the consolidated financial statements for further discussion of the accounting for C2M Medical.

*In-process research and development.* In 2007, upon our acquisition of DVO, Nexa and Axya we recognized an expense of \$15.1 million representing the estimated fair value of acquired IPR&D

Table of Contents

that had not yet reached technological feasibility and had no alternative future use. The fair value was determined by estimating the costs to develop the acquired IPR&D into commercially viable products, estimating the resulting net cash flows from this project and discounting the cash flows back to their present values. The resulting cash flows from the projects were based on our management's best estimates of revenue, cost of goods sold, research and development costs, selling and marketing costs, general and administrative costs and income taxes from the project.

*Interest expense.* Our interest expense increased to \$11.2 million in 2008 from \$2.4 million in 2007 due to the full-year impact of interest related to €34.5 million of notes payable issued in February of 2008. Of the \$11.2 million of interest expense, net recorded in 2008, \$4.7 million relates to non-cash amortization of debt discount recorded on the notes payable issued in 2008 and \$3.4 million relates to paid-in-kind interest accrued as additional principal value of the notes payable issued in 2008.

*Foreign currency transaction gain (loss).* Our foreign currency transaction gain increased to a gain of \$1.7 million in 2008 from a loss of \$5.9 million in 2007. The majority of our foreign currency gains and losses in 2008 and 2007 relates to the impact of revaluing certain of our intercompany debt and payables between our U.S. and European subsidiaries as a result of changes in the Euro to U.S. dollar exchange rate.

*Other non-operating (expense) income.* Other non-operating expenses decreased by 30% to \$1.4 million in 2008 from \$2.0 million in 2007. Our non-operating expenses in 2008 consisted primarily of charges related to the disposal of non-operating assets that were previously acquired in 2007. The \$2.0 million of non-operating expense in 2007 relates to certain value-added taxes incurred upon the transfer of acquisition-related expenses between legal entities to obtain future income tax deductibility.

*Income tax benefit.* Our income tax benefit decreased by 21% to \$5.2 million in 2008 from \$6.6 million in 2007, based on lower pre-tax loss. Our effective tax rate in 2008 and 2007 was 13% and 14%, respectively.

**Seasonality and Quarterly Fluctuations**

Our business is seasonal in nature. Historically, demand for our products has been the lowest in our third quarter as a result of the European holiday schedule during the summer months.

We have experienced and expect to continue to experience meaningful variability in our revenue and gross profit among quarters, as well as within each quarter, as a result of a number of factors, including, among other things, the number and mix of products sold in the quarter; the demand for, and pricing of, our products and the products of our competitors; the timing of or failure to obtain regulatory clearances or approvals for products; costs, benefits and timing of new product introductions; increased competition; the timing and extent of promotional pricing or volume discounts; changes in average selling prices; the availability and cost of components and materials; number of selling days; fluctuations in foreign currency exchange rates; and impairment and other special charges. In addition, we issued notes payable and warrants in both 2008 and 2009 in order to raise working capital. During 2009, we adopted new accounting guidance that requires we record the fair value of the warrants as a liability on our balance sheet and adjust that liability to fair value at each reporting period, which changes are recognized as either an expense or revenue in our statement of operations.

**Liquidity and Capital Resources**

Since inception, we have generated significant operating losses. These, combined with significant charges not related to cash from operations, such as IPR&D, amortization of acquired intangible assets, fair value adjustments to our warrant liability and accretion of noncontrolling interests, have resulted in an accumulated deficit of \$154.1 million as of April 4, 2010. Historically, our liquidity needs have been met through a combination of sales of our equity securities together with

Table of Contents

issuances of notes payable and warrants to both current shareholders and new investors and other bank related debt. Our notes payable have financial and operational covenants that could limit our ability to transfer or dispose of assets, merge with or acquire other companies, make investments, pay dividends, incur additional indebtedness and liens and conduct transactions with affiliates. As of April 4, 2010, we have \$47.6 million in debt excluding our notes payable. Certain of these other debt agreements also include financial covenants that (i) require us to have a minimum level of tangible net worth in our U.S. operating subsidiary, (ii) have various levels of performance tests of debt to equity and debt to modified income specifically related to our French operating subsidiary and (iii) restrict our ability to borrow in our U.S. operating subsidiary if there is a default under the agreement, all of which may have an impact on our liquidity.

The following table sets forth, for the periods indicated, certain liquidity measures:

	December 31, 2007	As of December 28, 2008	December 27, 2009	As of April 4, 2010
	(\$ in thousands)			
Cash and cash equivalents	\$ 17,347	\$ 21,348	\$ 37,969	\$ 38,311
Working capital	58,299	81,740	113,088	109,964
Line of credit availability	1,821	7,927	13,530	9,913

*Operating activities.* Net cash provided by operating activities was \$3.3 million for the first quarter of 2010 compared to \$1.4 million for the first quarter of 2009, primarily driven by higher levels of accounts payable and accruals due to timing and improved receivables management offset by increases in inventory and other current assets.

Net cash provided by operating activities was \$3.4 million in 2009 compared to net cash used in operating activities of \$25.3 million in 2008. This improvement in our cash flows from operations was primarily driven by an improvement in our consolidated net loss adjusted for non-cash items by approximately \$17.1 million, due to our increased leverage on operating expenses versus our increase in revenue. In addition, we decreased inventory by \$10.9 million due to improved inventory management and lower levels of inventory to support product launches. We also experienced \$5.4 million in favorable cash flows from lower receivable balances as a result of improved collection efforts in 2009. These cash flow improvements were partially offset by other changes in current assets and liabilities.

Net cash used in operating activities was \$25.3 million in 2008 compared to net cash used in operating activities of \$9.0 million for 2007. The increase in net cash used in operating activities in 2008 was primarily driven by increased inventory of \$25.7 million compared to 2007. The majority of this change in inventory was the result of inventory levels decreasing by \$16.7 million in 2007 as a result of the fair value step-up on the sale of inventory that was acquired through business acquisitions. The remaining growth in inventory in 2008 was related to the additional inventory necessary to support a larger number of new product launches. This increase in inventory was offset by improvements in our consolidated net loss adjusted for non-cash items, better collections of receivables and increased cash from changes in other current assets and liabilities.

*Investing activities.* Net cash used in investing activities, including our acquisition- and licensing-related payments, totaled \$8.4 million during the first quarter of 2010, compared to \$5.8 million during the first quarter of 2009. The increase in net cash used in investing activities is primarily due to an increase in property, plant and equipment in the first quarter of 2010 to finish preparing our new French manufacturing facility to begin production together with \$1.1 million in acquisition-related payments. The acquisition-related payments in the first quarter of 2010 relate to contingent purchase price related to a previous acquisition, as certain milestones were achieved in the first quarter and continued payments of contingent purchase price related to our consolidated subsidiary's acquisition of our Piton technology. The purchase agreement related to our acquisition of

Table of Contents

our Piton technology requires that we make payments equal to 25% of the sales of Piton for a three-year period ending in the fourth quarter of 2011.

Net cash used in investing activities, including our acquisition and licensing related payments, totaled \$7.7 million, \$12.7 million and \$88.5 million in 2009, 2008 and 2007, respectively. Acquisition- and licensing-related payments in 2009 and 2008 were primarily related to earn-out payments made to the shareholders of DVO as a part of the asset purchase agreement we entered into in 2007. The payments made in 2009 were the final earn-out payments to be made under this agreement. Acquisition-related payments in 2007 pertain to the purchase price paid for the acquisitions of Nexa and DVO. The amounts related to the addition of surgical instrumentation equipment was \$13.5 million, \$12.4 million and \$8.6 million in 2009, 2008 and 2007, respectively. The increase in surgical instrumentation in 2009 relates primarily to supporting continued revenue growth as well as certain new product launches. The increase in surgical instrumentation in 2008 as compared to 2007 relates primarily to the building of instrument sets to support a much larger group of new product launches. The amounts related to property, plant and equipment was \$11.1 million, \$13.5 million and \$8.3 million in 2009, 2008 and 2007 respectively. In 2009, we had approximately \$2.4 million on leasehold improvements in conjunction with moving our Irish manufacturing operations into a newly leased facility. In 2008, we had approximately \$6.1 million to purchase a new manufacturing facility in Grenoble, France.

Our industry is capital intensive, particularly as it relates to surgical instrumentation. Historically, our capital expenditures have consisted principally of purchased manufacturing equipment, research and testing equipment, computer systems, office furniture and equipment and surgical instruments.

*Financing activities.* Net cash provided by financing activities increased to \$4.8 million during the first quarter of 2010, from \$0.6 million during the first quarter of 2009. The increase in net cash provided by financing activities was due to an increase in borrowings under our revolving credit facilities during the first quarter of 2010 together with a higher level of new issuances of long-term debt net of payments on long-term debt. We also generated \$0.5 million in cash in the first quarter of 2010 through the sale of ordinary shares and exercise of stock options.

Net cash provided by financing activities totaled \$44.9 million, \$66.5 million and \$121.9 million in 2009, 2008 and 2007. During 2009 and 2008, proceeds of \$49.3 million and \$52.4 million, respectively, were generated from the issuance of notes payable and warrants to be used as working capital. Proceeds of \$2.9 million and \$8.9 million were generated in 2009 and 2008, respectively, through the sale of our ordinary shares to various investors. In 2007, we also sold our ordinary shares and issued mandatorily convertible bonds for total proceeds of \$100.9 million used primarily to fund our acquisitions of Nexa and DVO. During 2009, we made payments of \$3.5 million on short-term debt and made payments of \$3.9 million on long-term borrowing arrangements, net of cash generated from new long-term borrowing arrangements. This compares to payments on short-term debt of \$2.1 million and cash generated of \$7.3 million on long-term borrowing arrangements, net of payments on long-term debt, in 2008.

The decrease in proceeds generated by the issuance of long-term debt was due to our ability to raise a higher level of term loans in France secured by certain working capital balances during 2008. During 2007, we generated proceeds of \$11.1 million from additional borrowings under our short-term debt facilities and generated \$9.9 million in proceeds from the issuance of new long-term debt, net of payments on existing long-term borrowings. The additional proceeds generated on short-term borrowings during 2007 relate to a higher level of usage of our revolving credit facilities at the end of 2007 compared to 2008 to support near term cash needs. We were also able to generate a slightly higher level of proceeds from the issuance of new long-term debt agreements during 2007 compared to 2008 to support our working capital needs.

Table of Contents

*Other liquidity information.* We have funded our cash needs since our acquisition in 2006 through the issuance of equity, notes payable and warrants to a group of investors. Although it is difficult for us to predict our future liquidity requirements, we believe that our current cash balance of approximately \$38.3 million and our existing available credit lines of \$9.9 million will be sufficient to fund our working capital requirements and operations and permit anticipated capital expenditures in 2010. Our European subsidiaries have established a combination of secured and unsecured available lines of credit totaling in excess of \$21.7 million as of April 4, 2010. The secured lines of credit generally have between one and two year terms and are renewed at the end of the related term. The unsecured lines of credit do not include specific terms and can be terminated by the banks upon 60 days notice. These lines of credit have variable interest rates based on the Euro Overnight Index Average plus 0.3% to 1.3% or a three-month Euro rate plus 1% to 3%. We also have a \$6 million credit line secured by our U.S. operating subsidiary that expires in July 2010, is currently being renegotiated, and is callable by the bank at any time. This line is secured by working capital and equipment and bears interest at a 30-day LIBOR plus 2.25% interest rate. In the event that we would require additional working capital to fund future operations, we could seek to acquire that through additional equity or debt financing arrangements. If we raise additional funds by issuing equity securities, our shareholders may experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. There is no assurance that any financing transaction will be available on terms acceptable to us, or at all. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize.

**Contractual Obligations and Commitments**

The following table summarizes our outstanding contractual obligations as of December 27, 2009, for the categories set forth below, assuming only scheduled amortizations and repayment at maturity:

	Total	Less than 1 Year	1-3 Years	3-5 Years	More than 5 Years
(\$ in thousands)					
<b>Amounts reflected in consolidated balance sheet:</b>					
Bank debt	\$ 43,713	\$ 22,779	\$ 11,353	\$ 5,600	\$ 3,981
Notes payable	102,946			102,946	
Shareholder loan	1,015				1,015
Capital leases	1,460	520	709	231	
<b>Amounts not reflected in consolidated balance sheet:</b>					
Interest on bank debt	3,507	1,359	1,073	491	584
Accrued paid-in-kind interest on notes payable	49,431			47,661	
Interest on capital leases	109	60	47	2	
Operating leases	18,158	3,954	6,621	3,099	4,484
<b>Total</b>	<b>\$ 220,339</b>	<b>\$ 28,672</b>	<b>\$ 19,803</b>	<b>\$ 161,800</b>	<b>\$ 10,064</b>

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

The following table summarizes our outstanding contractual obligations as of April 4, 2010, for the categories set forth below, assuming only scheduled amortizations and repayment at maturity:

	Total	Less than 1 Year	1-3 Years	3-5 Years	More than 5 Years
	(\$ in thousands)				
<b>Amounts reflected in consolidated balance sheet:</b>					
Bank debt	\$ 43,961	\$ 24,471	\$ 10,299	\$ 5,099	\$ 4,092
Notes payable	96,296		46,465	49,831	
Shareholder loan	1,738				1,738
Capital leases	1,916	641	987	288	
<b>Amounts not reflected in consolidated balance sheet:</b>					
Interest on bank debt	3,461	1,303	1,176	583	399
Accrued paid-in-kind interest on notes payable	46,238		22,247	23,991	
Interest on capital leases	191	91	93	7	
Operating leases	18,004	3,900	6,561	3,084	4,459
<b>Total</b>	<b>\$ 211,805</b>	<b>\$ 30,406</b>	<b>\$ 87,828</b>	<b>\$ 82,883</b>	<b>\$ 10,688</b>

### **Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC, that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.

### **Critical Accounting Policies**

Our consolidated financial statements and related financial information are based on the application of U.S. GAAP. Our most significant accounting policies are described in Note 2 to our consolidated financial statements included elsewhere in this prospectus. The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

Certain of our more critical accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, terms of existing contracts, our observance of trends in the industry, information provided by our physician customers and information available from other outside sources, as appropriate. Changes in accounting estimates are reasonably likely to occur from period to period. Changes in these estimates and changes in our business could have a material impact on consolidated financial statements.

We believe that the following accounting policies are both important to the portrayal of our financial condition and results of operations and require subjective or complex judgments. Further, we believe that the items discussed below are properly recognized in our consolidated financial statements for all periods presented. Management has discussed the development, selection and disclosure of our critical financial estimates with the audit committee and our board of directors. The judgments about





Table of Contents

those financial estimates are based on information available as of the date of our consolidated financial statements. Our critical financial policies and estimates are described below:

***Revenue Recognition***

Our revenue is generated from sales to two types of customers: healthcare institutions and distributors. Sales to healthcare institutions represent the majority of our revenue. We utilize a network of independent sales agencies for sales in the United States and a combination of direct sales organizations, independent sales agencies and distributors for sales outside the United States. Revenue from sales to healthcare institutions is recognized at the time the device is implanted. We receive a notification of implant from the healthcare institution when the surgery occurs. Title to inventory generally does not transfer until the product is surgically implanted. We generally recognize revenue from sales to distributors at the time the product is shipped to the distributor. Distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at time of shipment. Our distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. In general, healthcare institutions and distributors do not have any rights of return or exchange.

***Allowance for Doubtful Accounts***

We maintain an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. We make estimates regarding the future ability of our customers to make required payments based on historical credit experience, delinquency and expected future trends. The majority of our receivables are due from healthcare institutions, many of which are government funded. Accordingly, our collection history with this class of customer has been favorable and has resulted in a low level of historical write-offs. We write off accounts receivable when we determine that the accounts receivable are uncollectible, typically upon customer bankruptcy or the customer's non-response to continued collection efforts.

We believe that the amount included in our allowance for doubtful accounts has been a historically appropriate estimate of the amount of accounts receivable that is ultimately not collected. While we believe that our allowance for doubtful accounts is adequate, the financial condition of our customers and the geopolitical factors that impact reimbursement under individual countries' healthcare systems can change rapidly, which may necessitate additional allowances in future periods. Our allowance for doubtful accounts was \$2.7 million and \$2.2 million at December 27, 2009, and December 28, 2008, respectively.

***Excess and Obsolete Inventory***

We value our inventory at the lower of the actual cost to purchase or manufacture the inventory on a first-in, first-out, or FIFO, basis or its net realizable value. We regularly review inventory quantities on hand for excess and obsolete inventory and, when circumstances indicate, we incur charges to write down inventories to their net realizable value. Our review of inventory for excess and obsolete quantities is based on an analysis of historical product sales together with our forecast of product demand and production requirements. A significant decrease in demand could result in an increase in the amount of excess inventory quantities on hand. Additionally, our industry is characterized by regular new product development that could result in an increase in the amount of obsolete inventory quantities on hand due to cannibalization of existing products. Also, our estimates of future product demand may prove to be inaccurate, in which case we may be required to incur charges for excess and obsolete inventory. In the future, if additional inventory write-downs are required, we would recognize additional cost of goods sold at the time of such determination. Regardless of changes in our estimates of future product demand, we do not increase the value of our inventory above its adjusted cost basis. Therefore, although we make every effort to ensure the accuracy of our forecasts of

Table of Contents

future product demand, significant unanticipated decreases in demand or technological developments could have a significant impact on the value of our inventory and our reported operating results. Charges incurred for excess and obsolete inventory were \$7.8 million, \$4.3 million and \$5.1 million for the fiscal years ended 2009, 2008 and 2007, respectively.

***Goodwill and Long-Lived Assets***

We have approximately \$136.9 million of goodwill recorded as a result of the acquisition of businesses. Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment exists. Based on our single business approach to decision-making, planning and resource allocation, we have determined that we have one reporting unit for purposes of evaluating goodwill for impairment. We use widely accepted valuation techniques to determine the fair value of our reporting unit used in our annual goodwill impairment analysis. Our valuation is primarily based on the income approach that is supported by a discounted cash flow analysis. The market approach used consists of comparisons to the valuations of a group of guideline public companies. We do not currently generate earnings from operations and therefore do not use the results of the market approach in our valuation. Rather, the results of our market approach are used to evaluate the reasonableness of the income approach. We performed our annual impairment test on the first day of the fourth quarter of 2009 and determined that the fair value of our reporting unit exceeded its carrying value and, therefore, no impairment charge was necessary.

The impairment evaluation related to goodwill requires the use of considerable management judgment to determine discounted future cash flows, including estimates and assumptions regarding the amount and timing of cash flows, cost of capital and growth rates. Cash flow assumptions used in the assessment are estimated using assumptions in our annual operating plan as well as our five-year strategic plan. Our annual operating plan and strategic plan contain revenue assumptions that are derived from existing technology as well as future revenues attributed to in-process technologies and the associated launch, growth and decline assumptions normal for the life cycle of those technologies. In addition, management considers relevant market information, peer company data and historical financial information. We also considered our historical operating losses in assessing the risk related to our future cash flow estimates and attempted to reflect that risk in the development of our weighted average cost of capital.

Our business is capital intensive, particularly as it relates to surgical instrumentation. We depreciate our property, plant and equipment and amortize our intangible assets based upon our estimate of the respective asset's useful life. Our estimate of the useful life of an asset requires us to make judgments about future events, such as product life cycles, new product development, product cannibalization and technological obsolescence, as well as other competitive factors beyond our control. We account for the impairment of long-lived assets in accordance with FASB ASC Section 360, Property, Plant and Equipment (FASB ASC 360). Accordingly, when indicators of impairment exist, we evaluate impairments of our property, plant and equipment based upon an analysis of estimated undiscounted future cash flows. If we determine that a change is required in the useful life of an asset, future depreciation and amortization is adjusted accordingly. Alternatively, if we determine that an asset has been impaired, an adjustment would be charged to earnings based on the asset's fair market value, or discounted cash flows if the fair market value is not readily determinable, reducing revenue in that period.

***Warrant Liability***

During 2008 and 2009 we raised additional working capital funds through the sale of notes payable and warrants to purchase our ordinary shares. In accordance with U.S. GAAP, these warrants were classified as a liability and carried at fair value because the warrants were denominated in a currency other than the functional currency of the issuing entity. We estimated the fair value of the

Table of Contents

warrant liability using a Black-Scholes option pricing model. The determination of the fair value of our warrant liability utilizing the Black-Scholes model is affected by our share price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life of our warrants was determined to be equal to the remaining contractual term as the warrants were fully detachable from the notes payable with which they were issued. As a non-public entity, historic volatility is not available for our ordinary shares. As a result, we estimated volatility based on a peer group of companies, which collectively provides a reasonable basis for estimating volatility. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero-coupon issues with a remaining term approximately equal to the remaining term of the warrants. The final input, which has a significant impact on the estimated fair value of our warrant liability, is our estimated fair value of our underlying ordinary shares. Refer to " Significant Factors Used in Determining Fair Value of Our Ordinary Shares" below for a detailed discussion of how we estimate the fair value of our underlying shares.

***Accounting for Income Taxes***

Our effective tax rate is based on income by tax jurisdiction, statutory rates and tax-saving initiatives available to us in the various jurisdictions in which we operate. Significant judgment is required in determining our effective tax rate and evaluating our tax positions. This process includes assessing temporary differences resulting from differing recognition of items for income tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheet. Realization of deferred tax assets in each taxable jurisdiction is dependent on our ability to generate future taxable income sufficient to realize the benefits. Management evaluates deferred tax assets on an ongoing basis and provides valuation allowances to reduce net deferred tax assets to the amount that is more likely than not to be realized.

Our valuation allowance balances totaled \$22.8 million and \$17.4 million as of December 27, 2009, and December 28, 2008, respectively, due to uncertainties related to our ability to realize, before expiration, some of our deferred tax assets for both U.S. and foreign income tax purposes. These deferred tax assets primarily consist of the carryforward of certain tax basis net operating losses and general business tax credits.

In July 2006, the Financial Accounting Standards Board, or FASB, issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN 48), effective January 1, 2007, which requires the tax effects of an income tax position to be recognized only if they are more-likely-than-not to be sustained based solely on the technical merits as of the reporting date. On December 30, 2008, the FASB further delayed the effective date of this guidance for certain non-public enterprises until annual financial statements for fiscal years beginning after December 15, 2008. Effective July 1, 2009, this standard was incorporated into FASB ASC Section 740, Income Taxes. We adopted these provisions of ASC Section 740 in 2009. As a multinational corporation, we are subject to taxation in many jurisdictions and the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various taxing jurisdictions. If we ultimately determine that the payment of these liabilities will be unnecessary, we will reverse the liability and recognize a tax benefit in the period in which we determine the liability no longer applies. Conversely, we record additional tax charges in a period in which we determine that a recorded tax liability is less than we expect the ultimate assessment to be. Our liability for unrecognized tax benefits totaled \$3.0 million as of December 27, 2009. See Note 11 to our consolidated financial statements for the fiscal year ended December 27, 2009, for further discussion of our unrecognized tax benefits.

***Share-Based Compensation***

The estimated fair value of share-based awards exchanged for employee and non-employee director services are expensed over the requisite service period. Option awards issued to non-employees

Table of Contents

(excluding non-employee directors) are recorded at their fair value as determined in accordance with authoritative guidance, are periodically revalued as the options vest and are recognized as expense over the related service period.

For purposes of calculating share-based compensation, we estimate the fair value of stock options using a Black-Scholes option pricing model. The determination of the fair value of share-based payment awards utilizing this Black-Scholes model is affected by our share price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends.

We do not have information available which is indicative of future exercise and post-vesting behavior to estimate the expected term. As a result, we adopted the simplified method of estimating the expected term of a stock option, as permitted by the Staff Accounting Bulletin No. 107. Under this method, the expected term is presumed to be the mid-point between the vesting date and the contractual end of the term. As a non-public entity, historic volatility is not available for our ordinary shares. As a result, we estimated volatility based on a peer group of companies, that we believe collectively provides a reasonable basis for estimating volatility. We intend to continue to consistently use the same group of publicly traded peer companies to determine volatility in the future until sufficient information regarding volatility of our ordinary share price becomes available or the selected companies are no longer suitable for this purpose. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero-coupon issues with a remaining term approximately equal to the expected life of our stock options. The estimated pre-vesting forfeiture rate is based on our historical experience together with estimates of future employee turnover. We do not expect to declare dividends in the foreseeable future.

The following table summarizes the amount of share-based compensation expense recognized in our statements of operations by expense category:

	December 31, 2007	Year ended December 28, 2008	December 27, 2009
	(\$ in thousands)		
Cost of goods sold	\$ 221	\$ 341	\$ 77
Selling and marketing	794	1,034	1,306
General and administrative	1,608	2,051	2,250
Research and development	213	246	280
<b>Total share-based compensation</b>	<b>\$ 2,836</b>	<b>\$ 3,672</b>	<b>\$ 3,913</b>

If factors change and we employ different assumptions, share-based compensation expense may differ significantly from what we have recorded in the past. If there is a difference between the assumptions used in determining share-based compensation expense and the actual factors which become known over time, specifically with respect to anticipated forfeitures, we may change the input factors used in determining share-based compensation costs for future grants. These changes, if any, may materially impact our results of operations in the period such changes are made. We expect to continue to grant stock options in the future, and to the extent that we do, our actual share-based compensation expense recognized in future periods will likely increase.

***Significant Factors Used in Determining Fair Value of Our Ordinary Shares***

The fair value of our ordinary shares that underlie the stock options we have granted has historically been determined by our board of directors based upon information available to it at the time of grant. Because, prior to this offering, there has been no public market for our ordinary shares, our board of directors has determined the fair value of our ordinary shares by utilizing, among other things, transactions involving sales of our ordinary shares, other financing events involving our ordinary

Table of Contents

shares and contemporaneous valuation studies conducted as of January 31, 2008, and December 27, 2009. The findings of these valuation studies were based on our business and general economic, market and other conditions that could be reasonably evaluated at that time. The analyses of the valuation studies incorporated extensive due diligence that included a review of our company, including its financial results, business agreements, intellectual property and capital structure. The valuation studies also included a thorough review of the conditions of the industry in which we operate and the markets that we serve. The methodologies of the valuation studies included an analysis of the fair market value of our company using three widely accepted valuation methodologies: (1) market multiple, (2) comparable transactions and (3) discounted cash flow. These valuation methodologies were based on a number of assumptions, including our forecasted future revenue and industry, general economic, market and other conditions that could reasonably be evaluated at the time of the valuation.

The market multiple methodology involved the multiplication of revenue by risk-adjusted multiples. Multiples were determined through an analysis of certain publicly traded companies, which were selected on the basis of operational and economic similarity with our principal business operations. Revenue multiples, when applicable, were calculated for the comparable companies based upon daily trading prices. A comparative risk analysis between us and the public companies formed the basis for the selection of appropriate risk-adjusted multiples for our company. The risk analysis incorporated factors that relate to, among other things, the nature of the industry in which we and other comparable companies are engaged. The comparable transaction methodology also involved multiples of earnings and cash flow. Multiples used in this approach were determined through an analysis of transactions involving controlling interests in companies with operations similar to our principal business operations. The discounted cash flow methodology involved estimating the present value of the projected cash flows to be generated from the business and theoretically available to the capital providers of our company. A discount rate was applied to the projected future cash flows to reflect all risks of ownership and the associated risks of realizing the stream of projected cash flows. Since the cash flows were projected over a limited number of years, a terminal value was computed as of the end of the last period of projected cash flows. The terminal value was an estimate of the value of the enterprise on a going concern basis as of that future point in time. Discounting each of the projected future cash flows and the terminal value back to the present and summing the results yielded an indication of value for the enterprise. Our board of directors took these three approaches into consideration when establishing the fair value of our ordinary shares.

The fair value of our ordinary shares was initially established on July 18, 2006, based on the price per share paid by the Investor Group's initial acquisition. During the first quarter of 2007, we sold approximately \$92.6 million of additional ordinary shares to our existing shareholders at a price of \$4.63 per share to fund certain acquisitions. This price was then used as the fair value of our ordinary shares until December 31, 2007. During 2007, we began to integrate three acquired companies, all of which expanded our product portfolio and helped to increase our sales by 22%. On January 1, 2008, we increased the value of our ordinary shares to \$5.66 per share based on the conclusions of our board of directors in analyzing several factors including an independent valuation. We believe this increase in fair value was warranted based on several factors including our continued revenue growth and broadening product portfolio, offset by our increased operating expenses from the acquired business. From January 1, 2008 to December 27, 2009, we granted 3,316,250 stock options at an exercise price of \$5.66 per share. During this period, we continued to experience revenue growth through continued product launches, new product licensing transactions and increased volumes and market share. However, during the same period we increased manufacturing costs and operating expenses to build an operational foundation on which we could sustain continued double digit revenue growth. As a result, we experienced a decrease in our operating profitability and higher levels of cash used to sustain our operations than compared to 2007. As a result of our continued high growth offset by increased spending levels, we determined that a change in the fair value of our ordinary shares was not necessary. This determination was supported by the fact that, during this time, we sold additional shares of our

Table of Contents

ordinary shares to various investors, including former shareholders of one of our 2007 acquisitions and certain other business partners all at a price of \$5.66 per share. During this time, we also raised additional working capital through the sale of \$52.4 million of notes payable and warrants in February 2008 and \$49.3 million of notes payable and warrants in April 2009. These sales of notes payable and warrants were to a combination of then current investors, certain new investors and members of management. In both instances, the exercise price of the warrants sold was set at \$5.66 per share as we continued to estimate the value of our ordinary shares to be \$5.66 per share. On December 27, 2009, we decided to increase our estimate of the fair value of our ordinary shares to \$7.50 per share. Our estimated fair value of \$7.50 per share was determined by our board of directors based on several factors including an independent valuation discussed previously. We believed the increase in the estimated fair value of our ordinary shares was appropriate during 2009 as our sales continued to grow at a high rate while our operating profit, excluding depreciation, amortization and share-based compensation, began to increase and our cash flow from operations also improved substantially. Stock options granted during these periods had exercise prices equal to the then estimated fair value of our ordinary shares.

Although it is reasonable to expect that the completion of our initial public offering will increase the value of our ordinary shares as a result of increased liquidity and marketability, at this stage the amount of additional value cannot be measured with precision or certainty.

**Recent Accounting Pronouncements**

We adopted the FASB Accounting Standards Codification, or ASC, Topic 105 as the single official source of authoritative, nongovernmental generally accepted accounting principles in the United States. On the effective date, all then-existing non-SEC accounting literature and reporting standards were superseded and deemed non-authoritative. The adoption of this pronouncement did not have a material impact on our consolidated financial statements; however, the ASC affected the way we reference authoritative guidance in our consolidated financial statements.

In December 2007, the FASB issued ASC Topic 805, formerly SFAS No. 141(R), Business Combinations. ASC Topic 805 establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. ASC Topic 805 is to be applied prospectively to business combinations for which the acquisition date is during or after 2009. As the guidance is applied prospectively, the adoption did not have a material impact on our current consolidated financial statements or results of operations.

In December 2007, the FASB also issued ASC Topic 810, formerly SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB 51. ASC Topic 810 changes the accounting and reporting for minority interests, which are recharacterized as noncontrolling interests and classified as a component of equity. ASC Topic 810 required retroactive adoption of the presentation and disclosure requirements for existing minority interests. The guidance became effective for fiscal years beginning on or after December 15, 2008, and interim periods within those fiscal years. The impact of adoption on the consolidated financial statements was immaterial.

In March 2008, the FASB issued ASC Topic 815, formerly SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities, an amendment to SFAS No. 133. ASC Topic 815 requires increased disclosure of our derivative instruments and hedging activities, including how derivative instruments and hedging activities affect consolidated statement of earnings, balance sheets and cash flows. The guidance was effective for fiscal years beginning on or after December 15, 2008,

Table of Contents

and interim periods within those fiscal years. The adoption of this guidance did not have a material impact on our financial position or results of operations.

In July 2006, the FASB issued ASC Topic 740, formerly FASB Interpretation No. (FIN) 48, Accounting for Uncertainty in Income Taxes An Interpretation of FASB Statement No. 109. ASC Topic 740 clarifies the accounting for uncertainty in income taxes recognized in a company's financial statements by defining the criterion that an individual tax position must meet in order to be recognized in the financial statements. ASC Topic 740 requires that the tax effects of a position be recognized only if it is more likely than not to be sustained based solely on the technical merits as of the reporting date. ASC Topic 740 further requires that interest that the tax law requires to be paid on the underpayment of taxes should be accrued on the difference between the amount claimed or expected to be claimed on the return and the tax benefit recognized in the financial statements. ASC Topic 740 also requires additional disclosures of unrecognized tax benefits, including a reconciliation of the beginning and ending balance. On December 30, 2008, the FASB further delayed the effective date of this guidance for certain non-public enterprises until annual financial statements for fiscal years beginning after December 15, 2008. We adopted these provisions of ASC Topic 740 in 2009. We recognized \$0.3 million in retained earnings as the impact of adoption. Refer to Note 11 to our consolidated financial statements and related notes thereto for details regarding the impact of adoption.

In June of 2008, the Emerging Issues Task Force, or EITF, issued ASC Topic 815, formerly EITF Issue 07-5, Determining Whether an Instrument (or an Embedded Feature) Is Indexed to an Entity's Own Stock. ASC Topic 815 addresses how an entity should determine if an instrument (or an embedded feature), such as the warrants issued by us in 2008 and 2009, is indexed to its own stock. The EITF reached a consensus that establishes a two-step approach to making this assessment. In the first step, an entity evaluates any contingent exercise provisions. In the second step, an entity will evaluate the instruments' settlement provisions. This guidance became effective for fiscal year 2009 for us, and is accounted for as a change in accounting principle through prospective application, with the cumulative effect of adoption of \$0.9 million recognized in accumulated deficit. In addition, adoption of this guidance required that warrants issued by us in 2008 be reclassified from equity to a liability. These warrants, as well as warrants issued in 2009, are now carried at fair value on the consolidated balance sheet as warrant liabilities. These liabilities were adjusted to fair value through current period earnings. We have subsequently settled our warrant liability in May of 2010 by exchanging all the outstanding warrants for our ordinary shares. See Note 8 to our consolidated financial statements and related notes thereto for further discussion.

**Quantitative and Qualitative Disclosures About Market Risk**

We are exposed to various market risks, which may result in potential losses arising from adverse changes in market rates and prices, such as interest rates and foreign currency exchange rate fluctuations. We do not enter into derivatives or other financial instruments for trading or speculative purposes. We believe we are not exposed to a material market risk with respect to our invested cash and cash equivalents.

***Interest Rate Risk***

Borrowings under our various revolving lines of credit in the United States and in Europe generally bear interest at variable annual rates. Borrowings under our various term loans in the United States and Europe are mixed between variable and fixed interest rates. As of April 4, 2010, we had \$17.8 million in borrowings under our revolving lines of credit and \$29.8 million in borrowings under various term loans. Based upon this debt level, a 10% increase in the interest rate on such borrowings would not have a material impact on interest expense.



Table of Contents

At April 4, 2010, our cash and cash equivalents were \$38.3 million. Based on our annualized average interest rate, a 10% decrease in the interest rate on such balances would result in an immaterial impact on an annual basis.

***Foreign Currency Exchange Rate Risk***

Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our financial results. In the first quarter of 2010 and fiscal years 2009 and 2008, approximately 45%, 43% and 48%, respectively, of our sales were denominated in foreign currencies. We expect that foreign currencies will continue to represent a similarly significant percentage of our sales in the future. Operating expenses related to these sales are largely denominated in the same respective currency, thereby limiting our transaction risk exposure. We therefore believe that the risk of a significant impact on our operating income from foreign currency fluctuations is not significant. However, for sales not denominated in U.S. dollars, if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In such cases and if we price our products in the foreign currency, we will receive less in U.S. dollars than we did before the rate increase went into effect. If we price our products in U.S. dollars and competitors price their products in local currency, an increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is transacted in the local currency.

In 2009, approximately 91% of our sales denominated in foreign currencies were derived from EU countries and were denominated in Euros. Additionally, we have significant intercompany payables and debt with certain European subsidiaries, which are denominated in foreign currencies, principally the Euro. Our principal exchange rate risk therefore exists between the U.S. dollar and the Euro. Fluctuations from the beginning to the end of any given reporting period result in the remeasurement of our foreign currency-denominated cash, receivables, payables and debt-generating currency transaction gains or losses that impact our non-operating revenue/expense levels in the respective period and are reported in foreign currency transaction gain (loss) in our consolidated financial statements. We recorded a foreign currency transaction loss of approximately \$0.9 million in 2009 related to the translation of our foreign-denominated receivables, payables and debt into U.S. dollars. We do not currently hedge our exposure to foreign currency exchange rate fluctuations. We may, however, hedge such exposure to foreign currency exchange rates in the future.

**Controls and Procedures**

We have not performed an evaluation of our internal control over financial reporting, such as required by Section 404 of the Sarbanes-Oxley Act, nor have we engaged our independent registered public accounting firm to perform an audit of our internal control over financial reporting as of any balance sheet date or for any period reported in our financial statements. Had we performed such an evaluation or had our independent registered public accounting firm performed an audit of our internal control over financial reporting, control deficiencies, including material weaknesses and significant deficiencies, in addition to those discussed below, may have been identified.

Solely in connection with the audit of our consolidated financial statements for 2007, 2008 and 2009, we and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness consisted of our lack of policies and procedures, with the associated internal controls, to appropriately identify, evaluate and document accounting analysis and conclusions for complex, non-routine transactions including related party transactions.

Table of Contents

Certain related party transactions that occurred in 2006, 2007 and 2008 were either not identified by us on a timely basis, or inappropriate accounting conclusions were reached at the time of the transactions. These transactions were identified and appropriate accounting conclusions were reached during 2009 in conjunction with our financial statement close process and the audit of our 2009 financial statements by our independent registered public accounting firm. We have taken numerous steps and plan to take additional steps intended to address the underlying causes of the material weakness, primarily through the development and implementation of formal policies, improved processes and documented procedures, and the hiring of additional accounting and finance personnel as necessary. The actions that we have taken are subject to ongoing senior management review, as well as audit committee oversight.

Presently, we are not an accelerated filer, as such term is defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and therefore our management team is not currently required to perform an annual assessment of the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is not required to express an opinion on management's assessment and on the effectiveness of our internal control over financial reporting. These requirements will first apply to our annual report on Form 10-K for our fiscal year ending January 1, 2011.

Notwithstanding the material weaknesses described above, we have performed additional analyses and other procedures to enable management to conclude that our consolidated financial statements included in this filing were prepared in accordance with U.S. generally accepted accounting principles.

Table of Contents

**BUSINESS**

*Overview*

We are a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. We refer to these surgeons as extremity specialists. We sell to this extremity specialist customer base a broad line of joint replacement, trauma, sports medicine and orthobiologic products to treat extremity joints. Our motto of "specialists serving specialists" encompasses this focus. In certain international markets, we also offer joint replacement products for the hip and knee. We currently sell over 70 product lines in approximately 35 countries.

We have had a tradition of innovation, intense focus on surgeon education and commitment to advancement of orthopaedic technology since our founding approximately 70 years ago in France by René Tornier. Our history includes the introduction of the porous orthopaedic hip implant, the application of the Morse taper, which is a reliable means of joining modular orthopaedic implants, and, more recently, the introduction of the reversed shoulder implant in the United States. This track record of innovation over the decades stems from our close collaboration with leading orthopaedic surgeons and thought leaders throughout the world.

We were acquired in 2006 by the Investor Group. They recognized the potential to leverage our reputation for innovation and our strong extremity joint portfolio as a platform upon which they could build a global company focused on the rapidly evolving upper and lower extremity specialties. The Investor Group has contributed capital resources and a management team with a track record of success in the orthopaedic industry in an effort to expand our offering in extremities and accelerate our growth. Since the acquisition in 2006, we have:

created a single, extremity specialist sales channel in the United States primarily focused on our products;

enhanced and broadened our portfolio of shoulder joint implants and foot and ankle products;

entered the sports medicine and orthobiologics markets through acquisitions and licensing agreements;

improved our hip and knee product offerings, helping us gain market share internationally; and

significantly increased investment in research and development and expanded business development activities to build a pipeline of innovative new technologies.

As a result of the foregoing actions, we believe our addressable worldwide market opportunity has increased from approximately \$2 billion in 2006 to approximately \$7 billion in 2009.

We believe we are differentiated by our full portfolio of upper and lower extremity products, our dedicated extremity-focused sales organization and our strategic focus on extremities. We further believe that we are well-positioned to benefit from the opportunities in the extremity products marketplace as we are already among the global leaders in the shoulder and ankle joint replacement markets with the #2 market position worldwide for sales of shoulder joint replacement products and the #1 market position in the United States in foot and ankle joint replacement systems in 2009 as measured by revenue. We more recently have expanded our technology base and product offering to include: new joint replacement products based on new materials; improved trauma products based on innovative designs; and proprietary orthobiologic materials for soft tissue repair. In the United States, which is the largest orthopaedic market, we believe that our single, "specialists serving specialists" distribution channel is strategically aligned with what we believe is an ongoing trend in orthopaedics for surgeons to specialize in certain parts of the anatomy or certain types of procedures.

Table of Contents

Our principal products are organized in four major categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics, and large joints and other. Our upper extremity products include joint replacement and bone fixation devices for the shoulder, hand, wrist and elbow. Our lower extremity products include joint replacement and bone fixation devices for the foot and ankle. Our sports medicine and orthobiologics product category includes products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries, in the case of sports medicine, or to support or induce remodeling and regeneration of tendons, ligaments, bone and cartilage, in the case of orthobiologics. Our large joints and other products include hip and knee joint replacement implants and ancillary products.

Innovations in the orthopaedic industry have typically consisted of evolutions of product design in implant fixation, joint mechanics, and instruments and modifications of existing metal or plastic-based device designs rather than new products based on combinations of new designs and new materials. In contrast, the growth of our target markets has been driven by the development of products that respond to the particular mechanics of small joints and the importance of soft tissue to small joint stability and function. We are committed to the development of new designs utilizing both conventional materials and new tissue-friendly biomaterials that we expect will create new markets. We believe that we are a leader in researching and incorporating some of these new technologies across multiple product platforms.

In the United States, we sell products from our upper extremity joints and trauma, lower extremity joints and trauma, and sports medicine and orthobiologics product categories; we do not actively market large joints in the United States nor do we currently have plans to do so. While we market our products to extremity specialists, our revenue is generated from sales to healthcare institutions and distributors. We sell through a single sales channel consisting of a network of independent commission-based sales agencies. Internationally, where the trend among surgeons toward specialization is not as advanced as in the United States, we sell our full product portfolio, including upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics and large joints. We utilize several distribution approaches depending on the individual market requirements, including direct sales organizations in the largest European markets and independent distributors for most other international markets. In 2009, we generated revenue of \$201.5 million, 57% of which was in the United States and 43% of which was international.

***Our Business Strategies***

Our goal is to strengthen our leadership position serving extremity specialists. The key elements of our strategy include:

*Leveraging our "specialists serving specialists" strategy:* We believe our focus on and dedication to extremity specialists enables us to better understand and address the clinical needs of these surgeons. We believe that extremity specialists, who have emerged as a significant constituency in orthopaedics only in the last ten to 15 years, have been underserved in terms of new technology and also inefficiently served by the current marketplace. We offer a comprehensive portfolio of extremity products, and also serve our customers through a sales channel that is dedicated to extremities, which we believe provides us with a significant competitive advantage, because our sales agencies and their representatives have both the knowledge and desire to comprehensively meet the needs of extremity specialists and their patients, without competing priorities.

*Advancing scientific and clinical education:* We believe our specialty focus, commitment to product innovation and culture of scientific advancement attract both thought leaders and up-and-coming surgeon specialists who share these values. We actively involve these specialists in the development of world-class training and education programs and encourage ongoing scientific study of our products. Specific initiatives include the Tornier Master's Courses in shoulder and ankle joint replacement, The Fellows and Chief Residents Courses, and a number of clinical concepts courses. We

Table of Contents

also maintain a registry that many of our customers utilize to study and report on the outcomes of procedures in which our extremity products have been used. We believe our commitment to science and education also enables us to reach surgeons early in their careers and provide them access to a level of training in extremities that we believe is not easily accessible through traditional orthopaedic training.

*Introducing new products and technologies to address more of our extremity specialists' clinical needs:* Our goal is to continue to introduce new technologies for extremity joints that improve patient outcomes and thereby continue to expand our market opportunity and share. Our efforts have been focused on joint replacement, as well as sports medicine and orthobiologics, given the importance of these product categories to extremity surgeons. Since our acquisition by the Investor Group, we have significantly increased our investment in research and development to accelerate the pace of new product introduction. During 2009, we invested \$18.1 million in research and development and introduced 18 new products, and in 2008, we invested \$20.6 million and introduced nine new products, up from only \$13.3 million and four new products in 2007. We have also been active in gaining access to new technologies through external partnerships, licensing agreements and acquisitions. We believe that our reputation for effective collaboration with industry thought leaders as well as our track record of effective new product development and introductions will allow us to continue to gain access to new ideas and technologies early in their development.

*Expanding our international business:* We face a wide range of market dynamics that require our distribution channels to address both our local market positions and local market requirements. For example, in France, which is a more developed extremities market and where we have a diversified extremities, hip and knee business, we have two direct sales organizations. One is focused on products for upper extremities, and the other focused on hip and knee replacements and products for lower extremities. In other European markets, we utilize a combination of direct and distributor strategies that have evolved to support our expanding extremity business and also to support our knee and hip market positions. In large international markets where the extremity market segment is relatively underdeveloped, such as Japan and China, the same sales channel sells our hip and knee product portfolios and extremity joint products, which provides these sales channels sufficient product breadth and economic scale. We plan on expanding our international business by continuing to adapt our distribution channels to the unique characteristics of individual markets.

*Achieving and improving our profitability through operating leverage:* With the additional capital resources brought by the Investor Group, we have made significant investments over the last several years in our research and development, sales and marketing, and manufacturing operations to build what we believe is a world-class organization capable of driving sustainable global growth. For example, we grew our research and development organization from approximately 20 employees as of December 31, 2006 to 79 employees as of December 27, 2009. We created a new global sales and marketing leadership team by integrating key personnel from acquired organizations and recruiting additional experienced medical device sales and marketing professionals. We also expanded our manufacturing capacity with two new plants in Ireland and France. With these organizational and infrastructure investments in place, we believe we have the infrastructure to support our growth for the foreseeable future. As a result, we believe we can increase revenue and ultimately achieve and improve profitability.

***Our Surgeon Customers***

We estimate that there are over 80,000 orthopaedic and over 9,000 podiatric surgeons worldwide who specialize in surgical treatment of the musculoskeletal system, including bones, joints and soft tissues such as tendons and ligaments. In the United States and certain other developed markets, there has been a trend over the past two decades for these surgeons to specialize in certain parts of the anatomy or certain types of procedures. We believe that the trend toward specialization has

Table of Contents

been supported by the expansion of specialist professional societies and an increase in the number of fellowship programs. We focus on the following orthopaedic specialist groups:

*Upper Extremity Specialists:* Upper extremity specialists perform joint replacement and trauma and soft tissue repair procedures for the shoulder, elbow, wrist and hand. We believe the evolution of this specialty has been driven by the unique requirements of these joints due to the relative importance of soft tissue to joint function and the increased complexity and breadth of technology available for use in these procedures. For this reason, in addition to joint replacement and trauma products, upper extremity specialists utilize a broad range of sports and orthobiologic products. We believe upper extremity specialists now perform the majority of shoulder joint replacements that were previously performed by reconstructive and general orthopaedic surgeons.

*Lower Extremity Specialists:* Lower extremity specialists perform a wide range of joint replacement, trauma, reconstruction and soft tissue repair procedures for the foot and ankle. This specialist group principally consists of orthopaedic surgeons who have received fellowship or other specialized training. Additionally, Doctors of Podiatric Medicine with special surgical training may perform certain foot and ankle surgical procedures in the United States, Canada and United Kingdom.

*Sports Medicine Specialists:* Sports medicine specialists are surgeons who use minimally invasive surgical techniques, including arthroscopy, for the repair of soft tissues. Arthroscopy is a minimally invasive surgical technique in which a surgeon creates several small incisions at the surgery site; inserts a fiber optic scope with a miniature video camera as well as surgical instruments through the incisions to visualize, access and conduct the procedure; and uses a video monitor to view the surgery itself. The sports medicine specialty is not just limited to treatment of athletes, but rather all patients with orthopaedic soft tissue injuries or disease. The most common sports medicine procedures are ligament repairs in the knee and rotator cuff tendon repair in the shoulder.

*Reconstructive and General Orthopaedic Surgeons:* Reconstructive and general orthopaedic surgeons are important customers for us in selected European countries and other international markets. In these markets orthopaedic surgeons may treat multiple areas of bone and joint disease and trauma, and commonly perform procedures involving extremity joints as well as hip and knee joint replacement. For these target customers, we are able to provide not only our broad product category for extremity joint procedures, but also our hip and knee joint replacement products.

***Our Target Markets***

We compete on a worldwide basis providing upper and lower extremity specialist surgeons a wide range of products from several major segments of the orthopaedic market, including extremity joints, sports medicine, orthobiologics and trauma. In addition, we compete in the hip and knee segments of certain international markets where we have a strong legacy presence such as in France, where participation in the local hip and knee market is important to our distributor partners, and in China, where the market for our extremity focused products is still small. The table below provides the estimated portion of the various market segments that are addressed by our currently marketed products as well as the estimated compound annual growth rate, or CAGR, for each market segment.

Table of Contents

The table also provides an estimate of the total market size, which includes the portion addressable by our products, for each of the market segments.

	Estimated addressable market		Estimated total global
	2009	2009-2013	orthopaedic market(2)
	market size	estimated	2009
	(\$ in billions)	CAGR	market size
			(\$ in billions)
Extremity Joints	\$ 0.9(1)	11%(1)	\$ 0.9
Sports Medicine	\$ 1.1(1)	10%(1)	\$ 3.3
Orthobiologics	\$ 0.7(1)	11%(1)	\$ 3.9
Trauma	\$ 2.3(1)	12%(1)	\$ 5.2
Knee Joints	\$ 1.0(2)	5%(2)	\$ 6.8
Hip Joints	\$ 0.9(2)	5%(2)	\$ 5.7
Spine	NA	NA	\$ 7.2
<b>Total</b>	<b>\$ 7.0</b>	<b>10%</b>	<b>\$ 33.0</b>

(Sum of numbers may not match total due to rounding)

(1) Based on data provided by Millennium Research Group.

(2) Based on management's experience and industry data. Our hip and knee addressable market is limited to selected international geographies.

We believe our addressable portion of the market will grow at a faster rate than the overall orthopaedic market due to the introduction of new technologies with improved clinical outcomes, a growing number of extremity specialists, the aging of the general population and the desire for people to remain physically active as they grow older. Overviews of the major orthopaedic markets in which we compete, as well as our targeted participation in those markets, are as follows:

**Extremity Joints:** The extremity joint market includes implantable devices used for the replacement of shoulder, elbow, hand, and foot and ankle joints. We believe this market has been under-served and underdeveloped by major orthopaedic companies, which have generally focused on the much larger hip, knee and spine markets. As a result, the growth of the extremity joint market is still benefiting from market-expanding design and materials technologies and from growth in the number of upper and lower extremity specialists. We believe that we are a leader in both the shoulder and ankle joint replacement portions of this market based upon revenue.

**Sports Medicine:** Sports medicine refers to the repair of soft tissue injuries that often occur when people are engaged in physical activity, but that also result from age-related wear and tear. We believe market growth has been driven by both new technology and the continued acceptance of minimally invasive surgical techniques. The most common sports medicine procedures are anterior cruciate ligament repairs in the knee and rotator cuff repairs in the shoulder. The primary sports medicine products include capital equipment and related disposables as well as bone anchors, which are implantable devices used to attach soft tissue to bone, sutures, or thread for soft tissue, and handheld instruments. We estimate that our products currently address only a portion of the sports medicine market, primarily bone anchors and other products utilized for rotator cuff repairs. The total sports medicine market also includes capital or powered equipment and related disposables, but we do not have any product offerings in these areas.

**Orthobiologics:** Orthobiologics refer to products, both biologic and synthetic, that are utilized to stimulate hard and soft tissue healing following surgery for a wide range of orthopaedic injuries or disorders. We believe market growth is being driven by the application of an expanding biotechnology knowledge base to the development of products that can improve clinical outcomes by inducing tissue healing and regeneration. The primary product categories in the total orthobiologics market are bone

Table of Contents

grafting materials, cell therapy systems, including growth factors, and tendon and ligament grafts. We currently only offer tendon and ligament graft products for extremities.

**Trauma:** The trauma market includes devices that are used to treat fractures, joint dislocations, severe arthritis and deformities that result from either acute injuries or chronic wear and tear. The major products in the trauma market include metal plates, screws, pins, wires and external fixation devices used to hold fractured bone fragments together until they heal properly. These devices are also utilized in the treatment of a wide range of non-traumatic surgical procedures, especially in the foot and ankle. As the market has transitioned from external casting performed in the emergency room, to internal fixation performed on a scheduled basis in the operating room, our extremity specialist customers have expanded their role in treating trauma injuries. Our products currently address only a portion of the trauma market, consisting primarily of plating systems, screws and pins for the repair of extremity joint injuries and disorders.

**Knee Joints:** Knee joint replacements are performed for patients who have developed an arthritic condition that compromises the joints' articulating surfaces (articulating surfaces are bone segments connected by a joint). The knee joint replacement system has multiple components including a femoral component, a tibial component and a patella component (knee cap). We currently provide a broad line of knee joint replacement products in selected international geographies. We do not currently address the knee joint market in the United States.

**Hip Joints:** Hip joint replacements are performed for patients who have suffered a femoral fracture or suffer from severe arthritis or other conditions that have led to the degradation of the articular cartilage or bone structure residing between the femoral head and the acetabulum (hip socket). The hip joint replacement system generally includes both femoral and acetabular components. We currently provide a broad line of hip joint replacement products in selected international geographies. We do not currently address the hip joint market in the United States.

**Our Product Portfolio**

We offer a broad product line designed to meet the needs of our extremity specialists and their patients. Although the industry traditionally organizes the orthopaedic market based on the mechanical features of the products, we organize our product categories in a way that aligns with the types of surgeons who use them. Therefore, we distinguish upper extremity joints and trauma from lower extremity joints and trauma, as opposed to viewing joint implants and trauma products as distinct product categories. Along these lines, our product offering is as follows:

<b>Product category</b>	<b>Target addressable geography</b>	<b>Estimated addressable market size 2009 (\$ in billions)(1)</b>	
Upper extremity joints and trauma	United States and International	\$	2.0
Lower extremity joints and trauma	United States and International	\$	1.2
Sports medicine and orthobiologics	United States and International	\$	1.8
Large joints and other	Selected International Markets	\$	1.9
<b>Total</b>		<b>\$</b>	<b>7.0</b>

(Sum of numbers may not match total due to rounding)

(1) Based on data provided by Millennium Research Group, except for large joints and other. Large joints and other estimated addressable market data is based on management's experience and industry data.

See Fiscal Year Comparisons contained in the Management's Discussion and Analysis of Financial Condition and Results of Operation section of this prospectus for three year revenue history by product category.



Table of Contents***Upper Extremity Joints and Trauma***

The upper extremity joints and trauma product category includes joint implants and bone fixation devices for the shoulder, hand, wrist and elbow. Our global revenue from this category for the year ended December 27, 2009, was \$125.5 million, or 62% of revenue, which represents growth of 15% over the prior fiscal year.

*Shoulder Joint Replacement and Trauma Implants* We believe we had the #2 market position worldwide for sales of shoulder joint replacement products in 2009 as measured by revenue. We expect the shoulder to continue to be the largest and most important product category for us for the foreseeable future. Our shoulder joint implants are used to treat painful shoulder conditions due to arthritis, irreparable rotator cuff tendon tears, bone disease, fractured humeral heads or failed previous shoulder replacement surgery. Our products are designed for the following:

Our total joint replacement products have two components – a humeral implant consisting of a metal stem attached to a metal ball, and a plastic implant for the glenoid (shoulder socket). Together, these two components mimic the function of a natural shoulder joint.

Our hemi joint replacement products replace only the humeral head and allow it to articulate against the native glenoid.

Our reversed implants are used in arthritic patients lacking rotator cuff function. The components are different from a traditional "total" shoulder in that the humeral implant has the plastic socket and the glenoid has the metal ball. This design has the biomechanical impact of shifting the pivot point of the joint away from the body centerline and giving the deltoid muscles a mechanical advantage to enable the patient to elevate the arm.

Our resurfacing implants are designed to minimize bone resection to preserve bone, which may benefit more active or younger patients with shoulder arthritis.

Trauma devices, such as plates, screws and nails, are non-articulating implants used to help stabilize fractures of the humerus.

We offer a complete range of these shoulder implants as described in the table below:

***Shoulder Joint Replacement and Trauma Implants***

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
Aequalis Shoulder Joint	Shoulder joint replacement implant to treat pain or disability due to arthritis, severe trauma and other conditions. The Aequalis system includes versions for traditional resurfacing, reverse, fracture and reverse fracture joint replacement.	1991-2009	United States and International
Affiniti Shoulder Joint	Shoulder joint replacement implant to treat pain or disability due to arthritis, severe trauma and other conditions. The Affiniti system is designed to facilitate a simple, reproducible surgical technique.	2007	United States and International
Ascend Shoulder Joint	Shoulder joint replacement implant to treat pain or disability due to arthritis, severe trauma and other conditions. The Ascend system is a bone-sparing design.	2009	United States
Aequalis Trauma Systems	Specialty shoulder plates and nails for reconstruction of humeral fractures.	2007-2009	United States and International

Table of Contents

*Hand, Wrist and Elbow Joint Replacement and Trauma Implants* We offer joint replacement products that are used to treat arthritis in the hand, wrist and elbow. In addition, we offer trauma products including plates, screws and pins, to treat fractures of the hand, wrist and elbow. One of our distinctive product offerings for these smaller, non-load bearing joints are implants made from a biocompatible material called pyrocarbon, which has low joint surface friction and a high resistance to wear. We offer a wide range of pyrocarbon implants internationally and have begun to introduce some of these products into the United States. Our hand, wrist and elbow products are described in the table below:

*Hand, Wrist and Elbow Joint Replacement and Trauma Implants*

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
CoverLoc Wrist Plate	Metallic trauma plate used to stabilize wrist fractures as they heal. The CoverLoc technology allows the screws to pull bone fragments to the plate and lock them for stability, while also covering the screw heads to minimize soft tissue irritation.	2006	United States and International
Latitude Elbow	Elbow joint replacement implant to treat pain or disability due to arthritis, severe trauma and other conditions. The Latitude system provides for anatomic reconstruction of the elbow joint.	2000	United States and International
Pyrocarbon Radial Head	Radial head (of the elbow joint) replacement implant made of pyrocarbon and titanium to treat pain or disability due to arthritis, severe trauma, and other conditions.	2002	International
RHS Radial Head System	Radial head (of the elbow joint) replacement implant to treat pain or disability due to arthritis, severe trauma and other conditions. The anatomic bipolar system consists of multiple stem diameters and head sizes to match a wide range of patients.	2006	United States and International
Pyrocarbon Hand and Wrist	A range of spacers and joint replacements manufactured from pyrocarbon for arthritic bones to relieve pain and restore function of the hand and wrist joints.	1994-2009	International (some thumb implants in the United States)
Intrafocal Pin Plate	Internal pin-and-plate fixation system for minimally invasive stabilization of wrist fractures.	2005	United States and International

Table of Contents***Lower Extremity Joints and Trauma***

Our global revenue from lower extremity joints and trauma for the year ended December 27, 2009, was \$20.4 million, 10% of revenue, which represents growth of 12% over the prior fiscal year.

***Ankle Joint Implants*** We believe we held the #1 market position by revenue in the United States in foot and ankle joint replacement systems in 2009. Ankle arthritis is a painful condition that can be treated by fusing the ankle joint with plates or screws or by replacing the joint with an articulating multi-component implant. These joint implants may be mobile bearing, in which the plastic component is free to slide relative to the metal bearing surfaces, or fixed bearing, in which this component is constrained. Precision bearing implants are highly anatomic fixed bearing implants. These products include:

***Ankle Joints Implants***

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
Salto Talaris Ankle Joint	Total ankle joint replacement implant to treat pain or disability from severe arthritis. The Salto Talaris is a precision bearing (2-part) implant.	2007	United States
Salto Ankle Joint	Total ankle joint replacement implant to treat pain or disability from severe arthritis. The Salto is a mobile bearing (3-part) implant.	1997	International

***Other Foot and Ankle Joint and Trauma Implants*** Our products include joint replacement implants to treat arthritis of the toes and other small bone joints, trauma and bone fusion implants for

Table of Contents

the foot and ankle, and other implants to address certain other deformities of the foot. These products include:

***Other Foot and Ankle***

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
Nexfix Fixation System	Specialty plates, compression screws and pins with instrumentation designed to facilitate bone and joint fusion procedures of the foot.	2007	United States and International
Futura Foot Implants	The Futura product line includes forefoot joint replacement implants to treat pain or disability from severe arthritis or other conditions, and flatfoot correction implants.	1996-2004	United States and International
Stayfuse Fusion System	A two-part locking implant to fuse joints of the toes.	2001	United States and International
Wave Calcaneal Plate	Metallic trauma plate used in calcaneal fractures (heel bone) with a small incision.	2009	United States
Ankle Fusion Plate	Specialty CoverLoc plates to stabilize the ankle joint for fusion procedures.	2010	United States
Resorbable Fixation System	Bioresorbable pins and screws used in trauma and bone fusion to stabilize bone fragments.	2007	United States and Selected International Countries
Osteocure	Cylindrical and wedge shaped implants with a bioresorbable, porous scaffold to support bony in-growth and to fill defects left by surgery, trauma or disease in the foot.	2005	United States

***Sports Medicine and Orthobiologics***

Our revenue from sports medicine and orthobiologics for the year ended December 27, 2009, was \$6.6 million, or 3.3% of overall revenue, which represents growth of 162% over the prior fiscal year. Nearly all of our products in this product category were launched during the first half of 2009 and only in the United States. We have introduced many of these products internationally in 2010.

*Sports Medicine* The sports medicine product category includes products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries. Because of its close relationship to shoulder joint replacement, the sports medicine market is of critical strategic importance to us. Rotator cuff repair is the largest sub-segment in the sports medicine market. Other procedures

Table of Contents

include shoulder instability treatment, Achilles tendon repair and soft tissue reconstruction of the foot and ankle and several other soft tissue repair procedures. Our current product offering includes:

*Sports Medicine*

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
Piton Knotless Suture Anchor	Knotless suture anchor fixation system for securing soft tissue to bone. Used for soft tissue procedures in the upper and lower extremities including rotator cuff and Achilles tendon repair.	2008	United States and Selected International Countries
ArthroTunneler	Single-use device for creating intersecting bone tunnels, which enable anchor-less fixation of tendon to bone in rotator cuff repair.	2009	United States and Selected International Countries
Insite Suture Anchors	Screw-in suture anchor fixation system for securing soft tissue to bone. Used for soft tissue procedures in the upper and lower extremities including rotator cuff and Achilles tendon repair. Insite implants are available in titanium, high strength polymer and resorbable polymer versions.	2008	United States and Selected International Countries

*Orthobiologics* The field of orthobiologics employs tissue engineering and regenerative medicine technologies focused on remodeling and regeneration of tendons, ligaments, bone and cartilage. Biologically or synthetically derived soft tissue grafts and scaffolds are used to treat soft tissue injuries and are complementary to many sports medicine applications, including rotator cuff tendon repair and Achilles tendon repair. Hard tissue orthobiologics products are used in many bone fusion or trauma cases where healing potential may be compromised and additional biologic factors are desired to enhance healing, where the surgeon needs additional bone stock and does not want to harvest a bone graft from another surgical site or in cases where the surgeon wishes to use materials that are naturally incorporated by the body over time in contrast to traditional metallic-based products that may require later removal. We recently commercialized our first orthobiologics product through an exclusive collaboration with LifeCell:

*Orthobiologics*

<b>Product</b>	<b>Description</b>	<b>Year of introduction</b>	<b>Region currently marketed</b>
Conexa	Orthobiologic reconstructive tissue matrix used in the repair of injured or surgically reconstructed soft tissue such as rotator cuff or Achilles tendons. The graft supports regeneration of soft tissue.	2008	United States and Selected International Countries

We have a robust pipeline of orthobiologics products under development and are actively pursuing new product additions. We have in-licensed biologic materials such as Biofiber, an advanced high-strength resorbable polymer fiber produced using recombinant DNA technology as well as our F2A peptide, a synthetic version of the natural human FGF-2 growth factor.

Table of Contents***Large Joints and Other***

The large joints and other product category includes hip and knee joint replacement implants and ancillary products. Hip and knee joint replacements are used to treat patients with painful arthritis in these larger joints. Our global revenue from large joints and other products for the year ended December 27, 2009, was \$49.0 million, or 24% of overall revenue, which represents growth of 2% over the prior fiscal year.

We generated nearly all of our revenue from this category outside of the United States. We have continued to innovate in this area so that we can maintain or grow market share in several international markets where the extremity markets have not yet reached a size to permit the type of channel focus that we have in the United States or where extremities specialization is not as prevalent as in the United States. We currently have no plans to actively market our large joint implants in the United States.

***Hip Joints***

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
Hip stems	Linea: The Linea anatomic stem is used for total hip replacement procedures. The implant is available in both cemented and cementless versions.	1992	International
	Oceane: The Oceane stem is used for total hip replacement for cemented applications.	1997-2009	International
	Meije Duo: The Meije Duo stem is used for total hip replacement procedures. The stem's taper is engineered to associate with ceramic femoral heads.	2005	International
Hip heads	Femoral heads are matched with hip stems and cups depending on the surgeon preference. Hip head materials include cobalt chrome, ceramic and high carbon content forged metal-on metal bearings.	1992-2002	International
Hip cups	Hip cups replace the damaged hip socket and articulate with the hip head implants. The hip cups include polyethylene, ceramic and metal materials in multiple configurations.	2003-2009	International
Pleos Hip Navigation System	The Pleos Computer-Assisted Surgery hip navigation system allows the surgeon to obtain optimum positioning of the implants.	2004	International

Table of Contents*Knee Joints*

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
HLS Knee Implants	Noetos: Knee joint replacement implant used to relieve pain caused by severe arthritis. It is available in cemented or cementless versions, and with fixed or mobile tibial bearings. Kneetec: Knee joint replacement implant used to relieve pain caused by severe arthritis with an improved anatomic shape.	2001	International
	Uni Evolution Knee: Bone-sparing resurfacing implant that replaces only one side of the knee to relieve pain due to arthritis localized to only one side of the knee	1996	International
Pleos Knee Navigation System	The Pleos Computer-Assisted Surgery knee navigation system allows the surgeon to simulate surgical approaches before actually cutting the femoral bone.	2007	International

*Instruments and Other*

<b>Product</b>	<b>Description</b>	<b>Year(s) of introduction</b>	<b>Region currently marketed</b>
TBCem Bone Cement	Bone cement is used to secure implant stems to bone. Four cements are available: standard or low viscosity, either with or without antibiotics.	2009	International
Instruments	Custom surgical instruments used to prepare the joint for the implant.	Various	United States and International

*Our Technologies*

The orthopaedic industry has produced many innovations in product design over the years. These innovations have typically consisted of evolutions of product design in implant fixation, joint mechanics, and instruments and modifications of existing metal or plastic-based device designs rather than new products based on combinations of new designs and new materials. In contrast, the growth of our target markets has been driven by the development of products that respond to the particular mechanics of small joints and the importance of soft tissue to small joint stability and function. We are committed to the development of new designs utilizing both conventional materials and new tissue-friendly biomaterials that we expect will create new product categories. We believe that we are a leader in researching and incorporating some of these new technologies across multiple product platforms. A few selected examples are listed below:

*Advanced Design Technologies*

**Bone sparing implants:** Several of our newer implants, such as our Ascend Shoulder, as well as our current implants, such as our Salto Talaris ankle implant, follow a philosophy of bone sparing site preparation to minimize the amount of native tissue that must be removed for

Table of Contents

the implant. We believe this philosophy results in a more anatomic implant that is less traumatic to the patient. By preserving native tissue, we believe surgeons retain more options compared to traditional implants should a revision procedure be required in the future.

**Adjustable locking plates:** We have incorporated CoverLoc technology into some of our plating systems, including wrist and ankle plates. CoverLoc technology is based upon high precision machining that places screw holes through metal plates at anatomic angles. Each hole is angled to achieve optimal screw or peg placement aimed at reducing the risk of screw loosening. Furthermore, the technology provides the surgeon the ability to pull bone fragments to the plate and then lock the screws in the desired angle with the cover plate, while providing protection for the surrounding soft tissues from the screw heads.

**Knotless suture locking:** Cinch technology is a patented mechanism that is the basis for our knotless suture anchor platform. The Piton suture anchor is the first product to incorporate Cinch technology. Cinch technology eliminates the need for knots while allowing surgeons to independently and sequentially tension each suture, even after inserters are removed. We believe this innovative design makes it easier for surgeons to perform arthroscopic surgery, eliminates knot slippage, and enables a uniform soft tissue repair across the repaired surface.

*Advanced Materials*

**Pyrocarbon:** This material is gaining acceptance for use in orthopaedics due to its biocompatibility, low joint surface friction and high resistance to wear. Pyrocarbon also has a stiffness similar to bone, making it an ideal material for orthopaedic implants. We offer several joint replacement or joint spacer devices made from pyrocarbon in the hand, wrist and elbow, and have recently announced what we believe to be the first human implant of a pyrocarbon shoulder implant.

**Resorbable polymers:** Some of our products utilize resorbable polymers, the benefit of which is that once a soft tissue injury has healed and the implant is no longer necessary, there is no longer a foreign substance residing in the body. Our Biofiber material is a high-strength resorbable polymer that can be processed in many physical configurations including fiber, mesh and film. These materials are biocompatible and non-inflammatory. They degrade by cell-friendly processes into metabolites that already exist in humans, unlike other acidic bioresorbable materials. We also offer high strength next-generation resorbable materials in our Resorbable Fixation System product line of trauma pins and screws. These products benefit from a combination of materials having a long history of surgical use and our supplier's ability to produce a high-strength, reliable, biodegradable implant.

*Orthobiologic Technologies*

**Orthobiologic tissue grafts:** Our Conexa reconstructive tissue matrix product line was introduced through a partnership with LifeCell. The Conexa material provides a complex three-dimensional biologic architecture to support cellular repopulation and vascular channels that allow for rapid capillary in-growth. Surgeons use this product in procedures to support regeneration of soft tissue, such as rotator cuff and Achilles tendons repairs.

**Synthetic Growth Factors:** F2A is an engineered peptide that is a synthetic version of the natural human FGF-2 growth factor. FGF-2 and other naturally occurring growth factors may play key roles in the body's healing and repair processes. Synthetic growth factors may address many of the manufacturing, handling and shelf life challenges that have limited the clinical role of natural growth factors. We have recently conducted pre-clinical testing of a scaffold incorporating F2A that demonstrates tissue regeneration in both small and large animal models. F2A has not yet been approved by the FDA.



Table of Contents

***Distribution***

We have developed our distribution channels to serve the needs of our customers, primarily extremity specialist surgeons in the United States and a mix of extremity specialist and general orthopaedic surgeons in international markets. In the United States, we have a broad offering of joint replacement and repair, sports and biologic products targeting extremity specialists through a single distribution channel. Internationally, we utilize several distribution approaches depending on individual market requirements. We utilize direct sales organizations in several mature European markets and independent sales agencies for most other international markets. In France, we have two direct sales forces, one handling our upper extremity focused products and one handling our lower extremity portfolio. In emerging international markets such as China and Japan, where extremity markets are still undeveloped, we utilize independent sales agencies that carry both our extremity-focused and our hip and knee portfolios.

*United States*

In the United States, we sell upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics products. We do not actively market hip or knee replacement joints in the United States, although we have FDA clearance for selected large joint products. We sell our products through a single sales channel. Our U.S. sales force consists of a network of approximately 23 independent commission-based sales agencies, which in aggregate utilized over 300 sales representatives as of April 4, 2010. We believe a significant portion of these sales agencies' commission revenue is generated by sales of our products. Our success depends largely upon our ability to motivate these sales agencies and their representatives to sell our products. Additionally, we depend on their sales and service expertise and relationships with the surgeons in the marketplace. Our independent sales agencies are not obligated to renew their contracts with us, may devote insufficient sales efforts to our products or may focus their sales efforts on other products that produce greater commissions for them. A failure to maintain our existing relationships with our independent sales agencies and their representatives could have an adverse effect on our operations. We do not control our independent sales agencies and they may not be successful in implementing our marketing plans. We employ four area business directors to support these independent sales agencies and have also recently started a Field Marketing Manager program, to help drive adoption of our newly introduced extremities, sports and orthobiologics products. During the course of the year, we host numerous opportunities for product training throughout the United States.

*International*

We sell our full product portfolio, including upper and lower extremities, sports medicine and orthobiologics and large joints, in most international markets. We believe our full range of hip and knee products enable us to more effectively and efficiently service these markets where procedure or anatomic specialization is not as prevalent as in the United States and where extremities, sports medicine and orthobiologics markets have not yet reached a size to permit the degree of channel focus we have in the United States. Our international distribution system consists of nine direct sales offices and approximately 32 distributors that sell our products in approximately 35 countries. Our largest international market is France, where we have a direct sales force of 26 direct sales representatives. We also have direct sales offices and corporate subsidiaries in Germany, Italy, Spain, Switzerland, The Netherlands, the United Kingdom, Denmark and Australia that employ direct sales employees. Additional European countries, as well as countries in Latin America and Asia, are served by distributors who purchase products directly from us for resale to their local customers, with product ownership generally passing to the distributor upon shipment. As part of our strategy to grow internationally, we have selectively converted from distributors to direct sales representation in certain countries, as we did in the United Kingdom and Denmark in 2009. We intend to focus on expanding

Table of Contents

our presence in underserved countries, such as China, where we signed an agreement in 2009 with the Weigao group for the exclusive distribution of our shoulder, hip and knee products for a four-year term. Under this agreement, Weigao committed to a minimum purchase amount of €418,000 for 2010. Purchase quotas and prices for the following years will be set at the end of each year. The agreement may be terminated prior to its expiration in 2014 upon breach by either party, including Weigao's failure to meet the purchase quota.

Our total revenue in France was \$46.3 million in 2009, \$43.2 million in 2008 and \$37.3 million in 2007. Our total revenue in The Netherlands was \$3.6 million in 2009, \$3.4 million in 2008 and \$2.9 million in 2007.

***Research and Development***

We are committed to a strong research and development program and have significantly increased our investment in this area since the acquisition by the Investor Group in 2006. Our research and development expenses were \$18.1 million, \$20.6 million and \$13.3 million in 2009, 2008 and 2007, respectively. As of April 4, 2010, we had a research and development staff of 79 people, or 10% of total employees, principally located in Warsaw, Indiana and Montbonnot, France, with additional staff in Grenoble, France, San Diego, California and Boston, Massachusetts.

We have dedicated internal product development teams focused on continuous innovation and introduction of new products for extremity joint replacements, extremity joint trauma, soft tissue repair and large joint replacement. We also have an active business development team that seeks to in-license development-stage products, which our internal team assists in bringing to market. In collaboration with our internal teams, we work closely with external research and development consultants and a global network of leading surgeon inventors to ensure we have broad access to best-in-class ideas and technology to drive our product development pipeline.

Our investment in internal and external development programs has driven consistent new product introductions. For example, we introduced 18 new products in 2009 and nine new products in 2008, up from four new products in 2007.

***Manufacturing and Supply***

We manufacture substantially all of our products at five sites including Montbonnot, Saint-Ismier and Grenoble, France, and Dunmanway and Macroom, Ireland. Our operations in France have a long history and deep experience with orthopaedic manufacturing and innovation and we have invested in facilities upgrades to both expand capabilities and establish incremental lean cellular manufacturing practices there as well. Our Ireland location has been practicing lean cellular manufacturing concepts for many years with a philosophy focused on continuous operational improvement and optimization. We continually evaluate the potential to in-source products currently purchased from outside vendors to on-site production. We are continuously working on product and process improvement projects to optimize our manufacturing processes and product costs to improve our profitability and cash flow. We believe that our manufacturing facilities and relationships will support our potential capacity needs for the foreseeable future.

We use a diverse and broad range of raw materials in the manufacturing of our products. We purchase all of our raw materials and select components used in manufacturing our products from external suppliers. In addition, we purchase some supplies from single sources for reasons of proprietary know-how, quality assurance, sole source availability, cost-effectiveness or constraints resulting from regulatory requirements. For example, we rely on one supplier for raw materials and select components in several of our products, including Poco Graphite, Inc., which supplies graphite for pyrocarbon on a purchase order basis, CeramTec Group, which supplies ceramic for ceramic heads for hips, and Heymark Metals Ltd., which supplies CoCr used in certain of our hip, shoulder and elbow

Table of Contents

products on a purchase order basis. We believe we are the only vertically integrated manufacturer of pyrocarbon orthopaedic products with production equipment to enable production of larger-sized implants. While we rely on an external supplier to supply us with surgical grade substrate material, we control the remaining pyrocarbon manufacturing process, which we believe gives us a competitive advantage in design for manufacturing and prototyping of this innovative material.

We work closely with our suppliers to ensure continuity of supply while maintaining high quality and reliability. To date, we have not experienced any significant difficulty in locating and obtaining the materials necessary to fulfill our production requirements.

Some of our products are provided by suppliers under a private label distribution agreement. Under these agreements, the supplier generally retains the intellectual property and exclusive manufacturing rights. The supplier private labels the products under the Tornier brand for sale in certain fields of use and geographic territories. These agreements may be subject to minimum purchase or sales obligations. Examples of such products are our Conexa products and our NexFix Resorbable Fixation System.

***Competition***

The market for orthopaedic devices is highly competitive and subject to rapid and profound technological change. Our currently marketed products are, and any future products we commercialize will be, subject to intense competition. We believe that the principal competitive factors in our markets include product features and design, reputation and service. One of the key factors to our future success will be our ability to continue to introduce new products and improve existing products and technologies.

We face competition from large diversified orthopaedic manufacturers, such as DePuy, Zimmer and Stryker, and established mid-sized orthopaedic manufacturers, such as Arthrex, Wright Medical and ArthroCare. Many of the companies developing or marketing competitive orthopaedic products are publicly traded or are divisions of publicly traded companies and may enjoy several competitive advantages, including:

greater financial and human resources for product development and sales and marketing;

significantly greater name recognition;

established relationships with surgeons, hospitals and third-party payors;

broader product lines and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage;

established sales and marketing and distribution networks; and

more experience in conducting research and development, manufacturing, preparing regulatory submissions and obtaining regulatory approval for products.

We also compete against smaller, entrepreneurial companies with niche product lines. Our competitors may develop and patent processes or products earlier than us, obtain regulatory clearance or approvals for competing products more rapidly than us and develop more effective or less expensive products or technologies that render our technology or products obsolete or non-competitive. We also compete with our competitors in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies and technology licenses complementary to our products or advantageous to our business. If our competitors are more successful than us in these matters, our business may be harmed.

Table of Contents

*Intellectual property*

Patents and other proprietary rights are important to the continued success of our business and as of December 27, 2009, we have filed more than 117 patent applications, with over 305 applications claiming priority to such applications throughout the world and 126 patents issued throughout the world, approximately 85 of which are U.S. patents. Of our issued patents, 60% will expire within the next 10 years and the remaining 40% will expire within the next 20 years. Within the next three years, the following number of U.S. patents held by us are set to expire: one patent in 2011, four patents in 2012 and two patents in 2013. The expiration of these patents is not expected to have a material adverse effect on our business. We currently have 89 pending U.S. patent applications.

We also rely upon trade secrets, know-how, continuing technological innovation and licensing opportunities to develop and maintain our competitive position. We protect our proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information.

Although we believe our patents are valuable, our knowledge and experience, our creative product development and marketing staff, and our trade secret information with respect to manufacturing processes, materials and product design, have been equally important in maintaining our proprietary product lines. As a condition of employment, we generally require employees to execute a confidentiality agreement relating to proprietary information and assigning patent rights to us. We cannot be assured that our patents will provide competitive advantages for our products, or that our competitors will not challenge or circumvent these rights. In addition, we cannot be assured that the United States Patent and Trademark Office, or USPTO, or foreign patent offices will issue any of our pending patent applications. The USPTO and foreign patent offices may also deny or require significant narrowing of claims in our pending patent applications and patents issuing from the pending patent applications. Any patents issuing from our pending patent applications may not provide us with significant commercial protection. We could incur substantial costs in proceedings before the USPTO or foreign patent offices, including interference or opposition proceedings. These proceedings could result in adverse decisions as to the priority of our inventions. Additionally, the laws of some of the countries in which our products are or may be sold may not protect our products and intellectual property to the same extent as the laws in the United States, or at all.

While we do not believe that any of our products infringe any valid claims of patents or other proprietary rights held by third parties, we cannot be assured that we do not infringe any patents or other proprietary rights held by third parties. If our products were found to infringe any proprietary right of a third party, we could be required to pay significant damages or license fees to the third party or cease production, marketing and distribution of those products. Litigation may also be necessary to enforce patent rights we hold or to protect trade secrets or techniques we own.

We also rely on trade secrets and other unpatented proprietary technology. We cannot be assured that we can meaningfully protect our rights in our unpatented proprietary technology or that others will not independently develop substantially equivalent proprietary products or processes or otherwise gain access to our proprietary technology. We seek to protect our trade secrets and proprietary know-how, in part, with confidentiality agreements with employees and consultants. We cannot be assured, however, that the agreements will not be breached, that we will have adequate remedies for any breach or that our competitors will not discover or independently develop our trade secrets.

Table of Contents

**Corporate History**

We were founded in the 1940s by René Tornier in Saint-Ismier, France and are one of the early pioneers of the orthopaedic implant market. We originally manufactured dental surgical products, and diversified into screws and plates for orthopaedic surgery in the 1950s, and entered the joint replacement market with a hip implant in the 1960s. Alain Tornier, René Tornier's son, began to work for us in 1970 and assumed a leadership role in 1976 when René Tornier died. Alain Tornier modernized our manufacturing; organized and expanded commercial operations with a direct sales force in France; introduced a knee implant product line; and established our first international subsidiary in Spain. During the 1990s and early 2000s, Alain Tornier continued to improve upon our growth by introducing new products and expanding into new international markets. In 2006, Alain Tornier sold a majority stake in us to the Investor Group, but retained a minority equity position and became a non-executive director and consultant.

Since the acquisition by the Investor Group, we have significantly increased our investment in research and development, from \$3.0 million in 2006 to \$18.1 million in 2009. In addition, we have expanded our product portfolio and ability to serve our target customers through a series of strategic acquisitions, licensing and distribution agreements. Each of these transactions was specifically targeted for its potential to either improve our ability to compete in an existing market or expand our addressable market by broadening our product portfolio into a related area. The entry into the sports medicine market in particular expanded our addressable market to include the core products used by our shoulder surgeon customers, who typically perform both shoulder joint replacement and shoulder sports medicine procedures. In addition, we have been active in licensing new material technologies with longer-term potential to differentiate our product offering. Finally, we expanded geographically in selected international markets.

See "Management's Discussion and Analysis of Financial Condition and Results of Operations-Material Corporate Transactions" for a discussion of our material corporate transactions.

***Government regulation***

**Regulatory Matters**

*FDA Regulation*

Both before and after approval or clearance our products and product candidates are subject to extensive regulation. In the United States, we are regulated by the FDA under the Federal Food, Drug, and Cosmetic Act, as well as other regulatory bodies. These regulations govern, among other things, the following activities in which we and our contract manufacturers, contract testing laboratories and suppliers are involved:

product development;

product testing;

product manufacturing;

product labeling;

product safety;

product storage;

product market clearance or approval;

product advertising and promotion;

product import and export; and

product sales and distribution.

Table of Contents

Failure to comply with the Federal Food, Drug, and Cosmetic Act could result in, among other things, warning letters, civil penalties, delays in approving or refusal to approve a product candidate, product recall, product seizure, interruption of production, operating restrictions, suspension on withdrawal of product approval, injunctions or criminal prosecution.

*FDA Approval or Clearance of Medical Devices*

In the United States, medical devices are subject to varying degrees of regulatory control and are classified in one of three classes depending on risk and the extent of controls the FDA determines are necessary to reasonably ensure their safety and efficacy. These classifications generally require the following:

Class I: general controls, such as labeling and adherence to quality system regulations;

Class II: general controls, premarket notification (510(k)) and special controls such as performance standards, patient registries and postmarket surveillance; and

Class III: general controls and approval of a PMA.

Most of our new products fall into FDA classifications that require the submission of a Premarket Notification (510(k)) to the FDA. In the 510(k) process, the FDA reviews a premarket notification and determines whether a proposed device is "substantially equivalent" to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976, for which the FDA has not yet called for the submission of PMA applications, referred to as a predicate device. In making this determination, the FDA compares the proposed device to the predicate device. If the two devices are comparable in intended use and safety and effectiveness, the device may be cleared for marketing. 510(k) submissions generally include, among other things, a description of the device and its manufacturing, device labeling, medical devices to which the device is substantially equivalent, safety and biocompatibility information and the results of performance testing. In some cases, a 510(k) submission must include data from human clinical studies. Marketing may commence only when the FDA issues a clearance letter finding the proposed device to be substantially equivalent to the predicate. After a device receives 510(k) clearance, any product modification that could significantly affect the safety or effectiveness of the product, or that would constitute a significant change in intended use, requires a new 510(k) clearance or, if the device would no longer be substantially equivalent, would require a PMA. If the FDA determines that the product does not qualify for 510(k) clearance, then the company must submit and the FDA must approve a PMA before marketing can begin.

Other devices we may develop and market may be classified as Class III for which the FDA has implemented stringent clinical investigation and PMA requirements. The PMA process would require us to provide clinical and laboratory data that establishes that the new medical device is safe and effective. Information about the device and its components, device design, manufacturing and labeling, among other information, must also be included in the PMA. As part of the PMA review, the FDA will typically inspect the manufacturer's facilities for compliance with QSR requirements, which govern testing, control, documentation and other aspects of quality assurance with respect to manufacturing. The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). The PMA can include post-approval conditions including, among other things, restrictions on labeling, promotion, sale and distribution, or requirements to do additional clinical studies post-approval. Even after approval of a PMA, a new PMA or PMA supplement is required to authorize certain modifications to the device, its labeling or its manufacturing process.

All of our devices marketed in the United States have been listed, cleared or approved by the FDA. Some low-risk medical devices (including most instruments) do not require FDA review and

Table of Contents

approval or clearance prior to commercial distribution, but are subject to FDA regulations and must be listed with the FDA. The FDA has the authority to: halt the distribution of certain medical devices; detain or seize adulterated or misbranded medical devices; or order the repair, replacement of or refund the costs of such devices. There are also requirements of state, local and foreign governments that we must comply with in the manufacture and marketing of our products. For example, some jurisdictions require compliance with the Pharmaceutical Research and Manufacturers of America's Code on Interactions with Healthcare Professionals or its equivalent. Laws and regulations and the interpretation of those laws and regulations may change in the future. We cannot foresee what effect, if any, such changes may have on us.

*Clinical Trials*

One or more clinical trials are almost always required to support a PMA application and are sometimes required to support a 510(k) submission. Clinical studies of unapproved or uncleared medical devices or devices being studied for uses for which they are not approved or cleared (investigational devices) must be conducted in compliance with FDA requirements. If an investigational device could pose a significant risk to patients, the sponsor company must submit an application for an investigational device exemption, or IDE, to the FDA prior to initiation of the clinical study. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. Clinical studies of investigational devices may not begin until an institutional review board, or IRB, has approved the study.

During the study, the sponsor must comply with the FDA's IDE requirements including, for example, for investigator selection, trial monitoring, adverse event reporting and recordkeeping. The investigators must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of investigational devices and comply with reporting and recordkeeping requirements. We, the FDA and the IRB at each institution at which a clinical trial is being conducted may suspend a clinical trial at any time for various reasons, including a belief that the subjects are being exposed to an unacceptable risk. During the approval or clearance process, the FDA typically inspects the records relating to the conduct of one or more studies supporting the application.

*Post-market Regulation*

After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:

the QSR regulation, which governs, among other things, how manufacturers design, test, manufacture, exercise quality control over and document manufacturing of their products;

labeling and claims regulations, which prohibit the promotion of products for unapproved or "off-label" uses and impose other restrictions on labeling; and

the Medical Device Reporting regulation, which requires reporting to the FDA certain adverse experiences associated with use of the product.

We continue to be subject to inspection by the FDA to determine our compliance with regulatory requirements, as do our suppliers, contract manufacturers and contract testing laboratories.

*International Regulation*

We are subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of:

design, development, manufacturing and testing;



Table of Contents

product standards;

product safety;

marketing, sales and distribution;

packaging and storage requirements;

labeling requirements;

content and language of instructions for use;

clinical trials;

record keeping procedures;

advertising and promotion;

recalls and field corrective actions;

post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;

import and export restrictions; and

tariff regulations, duties and tax requirements.

The time required to obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from FDA requirements.

In many of the foreign countries in which we market our products, we are subject to local regulations affecting, among other things, design and product standards, packaging requirements and labeling requirements. Many of the regulations applicable to our devices and products in these countries are similar to those of the FDA.

In the EEA, our devices are required to comply with the essential requirements of the EU Medical Devices Directives (Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, as amended, and Council Directive 90/385/EEC of 20 June 2009 relating to active implantable medical devices, as amended). Compliance with these requirements entitles us to affix the CE conformity mark to our medical devices, without which they cannot be commercialized in the EEA. In order to demonstrate compliance with the essential requirements and obtain the right to affix the CE conformity mark we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low-risk medical devices (Class I), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the essential requirements of the Medical Devices Directives, a conformity assessment procedure requires the intervention of a Notified Body, which is an organization accredited by a Member State of the EEA to conduct conformity assessments. The Notified Body would typically audit and examine the quality system for the manufacture, design and final inspection of our devices before issuing a certification demonstrating compliance with the essential requirements. Based on this

## Edgar Filing: Tornier B.V. - Form S-1/A

certification we can draw up an EC Declaration of Conformity, which allows us to affix the CE mark to our products.

### *U.S. Anti-kickback and False Claims Laws*

In the United States, there are federal and state anti-kickback laws that prohibit the payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of healthcare products and services. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal healthcare programs. These laws are

Table of Contents

potentially applicable to manufacturers of products regulated by the FDA, such as us, and hospitals, physicians and other potential purchasers of such products.

In particular, the federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. The definition of "remuneration" has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. In addition, the recently enacted Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively, the PPACA, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the false claim statutes. The lack of uniform interpretation of the Anti-Kickback Law makes compliance with the law difficult. The penalties for violating the Anti-Kickback Law can be severe. These sanctions include criminal penalties and civil sanctions, including fines, imprisonment and possible exclusion from participation in federal healthcare programs.

Recognizing that the Anti-Kickback Law is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the U.S. Department of Health and Human Services issued regulations in July of 1991, which the Department has referred to as "safe harbors." These safe harbor regulations set forth certain provisions which, if met in form and substance, will assure medical device manufacturers, healthcare providers and other parties that they will not be prosecuted under the federal Anti-Kickback law. Additional safe harbor provisions providing similar protections have been published intermittently since 1991. Our arrangements with physicians, hospitals and other persons or entities who are in a position to refer may not fully meet the stringent criteria specified in the various safe harbors. Although full compliance with these provisions ensures against prosecution under the federal Anti-Kickback Law, the failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-Kickback law will be pursued. Even though we continuously strive to comply with the requirements of the Anti-Kickback Law, liability under the Anti-Kickback Law may still arise because of the intentions or actions of the parties with whom we do business, including our independent distributors. While we are not aware of any such intentions or actions, we have only limited knowledge regarding the intentions or actions underlying those arrangements. Conduct and business arrangements that do not fully satisfy one of these safe harbor provisions may result in increased scrutiny by government enforcement authorities.

Other provisions of state and federal law provide civil and criminal penalties for presenting, or causing to be presented, to third-party payors for reimbursement, claims that are false or fraudulent, or that are for items or services that were not provided as claimed. Although our business is structured to comply with these and other applicable laws, it is possible that some of our business practices in the future could be subject to scrutiny and challenge by federal or state enforcement officials under these laws. This type of challenge could have a material adverse effect on our business, financial condition and results of operations.

*Third-Party Coverage and Reimbursement*

We anticipate that sales volumes and prices of our products will depend in large part on the availability of coverage and reimbursement from third-party payors. Third-party payors include governmental programs such as Medicare and Medicaid, private insurance plans and workers' compensation plans. These third-party payors may deny coverage or reimbursement for a product or

Table of Contents

therapy if they determine that the product or therapy was not medically appropriate or necessary. The third-party payors also may place limitations on the types of physicians that can perform specific types of procedures. Also, third-party payors are increasingly challenging the prices charged for medical products and services. Some third-party payors must also approve coverage for new or innovative devices or therapies before they will reimburse healthcare providers who use the products or therapies. Even though a new product may have been cleared for commercial distribution, we may find limited demand for the device until reimbursement approval has been obtained from governmental and private third-party payors.

The Centers for Medicare & Medicaid Services, or CMS, the agency responsible for administering the Medicare program, sets coverage and reimbursement policies for the Medicare program in the United States. CMS policies may alter coverage and payment related to our product portfolio in the future. These changes may occur as the result of national coverage determinations issued by CMS or as the result of local coverage determinations by contractors under contract with CMS to review and make coverage and payment decisions. Medicaid programs are funded by both federal and state governments, may vary from state to state and from year to year and will likely play an even larger role in healthcare funding pursuant to the PPACA.

A key component in ensuring whether the appropriate payment amount is received for physician and other services, including those procedures using our products, is the existence of a Current Procedural Terminology, or CPT, code. To receive payment, health care practitioners must submit claims to insurers using these codes for payment for medical services. CPT codes are assigned, maintained and annually updated by the American Medical Association and its CPT Editorial Board. If the CPT codes that apply to the procedures performed using our products are changed, reimbursement for performances of these procedures may be adversely affected.

In the United States, some insured individuals enroll in managed care programs, which monitor and often require pre-approval of the services that a member will receive. Some managed care programs pay their providers on a per capita basis, which puts the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member per month and, consequently, may limit the willingness of these providers to use our products.

We believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry to reduce the costs of products and services. All third-party reimbursement programs are developing increasingly sophisticated methods of controlling healthcare costs through prospective reimbursement and capitation programs, group purchasing, redesign of benefits, requiring second opinions prior to major surgery, careful review of bills, encouragement of healthier lifestyles and other preventative services and exploration of more cost-effective methods of delivering healthcare. There can be no assurance that third-party reimbursement and coverage will be available or adequate, or that future legislation, regulation or reimbursement policies of third-party payors will not adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third-party payor coverage or reimbursement could have a material adverse effect on our business, operating results and financial condition.

In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific product lines and procedures. There can be no assurance that procedures using our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available or that the third-party payors' reimbursement policies will not adversely affect our ability to sell our products profitably.

Table of Contents

**Litigation**

On October 25, 2007, two of our former sales agents filed a complaint in the U.S. District Court for the Southern District of Illinois, alleging that we had breached their agency agreements and committed fraudulent and negligent misrepresentations. The plaintiffs, Garry Boyd of Boyd Medical, Inc. and Charles Wetherill of Addison Medical, Inc., claimed that we had intentionally set their 2007 quotas too high, in hopes that Messrs. Boyd and Wetherill would not meet the quotas so that we could terminate them for cause and install another distributor in their territories. The complaint also included allegations that we had falsely suggested to the plaintiffs that if they dropped all other product lines, we would fill the void with new product lines. The jury rendered a verdict on July 31, 2009, awarding the plaintiffs a total of \$2.6 million in actual damages and \$4 million in punitive damages. While the court struck the award of punitive damages on March 31, 2010, it denied our motion to set aside the verdict or order a new trial. We have filed a notice of appeal with the U.S. Court of Appeals for the Seventh Circuit in respect of the actual damages claims. Plaintiffs have also appealed the court's striking of the punitive damages award, and the appeal has been consolidated with our appeal. Opening briefs were submitted to the U.S. Court of Appeals for the Seventh Circuit on July 7, 2010.

We are also involved in litigation and proceedings in the ordinary course of business. We do not believe that such litigation or proceedings, individually or in the aggregate, are likely to have a material adverse effect on our business, financial position or results of operations.

**Facilities**

Our U.S. headquarters are located in a 19,100 square foot facility in Edina, Minnesota, where we conduct our principal executive, sales and marketing and administrative activities. This facility is leased through 2015. Our U.S. distribution and customer service operations are based in an owned 20,000 square foot facility in Stafford, Texas and our research and development operations are based in a 12,200 square foot leased facility in Warsaw, Indiana, with small satellite quality, marketing and research and development offices in Beverly, Massachusetts and San Diego, California

Our global corporate headquarters are located in Amsterdam, The Netherlands. Outside the United States, our primary manufacturing facilities are in Montbonnot, Saint-Ismier and Grenoble, France; and Dunmanway and Macroom, Ireland. In the 112,000 square foot Montbonnot campus, we conduct manufacturing, sales and marketing, research and development, quality and regulatory assurance, distribution and administrative functions. In our 54,900 square foot Saint-Ismier facility and 15,200 square foot Dunmanway and 84,700 square foot Macroom facilities, we solely conduct manufacturing operations and manufacturing support such as purchasing, engineering and quality assurance functions. Our pyrocarbon manufacturing is performed at our 10,000 square foot facility in Grenoble, France. In addition, we maintain subsidiary sales offices and distribution warehouses in various countries, including France, Germany, Italy, Netherlands, Denmark, Spain, Switzerland, United Kingdom and Australia. We believe that our facilities are adequate and suitable for their use.

The value of our long-lived assets in the United States was \$16.0 million in 2009, \$15.1 million in 2008 and \$11.1 million in 2007. The value of our long-lived assets in France was \$32.5 million in 2009, \$27.2 million in 2008 and \$20.3 million in 2007. The value of our long-lived assets in The Netherlands was \$0.5 million in 2009, \$0.5 million in 2008 and \$0.5 million in 2007.

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

Below is a summary of our material facilities:

Entity	City	State/Country	Owned or Leased	Occupancy	Square Footage	Lease Expiration Date
Tornier, Inc.	Stafford	Texas, United States	Owned	Offices/Warehouse/Distribution	20,000	N/A
Tornier, Inc.	Warsaw	Indiana, United States	Leased	Offices/R&D	12,200	2/28/2015
Tornier, Inc.	Edina	Minnesota, United States	Leased	Offices	19,100	12/31/2015
Tornier SAS	St Ismier	France	Leased	Offices/Manufacturing/Warehouse/Distribution	54,900	5/29/2012
Tornier SAS	Montbonnot	France	Leased	Offices	15,100	5/29/2012
Tornier SAS	Montbonnot	France	Leased	Warehouse/Distribution/Offices	19,500	5/29/2012
Tornier SAS	Montbonnot	France	Leased	Offices/R&D	25,500	5/29/2012
Tornier SAS	Montbonnot	France	Owned 51%	Manufacturing/Offices	51,700	9/3/2018
BioProfile	Grenoble	France	Leased	Manufacturing/Offices/R&D	9,900	7/22/2012
Tornier Deutschland GmbH	Burscheid	Germany	Owned	Sales Office	1,900	N/A
Tornier Orthopedics Ireland Limited	Dunmanway	Ireland	Owned	Manufacturing/Offices	15,200	N/A
Tornier Orthopedics Ireland Limited	Macroom	Ireland	Leased	Manufacturing/Offices	84,700	12/1/2028
Tornier B.V.	Schiedam	The Netherlands	Leased	Offices	720	10/31/2010

### **Employees**

As of December 27, 2009, we had approximately 769 employees, including 331 in manufacturing and operations, 79 in research and development and the remaining in sales, marketing and related administrative support. Of our 769 worldwide employees, 157 employees were located in the United States and 612 employees were located outside of the United States, primarily throughout Europe.

### **Insurance**

We maintain property insurance and general, commercial and product liability policies in amounts we consider adequate and customary for a business of our kind. However, because of the nature of our business, we cannot ensure that we will be able to maintain insurance on a commercially reasonable basis or at all, or that any future claims will not exceed our insurance coverage.

Table of Contents**MANAGEMENT****Directors and Executive Officers**

Our board of directors consists of eight members. The following table sets forth, as of June 3, 2010, certain information concerning our directors and executive officers:

<b>Name</b>	<b>Age</b>	<b>Position</b>
Douglas W. Kohrs	52	President, Chief Executive Officer and Director
Carmen L. Diersen	49	Global Chief Financial Officer
Robert J. Ball	38	Vice President, Global Research and Development
Ralph E. Barisano, Jr.	50	Vice President, Global Quality Assurance and Regulatory Affairs
Stéphan Epinette	39	Vice President, International Commercial Operations
Andrew E. Joiner	49	Vice President and General Manager, U.S. Commercial Operations
Jamal D. Rushdy	39	Vice President, Global Business and Corporate Development
James C. Harber	40	Vice President, Distal Extremities Global Business Strategy
James E. Kwan	51	Vice President, Global Supply Chain
Sean D. Carney(2), (3)	41	Chairman, Director
Richard B. Emmitt(1)	65	Director
Kevin C. O'Boyle(1)	54	Director
Alain Tornier(3)	63	Director
Simon Turton, Ph.D.	43	Director
Richard F. Wallman(1), (3)	59	Director
Elizabeth H. Weatherman(2)	50	Director

(1) Member of the audit committee. The audit committee will be established upon the effectiveness of this registration statement.

(2) Member of the compensation committee. The compensation committee will be established upon the effectiveness of this registration statement.

(3) Member of the nominating and corporate governance committee. The nominating and corporate governance committee will be established upon the effectiveness of this registration statement.

The following is a biographical summary of the experience of our directors and executive officers:

Edgar Filing: Tornier B.V. - Form S-1/A

*Douglas W. Kohrs* was appointed as our President, Chief Executive Officer and a director in July 2006. Mr. Kohrs was appointed as a director in connection with the Securityholders' Agreement that we entered into with certain holders of our securities. For more information regarding the Securityholders' Agreement, please refer to the discussion below under "Related Party Transactions."



Table of Contents

Mr. Kohrs has 29 years of experience in the medical device industry. Prior to joining us he served as President and Chief Executive Officer of American Medical Systems Holdings, Inc., a publicly held medical device company, from April 1999 until January 2005 and served as Chairman of the American Medical Systems Holdings, Inc. board of directors until May 2006. During the past ten years, Mr. Kohrs has also served on the board of directors of nine different medical device companies. Mr. Kohrs currently serves on the board of ev3, Inc., a publicly held medical device company, and previously served on the board of Kyphon, Inc., also a publicly held medical device company. Prior to joining American Medical Systems Holdings, Inc., Mr. Kohrs was General Manager of Sulzer Spine-Tech Inc., an orthopaedic implant manufacturer of which he was a founding member beginning in August 1991. Mr. Kohrs holds a Master of Business Administration from Northeastern University, a Bachelor of Science in Bioengineering from Texas A&M University and a Bachelor of Arts in Engineering Sciences from Austin College. Mr. Kohrs' prior experience, including as Chief Executive Officer of American Medical Systems Holdings, Inc. at the time of its initial public offering, and his understanding of our business and industry has led our board of directors to the conclusion that he should serve as a director at this time in light of our business and structure.

*Carmen L. Diersen* joined us in June 2010 as Global Chief Financial Officer. She has 18 years of experience in the medical device industry, including nine years in spinal orthopaedics. Prior to joining us, she served from September 2006 to June 2010 as the Chief Operating and Financial Officer of Spine Wave, Inc., a privately held developer of advanced materials, techniques, and implant systems for spinal surgery. From March 2004 to September 2006, Ms. Diersen served as Executive Vice President and Chief Financial Officer of American Medical Systems Holdings, Inc., a publicly held medical device company. Prior to American Medical Systems Holdings, Inc., Ms. Diersen spent 12 years in financial leadership positions at Medtronic, Inc., in the cardiac surgery, cardiac rhythm management and spinal surgery businesses, concluding her career there as the Vice President and General Manager of Musculoskeletal Tissue Services for Medtronic Sofamor Danek. Prior to Medtronic, Inc., she spent 10 years at Honeywell, Inc. Ms. Diersen earned a Master of Business Administration from the Carlson School of Management at the University of Minnesota and a Bachelor of Science in Accounting from the University of North Dakota. She became a Certified Public Accountant in 1983. Ms. Diersen has served on the board of directors of SonoSite, Inc., a publicly held leader in point of care ultrasound systems, since October 2005 and previously served on the board of directors of Memry Corporation, a publicly held medical specialty materials company, from December 2004 through September 2008 when the company was sold and Wright Medical Group, Inc., a publicly held medical device company from December 2009 until June 2010 when she joined us.

*Robert J. Ball* joined us in September 2006 as Vice President, Global Research and Development. He has over 11 years of experience in the orthopaedic medical device industry. Prior to joining us he served as Vice President of Research Development of Kinetikos Medical Incorporated, or KMI, a medical device company, beginning in December 2002, and also assumed responsibility for Marketing and Product Development in May 2005, continuing in each capacity until August 2006, when KMI was acquired by Integra LifeSciences Holdings Corporation. Prior to joining KMI, Mr. Ball held positions at DePuy, where he oversaw the development and launch of orthopaedic products in the upper extremity. Prior to joining DePuy, he served in the automotive manufacturing industry with SPX Corporation as Program and Engineering Manager, overseeing construction and tooling of a large scale casting and machining facility. Mr. Ball has Bachelor of Science and Master of Science degrees in mechanical engineering from Kettering University (formerly GMI Engineering and Management Institute) and has over 30 issued and pending patents.

*Ralph E. Barisano, Jr.* joined us in April 2007 and leads our quality assurance and regulatory affairs programs as our Vice President, Global Quality Assurance and Regulatory Affairs. He has over 25 years of experience in the medical device industry. Prior to joining us he consulted for Axya, a medical device company, from November 2006 to April 2007, where he directed Quality Assurance and

Table of Contents

Regulatory Affairs including during its acquisition by us. Prior to joining Axya, he served as Director of Quality Assurance for Smith & Nephew Endoscopy, a manufacturer of surgical equipment and tools, from January 2002 to November 2006. Mr. Barisano has also held other Quality and Regulatory roles at a number of other medical device companies, including Hologic Systems Inc., C.R. Bard, Inc. and Allergan, Inc. Mr. Barisano earned a Master of Business Administration from the Isenberg School of Management, University of Massachusetts Amherst and a Bachelor of Science in Mechanical Engineering Technology from the University of Massachusetts, North Dartmouth.

*Stéphan Epinette* joined us in December 2008 and leads our international commercial operations (Europe, Asia Pacific, Latin America) and large joints business as Vice President of International Commercial Operations. He has over 17 years of experience in the orthopaedic medical device industry. Prior to joining us, he served in various leadership roles with Stryker Corporation, a medical device and equipment company, in its MedSurg and Orthopaedic divisions in France, the United States and Switzerland from 1993 to December 2008, including as Business Unit Director France from 2005 to 2008. His past functions at Stryker Corporation also included Marketing Director MedSurg EMEA, Assistant to the EMEA President and Director of Business Development & Market Intelligence EMEA. Mr. Epinette earned a Masters Degree in Health Economics from Sciences Politiques, Paris, a Masters Degree in International Business from Paris University XII and a Bachelor of Arts from EBMS Barcelona. He also attended the INSEAD executive course in Finance and in Marketing.

*Andrew E. Joiner* joined us in April 2008 and leads our U.S. sales and marketing activities and the global shoulder and sports medicine businesses as our Vice President and General Manager, U.S. Commercial Operations. He has over 19 years of experience in the medical device industry. Prior to joining us, he served as the Vice President and General Manager of Women's Health at American Medical Systems Holdings, Inc. from January 2007 to April 2008, and as the Vice President of Global Marketing at American Medical Systems Holdings, Inc., from 2005 to December 2006. Prior to American Medical Systems Holdings, Inc., Mr. Joiner worked for ten years for United States Surgical Corporation, a surgical tools company, in a variety of sales functions, concluding his career there as Director of Sales for the Southwest Region of the U.S. Mr. Joiner holds a Bachelor of Science in Telecommunications from the University of Georgia.

*Jamal D. Rushdy* joined us in February 2007 when we acquired Nexa, a medical device company, and leads our corporate strategic planning and acquisition, licensing and partnership programs and our orthobiologics business, serving as our Vice President, Global Business and Corporate Development since June 2007. He has over 15 years of experience in the orthopaedic medical device industry. At Nexa, he served from January 2006 to May 2007 as the Vice President of Operations and Business Development until its acquisition by us. Prior to Nexa, he served as Director of Marketing and Business Development for dj Orthopedics LLC, a medical device company, where he also served in various leadership roles in finance and operations from June 2001 to January 2006. Mr. Rushdy earned a Master of Business Administration from the University of California, Irvine and a Bachelor of Science in Mechanical Engineering from the University of California, San Diego.

*James C. Harber* joined us in February 2007 following our acquisition of Nexa and leads our distal extremities organization as our Vice President, Distal Extremities Global Business Strategy, which consists of our foot, ankle, hand, wrist, and elbow joints and trauma products. He has over 20 years of experience in the orthopaedic medical device industry. At Nexa, he served as the Vice President of Marketing and Sales from March 2006 until June 2007. Prior to joining Nexa, Mr. Harber held the position of Vice President, Marketing at Hand Innovations LLC, an orthopaedic manufacturer from August 2003 to February 2006. He has also held marketing positions at Wright Medical Group, Inc. and Smith & Nephew plc, which are both medical device companies, and was Vice President of Sales and Marketing at a development stage computer assisted surgery venture. Mr. Harber earned a Bachelor of Science in Marketing from Christian Brothers University.

Table of Contents

*James E. Kwan* joined us in September 2006 and leads our global supply chain organization as our Vice President, Global Supply Chain. Mr. Kwan has also served as Director of Tornier Orthopaedics Ireland Ltd., one of our subsidiaries, since March 2010. He has over 20 years of experience in the medical device industry. Prior to joining us, he served as the Vice President of Operations for the Cardiac Surgery Division for St. Jude Medical, Inc., a medical technology company, from 2004 to 2006. At St. Jude Medical, Inc., Mr. Kwan also served as the Director of Hybrid Microelectronics operations for the Cardiac Rhythm Management Division and managed the Pyrolytic Carbon Technology operations for the Heart Valve Division. Prior to joining St. Jude Medical, Inc., Mr. Kwan served as a Director of Manufacturing at SciMed Life Systems, an interventional cardiology company, and before that held various technical positions within the Defense Systems Division of Honeywell International, Inc., a diversified technology company. Mr. Kwan received a Bachelor of Science in Mechanical Engineering from South Dakota School of Mines & Technology and a Master of Business Administration from the University of St. Thomas.

*Sean D. Carney* is one of our directors and has served as a director since July 2006. Mr. Carney was appointed as a director in connection with the Securityholders' Agreement that we entered into with certain holders of our securities. Mr. Carney became the Chairman of the Company's board of directors in May 2010. For more information regarding the Securityholders' Agreement, please refer to the discussion below under "Related Party Transactions." Since 1996, Mr. Carney has been employed by Warburg Pincus LLC and has served as a Member and Managing Director of Warburg Pincus LLC and General Partner of Warburg Pincus & Co. since January 2001. Warburg Pincus LLC and Warburg Pincus & Co. are part of the Warburg Pincus entities collectively referred to elsewhere in this prospectus as Warburg Pincus, our stockholder that owns 62.6% of our ordinary shares as of May 31, 2010. Mr. Carney currently serves on the board of directors of Arch Capital Group Ltd., a publicly held company. He is also a member of the board of directors of Bausch & Lomb Inc. and several other private companies. During the past five years, Mr. Carney previously served on the board of directors of DexCom, Inc., a publicly held medical device company. Mr. Carney received a Master of Business Administration from Harvard Business School and a Bachelor of Arts from Harvard College. Mr. Carney's substantial experience as an investor and director in medical device companies and his experience evaluating financial results has led our board of directors to the conclusion that he should serve as a director at this time in light of our business and structure.

*Richard B. Emmitt* is one of our directors and has served as a director since July 2006. Mr. Emmitt was appointed as a director in connection with the Securityholders' Agreement that we entered into with certain holders of our securities. For more information regarding the Securityholders' Agreement, please refer to the discussion below under "Related Party Transactions." Mr. Emmitt served as a General Partner of The Vertical Group LP, an investment management and venture capital firm focused on the medical device and biotechnology industries, from its inception in 1989 through December 2007. Commencing in January 2008, he has been a Member and Manager of The Vertical Group GP, LLC, which controls The Vertical Group LP. Mr. Emmitt currently serves on the board of directors of American Medical Systems Holdings, Inc. and ev3, Inc., both publicly held companies, as well as several privately held companies. During the past five years, Mr. Emmitt previously served on the board of directors of Wright Medical Group, Inc. and Micro Therapeutics, Inc., both publicly held medical device companies. Mr. Emmitt holds a Master of Business Administration from the Rutgers School of Business and a Bachelor of Arts from Bucknell University. Mr. Emmitt's substantial experience as an advisor to numerous venture-backed growth companies and as an advisor to high-growth companies has led our board of directors to the conclusion that he should serve as a director at this time in light of our business and structure.

*Kevin C. O'Boyle* is one of our directors and has served as a director since June 2010. From January 2003 until his retirement in December 2009, Mr. O'Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company that completed its initial public offering in May 2004.

Table of Contents

Prior to that time, Mr. O'Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a publicly held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Mr. O'Boyle also held various positions during his seven years with Albert Fisher North America, Inc., a publicly held international food company, including Chief Financial Officer and Senior Vice President of Operations. He currently serves on the board of GenMark Diagnostics, Inc., a privately held molecular diagnostics company. Mr. O'Boyle is a Certified Public Accountant and received a Bachelor of Science in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School. Mr. O'Boyle's executive experience in the healthcare industry, his experience with companies during their transition from a privately held to a public company and his financial and accounting expertise have led our board of directors to the conclusion that Mr. O'Boyle should serve as a director and on our audit committee at this time in light of our business and structure.

*Alain Tornier* is one of our directors and has served as a director since May 1976. Mr. Tornier assumed a leadership role in our predecessor entity in 1976, following the death of his father, René Tornier, our founder. He later served as our President and Chief Executive Officer until our acquisition by the Investor Group in September 2006, when he retired. Mr. Tornier holds a Master of Sciences degree from Grenoble University. Mr. Tornier's significant experience in the global orthopaedics industry and deep understanding of our company's history and operations have led our board of directors to the conclusion that he should serve as a director at this time in light of our business and structure.

*Simon Turton, Ph.D.* is one of our directors and has served as a director since July 2006. Dr. Turton was appointed as a director in connection with the Securityholders' Agreement that we entered into with certain holders of our securities. For more information regarding the Securityholders' Agreement, please refer to the discussion below under "Related Party Transactions." Dr. Turton heads Warburg Pincus LLC's healthcare investing activities in Europe and was a Principal at Index Ventures, a venture capital firm, in Geneva prior to joining Warburg Pincus in 2003. Warburg Pincus LLC is part of the Warburg Pincus entities collectively referred to elsewhere in this prospectus as Warburg Pincus, our stockholder that owns 62.6% of our ordinary shares as of May 31, 2010. He has 10 years of experience investing in healthcare companies following a ten-year career in the international pharmaceutical industry incorporating research, business development and general management. He is a director of Eurand N.V. and ProStrakan Group plc, both publicly held companies. Dr. Turton has a Master of Business Administration from INSEAD, which he attended as a Sainsbury Management Fellow in the life sciences, and a Ph.D. in pharmacology from the University of London. Dr. Turton's substantial experience as an investor and director in European healthcare companies and experience evaluating financial results have led our board of directors to the conclusion that he should serve as a director at this time in light of our business and structure.

*Richard F. Wallman* is one of our directors and has served as a director since December 2008. From 1995 through his retirement in 2003, Mr. Wallman served as the Senior Vice President and Chief Financial Officer of Honeywell International, Inc., a diversified technology company, and AlliedSignal, Inc., a diversified technology company (prior to its merger with Honeywell International, Inc.). Prior to joining AlliedSignal, Inc. as Chief Financial Officer, Mr. Wallman served as Controller of International Business Machines Corporation. In addition to serving as one of our directors, he is also a member of the board of directors of Ariba, Inc., Convergys Corporation, Dana Holding Corporation, and Roper Industries, Inc., all publicly held companies. He is also a member of the board of directors of Bausch & Lomb Inc. During the past five years, Mr. Wallman previously served on the board of directors of ExpressJet Holdings Inc. and Avaya Inc., as well as auto suppliers Lear Corporation and Hayes Lemmerz International, Inc., all publicly held companies. Mr. Wallman holds a Master of Business Administration from the University of Chicago Booth School of Business

Table of Contents

with concentrations in finance and accounting and a Bachelor of Science in Electrical Engineering from Vanderbilt University. Mr. Wallman's prior public company experience, including as Chief Financial Officer of Honeywell, and his financial experience and expertise, have led our board of directors to the conclusion that he should serve as a director at this time in light of our business and structure.

*Elizabeth H. Weatherman* is one of our directors and has served as a director since July 2006. Ms. Weatherman was appointed as a director in connection with the Securityholders' Agreement that we entered into with certain holders of our securities. For more information regarding the Securityholders' Agreement, please refer to the discussion below under "Related Party Transactions." Ms. Weatherman is a General Partner of Warburg Pincus & Co., a Managing Director of Warburg Pincus LLC and a member of the firm's Executive Management Group. Ms. Weatherman joined Warburg Pincus in 1988 and is currently responsible for the firm's U.S. healthcare investment activities. Warburg Pincus LLC and Warburg Pincus & Co. are part of the Warburg Pincus entities collectively referred to elsewhere in this prospectus as Warburg Pincus, our stockholder that owns 62.6% of our ordinary shares as of May 31, 2010. Ms. Weatherman currently serves on the board of directors of ev3, Inc., a publicly held medical device company. She is also a member of the board of directors of Bausch & Lomb Inc. and several other privately held companies. During the past five years, Ms. Weatherman previously served on the board of directors of American Medical Systems Holdings, Inc., Kyphon, Inc., Micro Therapeutics, Inc., and Wright Medical Group, Inc., all publicly held companies. Ms. Weatherman earned a Master of Business Administration from Stanford Graduate School of Business and a Bachelor of Arts from Mount Holyoke College. Ms. Weatherman's extensive experience as a director of public companies in the medical device industry have led our board of directors to the conclusion that she should serve as a director at this time in light of our business and structure.

**Board of Directors**

Our board of directors currently consists of eight directors, seven of whom are non-executive directors. The Chief Executive Officer is the executive director. All of our non-executive directors, except Mr. Tornier, are independent under the independence criteria of NASDAQ; therefore, six of the eight directors are independent. Independence requirements for service on the audit committee is discussed below under " Committees of the Board of Directors Audit Committee." Mr. Wallman and Mr. O'Boyle are independent under the independence definition in the Dutch Corporate Governance Code. Because we will comply with the NASDAQ corporate governance requirements, the Dutch Corporate Governance Code requirement that a majority of our directors be independent will not apply so long as we explain such deviation in our annual report.

Our amended articles of association provide that the number of members of the board of directors will be determined by the board of directors, provided that at all times the board of directors shall be comprised of at least one executive director and two non-executive directors. Upon the completion of this offering, our board of directors will be divided into three classes, as nearly equal in number as possible, with each director serving a three-year term and one class being elected at each year's annual meeting of shareholders. Alain Tornier, Simon Turton and Elizabeth H. Weatherman will be in the class of directors whose term expires at the 2011 annual meeting of our shareholders. Sean D. Carney, Douglas W. Kohrs and Richard B. Emmitt will be in the class of directors whose term expires at the 2012 annual meeting of our shareholders. Richard F. Wallman and Kevin C. O'Boyle will be in the class of directors whose term expires at the 2013 annual meeting of our shareholders. At each annual meeting of our shareholders, successors to the class of directors whose term expires at such meeting will be elected to serve for three-year terms or until their respective successors are elected and qualified.

The general meeting appoints the members of the board of directors, subject to a binding nomination of the board of directors in accordance with the relevant provisions of the Dutch Civil

Table of Contents

Code. The board of directors will make the binding nomination based on a recommendation of the Nominating and Corporate Governance Committee. A nominee is deemed appointed unless the general meeting opposes the use of the binding nomination procedure by a resolution passed with the affirmative vote of at least two-thirds majority of the votes cast, which votes also represent more than 50% of our issued share capital. In such case, a new meeting is called to fill the vacancies for which the binding nominations were initially made. Nominees for appointment are presented by the board of directors. These nominations are not binding. The resolution for appointment in such meeting shall require the affirmative vote of at least two-thirds majority of the votes cast representing more than 50% of our issued share capital.

If the board of directors fails to use its right to submit a binding nomination, the general meeting may appoint members of the board of directors with a resolution passed with the affirmative vote of at least a two-thirds majority of the votes cast, representing more than 50% of our issued share capital. A resolution of the general meeting to suspend a member of the board of directors requires the affirmative vote of an absolute majority of the votes cast. A resolution of the general meeting to suspend or dismiss members of the board of directors, other than pursuant to a proposal by the board of directors, requires a majority of at least two-thirds of the votes cast, representing more than 50% of our issued share capital.

Pursuant to the Securityholders' Agreement dated July 18, 2006, by and among Tornier B.V., formerly known as TMG B.V., and TMG Holdings Coöperatief U.A., or TMG, TMG Partners U.S. LLC, Mr. Kohrs, Vertical Fund I, L.P., or VFI, Vertical Fund II, L.P., or VFII, KCH Stockholm AB, or KCH, Mr. Tornier, WP Bermuda and (by subsequent joinder agreements) TMG Partners II LLC, TMG Partners III LLC, Split Rock Partners, L.P., or Split Rock, Stichting Administratiekantoor Tornier, or STAK, and DVO TH, L.L.C., or DVO TH, as we currently contemplate amending prior to the consummation of the offering, WP Bermuda will be entitled to nominate three of the eight directors to our board of directors for so long as Warburg Pincus beneficially owns more than 25% of the outstanding shares, two of the eight directors for so long as Warburg Pincus beneficially owns more than 10% of the outstanding shares and one of the eight directors for so long as Warburg Pincus beneficially owns more than 5% of the outstanding shares. In addition, Mr. Kohrs will continue to be entitled to be nominated for election to the board of directors until termination of his employment.

No family relationships exist among any of our directors, executive officers or key employees.

Warburg Pincus may own more than 50% of the voting power of our ordinary shares after this offering, and if so, we would be considered a "controlled company" for the purposes of the NASDAQ listing requirements. As such, we would be permitted to opt out of the NASDAQ listing requirements that would otherwise require our board of directors to be comprised of a majority of independent directors. Although we intend to comply with these listing requirements whether or not we are a controlled company, there is no guarantee that we will not take advantage of these exemptions in the future. Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to all of the NASDAQ corporate governance requirements.

If a majority of our members of the board of directors will not qualify as independent under the Dutch Corporate Governance Code, we shall explain the reason for this in our annual report in accordance with the Dutch Corporate Governance Code.

Under our amended articles of association, the internal rules for the board of directors and the board committees and Dutch law, the members of the board of directors are collectively responsible for the management, general and financial affairs and policy and strategy of our company.

The executive director is our Chief Executive Officer, who is primarily responsible for managing our day-to-day affairs as well as other responsibilities that have been delegated to the

Table of Contents

executive director in accordance with our amended articles of association and our internal rules for the board of directors. The non-executive directors supervise the Chief Executive Officer and our general affairs and provide general advice to our Chief Executive Officer. In performing their duties, the non-executive directors are guided by the interests of the Company and shall, within the boundaries set by relevant Dutch law, take into account the relevant interests of our stakeholders. The internal affairs of the board of directors are governed by our rules for the board of directors.

It is expected that all meetings of the board of directors will be held in The Netherlands. Each director has the right to cast one vote and may be represented at a meeting of the board of directors by a fellow director. The board of directors may pass resolutions only if a majority of the directors is present at the meeting. All resolutions must be passed by a majority of the directors present or represented.

Subject to Dutch law and any director's objection, resolutions may be passed in writing by a majority of the directors in office. Pursuant to the internal rules for our board of directors, a director may not participate in discussions or the decision-making process on a transaction or subject in relation to which he or she has a conflict of interest with us. Resolutions to enter into such transactions must be approved by a majority of our board of directors, excluding such interested director or directors.

**Committees of the Board of Directors**

As of the effectiveness of this registration statement, our board of directors will have an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has or will have the composition and responsibilities described below.

*Audit Committee.* Our audit committee will oversee a broad range of issues surrounding our accounting and financial reporting processes and audits of our financial statements. Our audit committee will (i) assist our board of directors in monitoring the integrity of our financial statements, our compliance with legal and regulatory requirements, our independent auditor's qualifications and independence and the performance of our internal audit function and independent auditors; (ii) assume direct responsibility for the appointment, compensation, retention and oversight of the work of any independent registered public accounting firm engaged for the purpose of performing any audit, review or attest services and for dealing directly with any such accounting firm; and (iii) provide a medium for consideration of matters relating to any audit issues.

Upon the completion of this offering, our audit committee will consist of Mr. Wallman (Chair), Mr. Emmitt and Mr. O'Boyle. We believe that the composition of our audit committee will comply with the applicable rules of the SEC and the NASDAQ Global Market. The board of directors has determined that Mr. Wallman, Mr. Emmitt and Mr. O'Boyle are each an "audit committee financial expert," as defined in the SEC rules, and satisfy the financial sophistication requirements of the NASDAQ Global Market. Messrs. Wallman, Emmitt and O'Boyle are independent as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and the rules of the NASDAQ Global Market. Messrs. Wallman and O'Boyle are independent as such term is defined under the Dutch Corporate Governance Code.

Our board of directors will adopt a written charter for the audit committee, which will be available on our website upon the completion of this offering.

*Compensation Committee.* Within the scope of the compensation policy adopted by the general meeting, our compensation committee will review and recommend policy relating to compensation for and benefits of our officers and employees, including reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other senior officers, evaluating the performance of these officers in light of those goals and objectives and setting compensation of these officers based on such evaluations. The compensation committee will

Table of Contents

review and evaluate, at least annually, the performance of the compensation committee and its members, including compliance of the compensation committee with its charter. Our compensation committee will have sole discretion concerning the administration of our option plans, including the selection of individuals to receive awards and the time at which awards will be granted.

Upon the effectiveness of this registration statement, our compensation committee will consist of Mr. Carney (Chair) and Ms. Weatherman.

Our board of directors will adopt a written charter for the compensation committee that will be available on our website upon the completion of this offering.

*Nominating and Corporate Governance Committee.* The nominating and corporate governance committee will oversee and assist our board of directors in identifying, reviewing and recommending nominees for election as directors; evaluate our board of directors and our management; develop, review and recommend corporate governance guidelines and a corporate code of business conduct and ethics; and generally advise our board of directors on corporate governance and related matters.

Upon the effectiveness of this registration statement, our nominating and corporate governance committee will consist of Mr. Carney (Chair), Mr. Tornier and Mr. Wallman.

Our board of directors will adopt a written charter for the nominating and corporate governance committee, which will be available on our website upon the completion of this offering.

Our board of directors may from time to time establish other committees.

**Compensation Committee Interlocks and Insider Participation**

None of our executive officers have served as a member of the board of directors or compensation committee of any entity that has an executive officer serving as a member of our board of directors.

**Compensation of Directors and Executive Officers**

See "Compensation Discussion and Analysis," "Director Compensation" and "Related Party Transactions Consulting Arrangement."

**Limitation on Liability and Indemnification Matters**

Under Dutch law, indemnification provisions may be included in the articles of association. Our amended articles of association that will be in effect upon the completion of this offering provide that we shall indemnify any of our directors against all adverse financial effects incurred by such person in connection with any action, suit or proceeding if such person acted in good faith and in a manner he or she reasonably could believe to be in or not opposed to our best interests. In addition, upon completion of this offering, we expect to enter into indemnification agreements with our directors and officers.

At present, there is no pending litigation or proceeding involving any board of directors, member, officer, employee or agent where indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.



Table of Contents

**Dutch Corporate Governance**

Although we intend to list on the NASDAQ Global Market, we are governed by the Dutch Corporate Governance Code, as our registered office is located in The Netherlands. The Dutch Corporate Governance Code requires us to either comply with its Principles and Best Practice Provisions or to disclose and explain any deviation in our annual report filed with the Dutch Chamber of Commerce (*Kamer van Koophandel*), or our Dutch Annual Report. If the general meeting of shareholders explicitly approves a company's corporate governance policy and structure and endorses the explanation for any deviation from the Principles and Best Practice Provisions, such company will be deemed in compliance with the Dutch Corporate Governance Code. Prior to the completion of this offering, we expect our shareholders to approve our corporate governance structure and policy and endorse the explanation for deviations from the Principles and Best Practices.

As our shares are listed on the NASDAQ Global Market only, we intend to take all steps necessary to remain compliant with the corporate governance rules of the NASDAQ Global Market, the Sarbanes-Oxley Act of 2002 and related regulations. As a result, we will not apply a number of the Best Practice Provisions. Pursuant to the Dutch Corporate Governance Code, we will disclose each deviation as well as the reasons for it in our Annual Report.

The following discussion summarizes the most important differences between our expected corporate governance structure following this offering and the Principles and Best Practice Provisions of the Dutch Corporate Governance Code:

Under the Best Practice Provisions, non-executive directors may not be granted any rights to shares as part of their compensation. In addition, any shares held by a non-executive director must be held as long-term investments. Further, any options that may be granted to members of our board of directors cannot be exercisable for three years and should be conditioned on predetermined performance criteria. Executive directors must retain shares granted to them for at least five years or the duration of their employment. Such grants to executive directors should be similarly conditioned upon performance targets defined in advance.

In July 2006, we created a stock option plan to help us recruit eligible members for our board of directors in a competitive international environment and to align our long-term interests with those of these directors. We have amended the stock option plan several times since 2006 and its most recent version was approved by our general meeting of shareholders on June 3, 2010. According to its terms, certain members of our board of directors have been granted options that are not tied to predetermined performance criteria as called for by Best Practice Provisions. Some of these options are exercisable within three years of the date they were granted. We believe that these options enable us to attract and retain high caliber directors and thereby create value for our other shareholders.

Under the Best Practice Provisions, once an option has been granted, its exercise price and conditions may not be modified during its term (subject to limited exceptions). Consistent with market practice, our board of directors has the ability to amend, suspend or terminate the stock option plan and options granted thereunder at any time, provided that no amendment or termination will impair the rights of any person holding options at the time of such amendment or termination. Our board's ability to modify and enhance the stock option plan and the options granted thereunder allows us to maintain a good position in the market for directors and offer an attractive compensation package.

Under the Best Practice Provisions, the majority of the members of the board of directors shall be non-executive directors and independent within the meaning of Best Practice Provision III.2.2. Our board of directors consists of eight members, of whom one is an executive and seven are non-executives. On our board of directors, two non-executive directors will be independent under the Dutch Corporate Governance Code. We have determined that a majority of our directors are independent under the Rules of NASDAQ. Even if they are not independent under Dutch law, the

Table of Contents

non-executive directors are obliged to perform their tasks in our best interests. Under the Dutch Corporate Governance Code, a non-executive director shall be deemed to be independent if the director is not:

A person who had an important business relationship with the company in the year prior to the appointment. The consulting agreement described in this prospectus between Mr. Tornier and us created such relationship and therefore he is not deemed independent under the Dutch Corporate Governance Code.

A person who is a member of our management board or supervisory board and is a representative in some other way of a legal entity which holds at least ten percent of our shares, unless such entity is a member of the same group as us. Mr. Carney, Mr. Turton and Mrs. Weatherman's relationship with Warburg Pincus and Mr. Emmitt's relationship with the Vertical Group, as shareholders as described in this prospectus, would make them not independent under the Dutch Corporate Code.

A person who has been an employee or member of our management board (including our group companies and companies in which we hold more than 25% of the ownership interest) in the five years prior to the appointment. Mr. Kohrs has been an employee of ours and is therefore not independent under the Dutch Corporate Governance Code.

Under Dutch law and our amended articles of association, our board of directors may make binding nominations of members to be elected to the board of directors. A director who receives a binding nomination will become a director unless the shareholders vote otherwise at a general meeting. Under the Best Practice Provisions, the general meeting of shareholders may, by a simple majority vote, dismiss directors and cancel binding nominations of candidates for the board of directors. We may require a quorum of at least one third of the voting rights outstanding for such a vote. However, in the case of a majority vote in the absence of a one-third quorum, a second meeting will be convened whose vote will be binding, even without a one-third quorum. Our amended articles of association currently provide that the general meeting of shareholders may overrule a binding nomination only by at least a two-thirds majority of votes cast, which votes also represent more than half of the issued share capital. We hold the view that these provisions will enhance the continuity of our management and policies.

Table of Contents

**COMPENSATION DISCUSSION AND ANALYSIS**

Our "named executive officers" for 2009 consisted of the following individuals:

Douglas W. Kohrs, who currently serves as our Chief Executive Officer and Director;

Michael J. Doty, who served as our Chief Financial Officer until February 19, 2010;

Andrew E. Joiner, who currently serves as our Vice President and General Manager, U.S. Commercial Operations;

Stéphan Epinette, who currently serves as our Vice President, International Commercial Operations; and

Robert J. Ball, who currently serves as our Vice President, Global Research and Development.

**Compensation Overview and Objectives**

Because we are a private company, compensation decisions with respect to our named executive officers have generally been based on the goal of achieving performance at levels necessary to provide meaningful returns to our shareholders upon an ultimate liquidity event. To that end, in addition to the typical need to attract, motivate and retain talented executives, our compensation programs have been specifically designed to incentivize our named executive officers to achieve short- and long-term performance goals that would enable us to substantially increase our equity value and make us an attractive candidate for either a public offering of our ordinary shares or a sale, and to provide our named executive officers with meaningful compensation upon the occurrence of such an event. Our compensation programs are weighted toward performance-based compensation, including equity-based compensation, such that our named executive officers will see returns primarily based upon the returns achieved by our shareholders.

**Determination of Compensation**

For services performed for us and our subsidiaries during 2009, our named executive officers were generally compensated by the operating subsidiary to which such named executive officer primarily provided services. Our board of directors was ultimately responsible for determining our compensation and benefit plans generally, and has established and reviewed all compensatory plans and arrangements with respect to our named executive officers. The board of directors meets not less than annually to specifically review and determine adjustments, if any, to all elements of compensation, including base salary, annual bonus compensation and long-term equity awards, including to evaluate the achievement of performance goals for the prior fiscal year and to set new performance goals for the current fiscal year. The board of directors also meets periodically to discuss compensation-related matters as they arise during the year. In addition, with respect to the compensation of our named executive officers, the board of directors seeks the input and recommendation of our Chief Executive Officer. Our Chief Executive Officer reviews each named executive officer's (other than his own) overall performance and contribution to the Company at the end of each fiscal year and makes recommendations regarding each element of their compensation to Mr. Carney, one of our directors, who then consults informally with our Chief Executive Officer regarding his recommendations and in turn presents his recommendations to our full board of directors for final determinations. Our Chief Executive Officer's compensation is determined based on recommendations made by Mr. Carney to the full board of directors. Our Chief Executive Officer does not participate in any formal discussion with the board of directors regarding his compensation decisions and he recuses himself from meetings when his compensation is discussed.

The board of directors does not generally rely on formulaic guidelines for determining the mix or levels of cash and equity-based compensation, but rather maintains a flexible compensation program that allows it to adapt components and levels of compensation to motivate and reward individual

Table of Contents

executives within the context of our desire to attain certain strategic and financial goals. Subjective factors considered in compensation determinations include an executive's skills and capabilities, contributions as a member of the executive management team, contributions to our overall performance and whether the total compensation potential and structure is sufficient to ensure the retention of an executive when considering the compensation potential that may be available elsewhere.

In making its determination, the board of directors has not undertaken any formal benchmarking or reviewed any formal surveys of compensation for our competitors, but has instead relied primarily on its members' general knowledge of the competitive market.

**Components of Compensation for 2009**

For 2009, the compensation provided to our named executive officers consisted of base salary, annual bonus, long-term equity-based compensation, retirement benefits and other perquisites and benefits, each of which is described in more detail below. We believe that the mix of cash- and equity-based compensation, as well as the relationship of fixed to performance-based compensation, is properly balanced and provides us with an effective means to attract, motivate and retain our named executives, as well as reward them for creation of shareholder value.

***Base Salary***

The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive's skill set, experience, role and responsibilities. Base salary amounts are established under each named executive officer's employment agreement, but are subject to upward adjustment by the board of directors based on its consideration of, among other factors, the scope of the executive's responsibilities, individual performance for the prior year, the mix of fixed compensation to overall compensation and consistency with what the board of directors and our Chief Executive Officer consider to be the market standard for compensation paid to similarly-situated executives at other companies. Initially, base salary was determined at the time of a named executive officer's hire, based on the above elements at such time, and such initial amount forms the basis for base salary throughout a named executive officer's tenure with the Company, with adjustments being made by the board of directors as and when appropriate, based on changes in the above elements over time and consistent with our compensation objectives. In 2009, our board of directors established a company-wide guideline that provided for an average salary increase for all employees, other than employees in performance review, of an approximate cost of living adjustment of 3% of 2008 salary, with the actual amount of any employee's raise determined based on 2008 performance. In 2009, Messrs. Kohrs and Ball received 4% raises and Mr. Doty received a 3.5% raise pursuant to these guidelines and based on the board's subjective evaluation of their performance. Mr. Joiner's base salary was increased by 5% in 2009 to reward him for his service based on the board's subjective evaluation of his performance as to the performance factors described above and to bring his base salary in line with what the board of directors and our Chief Executive Officer determined was the market standard for compensation paid to similarly-situated executives at other companies based on their general knowledge of the competitive market.

***Annual Bonuses***

Annual bonuses are intended to compensate executives for achieving annual company-wide financial goals and individual performance goals. Target bonus amounts (60% of base salary for Mr. Kohrs, 50% of base salary for Mr. Joiner, 40% of base salary for Mr. Doty, 35% of base salary for Mr. Ball and 30% of base salary for Mr. Epinette) were established under each named executive officer's employment agreement at the time such agreements were entered into, with actual bonuses for a given fiscal year being based upon the achievement of the applicable performance objectives. For more information regarding each named executive officer's target bonus, please refer to the discussion below under "Narrative Disclosure Relating to Summary Compensation Table and Grant of Plan-Based

Table of Contents

Awards Table Employment Agreements." For 2009, the payment of annual bonuses to our named executive officers was based 50% upon achievement of objective performance goals relating to our cash flows, sales, sales over net inventories plus gross instruments, year-end days sales outstanding, or DSO, and Modified EBITDA, and 50% upon the named executive officer's achievement of individual performance goals described below. During 2010, we intend for the payment of annual bonuses to our named executive officers to be based 80% upon the achievement of objective performance goals and 20% upon the named executive officer's achievement of individual performance goals.

The following table sets forth the financial performance criteria for the 2009 bonus program, which were established by the board of directors on March 26, 2009, the range of possible payouts and the actual payout percentage for named executive officers based on the performance achieved. If performance achieved falls between the threshold, target and maximum levels, actual payout percentages are determined on a sliding scale basis, with payouts starting at 50% of target for minimum performance achievement and capped at 150% of target for maximum achievement. For 2009, the total weighted-average payout percentage applicable to the portion of the 2009 annual bonus tied to objective performance goals was 108%, as detailed in the table below. The board approved payouts at this percentage for the portion of the named executive officers' bonuses tied to objective performance goals.

Modified metrics(1)	Weight (% of 2009 bonus tied to performance of this metric)	Performance targets			Payout percentage			2009 performance (\$)	Level of 2009 payout
		Threshold	Target	Maximum	Threshold	Target	Maximum		
Modified Sales	12%	\$174.5 million	\$205.3 million	\$236.1 million	50%	100%	150%	\$200.9 million	93%
Modified EBITDA(2)	12%	\$11.5 million	\$13.5 million	\$15.5 million	50%	100%	150%	\$12.5 million	76%
Modified Sales/(Net Inventories + Gross Instruments)(3)	10%	1.37	1.61	1.85	50%	100%	150%	1.60	99%
Modified Cash From Operations(4)	8%	\$(29.7) million	\$(25.8) million	\$(22.0) million	50%	100%	150%	\$(21.2) million	150%
Modified DSO (Year-End)(5)	8%	96.6	84.0	71.4	50%	100%	150%	65.7	150%

- (1) The board of directors determined 2009 bonus amounts after reviewing our unaudited financial statements for the 2009 fiscal year, which are adjusted for changes to the foreign exchange rates and which are subject to discretionary adjustment by our management for items that are unusual and not reflective of normal operations. For purposes of determining 2009 bonus amounts, in addition to the foreign exchange adjustments, the board made additional adjustments discussed in footnotes below. Accordingly, the figures included in the "2009 Performance" column reflect foreign exchange rate and discretionary management adjustments and differ from the figures reported in our audited financial statements.
- (2) "Modified EBITDA" means our earnings before interest, taxes, depreciation and amortization, adjusted as described in footnote (1) to exclude the negative impact of terminating our distribution agreement in the United Kingdom (which resulted in a \$0.9 million adjustment), the expenses related to opening sales offices in the United Kingdom and Scandinavia (which resulted in a \$0.8 million adjustment), our licensing and manufacturing agreement with T.A.G. Medical Products Corporation Ltd. (which resulted in a \$0.2 million adjustment), our exclusivity agreements with distributors (which resulted in a \$0.8 million adjustment), and the impact of foreign exchange (which resulted in a \$0.2 million adjustment), and to exclude the positive impact of the consolidation of C2M Medical (which resulted in a \$0.7 million adjustment) and the difference between budget and actual bonus performance (which resulted in a \$0.4 million adjustment).
- (3) "Modified Sales/(Net Inventories + Gross Instruments)" means our annual revenue divided by the annual average of the sum of net inventories and gross instruments before accumulated depreciation. Gross instruments refers to the acquisition cost of the fixed assets. Modified Sales have been adjusted as described in footnote (1) to exclude the positive impact of foreign exchange (which resulted in a \$2.0 million adjustment) and to exclude the negative impact of terminating our distribution agreement in the United Kingdom (which resulted in a \$1.4 million adjustment).
- (4) "Modified Cash from Operations" means our cash generated by (used in) operations, adjusted as described in footnote (1) to include capital expenditures (which resulted in a \$11.1 million adjustment) and instrument expenditures (which resulted in a \$13.5 million adjustment).
- (5) "Modified DSO (Year-End)" is a measure of the average number of days elapsed between the time a sale is made and the time revenue is collected for sales made in a given year, adjusted as described in footnote (1) to exclude the positive impact of foreign exchange (which resulted in a \$2.0 million adjustment) and to exclude the negative revenue impact of terminating our distribution agreement in the United Kingdom (which resulted in a

\$1.4 million adjustment).

Table of Contents

Individual performance goals for 2009 were communicated to each of our named executive officers by our Chief Executive Officer (or, in the case of our Chief Executive Officer, our board of directors) at the beginning of 2009. These individual performance goals were primarily based on the named executive officer's ability to interact with his peers, performance of his direct reports (including the success in recruiting top level talent), development and strengthening of his relationships with our vendors, distributors and customers, and overall contribution to the Company. The portion of the 2009 annual bonus tied to individual performance goals is capped at 100% of target for maximum achievement. For 2009, the board of directors considered Mr. Kohrs' individual performance relative to individual performance goals, and with respect to named executive officers other than Mr. Kohrs, considered Mr. Kohrs' recommendations, which were based on his consideration of the named executive officers' individual performance relative to individual performance goals, and qualitatively determined that Messrs. Kohrs, Joiner, Epinette and Ball achieved 94%, 98%, 99% and 100% of their respective individual performance goals and approved payouts at these percentages for the portion of the named executive officers' bonuses tied to individual performance goals. Pursuant to the terms of Mr. Doty's separation agreement, the portion of Mr. Doty's 2009 annual bonus tied to individual performance goals was paid out at 100% of target.

For 2009, the payout percentages attributable to objective performance and individual performance each represented 50% of the named executive officers' overall annual bonus, which resulted in payouts at the following aggregate percentages: (i) Mr. Kohrs 101%, (ii) Mr. Doty 104%, (iii) Mr. Joiner 103%, (iv) Mr. Epinette 103.5% and (v) Mr. Ball 104%. Actual 2009 bonus amounts are set forth below in the Summary Compensation Table and were paid in February 2010.

***French Incentive Compensation Scheme***

In addition to participating in our annual bonus program, Mr. Epinette participates in an incentive compensation scheme on the same basis as other employees of our French operating subsidiary. This incentive compensation scheme enables our French operating subsidiary to provide its employees with a form of compensation that is efficient with respect to income tax and mandated social contributions in France, insofar as the payments made under the incentive compensation scheme, which receives preferential tax treatment, are exempted from social security contributions. Pursuant to the incentive compensation scheme, employees may receive an annual incentive payment equal to a specified percentage of base salary, up to certain statutory limits. In 2009, employees were eligible to receive up to 16% of base salary, up to a statutory limit of \$23,918. For 2009, annual incentive payments were dependent on the achievement of performance goals relating to sales, Modified EBITDA, net value of implants and instruments to target and on-time delivery to market of certain new products. The following table sets forth the 2009 financial performance metrics for the incentive compensation scheme, the range of possible payouts and the actual payout percentage for Mr. Epinette based on the performance achieved. If performance achieved falls between the threshold and target/maximum levels, actual payout percentages are determined on a sliding scale basis, with payouts starting at 0.25% of base salary for minimum performance achievement and capped at 4% of base salary for target/maximum achievement. Mr. Epinette's actual 2009 incentive payment amount, including the amount paid pursuant to the French scheme and the annual bonus program, is set forth below in the Summary Compensation Table and will be paid in July 2010. The actual 2009 amount earned by Mr. Epinette pursuant to the French incentive compensation scheme was \$23,918, which was based on 83% overall achievement of target levels, as detailed below, which resulted in an annual

Table of Contents

incentive payment equal to 13.25% of base salary. Mr. EpINETTE's 2009 annual incentive payment was limited to \$23,918 pursuant to the statutory cap described above.

Modified metrics(1)	Weight (% of payment tied to performance of this metric)	Performance targets		Payout			Level of 2009 payout
		Threshold	Target/max. (2)	Threshold (% of base salary)	Target/max. (% of base salary)	2009 performance	
Modified Sales	25%	\$174.5 million	\$205.3 million	0.25%	4%	\$200.9 million	81%
Modified EBITDA(3)	25%	\$11.5 million	\$13.5 million	0.25%	4%	\$12.5 million	50%
Modified Net Value of Implants and Instruments(4)	25%	1.62	1.91	0.25%	4%	2.03	100%
On-time Delivery to Market of New Products(5)	25%	n/a	n/a	0.80%	4%	achieved	100%

- (1) The figures in the "2009 Performance" column reflect certain adjustments to our unaudited financial statements for the 2009 fiscal year, consisting of adjustments for changes to the foreign exchange rates and discretionary adjustments by our management for items that were unusual and not reflective of normal operations and, thus, differ from the figures reported in our audited financial statements. For purposes of determining 2009 bonus amounts, in addition to the adjustments, the board made additional adjustments discussed in the footnotes below.
- (2) Under the French incentive compensation scheme, the maximum possible payout is 16% of base salary, up to a statutory limit of \$23,918, which is based on 100% achievement of target levels. Therefore, target and maximum performance and payout amounts are the same for the purposes of the French incentive compensation scheme.
- (3) "Modified EBITDA" means our earnings before interest, taxes, depreciation and amortization, adjusted as described in footnote (1) to exclude the negative impact of terminating our distribution agreement in the United Kingdom (which resulted in a \$0.9 million adjustment), the expenses related to opening sales offices in the United Kingdom and Scandinavia (which resulted in a \$0.8 million adjustment), our licensing and manufacturing agreement with T.A.G. Medical Products Corporation Ltd. (which resulted in a \$0.2 million adjustment), our exclusivity agreements with distributors (which resulted in a \$0.8 million adjustment), and the impact of foreign exchange (which resulted in a \$0.2 million adjustment), and to exclude the positive impact of the consolidation of C2M Medical (which resulted in a \$0.7 million adjustment) and the difference between budget and actual bonus performance (which resulted in a \$0.4 million adjustment).
- (4) "Modified Net Value of Implants and Instruments" means sales, divided by the net value of our inventory of raw materials and semi-finished products, including inventory in warehouses and with customers adjusted as described in footnote (1) to exclude the positive impact of foreign exchange on revenue (which resulted in a \$2.0 million adjustment) and on the net value of implants and instruments (which resulted in a \$3.2 million adjustment) and to exclude the negative impact of terminating our distribution agreement in the United Kingdom (which resulted in a \$1.4 million adjustment).
- (5) "On-Time Delivery to Market of New Products" means the timely release of certain new, strategic products by specific dates. The target/maximum payout amount with respect to this metric assumes the timely release of all new products scheduled to be delivered for a given year, whereas the threshold payout amount is determined by dividing 4% (the target/maximum payout for this metric) by the number of new products scheduled to be delivered for a given year.

**Long-Term Equity Compensation**

We maintain a stock option plan, in an effort to align the equity ownership of our employees with the long-term interests of our shareholders, under which our named executive officers and other employees are eligible to receive option grants. We believe that options effectively incentivize our employees to maximize Company performance, as the value of awards is directly tied to an appreciation in the value of our shares, and provide an effective retention mechanism as a result of the applicable vesting mechanics of the options.

In 2009, each of our named executive officers received a grant of options. The number of options granted to each named executive officer (other than Mr. EpINETTE) was determined by our board of directors, based upon recommendations from Mr. Carney and, other than with respect to his grants, the Chief Executive Officer, based on each executive's position, role and responsibilities, and individual and overall



## Edgar Filing: Tornier B.V. - Form S-1/A

Company performance as determined by the board of directors. In determining the actual number of options awarded to Mr. Kohrs during 2009, the board of directors considered our past grant practices and targeted an ownership rate appropriate for Mr. Kohrs' current equity held and the relative percentage of total equity that his current equity holdings and proposed option grant would represent, and determined that an award to Mr. Kohrs of 200,000 options was consistent with our overall compensation objectives. Those objectives include providing a substantial portion of named executive officer compensation in the form of equity-based compensation and aligning our named

Table of Contents

executive officers' interests with those of our shareholders. Historically (and in 2009) the board of directors has determined the actual number of options awarded to our named executive officers during a given fiscal year by assessing targeted long-term ownership levels and the relative percentage of total equity outstanding that each option grant represents. Consistent with past practices, Mr. Epinette was granted 200,000 options in 2009, in connection with the commencement of his employment. Our stock option plan provides that, except as may otherwise be determined by the board of directors, options vest over a four-year period, with 25% vesting on the first anniversary of the applicable vesting commencement date and the remaining 75% vesting on a pro-rata basis on each quarterly anniversary of the applicable vesting commencement date over the three-year period thereafter. Options granted pursuant to the stock option plan will expire no later than the ten-year anniversary of the applicable date of the grant. Generally, upon a termination of employment (other than certain terminations within twelve months following a change in control), option holders will forfeit all unvested options they hold at the time of their termination. Additionally, option holders will forfeit their outstanding options to the extent they, as determined by our board of directors, engage in competitive activities (as defined in the stock option plan) during the course of their employment or during the six-month period following their termination. We believe that granting options subject to a four-year vesting schedule provides us with an effective mechanism to incentivize and to retain our named executive officers and to align their interest with the long-term interests of our shareholders.

For more information on the stock option plan, see the discussion below under "Narrative Disclosure to Summary Compensation Table and Grant of Plan-Based Awards Table Stock Option Plan."

***Retirement Benefits***

In 2009, each of our named executive officers had the opportunity to participate in retirement plans maintained by our operating subsidiaries, including our U.S. operating subsidiary's 401(k) plan and, with respect to Mr. Epinette, our French operating subsidiary's government-mandated pension plan and a government-mandated pension plan for managerial staff, or the *Retraite Complémentaire*, on the same basis as our other employees in 2009. We believe that these plans provide an enhanced opportunity for our named executive officers to plan for and meet their retirement savings needs. Mr. Epinette also participated in our French operating subsidiary's defined contribution pension plan for key employees, or the *Retraite Supplémentaire* on the same basis as other key employees. In 2009, pursuant to the *Retraite Supplémentaire*, our French operating subsidiary made contributions equal to 5% of Mr. Epinette's base salary on Mr. Epinette's behalf. The *Retraite Supplémentaire* is intended to supplement the state pension plans mandated by French labor laws and to provide participants with a form of compensation that is efficient with respect to income tax and mandated social contributions.

***Perquisites and Other Benefits***

In 2009, our named executive officers were eligible to receive the same benefits, including life and health benefits, that were available to all employees. We also provided certain additional perquisites to our named executive officers, on a case-by-case basis, including automobile and expatriate allowances. We offer Mr. Ball an expatriate allowance, which consists of, among other things, a housing allowance, an automobile allowance, a goods and services differential and a Medicare tax gross-up on foreign compensation. We believe it is necessary to provide Mr. Ball with such perquisites as an inducement for him to temporarily relocate to France and to make him whole for the additional expenses he incurs as an expatriate. We offer Mr. Epinette an automobile on the same basis as other key employees of our French operating subsidiary pursuant to a company policy, which we believe is needed in light of the competitive market for talent in our industry.

***Employment/Severance, Non-Competition and Non-Solicitation Agreements***

Each of our named executive officers is entitled to receive severance benefits upon certain qualifying terminations of employment, pursuant to the provision of such executive's employment

Table of Contents

agreement. Additionally, pursuant to their agreements, each of our named executive officers is entitled to receive certain enhanced severance benefits upon certain qualifying terminations of employment occurring within twelve months of a Change in Control (as such term is defined in the employment agreements). These severance arrangements were initially offered to induce the named executive officers to accept or continue employment with the Company and are primarily intended to retain our named executives, provide consideration to an executive for certain restrictive covenants that apply following a termination of employment and to provide continuity of management in connection with a threatened or actual Change in Control transaction. For more information on our employment agreements and severance arrangements with our named executive officers, see the discussions below under "Narrative Disclosure to Summary Compensation Table and Grant of Plan-Based Awards Table Employment Agreements" and "Potential Payments Upon a Termination or Change in Control."

**Compensation Decisions Relating to Fiscal Year 2010***Separation Agreement with Michael Doty*

Our U.S. operating subsidiary entered into a separation agreement with Mr. Doty in connection with his termination of employment, which became effective on February 19, 2010, pursuant to which, in exchange for his execution of a general release, Mr. Doty is entitled to the severance payments and benefits payable to him pursuant to his employment agreement in the event of an involuntary termination of employment without cause. The cost of the separation agreement includes \$315,667 of base salary and continued coverage on our health plans through February 19, 2011, with the full cost of such coverage, \$14,519, being borne by the Company. The exercise period applicable to Mr. Doty's vested, unexercised options was extended to August 19, 2011 pursuant to the agreement. Mr. Doty's severance payments totaling \$315,667, less applicable withholding and related taxes, will be made semi-monthly over a period of one year from the date of termination. Mr. Doty is restricted from engaging in competition with us or otherwise interfering with our business until the first anniversary of his termination.

*Employment Agreement with Carmen L. Diersen*

On June 21, 2010, in connection with her appointment as our Global Chief Financial Officer, our U.S. operating subsidiary entered into an employment agreement with Carmen L. Diersen. The agreement is substantially the same as the employment agreements in place with our other named executive officers, other than differences in base salary, target annual bonus percentages, and severance. The agreement provides for an initial base salary of \$325,000, subject to increase but not decrease, an annual target bonus equal to 50% of base salary, and a grant of 450,000 options to purchase our common stock, 25% of which vest on the first anniversary of the applicable vesting commencement date, and the remaining 75% of which vest on a pro-rata basis on each quarterly anniversary of the applicable vesting commencement date over the three-year period following the first anniversary of the vesting commencement date. The agreement has a specified term of three years, subject to automatic renewal for one-year terms unless either party provides written notice of their intent not to renew. If Ms. Diersen's employment is terminated without "cause" (as such term is defined in the employment agreement), in addition to any accrued but unpaid salary and benefits through the date of termination, Ms. Diersen will be entitled to base salary and health and welfare benefit continuation for twelve months following termination, and, in the event her employment is terminated without cause due to non-renewal of the employment agreement by Tornier, Inc., Ms. Diersen will also be entitled to a payment equal to her pro-rata annual bonus for the year of termination. In the event Ms. Diersen's employment is terminated without cause or by Ms. Diersen for "good reason" (as such term is defined in the employment agreement) within twelve months following a change in control, Ms. Diersen will be entitled to receive accrued but unpaid salary and benefits through the date of termination, a lump-sum payment equal to her base salary plus target bonus for the year of termination, health and welfare benefit continuation for twelve months following termination and accelerated vesting of all unvested options. The agreement also contains covenants intended to protect against the disclosure of confidential information during and following

Table of Contents

Ms. Diersen's employment, as well as restrictions on engaging in competition with Tornier, Inc. or otherwise interfering with our business relationships, which extend through the first anniversary of Ms. Diersen's termination of employment for any reason.

**Compensation Risk Management**

**Risk Management**

Our board of directors has reviewed our overall compensation policies and practices to determine whether those policies and practices are reasonably likely to have a material adverse effect on us and has concluded that they are not reasonably likely to have a material adverse effect on us based on the following analysis:

***Base Compensation***

Base compensation is a fixed portion of overall compensation that is set based on factors such as the scope of an employee's responsibilities and market practices, and which provides income regardless of our short-term performance. Our board of directors does not believe that base compensation creates an incentive for our employees to take undue risks.

***Bonus Programs***

Bonuses are intended to compensate our employees for achieving company-wide financial goals and individual performance goals. We maintain several incentive compensation programs, including our annual bonus program and an incentive compensation scheme for the benefit of employees of our French operating subsidiary, which is maintained in accordance with French labor laws. Our bonus programs are designed to focus employees on achieving annual goals that are important to our success. The fact that bonuses are awarded based on the achievement of company-wide financial goals may encourage some risk-taking behavior, but this risk is mitigated by the fact that awards are based on the achievement of a balanced mix of several broad-based criteria. Additionally, in the case of our annual bonus program, a portion of the annual bonus is awarded based on the achievement of qualitative individual performance goals, and in the case of our French incentive compensation scheme, payments are limited by local law and generally do not represent a significant portion of our employees' total compensation. For these reasons, our board of directors believes that our bonus programs appropriately balance risk and reward, and do not encourage employees to take unnecessary or excessive risks which could have a material adverse effect on us.

***Long-Term Equity Compensation***

We award certain employees equity compensation in the form of options in an effort to align the equity ownership of employees with the long-term interests of our shareholders. Our board of directors believes that long-term equity compensation discourages our employees from engaging in unnecessary or excessive risk taking, because the ultimate value of the equity awards, which are subject to four-year vesting schedules, is determined based on the long-term appreciation in value of our shares.

***Retirement, Health, and Other Welfare Benefits***

Our employees are eligible to participate in retirement plans maintained by us and by our operating subsidiaries abroad. Our board of directors does not believe that such programs encourage our employees to take unnecessary or excessive risks which could have a material adverse effect on us, because they represent a small portion of overall compensation, are unrelated to our short-term performance, and are generally limited by local laws. Our board of directors does not believe that the health and welfare benefits we provide to our employees create an incentive for our employees to take undue risks, because the value of these benefits is unrelated to our short-term performance.

Table of Contents**Severance Benefits**

Our executive officers and our employees are eligible to receive severance payments and benefits upon certain terminations of employment pursuant to their employment agreements, our severance policy, or severance policies maintained by our operating subsidiaries abroad in accordance with local laws, which payments and benefits are limited by the terms of such applicable agreements, policies, and laws. Our board of directors does not believe that our severance policies and practices create an incentive for our employees to take undue risks.

**Perquisites and Expatriate Benefits**

We provide our executive officers and certain other employees with perquisites, including automobiles, and expatriate benefits. We offer expatriate benefits as an inducement for employees to relocate and to make such employees whole for the expenses they incur as expatriates. Our board of directors does not believe that the perquisites or expatriate benefits we provide are excessive, or that they encourage employees to take unnecessary or excessive risks.

After considering the risk implications of each element of our overall compensation program, our board of directors determined that the only components of employee compensation that might pose risks are the annual bonus program and the incentive programs. These programs encourage some level of risk taking by our employees; however, we believe that the risk is well managed and the level of risk acceptable, particularly in light of the balanced mix of fixed and variable elements, and of short- and long-term elements, in our overall compensation program. For these reasons, our board of directors concluded that our overall compensation policies and practices are not likely to have a material adverse effect on us.

**Executive Compensation****2009 Summary Compensation Table**

The following table shows compensation of our principal executive officer, our principal financial officer and three other executive officers for the fiscal year ending December 27, 2009.

Name and principal position	Year	Salary (\$)	Option awards (1)(\$)	Non-equity incentive plan compensation (\$)(2)	All other compensation (\$)	Total (\$)
Douglas W. Kohrs President, Chief Executive Officer and Director	2009	477,210	478,661	289,189	0	1,245,060
Michael J. Doty(3) Chief Financial Officer	2009	315,667	119,665	131,317	0	566,649
Andrew E. Joiner Vice President and General Manager, U.S. Commercial Operations	2009	304,500	239,330	156,818	0	700,648
Stéphan Epinette(4) Vice President, International Commercial Operations	2009	278,866	478,661	109,667	78,418 <sup>(5)</sup>	945,612
Robert J. Ball Vice President, Global Research and Development	2009	245,432	119,665	89,337	129,053 <sup>(6)</sup>	583,487

(1)

The amounts shown in the "Option Awards" column represent the aggregate grant date fair value of equity awards granted in 2009, computed in accordance with FASB ASC Topic 718. See Note 4 to our consolidated financial

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

statements for the year ended December 27, 2009, for a discussion of valuation assumptions for the aggregate grant date fair values.

- (2) Reflects the amount of annual incentive bonuses paid to our named executive officers (other than Mr. Epinette) in respect of 2009 performance, but paid in February 2010. For Mr. Epinette, the amount in this column represents the sum of (i) the annual incentive bonus paid in respect of 2009 performance, but paid in February 2010, and (ii) the bonus payable pursuant to the French incentive compensation scheme in July 2010 in respect of 2009 performance.
- (3) Mr. Doty's tenure as Chief Financial Officer of Tornier, Inc. terminated as of February 19, 2010.
- (4) Mr. Epinette's cash compensation was paid in Euro. The foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009, was used to calculate Mr. Epinette's base salary and all other compensation amounts, including his bonus payable pursuant to the French incentive compensation scheme. The foreign currency exchange rate of 1.3808 U.S. dollars for 1 Euro was used to calculate his annual incentive bonus, which reflects an average conversion rate for the period between January 25, 2010, and February 19, 2010, which was paid in February 2010.
- (5) Consists of \$2,727 in contributions to the French government-mandated pension plan, \$32,029 in contributions to our French operating subsidiary's Retraite Complémentaire on Mr. Epinette's behalf, \$14,088 in contributions to our French operating subsidiary's Retraite Supplémentaire on Mr. Epinette's behalf and \$29,574 related to automobile expenses. The foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009, was used to calculate Mr. Epinette's all other compensation amounts.
- (6) Consists of expatriate perquisites including a housing allowance of \$41,829, a goods and services differential of \$33,463, an automobile allowance of \$22,261, a Medicare tax gross-up on foreign compensation of \$2,354, a family travel allowance of \$18,949, and a utilities allowance of \$2,873, and \$7,325 in contributions to our U.S. operating subsidiary's 401(k) Plan on Mr. Ball's behalf. Mr. Ball's expatriate perquisites were paid in Euro and were converted based on a foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009.

### Grant of Plan-Based Awards

The following table sets forth summary information regarding all grants of plan-based awards made to our named executive officers for the year ended December 27, 2009.

Name(1)	Grant date	Estimated future payouts under non-equity incentive plan awards (\$)			All other option awards: number of securities underlying options (#)	Exercise or base price of option awards (\$/share)(4)	Grant date fair value of option awards(5)
		Threshold (2)	Target	Maximum (3)			
Douglas W. Kohrs	3/26/2009 5/1/2009	11,453	286,326	357,908	200,000	5.66	478,661
Michael J. Doty	3/26/2009 5/1/2009	5,051	126,267	157,834	50,000	5.66	119,665
Andrew E. Joiner	3/26/2009 5/1/2009	6,090	152,250	190,313	100,000	5.66	239,330
Stéphan Epinette(6)	3/26/2009 6/25/2009(7) 5/1/2009	3,346(8) 697(9)	83,660 23,918	104,575 23,918	200,000	5.66	478,661
Robert J. Ball	3/26/2009 5/1/2009	3,436	85,901	107,377	50,000	5.66	119,665

## Edgar Filing: Tornier B.V. - Form S-1/A

- (1) All of our named executive officers were granted non-equity incentive plan awards pursuant to our 2009 annual bonus scheme, and were granted stock options pursuant to our stock option plan. Mr. Epinette was also granted a non-equity incentive plan award pursuant to our French operating subsidiary's incentive compensation scheme.
- (2) The threshold amount for awards payable under our annual bonus program and our French operating subsidiary's incentive compensation scheme assumes that the threshold level of the lowest weighted financial performance objective has been satisfied.
- (3) Maximum amounts reflect payout of the portion of annual bonus tied to Company financial performance objectives at a rate of 150% of target and the portion of the annual bonus tied to individual performance objectives at a rate of

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

100% of target under our annual bonus program. Target and maximum payout amounts are the same for the purposes of the French incentive compensation scheme.

- (4) The exercise price of the options were set at the fair market value of one share of our ordinary shares at the time of the grant, with fair market value being determined by our board of directors in good faith.
- (5) The amounts shown in the "Option Awards" column represent the aggregate grant date fair value of equity awards granted in 2009, computed in accordance with FASB ASC Topic 718. See Note 4 to our consolidated financial statements for the fiscal year ended December 27, 2009 for a discussion of valuation assumptions for the aggregate grant date fair values.
- (6) The foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009, was used to calculate Mr. Epinette's target and maximum awards in respect of annual bonus and payments under the French incentive compensation scheme.
- (7) The terms of the 2009 French incentive compensation scheme were governed by an agreement entered into by our French operating subsidiary on June 25, 2009, which was subsequently amended on June 25, 2009 (pursuant to which the applicable performance criteria were established), July 24, 2009 (pursuant to which certain details of the performance criteria were clarified), and November 9, 2009 (to provide for a fiscal year end of December 27, 2009, rather than December 31, 2009).
- (8) Awards set forth on this line represent awards granted to Mr. Epinette pursuant to our annual bonus program.
- (9) Awards set forth on this line represent awards granted to Mr. Epinette pursuant to our French operating subsidiary's incentive compensation scheme.

### **Narrative Disclosure Relating to Summary Compensation Table and Grants of Plan-Based Awards Table**

#### ***Employment Agreements***

Tornier, Inc., our U.S. operating subsidiary, is a party to employment agreements with Messrs. Kohrs, Joiner and Ball, and was party to an employment agreement with Mr. Doty prior to his termination of employment, which agreements are substantially the same other than differences in base salary, target annual bonus percentages and severance. The agreements have specified terms of three years, subject to automatic renewal for one-year terms unless either party provides 60 days' advance notice of their desire not to renew. Under the agreements, each executive is entitled to an enumerated base salary, subject to increase but not decrease, is eligible to receive an annual bonus with a target bonus equal to an enumerated percentage of base salary (60% for Mr. Kohrs, 50% for Mr. Joiner, 40% for Mr. Doty and 35% for Mr. Ball), and is entitled to participate in the employee benefit plans and arrangements that we generally maintain for our senior executives. If an executive's employment is terminated by Tornier, Inc. without "cause" (as such term is defined in the employment agreements), in addition to any accrued but unpaid salary and benefits through the date of termination, the executive will be entitled to base salary and health and welfare benefit continuation for twelve months following termination, and, in the event their employment is terminated without cause due to non-renewal of their employment agreements by Tornier, Inc., the executives will also be entitled to a payment equal to their pro-rata annual bonus for the year of termination. In the event any of Messrs. Kohrs, Doty, Joiner or Ball's employment is terminated without cause or by the executive for "good reason" (as such term is defined in the employment agreements) within twelve months following a change in control, the executives will be entitled to receive accrued but unpaid salary and benefits through the date of termination, a lump-sum payment equal to their base salary plus target bonus for the year of termination, health and welfare benefit continuation for twelve months following termination and accelerated vesting of all unvested options. In addition, Mr. Kohrs' agreement provides that in the event the payments and benefits to which he is entitled pursuant to the agreement become subject to the excise tax under Section 4999 of the Internal Revenue Code of 1986, as amended, he will be entitled to a "gross-up" payment in order to cover such tax liability. The agreements also contain covenants intended to protect against the disclosure of confidential information during and following an executive's employment, as well as restrictions on engaging in competition with Tornier, Inc.

or



Table of Contents

otherwise interfering with our business relationships, which extend through the first anniversary of an executive's termination of employment for any reason.

Tornier SAS, our French operating subsidiary, is also a party to an employment agreement with Mr. Epinette, which does not have a specified term, but which may be terminated by either party in accordance with local law, and which is substantially similar to the employment agreements described above with respect to base salary, annual target bonus (30% of base salary), benefit participation and non-compete obligations. Pursuant to the agreement and French labor laws, Mr. Epinette is entitled to receive certain payments and benefits following a voluntary or involuntary termination of employment, including an amount equal to twelve months' base salary, which is payable as consideration for the restrictive covenants contained in the agreement, a payment equal to Mr. Epinette's French incentive compensation scheme payment for the year of his termination and, in the case of an involuntary termination of employment, a severance payment payable pursuant to French law, the amount of which is determined based on Mr. Epinette's gross monthly salary and years of service with Tornier SAS. If Mr. Epinette is terminated for reasons other than negligence or serious misconduct following a change in control (as such term is defined in the employment agreement), he is entitled to base salary continuation and health and welfare benefit continuation for twelve months following termination of employment, accelerated vesting of all unvested options, as well as a payment equal to Mr. Epinette's annual target bonus and French incentive compensation scheme payment for the year of his termination.

***Stock Option Plan***

Effective as of July 18, 2006, we adopted the stock option plan, which is designed to assist in attracting, retaining, motivating and rewarding eligible employees, directors and consultants, and promoting the creation of long-term value for our stockholders by closely aligning the interests of participants with those of such stockholders, by allowing grants of options to purchase shares of our common stock to such participants.

Our board of directors administers the stock option plan and is authorized to, among other things, designate participants, grant options, determine the terms and conditions relating to options, including vesting, prescribe option agreements, interpret the stock option plan, establish, amend and rescind any rules and regulations relating to the stock option plan, and to make any other determinations that it deems necessary or advisable for the administration of the stock option plan. Our board of directors may also delegate to our officers or employees, or other committees, subject to applicable law, the authority, subject to such terms as our board of directors determines appropriate, to perform such functions, including but not limited to administrative functions, including the appointment of agents to assist in the administration of the stock option plan. Any action of our board of directors (or its authorized delegates) will be final, conclusive and binding on all persons, including participants and their beneficiaries.

Our stock option plan reserves 15,000,000 shares of our ordinary shares for issuance, subject to adjustment in the event of any stock dividend or split, reorganization, recapitalization, merger, share exchange or any other similar corporate transaction or event. For purposes of determining the remaining ordinary shares available for grant under the stock option plan, to the extent that an option expires or is canceled, forfeited, settled in cash or otherwise terminated without a delivery to the participant of the full number of ordinary shares to which the option related, the undelivered ordinary shares will again be available for grant. Similarly, ordinary shares withheld in payment of the exercise price or taxes relating to an option and shares equal to the number surrendered in payment of any exercise price or taxes relating to an option shall be deemed to constitute shares not delivered to the participant and shall be deemed to again be available for options under the stock option plan.

Table of Contents

The board of directors may, in the event of a Corporate Event (as defined in the stock option plan and which, for example includes a change in control of a reorganization of the Company), in its sole discretion, provide for adjustments or substitutions as to the number, price or kind of shares or other consideration subject to outstanding options, or provide for the termination of an option and the payment of a cash amount in exchange for the cancellation of an option. The board of directors has the ability to amend or terminate the stock option plan or options granted thereunder at any time, provided that no amendment or termination will be made that impairs the rights of the holder of any option outstanding on the date of such amendment or termination. The board of directors may also suspend or terminate the stock option plan at any time, and, unless sooner terminated, the stock option plan will terminate on July 18, 2016.

The terms of the stock option plan restrict a participant's ability to transfer shares acquired pursuant to the exercise of options granted thereunder until the expiration of the 180-day period following the occurrence of an initial public offering of our ordinary shares. The stock option plan contains provisions which provide our institutional investors with drag along rights and us with repurchase rights, which rights will terminate upon the occurrence of an initial public offering of our ordinary shares.

**Outstanding Equity Awards at Fiscal Year End**

The following table sets forth summary information regarding the outstanding equity awards held by our named executive officers at December 27, 2009.

Name	Number of securities underlying unexercised options(1) (#) exercisable	Number of securities underlying unexercised options(1) (#) unexercisable	Option exercise price (\$)	Option expiration date
Douglas W. Kohrs	1,421,875	328,125	4.46	7/18/2016
	782,782	355,805	4.63	2/26/2017
	178,126	296,874	5.66	4/24/2018
		200,000	5.66	2/1/2019
Michael Doty(4)	240,625	109,375	4.63	2/5/2017
	56,250	93,750	5.66	4/25/2018
		50,000	5.66	2/1/2019
Andrew Joiner	93,750	156,250	5.66	4/25/2018
		100,000	5.66	2/1/2019
Stéphan Epinette		200,000	5.66	3/26/2019
Robert Ball	203,125	46,875	4.46	1/12/2017
	51,565	23,435	4.63	2/26/2017
	28,126	46,874	5.66	4/24/2018
		50,000	5.66	2/1/2019

(1) All options were granted under the stock option plan. Our named executive officers did not exercise any outstanding options during 2009.

(2) 25% of the options vest on the first anniversary of the applicable vesting commencement date, and the remaining 75% of the options vest on a pro-rata basis on each quarterly anniversary of the applicable vesting commencement date over the three-year period following the first anniversary of the vesting commencement date. The vesting commencement date for each option is generally the date which is ten years earlier than the option expiration date listed on the table. Our named executive officers' unvested options will become fully vested as follows: (i) **Mr. Kohrs** for options expiring on July 18, 2016, 109,375 options vested or will vest on each of January 18, 2010, April 18, 2010, and July 18, 2010, for options expiring on February 26, 2017, 71,161 options vest on each February 26, May 26, August 26 and November 26 through February 26, 2011, for options expiring on April 24, 2018, 29,688 options vest on each April 25, July 23, October 23 and January 23 through April 24, 2012 (29,682 options will vest on April 24, 2012) and for options expiring on February 1, 2019, 50,000 options vested on February 1, 2010, and 12,500 options vest on each May 1, August 1, November 1 and February 1 occurring thereafter



Table of Contents

through February 1, 2013; (ii) **Mr. Doty** for options expiring on February 5, 2017, 21,875 options vest on each February 5, May 5, August 5 and November 5 through February 5, 2011, for options expiring on April 25, 2018, 9,375 options vest on each April 25, July 23, October 23, and January 23 through April 24, 2012, and for options expiring on February 1, 2019, 12,500 options vested on February 1, 2010, and 3,125 options vest on each May 1, August 1, November 1 and February 1 occurring thereafter through February 1, 2013; (iii) **Mr. Joiner** for options expiring on April 25, 2018, 15,625 options vest on each April 25, July 23, October 23 and January 23 through April 24, 2012, and for options expiring on February 1, 2019, 25,000 options vested on February 1, 2010, and 6,250 options vest on each May 1, August 1, November 1 and February 1 occurring thereafter through February 1, 2013; (iv) **Mr. Epinette** for options expiring on March 26, 2019, 50,000 options vested on March 26, 2010, and 12,500 options vest on each June 26, September 26, December 26 and March 26 occurring thereafter through March 26, 2013; and (v) **Mr. Ball** for options expiring on January 12, 2017, 15,625 options vest on each of March 5, 2010, June 5, 2010, and September 5, 2010, for options expiring on February 26, 2017, 4,687 options vest on each February 26, May 26, August 26 and November 26 through February 26, 2011, for options expiring on April 24, 2018, 4,688 options vest on each April 25, July 23, October 23 and January 23 through April 24, 2012 (4,682 options will vest on April 24, 2012), and for options expiring on February 1, 2019, 12,500 options vested on February 1, 2010, and 3,125 options vest on each May 1, August 1, November 1 and February 1 occurring thereafter through February 1, 2013.

- (3) The exercise price of the options were set at the fair market value of a share of our ordinary shares at the time of the grant, with fair market values being determined by our board of directors in good faith.
- (4) All unvested options held by Mr. Doty as of February 19, 2010 were forfeited in connection with the separation agreement.

Table of Contents**Potential Payments Upon a Termination or Change in Control**

Pursuant to the employment agreements with our named executive officers, upon certain terminations of employment, our named executive officers are entitled to payments of compensation and benefits as described above under "Narrative Disclosure to Summary Compensation Table and Grant of Plan-Based Awards Table Employment Agreements." The table below reflects the amount of compensation and benefits payable to each named executive officer in the event of (i) any termination (including for cause) or resignation, or a voluntary/for cause termination, (ii) an involuntary termination without cause, (iii) an involuntary termination without cause or a resignation for good reason within twelve months following a change in control, or a qualifying change in control termination, (iv) termination by reason of an executive's death and (v) termination by reason of an executive's disability. The amounts shown assume that the applicable triggering event occurred on December 27, 2009, and therefore are estimates of the amounts that would be paid to the named executive officers upon the occurrence of such triggering event.

Name	Type of payment	Triggering Events					
		Voluntary/ for cause termination (\$)	Involuntary termination without cause (\$)	Qualifying change in control termination (\$)	Death (\$)	Disability (\$)	
Douglas W. Kohrs	Cash Severance(1) Benefit		477,210	477,210			
	Continuation(2)		14,519	14,519			
	Target Bonus(3) Equity			286,326			
	Acceleration(4)			2,932,909			
	Gross-Up				0		
	<b>Total</b>			491,729	3,710,964		
Michael J. Doty(5)	Cash Severance(1) Benefit		315,667	315,667			
	Continuation(2)		14,519	14,519			
	Target Bonus(3) Equity			126,267			
	Acceleration(4)			578,406			
	<b>Total</b>			330,186	1,034,859		
	Andrew E. Joiner	Cash Severance(1) Benefit		304,500	304,500		
Continuation(2)			14,519	14,519			
Target Bonus(3) Equity				152,250			
Acceleration(4)				471,500			
<b>Total</b>				319,019	942,769		
Stéphan Epinette(6)		Cash Severance Benefit	278,866(8)	283,562(9)	278,866		278,866(8)
	Continuation			6,626			
	Target Bonus(7)	23,918	23,918	108,447	23,918	23,918	
	Equity						
	Acceleration(4)			368,000			
	<b>Total</b>	302,784	307,480	761,939	23,918	302,784	
Robert J. Ball	Cash Severance(1) Benefit		245,432	245,432			
	Continuation(2)		14,519	14,519			
	Target Bonus(3) Equity			85,901			
	Acceleration(4)			388,007			
	<b>Total</b>		259,951	733,859			

- (1) Includes the value of salary continuation for twelve months or payment of a lump sum equal to twelve months' salary following the executive's termination, as applicable.
- (2) Includes the value of medical, dental and vision benefit continuation for each executive and his family for twelve months following the executive's termination. With respect to a qualifying change in control termination, Tornier will bear the entire cost of coverage.

Table of Contents

- (3) Includes value of full target bonus for the year of the change in control.
- (4) Includes the value of acceleration of all unvested shares that are subject to options, based on a per share price of \$7.50, which is the value obtained in our most recent valuation.
- (5) Mr. Doty's tenure as Chief Financial Officer of Tornier, Inc. terminated as of February 19, 2010. In connection with his termination, Mr. Doty became entitled to the severance payments and benefits payable to him in the event of an involuntary termination without cause shown in the above table. For more information regarding the amounts payable to Mr. Doty in connection with this termination, please refer to the discussion above under "Compensation Discussion and Analysis Compensation Decisions Relating to Fiscal Year 2010 Separation Agreement with Michael Doty."
- (6) The foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009, was used to calculate Mr. Epinette's payments and benefits upon termination of employment.
- (7) Includes amounts payable pursuant to the French incentive compensation scheme maintained by Tornier SAS assuming 100% achievement of applicable performance metrics. Pursuant to French law, participants receive their annual incentive payment for the year of their termination of employment for any reason. Upon a qualifying termination following a change in control, Mr. Epinette will also receive his full target annual bonus for the year of the change in control.
- (8) Reflects an amount equal to twelve months' base salary, which is payable as consideration for the restrictive covenants contained in Mr. Epinette's employment agreement (the "Restrictive Covenant Consideration").
- (9) Reflects, in addition to the Restrictive Covenant Consideration, an amount equal to one-fifth of Mr. Epinette's gross monthly salary, multiplied by his number of years of service with Tornier SAS, which is intended to reflect an amount payable pursuant to French law in the event of Mr. Epinette's involuntary termination of employment. Mr. Epinette will receive these benefits following any involuntary termination of employment, except for a termination involving serious or gross misconduct.

Table of Contents**DIRECTOR COMPENSATION**

With the exception of Mr. Tornier, we did not pay our current directors any compensation for serving on our board of directors during 2009. Mr. Kohrs also did not receive additional compensation for his service as a director. The table below summarizes the compensation received by our non-employee directors for the year ended December 27, 2009.

**Director Compensation Table**

Name	Fees earned or paid in cash (\$)	All other compensation (\$)	Total (\$)
Sean D. Carney			
Richard B. Emmitt			
Alain Tornier	16,732(1)	267,706(2)	284,438
Simon Turton			
Richard F. Wallman			
Elizabeth H. Weatherman			

(1) The foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009, was used to calculate Mr. Tornier's cash compensation. The amount shown reflects meeting fees earned by Mr. Tornier in 2009, as described below.

(2) The foreign currency exchange rate of 1.3943 U.S. dollars for 1 Euro, which reflects an average conversion rate for 2009, was used to calculate Mr. Tornier's cash compensation. The amount shown reflects Mr. Tornier's annual compensation earned under his consulting agreement with us, as described below, pursuant to which he provides certain consulting services.

**Narrative Disclosure Relating to Director Compensation Table*****Director Compensation***

With the exception of Mr. Tornier, we did not pay our current directors any compensation for serving on our board of directors during 2009. We did, however, reimburse all directors for expenses incurred in connection with their service on the board of directors, including reimbursement of expenses incurred in connection with attending board of directors' meetings. In 2009, in addition to receiving reimbursement for travel expenses, Mr. Tornier was eligible to receive meeting fees of €3,000 per meeting attended, and earned €12,000 in total meeting fees in 2009.

***Consulting Agreement***

On July 31, 2006 we entered into a consulting agreement with Mr. Tornier, pursuant to which, in exchange for his services to us as a consultant, he was entitled to receive a consulting fee of €16,000 per month. Pursuant to the agreement, Mr. Tornier advised us and our executive officers with respect to investments, new opportunities for growth and general business matters. The agreement, which had a specified term of one year, was subject to automatic renewal for one-year terms unless either party provides three months' advance notice of their desire not to renew and contained covenants intended to protect against the disclosure of confidential information during and following the term of the agreement. On June 4, 2010, we issued 130,900 ordinary shares to KCH, a Swedish entity which is wholly owned by Mr. Tornier, having a value equal to €0.7 million (the total amount owed to Mr. Tornier for past services performed under the terms of the consulting agreement as of April 4, 2010), based on a per-share price of \$7.50 (which was equal to our estimate of the fair value of our ordinary shares at that time) and a foreign currency exchange rate of 1.3479 U.S. dollars for 1 Euro, the spot conversion rate on March 31, 2010. Mr. Tornier's consulting agreement was terminated effective as of March 31, 2010.



Table of Contents

*Option Grant*

On December 8, 2008, our board of directors granted 150,000 stock options to Mr. Wallman pursuant to our stock option plan, with an exercise price of \$5.66 per share. The options are subject to the same vesting schedule as those granted to our named executive officers, that is, subject to continued service on the board of directors, 25% of the options vested on the first anniversary of the applicable vesting commencement date, and the remaining 75% of the options will vest on a pro-rata basis on each quarterly anniversary of the vesting commencement date over the three-year period following the first anniversary of the vesting commencement date.

Table of Contents**PRINCIPAL SHAREHOLDERS**

The following table sets forth certain information concerning the beneficial ownership of our ordinary shares as of July 4, 2010, by:

each of our directors and executive officers;

all of our directors and executive officers as a group; and

each person known by us to beneficially own more than 5% of our ordinary shares.

The calculations in the table below assume that there are \_\_\_\_\_ ordinary shares outstanding immediately after the completion of this offering and that the underwriters do not exercise their over-allotment option, and 88,703,258 ordinary shares outstanding as of July 4, 2010.

Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of any other security. The shares that a shareholder has the right to acquire within 60 days, however, are not included in the computation of the percentage ownership of any other person.

Unless otherwise indicated, the address for each listed shareholder is c/o Tornier N.V., Olivier van Noortstraat 4, 3124 LA Schiedam, The Netherlands.

	Ordinary shares beneficially owned prior to completion of this offering		Ordinary shares beneficially owned after completion of this offering	
	number	%	number	%
<b>Directors and Executive Officers:</b>				
Douglas W. Kohrs(1)	4,363,488	4.8		
Carmen L. Diersen				
Robert J. Ball(2)	360,930	*		
Ralph E. Barisano, Jr.(3)	128,343	*		
Stéphan Epinette(4)	67,086	*		
Andrew E. Joiner(5)	178,125	*		
Jamal D. Rushdy(6)	174,281	*		
James C. Harber(7)	147,814	*		
James E. Kwan(8)	322,403	*		
Michael J. Doty(9)	370,716	*		
Elizabeth H. Weatherman(10)	55,475,428	62.5		
Sean D. Carney(11)	55,475,428	62.5		
Simon Turton, Ph.D.(12)	55,475,428	62.5		
Alain Tornier(13)	11,859,268	13.4		
Richard B. Emmitt(14)	10,149,304	11.4		
Kevin C. O'Boyle				
Richard F. Wallman(15)	136,000	*		
All Directors and Executive Officers as a Group	78,940,074	89.0		
<b>Principal Shareholders:</b>				
Warburg Pincus entities (TMG Holdings Coöperatief U.A.)(16)	55,475,428	62.5		
KCH Stockholm AB(17)	10,455,877	11.8		
Vertical Group, L.P.(18)	10,149,304	11.4		

\*

## Edgar Filing: Tornier B.V. - Form S-1/A

Represents beneficial ownership of less than 1% of our stock.

- (1) Includes 1,275,047 ordinary shares and options exercisable for 3,088,441 ordinary shares.
- (2) Includes options exercisable for 360,930 ordinary shares.

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

- (3) Includes 11,161 ordinary shares and options exercisable for 117,182 ordinary shares.
- (4) Includes 4,586 ordinary shares and options exercisable for 62,500 ordinary shares.
- (5) Includes options exercisable for 178,125 ordinary shares.
- (6) Includes 4,282 ordinary shares and options exercisable for 169,999 ordinary shares.
- (7) Includes 3,129 ordinary shares and options exercisable for 144,685 ordinary shares.
- (8) Includes 1,153 ordinary shares and options exercisable for 321,250 ordinary shares.
- (9) Includes options exercisable for 340,625 shares held by Mr. Doty and 30,091 ordinary shares held by STAK, on behalf of Mr. Doty's wife, Diane M. Doty.
- (10) Includes 55,475,428 shares held by affiliates of Warburg Pincus & Co., or WP. Ms. Weatherman is a Partner of WP and a Managing Director of Warburg Pincus LLC, or WP LLC. All shares indicated as owned by Ms. Weatherman are included because of her affiliation with the Warburg Pincus entities. Ms. Weatherman disclaims all beneficial ownership in such shares. Ms. Weatherman's address is c/o Warburg Pincus LLC, 450 Lexington Avenue, New York, New York 10017.
- (11) Includes 55,475,428 shares held by affiliates of WP. Mr. Carney is a Partner of WP and a Managing Director of WP LLC. All shares indicated as owned by Mr. Carney are included because of his affiliation with the Warburg Pincus entities. Mr. Carney disclaims all beneficial ownership in such shares. Mr. Carney's address is c/o Warburg Pincus LLC, 450 Lexington Avenue, New York, New York 10017.
- (12) Includes 55,475,428 shares held by affiliates of WP. Dr. Turton is a Managing Director of WP LLC. All shares indicated as owned by Dr. Turton are included because of his affiliation with the Warburg Pincus entities. Dr. Turton disclaims all beneficial ownership in such shares. Dr. Turton's address is c/o Warburg Pincus LLC, 450 Lexington Avenue, New York, New York 10017.
- (13) Includes 10,455,877 shares held by KCH Stockholm AB, or KCH, and 1,403,371 shares held by Phil Invest ApS. Mr. Tornier wholly owns both KCH and Phil Invest. All shares indicated as owned by Mr. Tornier are included because of his affiliation with these entities.
- (14) Includes 10,149,304 shares held by the Vertical Group, L.P., or The Vertical Group. Mr. Emmitt is a General Partner of The Vertical Group and a Member and Manager of The Vertical Group GP, LLC, which controls The Vertical Group. All shares indicated as owned by Mr. Emmitt are included because of his affiliation with The Vertical Group. Mr. Emmitt disclaims all beneficial ownership in such shares. Mr. Emmitt's address is c/o The Vertical Group, L.P., 25 DeForest Avenue, Summit, New Jersey 07901.
- (15) Includes 126,625 ordinary shares held by STAK on behalf of Mr. Wallman and options exercisable for 9,375 ordinary shares.
- (16) Reflects shares held by TMG Holdings Coöperatief U.A., or TMG, a Dutch coöperatief. TMG is owned by WP Bermuda, a Bermuda limited partnership, and WP (Bermuda) IX PE One Ltd., or PE One, a Bermuda company. The general partner of WP Bermuda is Warburg Pincus (Bermuda) Private Equity Ltd., or WPPE, a Bermuda company. Each of WP Bermuda, PE One and WPPE is managed by WP LLC. Charles R. Kaye and Joseph P. Landy are the Managing General Partners of WP, the sole member of WPPE and Managing Members and Co-Presidents of WP LLC and may be deemed to control the Warburg Pincus entities. Each of Mr. Kaye and Mr. Landy disclaims beneficial ownership of all shares owned by Warburg Pincus entities. TMG, WP Bermuda, PE One, WPPE, WP LLC and WP are collectively referred to in this Prospectus as Warburg Pincus. The address of the Warburg Pincus entities is 450 Lexington Avenue, New York, New York 10017.
- (17) KCH, a Swedish entity, is wholly owned by Alain Tornier, a member of our board of directors. The address of KCH is Hamilton Advokatbyrå Karlstad AB, Kungsgatan 2A, Box 606, 651 13 Karlstad, Sweden.
- (18) Includes 10,149,304 shares held by Vertical Fund I, L.P., or VFI, a Delaware limited partnership, and Vertical Fund II, L.P., or VFII, a Delaware limited partnership. The Vertical Group L.P., a Delaware limited partnership, is the sole general partner of each of VFI and VFII, and The Vertical

## Edgar Filing: Tornier B.V. - Form S-1/A

Group GP, LLC controls The Vertical Group L.P. The sole members and managers of The Vertical Group GP, LLC are Messrs. Stephen D. Baksa, Tony M. Chou, Richard B. Emmitt, Yue-Teh Jang, Jack W. Lasersohn and John E. Runnells, and these six individuals share voting and investment power over securities held by The Vertical Group, Mr. Lasersohn along with the other general partners of The Vertical Group, L.P., VFI and VFII. The address of The Vertical Group L.P., the Vertical Group GP, LLC, VFI and VFII is 25 DeForest Avenue, Summit, New Jersey 07901.

None of our shareholders has informed us that he or she is affiliated with a registered broker-dealer or is in the business of underwriting securities. None of our existing shareholders will have different voting rights from other shareholders after the completion of this offering. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.

Table of Contents**RELATED PARTY TRANSACTIONS**

We describe below transactions and series of similar transactions that have occurred this year or during our last three fiscal years to which we were a party or will be a party in which:

the amounts involved exceeded or will exceed \$120,000; and

a director, executive officer, holder of more than 5% of our ordinary shares or any member of their immediate family had or will have a direct or indirect material interest.

The following persons and entities that participated in the transactions listed in this section were related persons at the time of the transaction:

*KCH Stockholm AB and Alain Tornier.* KCH Stockholm AB, or KCH, holds more than 5% of our outstanding shares. In addition, KCH is wholly owned by Mr. Tornier, a member of our board of directors.

*TMG Holdings Coöperatief U.A., Warburg Pincus (Bermuda) Private Equity IX, L.P., Elizabeth H. Weatherman, Sean D. Carney and Dr. Simon Turton.* TMG Holdings Coöperatief U.A., or TMG, holds more than 5% of our outstanding shares. Our directors Ms. Weatherman, Mr. Carney and Dr. Turton are Managing Directors of Warburg Pincus LLC, which manages TMG as well as its parent entities Warburg Pincus (Bermuda) Private Equity IX, L.P., or WP Bermuda, WP (Bermuda) IX PE One Ltd. and Warburg Pincus (Bermuda) Private Equity Ltd., or WPPE. Furthermore, Ms. Weatherman and Mr. Carney are Partners of Warburg Pincus & Co., the sole member of WPPE.

*Vertical Fund I, L.P., Vertical Fund II, L.P. and Richard B. Emmitt.* Vertical Fund I, L.P., or VFI, and Vertical Fund II, L.P., or VFII, together hold more than 5% of our outstanding shares. In addition, Mr. Emmitt, a member of our board of directors, is a General Partner of The Vertical Group, L.P., or The Vertical Group, which is the sole general partner of each of VFI and VFII. Mr. Emmitt is also a Member and Manager of The Vertical Group GP, LLC, which controls The Vertical Group.

*Douglas W. Kohrs.* Mr. Kohrs is our Chief Executive Officer and a member of our board of directors.

*Richard F. Wallman.* Mr. Wallman is a member of our board of directors.

**Private Placements**

On February 29, 2008, we issued warrants and notes in a private placement transaction to related parties. The warrants were immediately exercisable and issued at an exercise price of \$5.66 per share as partial consideration for loans in the amounts indicated below. The notes carry a fixed interest rate of 8.0% per annum with interest payments accrued semi-annually and mature on February 28, 2013. The related parties involved in the transaction included:

<b>Related party</b>	<b>Number of warrants issued</b>	<b>Amount of note</b>
WP Bermuda	6,633,216 €	24,700,000
VFI and VFII	1,096,226 €	4,082,000
KCH	939,929 €	3,500,000
Douglas W. Kohrs	150,926 €	562,000
Diane Doty(1)	44,580 €	166,000

(1) Wife of Michael Doty, our Chief Financial Officer at the time.

Table of Contents

On April 3, 2009, we issued immediately exercisable warrants in a private placement to related parties at an exercise price of \$5.66 per share as partial consideration for loans in the amounts indicated below. The notes carry a fixed interest rate of 8.0% per annum with interest payments accrued semi-annually and mature on March 31, 2014. The related parties involved in the transaction included:

<b>Related party</b>	<b>Number of warrants issued</b>		<b>Amount of note</b>
WP Bermuda	2,672,332	€	11,204,000
KCH	572,438	€	2,400,000
Richard F. and Amy Wallman(1)	62,014	€	260,000
Douglas W. Kohrs	61,537	€	258,000

(1)

Wife of Mr. Wallman.

On March 26, 2010, we sold 40,000 shares to Mr. Wallman for \$300,000. Mr. Wallman's shares were purchased by Stichting Administratiekantoor Tornier, or STAK, on behalf of Mr. Wallman. STAK was established as a foundation under Dutch law to hold our ordinary shares on behalf of certain shareholders.

**Warrant Exchange**

On May 25, 2010, we completed agreements with 100% of the warrant holders that acquired warrants under the February 29, 2008, and April 3, 2009, private placement agreements listed above. Each warrant holder agreed to exchange their warrants under the February 29, 2008, and April 3, 2009, agreements for Tornier B.V. ordinary shares at an exchange ratio of 0.6133 and 0.6410, respectively. We completed this exchange in order to avoid future variability in our statement of operations from revaluation of the warrants as they were required to be valued at fair value at each reporting period with changes in the fair value reported in current period earnings. In addition, we believed that the number of existing warrants represented potential dilution that may not be desirable to future investors. The exchange ratio used was developed based on the ratio of our estimate of the fair value of each individual warrant to the fair value of each ordinary share. We estimated the fair value of each warrant used in the calculation of the exchange ratio using a Black-Scholes option pricing model.

**Acquisitions and Other Corporate Transactions with Related Parties**

On July 18, 2006, Tornier B.V., formerly known as TMG B.V., entered into a Securityholders' Agreement with TMG, TMG Partners U.S. LLC, Mr. Kohrs, VFI, VFII, KCH, Mr. Tornier, WP Bermuda and (by subsequent joinder agreements) TMG Partners II LLC, TMG Partners III LLC, Split Rock, STAK and DVO TH, or, collectively, the Securityholders. The agreement grants each of the Securityholders a right of first refusal with respect to shares sold by another Securityholder. The Securityholders are further obligated to observe certain limitations on the transfer of their shares, such as tag-along and drag-along rights. These limitations will terminate in the event of an initial public offering approved by our board of directors. In addition, as we currently contemplate amending prior to the consummation of the offering, the agreement will allow WP Bermuda to nominate three of the eight directors to our board of directors for so long as Warburg Pincus beneficially owns more than 25% of the outstanding shares, two of the eight directors for so long as Warburg Pincus beneficially owns more than 10% of the outstanding shares and one of the eight directors for so long as Warburg Pincus beneficially owns more than 5% of the outstanding shares, and to nominate Mr. Kohrs for election to our board of directors until the termination of his employment. The agreement terminates upon the written consent of all parties to the agreement. Mr. Kohrs serves as Manager of the Board of TMG Partners U.S. LLC, and as Managing Member of TMG Partners II LLC and TMG Partners III LLC.

Table of Contents

On February 9, 2007, we signed an exclusive, worldwide license and supply agreement with Tephra for its poly-4-hydroxybutyrate polymer for a license fee of \$110,000, plus an additional \$750,000 as consideration for certain research and development. Tephra is further entitled to royalties of up to 5% of sales under these licenses. We paid \$30,000 of minimum royalty payments in April of 2010 to Tephra under the terms of this agreement. VFI and VFII own approximately 20% of Tephra's outstanding common and preferred stock. In addition, Mr. Emmitt serves as a director to Tephra.

On February 27, 2007, we acquired 100% of the stock of Axya in exchange for 5,762,096 of our ordinary shares valued at approximately \$4.69 per share for a total value of \$27.0 million. Among the selling stockholders in this transaction were TMG which held 49.3% of Axya, VFI which held 38.0% of Axya, VFII which held 11.3% of Axya and Mr. Kohrs who held 1.5% of Axya. Mr. Carney, Mr. Emmitt and Mr. Kohrs were directors of Axya at the time of the acquisition.

At the time of the Axya acquisition, TMG entered into an agreement with KCH, which held mandatorily convertible zero coupon bonds issued by us at the time of the acquisition by the Investor Group. The bonds had a par value of €29,600,000 and were convertible into ordinary shares at a conversion price of €3.3543. In connection with the Axya transaction, TMG agreed that we would either issue to KCH additional mandatorily convertible zero coupon bonds or decrease the conversion price of the zero coupon bonds held by KCH to increase the number of shares issuable upon conversion, if the performance of Axya did not meet certain thresholds. Axya did not meet the performance thresholds within the prescribed time. On October 1, 2009, the mandatorily convertible zero coupon bonds were converted to ordinary shares pursuant to their terms and we issued 8,824,494 ordinary shares to KCH. Rather than adjust the notes or issue additional notes prior to conversion, we also issued KCH an additional 557,093 ordinary shares in satisfaction of the obligation created by TMG.

On November 21, 2007, we acquired 100% of the stock of Orthovert, Inc., or Orthovert, a medical device intellectual property holding company, in exchange for 90,000 ordinary shares with an approximate value of \$4.63 per share and an additional 210,000 ordinary shares contingent upon product commercialization. At the time, Orthovert was wholly owned by VFI and VFII.

In 2008, Incumed, Inc., received \$127,139 for services provided to us to assist in the development of our Piton products. Incumed provides inventors of medical devices with consulting and engineering services to develop their products. Incumed has not provided any services to us subsequent to 2008. VFI and VFII held a majority of the shares of Incumed and Mr. Emmitt serves on its board of directors.

On January 22, 2008, we signed an agreement with BioSET to develop, commercialize and distribute products incorporating BioSET's F2A synthetic growth factor technology in the field of orthopaedic and podiatric soft tissue repair. As amended on February 10, 2010, this agreement granted us an option to purchase an exclusive, worldwide license for such products in consideration for a payment of \$1 million. We exercised this option on February 10, 2010. Upon FDA approval of certain products, an additional \$2.5 million will become due. BioSET is entitled to royalties of up to 6% for sales of products under this agreement. We have not accrued or paid any royalties under the terms of this agreement. VFI and VFII own approximately 15% of BioSET's outstanding shares and Mr. Emmitt serves on its board of directors.

On March 28, 2008, we entered into an exclusive distribution agreement with LifeCell, a tissue engineering company, which is now a division of Kinetic Concepts, Inc., or KCI. Under the terms of the agreement, we gained certain exclusive rights to distribute LifeCell's xenograft reconstructive tissue matrix for orthopaedic and podiatric soft tissue procedures, which we market under the Conexa brand. LifeCell continues to market a version of this tissue matrix for other applications under the Strattice brand. The agreement obligates us to meet initial market development milestones and ongoing sales targets. VFI and VFII were shareholders of LifeCell prior to its purchase by KCI.



Table of Contents

On July 29, 2008, we formed a real estate holding company (SCI Calyx) together with Mr. Tornier. SCI Calyx is owned 51% by us and 49% by Mr. Tornier. SCI Calyx was initially capitalized by a contribution of capital of €10,000 funded 51% by us and 49% by Mr. Tornier. SCI Calyx then acquired a combined manufacturing and office facility in Grenoble, France, for approximately \$6.1 million. The manufacturing and office facility acquired will be used to support the manufacture of certain of our current products and house certain of our operations already located in Grenoble, France. This real estate purchase was funded through mortgage borrowings of \$4.1 million and \$2.0 million cash borrowed from the two current shareholders of SCI Calyx. The \$2.0 million cash borrowed from the SCI Calyx shareholders originally consisted of a \$1.0 million note due to Mr. Tornier and a \$1.0 million note due to Tornier SAS, which is our wholly owned French operating subsidiary. Both of the notes issued by SCI Calyx bear interest at the three month Euribor rate plus 0.5% and have no stated term. As of December 27, 2009, SCI Calyx had related-party debt outstanding to Mr. Tornier of \$1.0 million. The SCI Calyx entity is consolidated by us, and the related real estate and liabilities are included in the consolidated balance sheets. On September 3, 2008, Tornier SAS, our French operating subsidiary, entered into a lease agreement with SCI Calyx relating to these facilities. The agreement, which terminates in 2018, provides for an annual rent payment of €440,000, which has subsequently been increased and is currently €675,123 annually. At December 29, 2008, future minimum payments under this lease were €6,516,107 in the aggregate.

Since 2006, Tornier SAS has entered into various lease agreements with entities affiliated with Mr. Tornier or members of his family. On May 30, 2006, Tornier SAS entered into two lease agreements with Mr. Tornier and his sister, Colette Tornier, relating to our facilities in Saint-Ismier, France. The agreements provide for annual rent payments of €104,393 and €28,500, respectively, which have subsequently been increased and are currently €119,362 and €32,587 annually, respectively. On December 29, 2007, Tornier SAS entered into a lease agreement with Animus SCI, relating to our facilities in Montbonnot Saint Martin, France. The agreement provides for an annual rent payment of €242,545, which has subsequently been increased and is currently €288,756 annually. Animus SCI is wholly owned by Mr. Tornier. On December 29, 2007, Tornier SAS entered into a lease agreement with Cymaise SCI, relating to our facilities in Saint-Ismier, France. The agreement provides for an annual rent payment of €315,865, which has subsequently been increased and is currently €361,158 annually. Cymaise SCI is wholly owned by Mr. Tornier and his sister, Colette Tornier. On February 6, 2008, Tornier SAS entered into a lease agreement with Balux SCI, effective as of May 22, 2006, relating to our facilities in Montbonnot Saint Martin, France. The agreement provides for a quarterly rent payment of €120,000, which has subsequently been increased and is currently €137,207 per quarter. Balux SCI is wholly owned by Mr. Tornier and his sister, Colette Tornier. Each of the agreements will terminate in 2012. At December 29, 2008, future minimum payments under these agreements were €5,402,764 in the aggregate.

On December 18, 2009, we entered into an agreement with Anova Corporation Ltd., or Anova, a spine surgery technology company, under which Anova purchased certain assets associated with our suture welding technology and licensed related intellectual property for the field of spine surgery for \$150,000 in addition to royalties of up to 7% of revenues derived under the license. We have not accrued or received any royalties under the terms of this agreement. An additional \$200,000 will become receivable upon Anova's commercialization of a product that they produce. VFI and VFII own approximately 44% of Anova's outstanding shares.

On June 17, 2008, we entered into an exclusive worldwide licensing agreement with C2M Medical, a medical device development company, under which we assumed the rights to certain intellectual property relating to bone anchor technology including the Cinch system. C2M had acquired the technology from Sapphire Medical, Inc., or Sapphire, in April 2007 for a purchase price of \$7.5 million and milestone payments of \$12.5 million, which C2M paid in 2008. In addition, we have committed, and are currently paying, to Sapphire quarterly earn-out fees of 25% of U.S. sales related

Table of Contents

to Cinch intellectual property for the first three years after launch, an obligation we assumed in the course of our agreement with C2M. The agreement also included an option to acquire C2M Medical. We exercised this option on March 26, 2010, when we purchased 100% of the stock of C2M Medical in exchange for approximately 3.1 million ordinary shares, valued at \$7.50 per share at the time. C2M Medical had been founded and was held in part by TMG, VFI, VFII and Mr. Kohrs. In addition, Mr. Carney, Mr. Emmitt and Mr. Kohrs were members of C2M Medical's board of directors. Prior to our exercise of the option C2M Medical was determined to be a variable interest entity in accordance with U.S. GAAP and we consolidated C2M Medical in our financial statements beginning in June of 2008, the date at which we signed an exclusive technology license with C2M Medical.

The transaction included:

<b>Related party</b>	<b>Number of shares issued</b>	<b>Total consideration value of shares issued</b>
TMG	1,514,629	\$ 11,359,714
VFI and VFII	1,514,628	\$ 11,359,714
Douglas W. Kohrs	46,400	\$ 348,000

**Review, Approval or Ratification of Transactions with Related Persons**

As provided by our audit committee charter, all related party transactions are to be reviewed and pre-approved by our audit committee. A "related party transaction" is defined to include any transaction or series of transactions exceeding \$120,000 in which we are a participant and any related person has a material interest. Related persons would include our directors, executive officers (and immediate family members of our directors and executive officers) and persons controlling over five percent of our outstanding ordinary shares. In determining whether to approve a related party transaction, the audit committee will generally evaluate the transaction in terms of (i) the benefits to us; (ii) the impact on a director's independence in the event the related person is a director, an immediate family member of a director or an entity in which a director is a partner, shareholder or executive officer; (iii) the availability of other sources for comparable products or services; (iv) the terms and conditions of the transaction; and (v) the terms available to unrelated third parties or to employees generally. The audit committee will then document its findings and conclusions in written minutes. In the event a transaction relates to a member of our audit committee, that member will not participate in the audit committee's deliberations.

Table of Contents

**DESCRIPTION OF ORDINARY SHARES**

The following summary of the material terms of our share capital is qualified in all respects by reference to our amended articles of association, which have been filed as an exhibit to the registration statement of which this prospectus forms a part.

Currently, our authorized share capital consists of 300 million ordinary shares. As of April 4, 2010, there were 77,186,382 ordinary shares outstanding, which were held by 12 shareholders.

Effective immediately prior to the closing of this offering our amended articles of association, our authorized share capital will consist of \_\_\_\_\_ shares, each with a nominal value of \_\_\_\_\_. Upon the completion of the offering, there will be \_\_\_\_\_ ordinary shares outstanding. See "Risk Factors Risks Related to This Offering WP Bermuda and its affiliates, our major shareholders, will control approximately \_\_\_\_\_% of our ordinary shares after this offering and this concentration of ownership may deter a change in control or other transaction that is favorable to our shareholders" for more information on the effects of this concentration of ownership.

**Form of Ordinary Shares**

Pursuant to our articles of association, which will have effect as of the closing of this offering, our ordinary shares may be held only in registered form. All of our ordinary shares are registered in a register kept by us and on our behalf by our transfer agent. Transfer of registered shares requires a written deed of transfer and the acknowledgement by us. Immediately prior to the consummation of this offering, our ordinary shares will be freely transferable except as otherwise restricted under U.S. securities laws.

**Issuance of Ordinary Shares**

We may issue ordinary shares subject to the maximum prescribed by our authorized share capital contained in our amended articles of association. Our board of directors has the power to issue ordinary shares if and to the extent that the general meeting has designated to the board of directors such authority. A designation of authority to the board of directors to issue ordinary shares remains effective for the period specified by the general meeting and may be up to five years from the date of designation. The general meeting may renew this designation annually. Without this designation, only the general meeting has the power to authorize the issuance of ordinary shares. Our board of directors is authorized to issue ordinary shares until \_\_\_\_\_, 2015 under the restrictions specified in our amended articles of association.

In connection with the issuance of ordinary shares, at least the nominal value must be paid for such shares. No obligation other than to pay up to the nominal amount of a share may be imposed upon a shareholder against the shareholder's will, by amendment of the articles of association or otherwise. Subject to Dutch law, payment for shares must be in cash to the extent no other contribution has been agreed and may be made in the currency approved by us.

Any increase in the number of authorized ordinary shares would require the approval of an amendment to our amended articles of association in order to effect such increase. Such amendment would need to be made by a proposal of the board of directors and adoption by the shareholders at a general meeting by a majority vote.

**Preemptive Rights**

Shareholders have a ratable preemptive right to subscribe for ordinary shares that we issue for cash unless the general meeting, or its designee, which in our case is our board of directors, limits or eliminates this right. Our shareholders have no ratable preemptive subscription right with respect to

Table of Contents

ordinary shares issued (1) for consideration other than cash, (2) to our employees or the employees of our group of companies or (3) to a party exercising a previously obtained right to acquire shares.

The right of our shareholders to subscribe for ordinary shares pursuant to this preemptive right may be eliminated or limited by the general meeting. If the general meeting delegates its authority to the board of directors for this purpose, then the board of directors will have the power to limit or eliminate the preemptive rights of holders of ordinary shares. Such a proposal requires the approval of at least two-thirds of the votes cast by shareholders at a general meeting where less than half of the issued share capital is represented or a majority of the votes cast at the general meeting where more than half of the share capital is represented. Designations of authority to the board of directors may remain in effect for up to five years and may be renewed for additional periods of up to five years.

Our board of directors is authorized to limit or eliminate the preemptive rights of holders of ordinary shares until \_\_\_\_\_, 2015 and our board of directors has eliminated that right with respect to the shares to be sold in this offering.

**Repurchases of Our Ordinary Shares**

We may acquire ordinary shares, subject to applicable provisions of Dutch law and of our articles of association, to the extent:

our shareholders' equity, less the amount to be paid for the ordinary shares to be acquired, exceeds the sum of (i) our share capital account plus (ii) any reserves required to be maintained by Dutch law or our articles of association; and

after the acquisition of ordinary shares, we and our subsidiaries would not hold, or hold as pledgees, ordinary shares having an aggregate nominal value that exceeds 50% of our issued share capital.

Our board of directors may repurchase ordinary shares only if our shareholders have authorized the board of directors to do so. Our board of directors is authorized to repurchase the maximum permissible amount of ordinary shares on the NASDAQ Global Market during the 18-month period ending in \_\_\_\_\_, 2012, the maximum initial term under Dutch law, at prices between an amount equal to the nominal value of the ordinary shares and an amount equal to 110% of the market price of the ordinary shares on the NASDAQ Global Market (the market price being deemed to be the average of the closing price on each of the five consecutive days of trading preceding the three trading days prior to the date of repurchase). The authorization is not required for the acquisition of our ordinary shares listed on the NASDAQ Global Market for the purpose of transferring the shares to employees under our equity incentive plans.

**Capital Reductions; Cancellation**

Upon a proposal of the board of directors, at a general meeting, our shareholders may vote to reduce our issued share capital by canceling shares held by us in treasury or by reducing the nominal value of the shares by amendment to our amended articles of association. In either case, this reduction would be subject to applicable statutory provisions. In order to be approved, a resolution to reduce the capital requires approval of a majority of the votes cast at a meeting if at least half the issued capital is represented at the meeting or at least two-thirds of the votes cast at the meeting if less than half of the issued capital is represented at the meeting.

A resolution that would result in the reduction of capital requires prior or simultaneous approval of the meeting of each group of holders of shares of the same class whose rights are prejudiced by the reduction. A resolution to reduce capital requires notice to our creditors who have the right to object to the reduction in capital under specified circumstances.

Table of Contents

**General Meetings of Shareholders**

Each shareholder has a right to attend general meetings, either in person or by proxy, and to exercise voting rights in accordance with the provisions of our articles of association. We must hold at least one general meeting each year. This meeting must be convened at one of three specified locations in The Netherlands (Amsterdam, Haarlemmermeer (Schiphol airport) and Schiedam) within six months after the end of our fiscal year. Our board of directors may convene additional general meetings as often as they deem necessary. Pursuant to Dutch law, one or more shareholders representing at least 10% of our issued share capital may request the Dutch courts to order that a general meeting be held. Dutch law does not restrict the rights of holders of ordinary shares who do not reside in The Netherlands from holding or voting their shares.

We will give notice of each meeting of shareholders by publication on our website and in any other manner that we may be required to follow in order to comply with applicable stock exchange and SEC requirements. We will give notice no later than the fifteenth day prior to the day of the meeting. As deemed necessary by the board of directors, either the notice will include or be accompanied by an agenda identifying the business to be considered at the meeting. Shareholders representing at least 1% of the issued share capital or the equivalent of at least €50 million in aggregate market value have the right to request the inclusion of additional items on the agenda of shareholder meetings, provided that such request is received by us no later than 60 days before the day the relevant shareholder meeting is held. Our board of directors may decide that shareholders are entitled to participate in, to address and to vote in the general meeting by way of an electronic means of communication, in person or by proxy, provided the shareholder may by the electronic means of communication be identified, directly take notice of the discussion in the meeting and participate in the deliberations. Our board of directors may adopt a resolution containing conditions for the use of electronic means of communication in writing. If our board of directors has adopted such regulations, they will be disclosed with the notice of the meeting as provided to shareholders.

**Board Seats**

We maintain a single-tiered board of directors comprising both executive directors and non-executive directors. Under Dutch law, the board of directors is responsible for our policy and day-to-day management. The non-executive directors supervise and provide guidance to the executive directors. Each director owes a duty to us to properly perform the duties assigned to him and to act in our corporate interest. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers.

**Voting Rights**

Each share is entitled to one vote. Voting rights may be exercised by shareholders registered in our share register or by a duly appointed proxy of a registered shareholder, which proxy need not be a shareholder. Our amended articles of association do not limit the number of registered shares that may be voted by a single shareholder. Treasury shares, whether owned by us or one of our majority-owned subsidiaries, will not be entitled to vote at general meetings. Resolutions of the general meeting are adopted by a simple majority of votes cast, except as described in the following two paragraphs.

Matters requiring a majority of at least two-thirds of the votes cast, which votes also represent more than 50% of our issued share capital include, among others:

a resolution to cancel a binding nomination for the appointment of members of the board of directors;

Table of Contents

a resolution to appoint members of the board of directors, if the board of directors fails to use its right to submit a binding nomination, or if the binding nomination is set aside; and

a resolution to dismiss or suspend members of the board of directors other than pursuant to a proposal by the board of directors.

Matters requiring a majority of at least two-thirds of the votes cast, if less than 50% of our issued share capital is represented include, among others:

a resolution of the general meeting regarding restricting and excluding preemptive rights, or decisions to designate the board of directors as the body authorized to exclude or restrict preemptive rights;

a resolution of the general meeting to reduce our outstanding share capital; and

a resolution of the general meeting to have us merge or demerge.

**Quorum for General Meetings**

Under our amended articles of association, holders of at least one-third of the outstanding shares must be represented at a meeting to constitute a quorum.

**Adoption of Annual Accounts and Discharge of Management Liability**

Our board of directors must prepare annual accounts within five months after the end of our financial year, unless the shareholders have approved an extension of this period for up to six additional months due to certain special circumstances. The annual accounts must be accompanied by an auditor's certificate, an annual report and certain other mandatory information and must be made available for inspection by our shareholders at our offices within the same period. Under Dutch law, our shareholders must approve the appointment and removal of our independent auditors, as referred to in Article 2:393 Dutch Civil Code, to audit the annual accounts. The annual accounts are adopted by our shareholders at the general meeting and will be prepared in accordance with Part 9 of Book 2 of the Netherlands Civil Code.

The adoption of the annual accounts by our shareholders does not release the members of our board of directors from liability for acts reflected in those documents. Any such release from liability requires a separate shareholders' resolution.

Our financial reporting will be subject to the supervision of The Netherlands Authority for the Financial Markets, or AFM. The AFM will review the content of the financial reports and has the authority to approach us with requests for information in case on the basis of publicly available information it has reasonable doubts as to the integrity of our financial reporting.

**Dividends**

Our amended articles of association provide that dividends may in principle only be paid out of profit as shown in the adopted annual accounts. We will have power to make distributions to shareholders and other persons entitled to distributable profits only to the extent that our equity exceeds the sum of the paid and called-up portion of the ordinary share capital and the reserves that must be maintained in accordance with provisions of Dutch law or our amended articles of association. The profits must first be used to set up and maintain reserves required by law and must then be set off against certain financial losses. We may not make any distribution of profits on ordinary shares that we hold. Our board of directors determines whether and how much of the remaining profit they will reserve and the manner and date of such distribution and notifies shareholders.

Table of Contents

All calculations to determine the amounts available for dividends will be based on our annual accounts, which may be different from our consolidated financial statements, such as those included in this prospectus. Our statutory accounts have to date been prepared and will continue to be prepared under Dutch GAAP and are deposited with the Commercial Register in Amsterdam, The Netherlands.

**Liquidation Rights**

In the event of a dissolution and liquidation, the assets remaining after payment of all debts and liquidation expenses are to be distributed to the holders of ordinary shares in proportion to their nominal possession of such shares. All distributions referred to in this paragraph shall be made in accordance with the relevant provisions of the laws of The Netherlands.

**Redemption, Conversion and Sinking Fund Rights**

Holders of ordinary shares have no redemption, conversion or sinking fund rights.

**Limitations on Non-residents and Exchange Controls**

There are no limits under the laws of The Netherlands or in our amended articles of association on non-residents of The Netherlands holding or voting our ordinary shares. Currently, there are no exchange controls under the laws of The Netherlands on the conduct of our operations or affecting the remittance of dividends.

**Market Abuse**

The Dutch Financial Supervision Act (*Wet op het financieel toezicht*), or the FSA, implementing the EU Market Abuse Directive 2003/6/EC and related Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC, provides for specific rules that intend to prevent market abuse, such as the prohibitions on insider trading, divulging inside information and tipping, and market manipulation. Non-compliance with these prohibitions may lead to criminal fines, administrative fines, imprisonment or other sanctions. We and our investors are subject to these Dutch market abuse rules. The Dutch prohibition on market manipulation may restrict our ability to buy-back our shares.

Pursuant to the FSA, we will adopt an internal code of conduct relating to the possession of and transactions by members of our board of directors and employees in the shares or in financial instruments the value of which is (co)determined by the value of the shares, which will be available on our website.

**Netherlands Squeeze-Out Proceedings**

Pursuant to Section 2:92a of the Dutch Civil Code, a shareholder who for his own account contributes at least 95% of our issued capital may institute proceedings against our other shareholders jointly for the transfer of their shares to the claimant. The proceedings are held before the Enterprise Chamber of the Amsterdam Court of Appeal and can be instituted by means of a writ of summons served upon each of the minority shareholders in accordance with the provisions of the Dutch Code of Civil Procedure (*Wetboek van Burgerlijke Rechtsvordering*). The Enterprise Chamber may grant the claim for squeeze out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value to be paid for the shares of the minority shareholders. Once the order to transfer becomes final before the Enterprise Chamber, the person acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the shares to be acquired whose addresses are known to him. Unless the addresses of all of them are known to him, he shall also publish the same in a newspaper with a national circulation.

Table of Contents

**Choice of Law and Exclusive Jurisdiction**

Our amended articles of association provide that, to the extent allowed by United States securities laws, the rights and obligations among or between us, any of our current or former directors, officers and employees and any current or former shareholder shall be governed exclusively by Dutch law, unless such rights or obligations do not relate to or arise out of the capacities above.

Any lawsuit or other legal proceeding by and between those persons relating to or arising out of their capacities listed above shall be exclusively submitted to the Dutch courts. All of our current and former directors and officers must agree in connection with any such lawsuit or other legal proceeding to submit to the exclusive jurisdiction of The Dutch courts, waive objections to such lawsuit or other legal proceeding being brought in such courts, agree that a judgment in any such legal action brought in The Dutch courts is binding upon them and may be enforced in any other jurisdiction, and elect domicile at our offices in Amsterdam, The Netherlands for the service of any document relating to such lawsuit or other legal proceedings.

For more information on shareholder enforcement of civil liabilities, see "Risk Factors Risks Related to this Offering Your rights as a holder of ordinary shares will be governed by Dutch law and will differ from the rights of shareholders under U.S. law."

**Securityholders' Agreement**

In July 2006, we entered into a Securityholders' Agreement with certain holders of our securities. Additional holders of our securities have subsequently become parties to the Securityholders' Agreement. In accordance with the Securityholders' Agreement, holders of our securities agreed to certain matters relating to the disposition and voting of such securities. Upon the closing of our initial public offering, certain provisions of the Securityholders' Agreement relating to the transfer of securities will terminate. However, pursuant to the Securityholders' Agreement, as we currently contemplate amending prior to the consummation of the offering, WP Bermuda will be entitled to nominate three of the eight directors to our board of directors for so long as Warburg Pincus beneficially owns more than 25% of the outstanding shares, two of the eight directors for so long as Warburg Pincus beneficially owns more than 10% of the outstanding shares and one of the eight directors for so long as Warburg Pincus beneficially owns more than 5% of the outstanding shares and Douglas W. Kohrs will continue to be entitled to be nominated for election to our board of directors until termination of his employment in accordance with terms of his employment agreement.

**Registration Rights**

We plan to enter into a registration rights agreement with certain of our shareholders and officers, including TMG, VFI, VFIL, KCH and Phil Invest ApS and Douglas W. Kohrs, who we refer to as the holders. Pursuant to the registration rights agreement, one hundred and eighty days after consummation of the offering, we will agree to (i) use our reasonable best efforts to effect up to three registered offerings of at least \$10 million each upon a demand of Warburg Pincus and one registered offering of at least \$10 million upon a demand of the Vertical Group, (ii) use our reasonable best efforts to become eligible for use of Form S-3 for registration statements and once we become eligible Warburg Pincus shall have the right to demand an unlimited number of registrations of at least \$10 million each on Form S-1 and (iii) maintain the effectiveness of each such registration statement for a period of 120 days or until the distribution of the registrable securities pursuant to the registration statement is complete.

Pursuant to the registration rights agreement, all holders will also have incidental or "piggyback" registration rights with respect to any registrable shares, subject to certain volume and marketing restrictions imposed by the underwriters of the offering with respect to which the rights are



Table of Contents

exercised. These rights do not apply to this offering and this offering is not being effected pursuant to the registration rights agreement.

We will bear the expenses, including the fees and disbursements of one legal counsel for the holders, in connection with the registration of the registrable securities, except for any underwriting commissions relating to the sale of the registrable securities.

**Differences in Corporate Law**

The following comparison between Dutch corporation law, which applies to us, and Delaware corporation law, the law under which many corporations in the United States are incorporated, discusses additional matters not otherwise described in this prospectus.

*Corporate governance*

*Duties of directors*

*The Netherlands.* In The Netherlands, a listed company typically has a two-tier board structure with a management board comprising the executive directors and a supervisory board comprising the non-executive directors. It is, however, also possible to have a single-tier board, comprising both executive directors and non-executive directors. We have a single-tier board.

Under Dutch law the board of directors is collectively responsible for the policy and day-to-day management of the company. The non-executive directors will be assigned the task of supervising the executive director and providing him with advice. Each director has a duty towards the company to properly perform the duties assigned to him. Furthermore, each board member has a duty to act in the corporate interest of the company. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the company also applies in the event of a proposed sale or break-up of the company, whereby the circumstances generally dictate how such duty is to be applied. Any board resolution regarding a significant change in the identity or character of the company requires shareholders' approval.

*Delaware.* The board of directors of a Delaware corporation bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise an informed business judgment in the performance of their duties. An informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.

*Director terms*

*The Netherlands.* Under Dutch law a director of a listed company is generally appointed for a maximum term of four years. There is no limit to the number of terms a director may serve. Our amended articles of association provide that our directors will be appointed for a maximum term of four years. A director may in principle be removed at any time, with or without cause by the shareholders' meeting.

*Delaware.* The Delaware General Corporation Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes with up to three-year terms,

Table of Contents

with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the shareholders. A director elected to serve a term on a "classified" board may not be removed by shareholders without cause. There is no limit to the number of terms a director may serve.

*Director vacancies*

*The Netherlands.* Under Dutch law, new members of the board of directors of a company such as ours are appointed by the general meeting. Our amended articles of association provide that such occurs from a binding nomination by the board of directors, in which case the general meeting may override the binding nature of such nomination by a resolution of two-thirds of the votes cast, which votes also represent more than 50% of the issued share capital.

*Delaware.* The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (a) otherwise provided in the certificate of incorporation or by-laws of the corporation or (b) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.

*Conflict-of-interest transactions*

*The Netherlands.* Under Dutch corporate governance rules, members of the board of directors may not take part in any vote on a subject or transaction in relation to which he or she has a conflict of interest with the company or any discussion on such matter. Our amended articles of association provide that in the event we have a conflict of interest with one or more members of the board of directors, we may still be represented by our sole executive director. However, under Dutch law and our amended articles of association, the general meeting, in the event of a conflict of interest, has the power to at any time designate one or more other persons to represent the company. Our amended articles of association provide that a director shall not take part in any vote on a subject or transaction in relation to which he has a conflict of interest with the company.

*Delaware.* The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:

the material facts as to the director's relationship or interest are disclosed and a majority of disinterested directors consents,

the material facts are disclosed as to the director's relationship or interest and a majority of shares entitled to vote thereon consents, or

the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the shareholders.

*Proxy voting by directors*

*The Netherlands.* An absent director may issue a proxy for a specific board meeting but only to another director in writing.

*Delaware.* A director of a Delaware corporation may not issue a proxy representing the director's voting rights as a director.

Table of Contents

**Shareholder rights**

*Voting rights*

*The Netherlands.* Under Dutch law, shares have one vote per share, provided such shares have the same par value. Certain exceptions may be provided in the articles of association of a company (which is currently not the case in our articles of association). All shareholder resolutions are taken by an absolute majority of the votes cast, unless the articles of association or Dutch law prescribe otherwise. Dutch law does not provide for cumulative voting.

If so resolved by the board of directors, shareholders as of the record date for a shareholders' meeting are entitled to vote at that meeting, and the record date established by the board of directors may not be determined earlier than the 30th day before the meeting. There is no specific provision in Dutch law for adjournments.

*Delaware.* Under the Delaware General Corporation Law, each shareholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event will a quorum consist of less than one-third of the shares entitled to vote at a meeting.

Shareholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than 10 days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the shareholders of record entitled to notice or to vote at a meeting of shareholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.

*Shareholder proposals*

*The Netherlands.* Pursuant to our articles of association, extraordinary shareholders' meetings will be held as often as the board of directors deems such necessary. Pursuant to Dutch law, one or more shareholders representing at least 10% of the issued share capital may request the Dutch Courts to order that a general meeting be held.

The agenda for a meeting of shareholders must contain such items as the board of directors or the person or persons convening the meeting decide. The agenda shall also include such other items as one or more shareholders, representing at least one-hundredth of the issued share capital or €50 million in listed share price value may request of the board of directors in writing, at least 60 days before the date of the meeting, provided no significant interest of the company dictates otherwise.

*Delaware.* Delaware law does not specifically grant shareholders the right to bring business before an annual or special meeting.

*Action by written consent*

*The Netherlands.* Under Dutch law, shareholders' resolutions may be adopted in writing without holding a meeting of shareholders, provided (a) the articles of association expressly so allow, (b) no bearer shares or depositary receipts are issued, (c) there are no persons entitled to the same rights as holders of depositary receipts, (d) the board of directors has been given the opportunity to

Table of Contents

give its advice on the resolution and (e) the resolution is adopted unanimously by all shareholders that are entitled to vote. For a listed company this method of adopting resolutions is therefore not feasible.

*Delaware.* Unless otherwise provided in the corporation's certificate of incorporation, any action required or permitted to be taken at any annual or special meeting of shareholders of a corporation may be taken without a meeting, without prior notice and without a vote, if one or more consents in writing, setting forth the action to be so taken, are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted.

*Appraisal rights*

*The Netherlands.* Subject to certain exceptions, Dutch law does not recognize the concept of appraisal or dissenters' rights. See " Shareholder vote on certain reorganizations."

*Delaware.* The Delaware General Corporation Law provides for shareholder appraisal rights, or the right to demand payment in cash of the judicially-determined fair value of the shareholder's shares, in connection with certain mergers and consolidations.

*Shareholder suits*

*The Netherlands.* In the event a third party is liable to a Dutch company, only the company itself can bring a civil action against that party. The individual shareholders do not have the right to bring an action on behalf of the company. Only in the event that the cause for the liability of a third party to the company also constitutes a tortious act directly against a shareholder does that shareholder have an individual right of action against such third party in its own name. The Dutch Civil Code provides for the possibility to initiate such actions collectively. A foundation or an association whose objective is to protect the rights of a group of persons having similar interests can institute a collective action. The collective action itself cannot result in an order for payment of monetary damages but may only result in a declaratory judgment (*verklaring voor recht*). In order to obtain compensation for damages, the foundation or association and the defendant may reach often on the basis of such declaratory judgment a settlement. A Dutch court may declare the settlement agreement binding upon all the injured parties with an opt-out choice for an individual injured party. An individual injured party may also itself institute a civil claim for damages.

*Delaware.* Under the Delaware General Corporation Law, a shareholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated shareholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a shareholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a shareholder not only at the time of the transaction that is the subject of the suit, but also throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.

*Repurchase of shares*

*The Netherlands.* Under Dutch law, a company such as ours may not subscribe for newly issued shares in its own capital. Such company may, subject to certain restrictions of Dutch law and its articles of association, acquire shares or depositary receipts for shares in its own capital. As a result, we may acquire our own shares either without paying any consideration, or, in the event any consideration must be paid, only if (a) the shareholders' equity less the payment required to make the acquisition is

Table of Contents

not less than the sum of called and paid-up capital and any reserve required by Dutch law and our articles of association, (b) we and our subsidiaries would not thereafter hold or hold as a pledgee shares with an aggregate nominal value exceeding 50% of the nominal value of our issued share capital, (c) our amended articles of association permit such acquisition, which currently is the case and (d) the general meeting has authorized the board of directors to do so, which authorization has been granted for the maximum period allowed under Dutch law and our articles of association, that period being 18 months.

*Delaware.* Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.

*Anti-takeover provisions*

*The Netherlands.* Neither Dutch law nor our articles of association specifically prevent business combinations with interested shareholders. Under Dutch law various protective measures are as such possible and admissible, within the boundaries set by Dutch case law and Dutch law, in particular the Dutch Corporate Governance Code.

*Delaware.* In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.

Section 203 of the Delaware General Corporation Law prohibits "business combinations," including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested shareholder that beneficially owns 15% or more of a corporation's voting stock, within three years after the person becomes an interested shareholder, unless:

the transaction that will cause the person to become an interested shareholder is approved by the board of directors of the target prior to the transactions;

after the completion of the transaction in which the person becomes an interested shareholder, the interested shareholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and also officers of interested shareholders and shares owned by specified employee benefit plans; or

after the person becomes an interested shareholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested shareholder.

A Delaware corporation may elect not to be governed by Section 203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the Company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. Such an amendment is not effective until twelve months following its adoption.

Table of Contents

*Inspection of books and records*

*The Netherlands.* The board of directors provides all information desired by the shareholders' meeting, but not to individual shareholders and unless a significant interest of the company dictates otherwise. Our shareholders' register is available for inspection by the shareholders, although such does not apply to the part of our shareholders' register that is kept in the United States pursuant to U.S. listing requirements.

*Delaware.* Under the Delaware General Corporation Law, any shareholder may inspect for any proper purpose the corporation's stock ledger, a list of its shareholders and its other books and records during the corporation's usual hours of business.

*Removal of directors*

*The Netherlands.* Under Dutch law, the general meeting has the authority to suspend or remove members of the board of directors at any time.

*Delaware.* Under the Delaware General Corporation Law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (a) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board is classified, shareholders may effect such removal only for cause, or (b) in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.

*Preemptive rights*

*The Netherlands.* Under Dutch law, in the event of an issuance of shares, each shareholder will have a pro-rata preemptive right to the number of shares held by such shareholder (with the exception of shares to be issued to employees or shares issued against a contribution other than in cash). Preemptive rights in respect of newly issued shares may be limited or excluded by the general meeting or by the board of directors if designated thereto by the general meeting or by the articles of association for a period not exceeding five years.

Our amended articles of association conform to Dutch law and authorize the general meeting or the board of directors, if so designated by a resolution of the general meeting or by amended articles of association, to limit or exclude preemptive rights for holders of our shares for a period not exceeding five years. In order for such a resolution to be adopted, a majority of at least two-thirds of the votes cast in a meeting of shareholders is required, if less than half of the issued share capital is present or represented or a majority of the votes cast at a general meeting where more than half of the share capital is represented. Pursuant to our amended articles of association, the authority to limit or exclude preemptive rights relating to issues of our shares for a period of five years (the maximum period permitted under Dutch law) was delegated to our board of directors until \_\_\_\_\_, 2015.

*Delaware.* Under the Delaware General Corporation Law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.

*Dividends*

*The Netherlands.* Dutch law provides that dividends may only be distributed after adoption of the annual accounts by the general meeting from which it appears that such dividend distribution is

Table of Contents

allowed. Moreover, dividends may be distributed only to the extent the shareholders' equity exceeds the sum of the amount of issued and paid-up capital and increased by reserves that must be maintained under the law or the articles of association. Interim dividends may be declared as provided in the articles of association and may be distributed to the extent that the shareholders' equity exceeds the amount of the issued and paid-up capital plus required legal reserves as described hereinbefore as apparent from an (interim) financial statement. Interim dividends should be regarded as advances on the final dividend to be declared with respect to the financial year in which the interim dividends have been declared. Should it be determined after adoption of the annual accounts with respect to the relevant financial year that the distribution was not permissible, the Company may reclaim the paid interim dividends as unduly paid. Under Dutch law, the articles of association may prescribe that the board of directors decide what portion of the profits are to be held as reserves. Pursuant to our articles of association, our board of directors may reserve a portion of our annual profits. The portion of our annual profits that remains unreserved will be distributed to our shareholders pro rata to the number of shares held by each shareholder. On the recommendation of our board of directors, the shareholders' meeting may resolve that we make distributions out of our general share premium account or out of any other reserves available for distributions under Dutch law, not being a reserve that must be maintained under Dutch law or pursuant to our articles of association. Dividends may be paid in the form of shares as well as in cash.

*Delaware.* Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared or the preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of ordinary shares, property or cash.

*Shareholder vote on certain reorganizations*

*The Netherlands.* Under our amended articles of association, the general meeting may resolve, upon a proposal of the board of directors, that we conclude a legal merger (*juridische fusie*) or a demerger (*splitsing*). In addition, the general meeting must approve resolutions of the board of directors concerning an important change in the identity or character of us or our business, in any event including:

the transfer of the enterprise or a substantial part thereof to a third party;

the entering into or ending of a long-lasting co-operation of the company or a subsidiary with a third party, if this co-operation or the ending thereof is of far-reaching significance for the company; and

the acquiring or disposing of an interest in the share capital of a company with a value of at least one-third of the company's assets according to the most recent annual accounts, by the company or a subsidiary.

Under Dutch law, a shareholder who owns at least 95% of the company's issued capital may institute proceedings against the company's other shareholders jointly for the transfer of their shares to that shareholder. The proceedings are held before the Enterprise Chamber (*Ondernemingskamer*), which may grant the claim for squeeze out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value of the shares.

Table of Contents

*Delaware.* Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.

Under the Delaware General Corporation Law, no vote of the shareholders of a surviving corporation to a merger is needed; however, unless required by the certificate of incorporation, if (a) the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (b) the shares of stock of the surviving corporation are not changed in the merger and (c) the number of ordinary shares of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation's common shares outstanding immediately prior to the effective date of the merger. In addition, shareholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the shareholders will be entitled to appraisal rights.

*Compensation of board of directors*

*The Netherlands.* Under Dutch law, the shareholders must adopt the compensation policy for the board of directors, which includes the outlines of the compensation of any members of our senior management who also serve on our board of directors.

*Delaware.* Under the Delaware General Corporation Law, the shareholders do not generally have the right to approve the compensation policy for the board of directors or the senior management of the corporation, although certain aspects of the compensation policy may be subject to shareholder vote due to the provisions of federal securities and tax law.

**Registrar and Transfer Agent**

A register of holders of the ordinary shares will be maintained by American Stock Transfer & Trust Company, LLC, or AST, in the United States, which will also serve as the transfer agent. The telephone number of AST is (800) 937-5449.



Table of Contents

**SHARES ELIGIBLE FOR FUTURE SALE**

Before this offering, no public market existed for our ordinary shares. Future sales of substantial amounts of ordinary shares in the public market, or the perception that such sales may occur, could adversely affect the market price of our ordinary shares. Although we have applied to list our ordinary shares on the NASDAQ Global Market, we cannot assure you that there will be an active market for our ordinary shares.

Upon completion of this offering, based upon the number of shares outstanding at April 4, 2010, there will be \_\_\_\_\_ ordinary shares outstanding, assuming no exercise of the underwriters' over-allotment option. Of these outstanding ordinary shares, the \_\_\_\_\_ ordinary shares sold in this offering will be freely tradable without restriction or future registration under the Securities Act, except for any shares purchased by our "affiliates," as that term is defined in Rule 144 under the Securities Act, whose sales may be made only in compliance with the limitations of Rule 144 described below.

The remaining \_\_\_\_\_ ordinary shares outstanding after this offering are deemed "restricted securities" under Rule 144. Restricted securities may be sold in the public market only if registered or if they qualify for an exemption under Rules 144 or 701 under the Securities Act, which rules are summarized below, or another exemption. As a result of the lock-up agreements described below and the provisions of Rule 144 and Rule 701, these restricted securities will be available for sale in the public market as follows:

Date of availability of sale	Approximate number of ordinary shares
90 days after the date of this prospectus	
180 days after the date of this prospectus and various times thereafter	

**Lock-Up Agreements**

Each of our directors, executive officers and certain of our existing shareholders has agreed, subject to certain exceptions described in "Underwriting", not to transfer or dispose of, directly or indirectly, any of our ordinary shares or any securities convertible into or exchangeable or exercisable for our ordinary shares for a period of 180 days after the date this prospectus becomes effective. After the expiration of the 180-day period, the ordinary shares held by our directors, executive officers and certain of our existing shareholders may be sold subject to the restrictions under Rule 144 under the Securities Act or by means of registered public offerings.

The 180-day restricted period is subject to adjustment under certain circumstances. If (1) during the last 17 days of the 180-day restricted period, we issue an earnings release or material news or a material event relating to us occurs; or (2) prior to the expiration of the 180-day restricted period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 180-day period, the restrictions will continue to apply until the expiration of the 180-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

**Rule 144**

Under Rule 144 as currently in effect, a person who has beneficially owned our restricted ordinary shares for at least six months is generally entitled to sell the restricted securities without registration under the Securities Act provided that such person is not deemed to have been one of our affiliates at the time of, or at any time during, the 90 days preceding such sale. Sales of our ordinary shares by any such person would be subject to the availability of current public information about us if the ordinary shares to be sold were held by such person for less than one year.

Table of Contents

Our affiliates that have held restricted ordinary shares for at least six months, or persons deemed to have been one of our affiliates at any time during the 90 days preceding a proposed sale and that have held restricted ordinary shares for at least six months, may sell within any three-month period a number of restricted ordinary shares that does not exceed the greater of the following:

1% of the then outstanding ordinary shares, which will equal approximately                      ordinary shares immediately after this offering; or

the average weekly trading volume of our ordinary shares on The NASDAQ Global Market, during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC.

Affiliates who sell restricted securities under Rule 144 may not solicit orders or arrange for the solicitation of orders, and they are also subject to notice requirements and the availability of current public information about us.

**Rule 701**

In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory share or option plan or other written agreement relating to compensation is eligible to resell such ordinary shares 90 days after we become a reporting company under the Exchange Act in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144. However, substantially all ordinary shares issued under Rule 701 are subject to the lock-up agreements described above and will only become eligible for sale when the 180-day lock-up agreements expire.

**Stock Plans**

We plan on filing a registration statement on Form S-8 under the Securities Act covering                      ordinary shares issuable upon exercise of outstanding options and                      ordinary shares reserved for issuance under our stock option plan. We expect to file this registration statement as soon as practicable after this offering, but no resale of these registered ordinary shares that are subject to lock-up agreements shall occur until after the expiration of the lock-up periods in such agreements.

**Registration Rights**

We plan to enter into a registration rights agreement with certain of our shareholders and officers, including TMG, VFI, VFII, KCH and Phil Invest ApS and Douglas W. Kohrs, who we refer to as the holders. Pursuant to the registration rights agreement, one hundred and eighty days after consummation of the offering, we will agree to (i) use our reasonable best efforts to effect up to three registered offerings of at least \$10 million each upon a demand of Warburg Pincus and one registered offering of at least \$10 million upon a demand of the Vertical Group, (ii) use our reasonable best efforts to become eligible for use of Form S-3 for registration statements and once we become eligible Warburg Pincus shall have the right to demand an unlimited number of registrations of at least \$10 million each on Form S-1 and (iii) maintain the effectiveness of each such registration statement for a period of 120 days or until the distribution of the registrable securities pursuant to the registration statement is complete.

Pursuant to the registration rights agreement, all holders will also have incidental or "piggyback" registration rights with respect to any registrable shares, subject to certain volume and marketing restrictions imposed by the underwriters of the offering with respect to which the rights are exercised. These rights do not apply to this offering and this offering is not being effected pursuant to the registration rights agreement.

We will bear the expenses, including the fees and disbursements of one legal counsel for the holders, in connection with the registration of the registrable securities, except for any underwriting commissions relating to the sale of the registrable securities.

Table of Contents

**TAXATION**

**Material Dutch Tax Consequences**

The information set out below is a general summary of material Dutch tax consequences in connection with the acquisition, ownership and transfer of ordinary shares. The summary does not purport to be a comprehensive description of all the Dutch tax considerations that may be relevant for a particular holder of ordinary shares. Such holders may be subject to special tax treatment under any applicable law and this summary is not intended to be applicable in respect of all categories of holders of ordinary shares. The summary is based upon the tax laws of The Netherlands as in effect on the date of this prospectus, including official regulations, rulings and decisions of The Netherlands and its taxing and other authorities available in printed form on or before such date and now in effect. These tax laws are subject to change, which could apply retroactively and could affect the continuing validity of this summary. As this is a general summary, we recommend investors and shareholders consult their own tax advisors as to the Dutch or other tax consequences of the acquisition, ownership and transfer of ordinary shares, including, in particular, the application of their particular situations of the tax considerations discussed below.

The following summary does not address the tax consequences arising in any jurisdiction other than The Netherlands in connection with the acquisition, ownership and transfer of ordinary shares.

***Dividend Withholding Tax***

We do not currently anticipate paying any dividends. If we were to pay dividends currently, the following discussion summarizes the relevant Dutch tax consequences to you. Dividends paid on ordinary shares to a holder of such ordinary shares are generally subject to withholding tax of 15% imposed by The Netherlands. Generally, the dividend withholding tax will not be borne by us, but will be withheld by us from the gross dividends paid on the ordinary shares. The term "dividends" for this purpose includes, but is not limited to:

distributions in cash or in kind, deemed and constructive distributions and repayments of paid-in capital not recognized for Dutch dividend withholding tax purposes;

liquidation proceeds, proceeds of redemption of shares or, generally, consideration for the repurchase of shares in excess of the average paid-in capital recognized for Dutch dividend withholding tax purposes;

the nominal value of shares issued to a shareholder or an increase of the nominal value of shares, as the case may be, to the extent that it does not appear that a contribution to the capital recognized for Dutch dividend withholding tax purposes was made or will be made; and

partial repayment of paid-in capital, recognized for Dutch dividend withholding tax purposes, if and to the extent that there are net profits (*zuivere winst*), within the meaning of the Dutch Dividend Withholding Tax Act 1965 (*Wet op de dividendbelasting 1965*), unless the General Meeting of Shareholders has resolved in advance to make such a repayment and provided that the nominal value of the shares concerned has been reduced by a corresponding amount by way of an amendment of our Articles of Association.

A holder of ordinary shares who is, or who is deemed to be, a resident of The Netherlands can generally credit the withholding tax against his Dutch income tax or Dutch corporate income tax liability and is generally entitled to a refund of dividend withholding taxes exceeding his aggregate Dutch income tax or Dutch corporate income tax liability, provided certain conditions are met, unless such holder of ordinary shares is not considered to be the beneficial owner of the dividends.

Table of Contents

A holder of ordinary shares who is the recipient of dividends, or the Recipient, will not be considered the beneficial owner of the dividends for this purpose if:

as a consequence of a combination of transactions, a person other than the Recipient wholly or partly benefits from the dividends;

whereby such other person retains, directly or indirectly, an interest similar to that in the ordinary shares on which the dividends were paid; and

that other person is entitled to a credit, reduction or refund of dividend withholding tax that is less than that of the Recipient ("Dividend Stripping").

With respect to a holder of ordinary shares, who is not and is not deemed to be a resident of The Netherlands for purposes of Dutch taxation and who is considered to be a resident of The Netherlands Antilles or Aruba under the provisions of the Tax Arrangement for the Kingdom of The Netherlands (*Belastingregeling voor het Koninkrijk*), or who is considered to be a resident of a country other than The Netherlands under the provisions of a double taxation convention The Netherlands has concluded with such country, the following may apply. Such holder of ordinary shares may, depending on the terms of and subject to compliance with the procedures for claiming benefits under the Tax Arrangement for the Kingdom of The Netherlands or such double taxation convention, be eligible for a full or partial exemption from or a reduction or refund of Dutch dividend withholding tax.

In addition, subject to certain conditions, an exemption from Dutch dividend withholding tax will generally apply to dividends distributed to entities that are resident in another EU Member State or in certain, designated countries that are party to the European Economic Area, or EEA, (at present Iceland and Norway) and that hold an interest of at least 5% of the nominal paid-in capital or, in relation to certain jurisdictions, of the voting power of the distributing entity. This exemption of dividend withholding tax is not applicable for cross-border dividend payments to entities that perform a similar function to Dutch fiscal investment institutions (*fiscale beleggingsinstellingen*) or exempt investment institutions (*vrijgestelde beleggingsinstellingen*). Furthermore, certain entities resident in an EU Member State and not subject to tax on their profits in such EU Member State might be entitled to obtain a full refund of Dutch dividend withholding tax provided they would not have been subject to Dutch corporate income tax had they been resident in The Netherlands.

Dividend distributions to a U.S. holder of ordinary shares (with an interest of less than 10% of the voting rights in us) are subject to 15% dividend withholding tax, which is equal to the rate such U.S. holder may be entitled to under the Convention Between the Kingdom of The Netherlands and the United States for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, executed in Washington on December 18, 1992, as amended from time to time, or The Netherlands-U.S. Convention. As such, there is no need to claim a refund of the excess of the amount withheld over the tax treaty rate.

On the basis of article 35 of The Netherlands-U.S. Convention, qualifying U.S. pension trusts are under certain conditions entitled to a full exemption from Dutch dividend withholding tax. Such qualifying exempt U.S. pension trusts must provide us form IB 96 USA, along with a valid certificate, for the application of relief at source from dividend withholding tax. If we receive the required documentation prior to the relevant dividend payment date, then we may apply such relief at source. If a qualifying exempt U.S. pension trust fails to satisfy these requirements prior to the payment of a dividend, then such qualifying exempt pension trust may claim a refund of Dutch withholding tax by filing form IB 96 USA with the Dutch tax authorities. On the basis of article 36 of The Netherlands-U.S. Convention, qualifying exempt U.S. organizations are under certain conditions entitled to a full exemption from Dutch dividend withholding tax. Such qualifying exempt U.S. organizations are not entitled to claim relief at source, and instead must claim a refund of Dutch withholding tax by filing form IB 96 USA with the Dutch tax authorities.

Table of Contents

The concept of Dividend Stripping, described above, may also be applied to determine whether a holder of ordinary shares may be eligible for a full or partial exemption from, reduction or refund of Dutch dividend withholding tax, as described in the preceding paragraphs.

In general, we will be required to remit all amounts withheld as Dutch dividend withholding tax to the Dutch tax authorities. However, in connection with distributions received by us from our foreign subsidiaries, we are allowed, subject to certain conditions, to reduce the amount to be remitted to Dutch tax authorities by the lesser of:

- (i) 3% of the portion of the distribution paid by us that is subject to Dutch dividend withholding tax; and
- (ii) 3% of the dividends and profit distributions, before deduction of foreign withholding taxes, received by us from qualifying foreign subsidiaries in the current calendar year (up to the date of the distribution by us) and the two preceding calendar years, insofar as such dividends and profit distributions have not yet been taken into account for purposes of establishing the above- mentioned deductions.

For purposes of determining the 3% threshold under (i) above, a distribution by us is not taken into account in case the Dutch dividend withholding tax withheld in respect thereof may be fully refunded, unless the recipient of such distribution is a qualifying entity that is not subject to corporate income tax.

Although this reduction reduces the amount of Dutch dividend withholding tax that we are required to pay to Dutch tax authorities, it does not reduce the amount of tax that we are required to withhold from dividends.

**Taxes on Income and Capital Gains**

The description of taxation set out in this section of this prospectus is not intended for any holder of ordinary shares, who:

is an individual and for whom the income or capital gains derived from ordinary shares are attributable to employment activities, the income from which is taxable in The Netherlands;

holds a Substantial Interest or a deemed Substantial Interest in us (as defined below);

is an entity that is a resident or deemed to be a resident of The Netherlands and that is not subject to or is exempt, in whole or in part, from Dutch corporate income tax;

is an entity for which the income or capital gains derived in respect of ordinary shares are exempt under the participation exemption (*deelnemingsvrijstelling*) as set out in the Dutch Corporate Income Tax Act 1969 (*Wet op de vennootschapsbelasting 1969*); or

who is a fiscal investment institution (*fiscale beleggingsinstelling*) or an exempt investment institution (*vrijgestelde beleggingsinstelling*) as defined in the Dutch Corporate Income Tax Act 1969 (*Wet op de vennootschapsbelasting 1969*).

Generally a holder of ordinary shares will have a substantial interest in us, or a Substantial Interest, if he holds, alone or together with his partner (statutorily defined term), whether directly or indirectly, the ownership of, or certain other rights over, shares representing 5% or more of our total issued and outstanding capital (or the issued and outstanding capital of any class of shares), or rights to acquire shares, whether or not already issued, that represent at any time 5% or more of our total issued and outstanding capital (or the issued and outstanding capital of any class of shares) or the ownership of certain profit participating certificates that relate to 5% or more of the annual profit or to 5% or more of our liquidation proceeds. A holder of ordinary shares will also have a Substantial Interest in us if one of certain relatives of that holder or of his partner has a Substantial Interest in us.



Table of Contents

If a holder of ordinary shares does not have a Substantial Interest, a deemed Substantial Interest will be present if (part of) a Substantial Interest has been disposed of, or is deemed to have been disposed of, without recognizing taxable gain.

*Residents of The Netherlands Individuals.* An individual who is resident or deemed to be resident in The Netherlands, or who opts to be taxed as a resident of The Netherlands for purposes of Dutch taxation, or a Dutch Resident Individual, and who holds ordinary shares is subject to Dutch income tax on income or capital gains derived from the ordinary shares at the progressive rate (up to 52% rate for 2010) if:

- (i) the holder derives profits from an enterprise or deemed enterprise, whether as an entrepreneur (*ondernemer*) or pursuant to a co-entitlement to the net worth of such enterprise (other than as an entrepreneur or a shareholder), to which enterprise the ordinary shares are attributable; or
- (ii) the holder derives income or capital gains from the shares that are taxable as benefits from "miscellaneous activities" (*resultaat uit overige werkzaamheden*, as defined in the Dutch Income Tax Act 2001; *Wet inkomstenbelasting 2001*), which include the performance of activities with respect to the ordinary shares that exceed regular, active portfolio management (*normaal, actief vermogensbeheer*).

If conditions (i) and (ii) mentioned above do not apply, any holder of ordinary shares who is a Dutch Resident Individual will be subject to Dutch income tax on a deemed return regardless of the actual income or capital gains benefits derived from the ordinary shares. This deemed return has been fixed at a rate of 4% (rate for 2010) of the average of the individual's yield basis (*rendementsgrondslag*) at the beginning of the calendar year and the individual's yield basis at the end of the calendar year, insofar as this exceeds a certain threshold (*heffingvrij vermogen*). The individual's yield basis is determined as the fair market value of certain qualifying assets held by the Dutch Resident Individual less the fair market value of certain qualifying liabilities, on January 1 and December 31 of the relevant year, divided by two. The deemed return of 4% will be taxed at a rate of 30% (rate for 2010).

*Residents of The Netherlands Entities.* An entity that is resident or deemed to be resident in The Netherlands, or a Dutch Resident Entity, will generally be subject to Dutch corporate income tax with respect to income and capital gains derived from the ordinary shares. The Dutch corporate income tax rate is 20% for the first €200,000 of taxable income and 25.5% for taxable income exceeding €200,000 (rates for 2010). As of 1 January 2011 the Dutch corporate income tax rate is expected to be 20% for the first €40,000 of taxable income, 23% for the taxable income exceeding €40,000 but not exceeding €200,000 and 25.5% for taxable income exceeding €200,000.

*Non-Residents of The Netherlands.* A person who is not a Dutch Resident Individual or Dutch Resident Entity, a Non-Dutch Resident, who holds ordinary shares is generally not subject to Dutch income or corporate income tax (other than dividend withholding tax described above) on the income and capital gains derived from the ordinary shares, provided that:

such Non-Dutch Resident does not derive profits from an enterprise or deemed enterprise, whether as an entrepreneur (*ondernemer*) or pursuant to a co-entitlement to the net worth of such enterprise (other than as an entrepreneur or a shareholder) which enterprise is, in whole or in part, carried on through a permanent establishment or a permanent representative in The Netherlands and to which enterprise or part of an enterprise, as the case may be, the ordinary shares are attributable or deemed attributable;

in the case of a Non-Dutch Resident who is an individual, such individual does not derive income or capital gains from the ordinary shares that are taxable as benefits from "miscellaneous activities" in The Netherlands (*resultaat uit overige werkzaamheden*, as defined

Table of Contents

the Dutch Income Tax Act 2001), which include the performance of activities with respect to the ordinary shares that exceed regular, active portfolio management (*normaal, actief vermogensbeheer*); and

such Non-Dutch Resident is neither entitled to a share in the profits of an enterprise nor co-entitled to the net worth of such enterprise effectively managed in The Netherlands, other than by way of the holding of securities or, in the case of an individual, through an employment contract, to which enterprise the ordinary shares or payments in respect of the ordinary shares are attributable.

***Gift, Estate or Inheritance Taxes***

No Dutch gift, estate or inheritance taxes will be levied on the transfer of ordinary shares by way of gift by or on the death of a holder, who is neither a resident nor deemed to be a resident of The Netherlands for the purpose of the relevant provisions, unless:

- (i) the transfer is construed as an inheritance or bequest or as a gift made by or on behalf of a person who, at the time of the gift or death, is or is deemed to be a resident of The Netherlands for the purpose of the relevant provisions; or
- (ii) such holder dies while being a resident or deemed resident of The Netherlands within 180 days after the date of a gift of the ordinary shares.

For purposes of Dutch gift, estate and inheritance tax, an individual who is of Dutch nationality will be deemed to be a resident of The Netherlands if he has been a resident in The Netherlands at any time during the ten years preceding the date of the gift or his death. For purposes of Dutch gift tax, an individual will, irrespective of his nationality, be deemed to be resident of The Netherlands if he has been a resident in The Netherlands at any time during the 12 months preceding the date of the gift.

***Value Added Tax***

There is no Dutch value added tax payable by a holder of ordinary shares in respect of payments in consideration for the offer of the ordinary shares (other than value added tax payable in respect of services not exempt from Dutch value added tax).

***Other Taxes and Duties***

No Dutch registration tax, capital tax, customs duty, stamp duty or any other similar tax or duty other than court fees is payable in The Netherlands by a holder of ordinary shares in connection with the acquisition, ownership and transfer of ordinary shares.

***Residence***

A holder of ordinary shares will not become or be deemed to become a resident of The Netherlands solely by reason of holding these ordinary shares.

**Material U.S. Federal Income Tax Consequences**

The following summary is based on the U.S. Internal Revenue Code of 1986, as amended, or IRC, The Netherlands-U.S. Convention, existing Treasury Regulations, revenue rulings, administrative interpretations and judicial decisions (all as currently in effect and all of which are subject to change, possibly with retroactive effect). This summary applies only if you hold your ordinary shares as capital assets within the meaning of Section 1221 of the IRC (generally, property held for investment). This



Table of Contents

summary does not discuss all of the tax consequences that may be relevant to holders in light of their particular circumstances. For example, certain types of investors, such as:

persons subject to the imposition of the U.S. federal alternative minimum tax;

partnerships or other pass-through entities treated as partnerships for U.S. federal income tax purposes;

insurance companies;

tax-exempt persons;

financial institutions;

regulated investment companies;

dealers in securities;

persons who hold ordinary shares as part of a hedging, straddle, constructive sale or conversion transaction;

persons who acquired ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;

persons whose functional currency is not the U.S. dollar; and

persons owning (directly, indirectly or constructively under applicable attribution rules) 10% or more of our voting shares

may be subject to different tax rules not discussed below. In particular, because we are a "controlled foreign corporation," or CFC, for U.S. federal income tax purposes for our current taxable year ending on December 31, 2010, a U.S. person owning 10% or more of our voting shares directly, indirectly or constructively under applicable attribution rules, may have U.S. federal income tax consequences significantly different from those described below. Such persons should consult their tax advisors regarding an investment in our ordinary shares.

If an entity treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, the tax treatment of a member of such an entity will generally depend on the status of the member and the activities of the entity treated as a partnership. If you are a member of an entity treated as a partnership for U.S. federal income tax purposes holding our ordinary shares, you should consult your tax advisor. Persons considering the purchase of the ordinary shares should consult their tax advisors with regard to the application of the U.S. federal income tax laws to their particular situations, as well as any tax consequences arising under the laws of any state or local jurisdiction or any jurisdictions outside of the United States.

This discussion applies to you only if you are a beneficial owner of ordinary shares and are, for U.S. federal income tax purposes, (1) an individual citizen or resident of the United States, (2) a corporation (or other entity taxable as a corporation) organized under the laws of the United States or any state of the United States (or the District of Columbia), (3) an estate the income of which is subject to U.S. federal income taxation regardless of its source or (4) a trust if both: (A) a U.S. court is able to exercise primary supervision over the administration of the trust and (B) one or more U.S. persons have the authority to control all substantial decisions of the trust.

This discussion assumes that we are not, and will not become, a passive foreign investment company, or PFIC (as described below).

Table of Contents

***Taxation of Dividends***

We do not currently anticipate paying any dividends. If we were to pay dividends currently, the following discussion summarizes the relevant U.S. tax consequences to you.

The gross amount of any distribution, including Dutch withholding tax thereon, with respect to our ordinary shares (other than certain pro rata distributions of ordinary shares) will be treated as a dividend for U.S. federal income tax purposes. Subject to applicable limitations, dividends paid to noncorporate holders, in taxable years beginning before January 1, 2011, will be taxable at a maximum rate of 15%. You should consult your tax advisor regarding the availability of this preferred tax rate under your particular circumstances. An additional 3.8% tax may apply to dividends received by certain U.S. holders of our ordinary shares, including individuals, estates and trusts, during taxable years beginning on or after January 1, 2013.

Subject to the next sentence, dividends paid on ordinary shares will constitute income from sources outside the United States for foreign tax credit limitation purposes and will not be eligible for the dividends-received deduction to U.S. corporate shareholders. However, some portion of any dividend received with respect to the ordinary shares may be treated as U.S. source income under the rules regarding "United States-owned foreign corporations." You should consult your tax advisor regarding the source of any dividend received.

The amount of any distribution paid in Euro will be the U.S. dollar value of the Euro on the date of your receipt of the dividend, determined at the spot rate in effect on such date, regardless of whether you convert the payments into U.S. dollars. Gain or loss, if any, recognized by you on the subsequent sale, conversion or disposition of Euro will be ordinary income or loss, and will be income or loss from sources within the United States for foreign tax credit limitation purposes.

Subject to certain conditions and limitations, and subject to the discussion in the next paragraph, tax withheld in The Netherlands at the rate provided for in The Netherlands-U.S. Convention will be treated as a foreign tax that you may elect to deduct in computing your U.S. federal taxable income or credit against your U.S. federal income tax liability. Amounts paid in respect of dividends on ordinary shares will be treated as "passive income" for purposes of calculating the amount of the foreign tax credit available to a U.S. shareholder. Foreign tax credits allowable with respect to each category of income cannot exceed the U.S. federal income tax payable on such category of income. Any amount withheld by us and paid over to the Dutch Tax Administration in excess of the rate applicable under The Netherlands-U.S. Convention will not be eligible for credit against your U.S. federal income tax liability. However, you may be able to obtain a refund of such excess amount by filing the appropriate forms with the Dutch Tax Administration requesting such refund and providing the required information.

Under certain circumstances, we will be allowed to reduce the amount of dividend withholding tax imposed on United States shareholders that is paid over to the Dutch Tax Administration by crediting withholding tax imposed on certain dividends paid to us by certain of our non-Dutch subsidiaries. In such event, the Dutch withholding tax imposed on dividends paid to you may not be fully creditable against your United States federal income tax liability. As noted above, we do not currently anticipate paying dividends. If we pay dividends in the future, we will endeavor to provide to you the information that you will need to calculate the amount of your foreign tax credit.

***Sale, Exchange or Other Taxable Disposition of the Ordinary Shares***

You will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of ordinary shares in an amount equal to the difference between the U.S. dollar value of the amount realized from such sale or exchange and your tax basis for such ordinary shares. Such gain or loss will be a capital gain or loss and will be long-term capital gain if the

Table of Contents

ordinary shares were held for more than one year. Long-term capital gains of noncorporate holders are currently taxed at a rate of 15%. For taxable years beginning on or after January 1, 2011, this long-term capital gain rate is scheduled to return to 20%. Any such gain or loss generally would be treated as income or loss from sources within the United States for foreign tax credit limitation purposes. If you receive Euro upon a sale, exchange or other taxable disposition of ordinary shares, gain or loss, if any, recognized on the subsequent sale, conversion or disposition of such Euro will be ordinary income or loss, and will generally be income or loss from sources within the United States for foreign tax credit limitation purposes. An additional 3.8% tax may apply to gains recognized by certain U.S. holders of our ordinary shares, including individuals, estates and trusts, upon the sale, exchange or other taxable disposition of ordinary shares occurring during taxable years beginning on or after January 1, 2013.

***Passive Foreign Investment Company***

A non-U.S. corporation will generally be considered a PFIC for U.S. federal income tax purposes for any taxable year if either (i) 75% or more of its gross income in such taxable year is passive income (the income test) or (ii) the average percentage (determined on the basis of a quarterly average) of the value of its assets that produce or are held for the production of passive income is at least 50% (the asset test). For this purpose, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, more than 25% (by value) of the stock.

The Company believes that it will not be considered a PFIC for United States federal income tax purposes for the current year and the Company does not expect to become a PFIC in the foreseeable future. However, since PFIC status depends upon the composition of a company's income and assets and the market value of its assets from time to time, there can be no assurance that the Company will not be considered a PFIC for any taxable year. If the Company were treated as a PFIC for any taxable year during which you held an ordinary share, certain adverse consequences could apply. Furthermore, the application of the PFIC asset test in respect of our current taxable year is uncertain because we currently are a CFC and the application of the asset test to a CFC in respect of its taxable year in which it becomes publicly traded after its first quarter is not clear.

If a CFC is a "publicly traded corporation" for the taxable year, the PFIC asset test is applied based on the value of its assets. Otherwise, the asset test for a CFC is applied based on the adjusted tax bases of its assets as determined for the purposes of computing earnings and profits under U.S. federal income tax principles. In both cases, the determination is made on the basis of a quarterly average. It is not clear, however, whether a corporation will be treated as a "publicly traded corporation" in respect of the taxable year in which it becomes a publicly traded corporation after the first quarter. We will be a CFC for our current taxable year ending on December 31, 2010, and we expect to become a publicly traded corporation as a result of the offering sometime this year. As a result, it is not clear how the asset test will apply to us in respect of the current taxable year. However, regardless of whether the asset test must be applied entirely based on the adjusted tax bases or entirely on the value of our assets during the current taxable year (or on a combination of these two methods, based on the number of quarters during which our ordinary shares are publicly traded in the current taxable year), we do not believe that we will be a PFIC in respect of our current taxable year. You should note, however, that the Internal Revenue Service could disagree with our conclusion.

If the Company is treated as a PFIC for any taxable year, gain recognized by you on a sale or other disposition of an ordinary share would be allocated ratably over your holding period for the ordinary share. The amounts allocated to the taxable year of the sale or other exchange and to any year before the Company became a PFIC would be taxed as ordinary income, rather than capital gains. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, and an interest charge would be imposed on the amount allocated to such taxable year. Further, any distribution in respect of ordinary shares in excess of 125%

Table of Contents

of the average of the annual distributions on ordinary shares received by you during the preceding three years or your holding period, whichever if shorter, would be subject to taxation as described above. Certain elections may be available (including a mark-to-market election) to U.S. persons that may mitigate the adverse consequences resulting from PFIC status.

In addition, if we were to be treated as a PFIC in a taxable year in which we pay a dividend or in the prior taxable year, the 15% dividend rate discussed above with respect to dividends paid to noncorporate holders would not apply.

Under newly enacted legislation, unless otherwise provided by the U.S. Treasury, each U.S. holder of shares of a PFIC is required to file an annual report containing such information as the U.S. Treasury may require. Prior to such legislation, a U.S. holder of shares of a PFIC was required to file Internal Revenue Service Form 8621 only for each taxable year in which such shareholder received distributions from the PFIC, recognized gain on a disposition of the PFIC stock, or made a "reportable election." If we are or become a PFIC, you should consult your tax advisor regarding any reporting requirements that may apply to you.

You are urged to consult your tax advisor regarding the application of the PFIC rules to your investment in our ordinary shares.

***Backup Withholding and Information Reporting***

Payment of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting and to backup withholding unless (i) you are an exempt recipient or (ii) in the case of backup withholding, you provide us with your correct taxpayer identification number on Internal Revenue Service Form W-9 and certify that you are not subject to backup withholding. For taxable years beginning after March 18, 2010, new legislation requires U.S. holders who are individuals and who hold interests in foreign financial assets exceeding \$50,000 to report our name and address and the information necessary to identify our ordinary shares held in an attachment to such individual's annual tax return, subject to certain exceptions (including an exception for shares held in accounts maintained by certain financial institutions).

The amount of any backup withholding from a payment to you will be allowed as a credit against your U.S. federal income tax liability and may entitle you to a refund, provided that the required information is furnished to the Internal Revenue Service.

Table of Contents**UNDERWRITING**

Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities Inc. are acting as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in a purchase agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of ordinary shares set forth opposite its name below.

Name	Number of ordinary shares
Merrill Lynch, Pierce, Fenner & Smith Incorporated	
J.P. Morgan Securities Inc.	
Piper Jaffray & Co.	
Credit Suisse Securities (USA) LLC	
Wells Fargo Securities, LLC	
William Blair & Company, L.L.C.	
Total	

Subject to the terms and conditions set forth in the purchase agreement, the underwriters have agreed, severally and not jointly, to purchase all of the ordinary shares sold under the purchase agreement if any of these ordinary shares are purchased. If an underwriter defaults, the purchase agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the purchase agreement may be terminated.

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities.

The underwriters are offering the ordinary shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the ordinary shares, and other conditions contained in the purchase agreement, such as the receipt by the underwriters of officer's certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

**Commissions and Discounts**

The representatives have advised us that the underwriters propose initially to offer the ordinary shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of \$\_\_\_\_\_ per ordinary share. The underwriters may allow, and the dealers may reallow, a discount not in excess of \$\_\_\_\_\_ per ordinary share to other dealers. After the initial offering, the public offering price, concession or any other term of the offering may be changed.

The following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their overallotment option.

	Per ordinary share	Without option	With option
Public offering price			
Underwriting discount			
Proceeds, before expenses, to Tornier N.V.			

Table of Contents

The expenses of the offering, not including the underwriting discount, are estimated at \$ \_\_\_\_\_ and are payable by us.

**Overallotment Option**

We have granted an option to the underwriters to purchase up to \_\_\_\_\_ additional ordinary shares at the public offering price, less the underwriting discount. The underwriters may exercise this option for 30 days from the date of this prospectus solely to cover any overallotments. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the purchase agreement, to purchase a number of additional ordinary shares proportionate to that underwriter's initial amount reflected in the above table.

**Reserved Shares**

At our request, the underwriters have reserved for sale, at the initial public offering price, up to \_\_\_\_\_ ( \_\_\_\_\_ % of the ordinary shares offered by this prospectus) for sale to some of our directors, officers, employees, sales agencies, dealers, business associates and related persons. If these persons purchase reserved ordinary shares, this will reduce the number of ordinary shares available for sale to the general public. Any reserved ordinary shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other ordinary shares offered by this prospectus.

**No Sales of Similar Securities**

We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any ordinary shares or securities convertible into, exchangeable for, exercisable for, or repayable with ordinary shares, for 180 days after the date of this prospectus without first obtaining the written consent of Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities Inc. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly:

offer, pledge, sell or contract to sell any ordinary shares;

sell any option or contract to purchase any ordinary shares;

purchase any option or contract to sell any ordinary shares;

grant any option, right or warrant for the sale of any ordinary shares;

lend or otherwise dispose of or transfer any ordinary shares;

request or demand that we file a registration statement related to the ordinary shares; or

enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any ordinary shares, whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise.

This lock-up provision applies to ordinary shares and to securities convertible into or exchangeable or exercisable for or repayable with ordinary shares. It also applies to ordinary shares owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. In the event that either (x) during the last 17 days of the lock-up period referred to above, we issue an earnings release or material news or a material event relating to us occurs or (y) prior to the expiration of the lock-up period, we announce that we will release earnings results or become aware that material news or a material event will occur during the 16-day period beginning on the last day of the lock-up period, the restrictions described

Table of Contents

above shall continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.

**NASDAQ Global Market Listing**

We expect the ordinary shares to be approved for listing on the NASDAQ Global Market, subject to notice of issuance, under the symbol "TRNX."

Before this offering, there has been no public market for our ordinary shares. The initial public offering price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price include:

the valuation multiples of publicly traded companies that the representatives believe to be comparable to us;

our financial information;

the history of, and the prospects for, our company and the industry in which we compete;

an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenue;

the present state of our development; and

the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.

An active trading market for the ordinary shares may not develop. It is also possible that after the offering the ordinary shares will not trade in the public market at or above the initial public offering price.

The underwriters do not expect to sell more than 5% of the ordinary shares in the aggregate to accounts over which they exercise discretionary authority.

**Price Stabilization, Short Positions and Penalty Bids**

Until the distribution of the ordinary shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing our ordinary shares. However, the representatives may engage in transactions that stabilize the price of the ordinary shares, such as bids or purchases to peg, fix or maintain that price.

In connection with the offering, the underwriters may purchase and sell our ordinary shares in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of ordinary shares than they are required to purchase in the offering. "Covered" short sales are sales made in an amount not greater than the underwriters' overallotment option described above. The underwriters may close out any covered short position by either exercising their overallotment option or purchasing shares in the open market. In determining the source of ordinary shares to close out the covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared to the price at which they may purchase ordinary shares through the overallotment option. "Naked" short sales are sales in excess of the overallotment option. The underwriters must close out any naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ordinary shares in the open market after pricing that could adversely affect investors who purchase in the





Table of Contents

offering. Stabilizing transactions consist of various bids for or purchases of ordinary shares made by the underwriters in the open market prior to the completion of the offering.

The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased ordinary shares sold by or for the account of such underwriter in stabilizing or short covering transactions.

Similar to other purchase transactions, the underwriters' purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on the NASDAQ Global Market, in the over-the-counter market or otherwise.

Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our ordinary shares. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.

**Electronic Offer, Sale and Distribution of Ordinary Shares**

A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations.

**Other Relationships**

Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.

In addition, on April 3, 2009, certain merchant banking funds affiliated with Piper Jaffray & Co., along with various other investors, acquired notes payable and warrants to purchase ordinary shares. On May 25, 2010, all investors holding warrants agreed to exchange their warrants for shares at an exchange ratio of 0.641. The exchange resulted in the issuance of 565,687 ordinary shares to the merchant banking funds affiliated with Piper Jaffray & Co., which represents less than 1% of our total shares outstanding.

**Notice to Prospective Investors in the EEA**

In relation to each Member State of the EEA which has implemented the Prospectus Directive (each, a Relevant Member State) an offer to the public of any ordinary shares which are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any ordinary shares may be made at any

Table of Contents

time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:

- (a) to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;
- (b) to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual net turnover of more than €50,000,000, as shown in its last annual or consolidated accounts;
- (c) by the underwriters to fewer than 100 natural or legal persons (other than "qualified investors" as defined in the Prospectus Directive) subject to obtaining the prior consent of the representatives for any such offer; or
- (d) in any other circumstances falling within Article 3(2) of the Prospectus Directive;

provided that no such offer of ordinary shares shall result in a requirement for the publication by us or any representative of a prospectus pursuant to Article 3 of the Prospectus Directive.

Any person making or intending to make any offer of ordinary shares within the EEA should only do so in circumstances in which no obligation arises for us or any of the underwriters to produce a prospectus for such offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of ordinary shares through any financial intermediary, other than offers made by the underwriters which constitute the final offering of ordinary shares contemplated in this prospectus.

For the purposes of this provision, and your representation below, the expression an "offer to the public" in relation to any ordinary shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any ordinary shares to be offered so as to enable an investor to decide to purchase any ordinary shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.

Each person in a Relevant Member State who receives any communication in respect of, or who acquires any ordinary shares under, the offer of ordinary shares contemplated by this prospectus will be deemed to have represented, warranted and agreed to and with us and each underwriter that:

- (A) it is a "qualified investor" within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive; and
- (B) in the case of any ordinary shares acquired by it as a financial intermediary, as that term is used in Article 3(2) of the Prospectus Directive, (i) the ordinary shares acquired by it in the offering have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than "qualified investors" (as defined in the Prospectus Directive), or in circumstances in which the prior consent of the representatives has been given to the offer or resale; or (ii) where ordinary shares have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of those ordinary shares to it is not treated under the Prospectus Directive as having been made to such persons.

In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are "qualified investors" (as defined in the Prospectus Directive) (i) who have professional experience in matters relating to

Table of Contents

investments falling within Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons.

**Notice to Prospective Investors in Switzerland**

This document, as well as any other material relating to the ordinary shares which are the subject of the offering contemplated by this prospectus, do not constitute an issue prospectus pursuant to Article 652a and/or 1156 of the Swiss Code of Obligations. The ordinary shares will not be listed on the SIX Swiss Exchange and, therefore, the documents relating to the ordinary shares, including, but not limited to, this document, do not claim to comply with the disclosure standards of the listing rules of SIX Swiss Exchange and corresponding prospectus schemes annexed to the listing rules of the SIX Swiss Exchange. The ordinary shares are being offered in Switzerland by way of a private placement, i.e., to a small number of selected investors only, without any public offer and only to investors who do not purchase the ordinary shares with the intention to distribute them to the public. The investors will be individually approached by the issuer from time to time. This document, as well as any other material relating to the ordinary shares, is personal and confidential and do not constitute an offer to any other person. This document may only be used by those investors to whom it has been handed out in connection with the offering described herein and may neither directly nor indirectly be distributed or made available to other persons without express consent of the issuer. It may not be used in connection with any other offer and shall in particular not be copied and/or distributed to the public in (or from) Switzerland.

**Notice to Prospective Investors in the Dubai International Financial Centre**

This document relates to an exempt offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority. This document is intended for distribution only to persons of a type specified in those rules. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority has no responsibility for reviewing or verifying any documents in connection with exempt offers. The Dubai Financial Services Authority has not approved this document nor taken steps to verify the information set out in it, and has no responsibility for it. The shares which are the subject of the offering contemplated by this prospectus may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this document you should consult an authorised financial advisor.

Table of Contents

**LEGAL MATTERS**

Certain legal matters with respect to U.S. federal and New York State law in connection with this offering will be passed upon for us by Willkie Farr & Gallagher LLP. The validity of the ordinary shares and other certain legal matters as to the law of The Netherlands will be passed upon for us by Stibbe N.V. Certain legal matters with respect to this offering will be passed upon for the underwriters by Latham & Watkins LLP, Costa Mesa.

**EXPERTS**

The consolidated financial statements, and schedule, of Tornier B.V. at December 28, 2008, and December 27, 2009, and for each of the three years in the period ended December 27, 2009, appearing in this prospectus and Registration Statement have been audited by Ernst & Young LLP, an independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

**WHERE YOU CAN FIND ADDITIONAL INFORMATION**

We have filed with the SEC a registration statement on Form S-1 under the Securities Act relating to the ordinary shares being offered by this prospectus. This prospectus, which constitutes part of that registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules which are part of the registration statement. For further information about us and the ordinary shares offered, see the registration statement and the exhibits and schedules thereto. Statements contained in this prospectus regarding the contents of any contract or any other document to which reference is made are not necessarily complete, and, in each instance where a copy of a contract or other document has been filed as an exhibit to the registration statement, reference is made to the copy so filed, each of those statements being qualified in all respects by the reference.

A copy of the registration statement, the exhibits and schedules thereto and any other document we file may be inspected without charge at the public reference facilities maintained by the SEC in 100 F Street, N.E., Washington, D.C. 20549 and copies of all or any part of the registration statement may be obtained from this office upon the payment of the fees prescribed by the SEC. The public may obtain information on the operation of the public reference facilities in Washington, D.C. by calling the SEC at 1-800-SEC-0330. Our filings with the SEC are available to the public from the SEC's website at [www.sec.gov](http://www.sec.gov).

Upon the completion of this offering, we will be subject to the information and periodic reporting requirements of the Exchange Act applicable to a company with securities registered pursuant to Section 12 of the Exchange Act. In accordance therewith, we will file proxy statements and other information with the SEC. All documents filed with the SEC are available for inspection and copying at the public reference room and website of the SEC referred to above. We maintain a website at [www.tornier.com](http://www.tornier.com). You may access our reports, proxy statements and other information free of charge at this website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information on such website is not incorporated by reference and is not a part of this prospectus.

Table of Contents

**TORNIER B.V.**

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**

	<b>Page</b>
<b>Consolidated Financial Statements</b>	
<u>Report of Independent Registered Public Accounting Firm</u>	<u>F-2</u>
<u>Consolidated Balance Sheets as of December 28, 2008, December 27, 2009, and April 4, 2010</u>	<u>F-3</u>
<u>Consolidated Statements of Operations for the years ended December 31, 2007, December 28, 2008, and December 27, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010</u>	<u>F-4</u>
<u>Consolidated Statements of Cash Flows for the years ended December 31, 2007, December 28, 2008, and December 27, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010</u>	<u>F-5</u>
<u>Consolidated Statements of Shareholders' Equity and Comprehensive Loss for the years ended December 31, 2007, December 28, 2008, and December 27, 2009, and for the first quarter ended April 4, 2010</u>	<u>F-6</u>
<u>Notes to Consolidated Financial Statements</u>	<u>F-7</u>
F-1	

---

Table of Contents

**Report of Independent Registered Public Accounting Firm**

The Board of Directors  
Tornier B.V.

We have audited the accompanying consolidated balance sheets of Tornier B.V. and subsidiaries (the Company), as of December 27, 2009, and December 28, 2008, and the related consolidated statements of operations, cash flows and shareholders' equity and comprehensive loss for each of the three years in the period ended December 27, 2009. Our audits also included the financial statement schedule listed in the index at Item 16b. These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Tornier B.V. and subsidiaries at December 27, 2009, and December 28, 2008, and the consolidated results of their operations and their cash flows for each of the three fiscal years in the period ended December 27, 2009, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

As discussed in Note 2 of the consolidated financial statements, the Company adopted the provisions of ASC Topic 740, *Income Taxes*, related to accounting for uncertainty in income taxes as of December 29, 2008. Additionally, as discussed in Note 8 of the consolidated financial statements, the Company adopted the provisions of ASC Topic 815-40, *Derivatives and Hedging*, and changed its method of accounting for certain instruments not indexed to the Company's own stock.

/s/ Ernst & Young LLP

April 9, 2010  
Minneapolis, Minnesota

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Consolidated Balance Sheets****(In Thousands, Except Per Share Amounts)**

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
<b>Assets</b>			
<i>Current assets:</i>			
Cash and cash equivalents	\$ 21,348	\$ 37,969	\$ 38,311
Accounts receivable (net of allowance of \$2,169, 2,667 and \$2,410, respectively)	40,584	40,447	40,424
Inventories	75,002	82,716	82,995
Income taxes receivable	2,517	2,835	3,447
Deferred income taxes	1,971	2,860	3,100
Prepaid taxes	9,418	10,356	10,704
Prepaid expenses	3,035	3,353	3,482
Other current assets	4,601	4,707	4,601
<b>Total current assets</b>	<b>158,476</b>	<b>185,243</b>	<b>187,064</b>
Instruments, net	22,319	26,355	25,736
Property, plant and equipment, net	28,626	35,076	35,963
Goodwill	130,632	136,949	132,342
Intangible assets, net	133,474	125,221	117,371
Deferred income taxes	415	10,530	12,007
Other assets	2,025	813	447
<b>Total assets</b>	<b>\$ 475,967</b>	<b>\$ 520,187</b>	<b>\$ 510,930</b>
<b>Liabilities and shareholders' equity</b>			
<i>Current liabilities:</i>			
Short-term borrowing and current portion of long-term debt	\$ 27,868	\$ 23,299	\$ 25,112
Accounts payable	19,456	12,925	15,714
Accrued liabilities	27,673	35,580	35,156
Income taxes payable		351	1,118
Deferred income taxes	1,739		
<b>Total current liabilities</b>	<b>76,736</b>	<b>72,155</b>	<b>77,100</b>
Notes payable	29,080	69,535	70,095
Mandatorily convertible bonds	47,845		
Other long-term debt	24,481	22,889	22,503
Deferred income taxes	26,663	21,557	21,130
Warrant liabilities		85,215	85,068
Contingent liabilities	3,900	3,167	2,743
Other non-current liabilities	3,737	2,622	2,799
<b>Total liabilities</b>	<b>212,442</b>	<b>277,140</b>	<b>281,438</b>
Redeemable non-controlling interest	23,200	23,259	
<i>Shareholders' equity:</i>			
Ordinary Shares, \$0.01 par value; authorized 300,000,000; issued and outstanding 62,700,404, 74,000,912 and 77,186,382 at December 28, 2008, December 27, 2009, and	804	968	1,012



Edgar Filing: Tornier B.V. - Form S-1/A

April 4, 2010, respectively			
Additional paid-in capital	309,550	344,049	368,681
Accumulated deficit	(90,696)	(144,718)	(154,074)
Accumulated other comprehensive income	20,667	19,489	13,873
<b>Total shareholders' equity</b>	<b>240,325</b>	<b>219,788</b>	<b>229,492</b>
Total liabilities and shareholders' equity	\$ 475,967	\$ 520,187	\$ 510,930

The accompanying notes are an integral part of the consolidated financial statements.

F-3

---

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Consolidated Statements of Operations****(In Thousands, Except Per Share Amounts)**

	December 31, 2007	Year ended December 28, 2008	December 27, 2009	First quarter ended March 29, 2009 (unaudited)	April 4, 2010 (unaudited)
Revenue	\$ 145,369	\$ 177,370	\$ 201,462	\$ 50,855	\$ 61,843
Cost of goods sold	49,959	49,085	58,472	14,690	18,365
Gross profit	95,410	128,285	142,990	36,165	43,478
Operating expenses:					
Sales and marketing	78,628	103,285	112,017	26,854	33,381
General and administrative	17,976	21,742	20,790	5,213	6,526
Research and development	13,305	20,635	18,120	4,725	4,813
Amortization of intangible assets	7,946	11,186	15,173	2,615	2,997
Special charges			1,864		224
In-process research and development	15,107				
Total operating expenses	132,962	156,848	167,964	39,407	47,941
Operating loss	(37,552)	(28,563)	(24,974)	(3,242)	(4,463)
Other income (expense):					
Interest expense	(2,394)	(11,171)	(19,667)	(3,059)	(5,830)
Foreign currency transaction gain (loss)	(5,859)	1,701	3,003	4,063	(2,294)
Other non-operating (expense) income	(1,966)	(1,371)	(28,461)	(1,900)	214
Loss before income taxes	(47,771)	(39,404)	(70,099)	(4,138)	(12,373)
Income tax benefit	6,580	5,227	14,413	621	2,322
Consolidated net loss	(41,191)	(34,177)	(55,686)	(3,517)	(10,051)
Net loss attributable to non-controlling interest		(1,173)	(1,067)	(420)	(695)
Net loss attributable to Tornier	(41,191)	(33,004)	(54,619)	(3,097)	(9,356)
Accretion of non-controlling interest		(3,761)	(1,127)	(420)	(679)
Net loss attributable to ordinary shareholders	\$ (41,191)	\$ (36,765)	\$ (55,746)	\$ (3,517)	\$ (10,035)
Net loss per share:					
Basic and diluted	\$ (0.62)	\$ (0.51)	\$ (0.76)	\$ (0.05)	\$ (0.14)
Weighted-average ordinary shares outstanding:					
Basic and diluted	66,666	71,791	73,224	72,928	74,293

The accompanying notes are an integral part of the consolidated financial statements.



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Consolidated Statements of Cash Flows****(In Thousands, Except Per Share Amounts)**

	December 31, 2007	Year ended December 28, 2008	December 27, 2009	First quarter ended March 29, 2009 (unaudited)	April 4, 2010 (unaudited)
<b>Cash flows from operating activities:</b>					
Consolidated net loss	\$ (41,191)	\$ (34,177)	\$ (55,686)	\$ (3,517)	\$ (10,051)
Adjustments to reconcile consolidated net loss to cash provided by (used in) operating activities:					
Depreciation and amortization	15,582	22,331	29,732	5,659	6,809
In-process research and development	15,107				
Non-cash foreign currency (gain) loss	5,859	(317)	(3,898)	(3,934)	1,677
Deferred income taxes	(9,224)	(5,732)	(11,807)	55	(2,143)
Share-based compensation	2,836	3,672	3,913	682	1,559
Non-cash interest expense and discount amortization	1,047	9,320	17,202	2,479	5,197
Inventory obsolescence	5,112	4,340	7,831	1,963	1,724
Change in fair value of warrant liability			28,027	1,900	(147)
Other non-cash items affecting earnings		861	2,062	(67)	285
Changes in operating assets and liabilities, net of acquisitions:					
Accounts receivable	(6,772)	(5,007)	425	(2,885)	(1,438)
Inventories	984	(24,765)	(13,851)	(3,030)	(5,426)
Accounts payable and accruals	(2,768)	794	497	205	5,660
Other current assets and liabilities	4,472	3,372	(870)	1,639	(1,196)
Other non-current assets and liabilities		36	(160)	329	794
Net cash provided by (used in) operating activities	(8,956)	(25,272)	3,417	1,478	3,304
<b>Cash flows from investing activities:</b>					
Acquisition-related cash payments	(88,459)	(12,730)	(7,656)		(1,061)
Consolidation of non-controlling interest		1,038			
Additions of instruments	(8,596)	(12,365)	(13,465)	(3,499)	(2,717)
Purchases of property, plant and equipment	(8,342)	(13,467)	(11,109)	(2,290)	(4,579)
Net cash used in investing activities	(105,397)	(37,524)	(32,230)	(5,789)	(8,357)
<b>Cash flows from financing activities:</b>					
Change in short-term debt	11,161	(2,122)	(3,506)	1,128	3,536
Repayments of long-term debt	(3,040)	(2,869)	(9,881)	(3,108)	(2,609)
Proceeds from issuance of long-term debt	12,892	10,198	6,030	2,538	3,364
	6,606				

Edgar Filing: Tornier B.V. - Form S-1/A

Proceeds from issuance of mandatorily convertible bonds					
Proceeds from the issuance of notes payable and warrants		52,406	49,332		
Issuance of ordinary shares	94,267	8,874	2,882		541
Net cash provided by financing activities	121,886	66,487	44,857	558	4,832
Effect of exchange rate changes on cash and cash equivalents	1,080	310	577	(186)	563
Increase in cash and cash equivalents	8,613	4,001	16,621	(3,939)	342
Cash and cash equivalents:					
Beginning of period	8,734	17,347	21,348	21,348	37,969
End of period	\$ 17,347	\$ 21,348	\$ 37,969	\$ 17,409	\$ 38,311
Supplemental disclosure:					
Income taxes (refunded) paid	\$ 4,748	\$ 1,317	\$ (2,163)	\$ (2,804)	\$ (277)
Interest paid	\$ 1,347	\$ 1,865	\$ 1,854	\$ 580	\$ 630

The accompanying notes are an integral part of the consolidated financial statements.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Consolidated Statements of Shareholders' Equity and Comprehensive Loss****(In Thousands, Except Per Share Amounts)**

	Ordinary shares		Additional paid-in capital	Accumulated other comprehensive income (loss)	Accumulated deficit	Total
	Shares	Amount				
Balance at December 31, 2006	35,175	\$ 441	\$ 158,791	\$ 6,967	\$ (16,501)	\$ 149,698
Net loss					(41,191)	(41,191)
Foreign currency translation adjustments				20,928		20,928
Other				(84)		(84)
<b>Total comprehensive loss</b>						<b>(20,347)</b>
Other issuances of ordinary shares	331	5	1,680			1,685
Issuance of ordinary shares related to acquisitions	25,621	336	115,234			115,570
Modification of mandatorily convertible bonds			427			427
Share-based compensation			2,843			2,843
Balance at December 31, 2007	61,127	\$ 782	\$ 278,975	\$ 27,811	\$ (57,692)	\$ 249,876
Net loss					(33,004)	(33,004)
Foreign currency translation adjustments				(7,211)		(7,211)
Other				67		67
<b>Total comprehensive loss</b>						<b>(40,148)</b>
Accretion of non-controlling interest			(3,761)			(3,761)
Issuance of warrants related to debt						
Issuance of warrants related to debt financing, net of \$7,466 tax			21,812			21,812
Issuance of ordinary shares related to acquisitions	910	14	5,138			5,152
Issuance of ordinary shares related to stock option exercise	26		117			117
Other issuances of ordinary shares	637	8	3,597			3,605
Share-based compensation			3,672			3,672
Balance at December 28, 2008	62,700	\$ 804	\$ 309,550	\$ 20,667	\$ (90,696)	\$ 240,325
Net loss					(54,619)	(54,619)
Foreign currency translation adjustments				(1,032)		(1,032)
Other				(146)		(146)
<b>Total comprehensive loss</b>						<b>(55,797)</b>
Accretion of non-controlling interest			(1,127)			(1,127)
Adoption of ASC Topic 740					(266)	(266)
Adoption of ASC Topic 815			(21,812)		863	(20,949)
Issuance of ordinary shares related to stock option exercise	30		135			135
Conversion of mandatorily convertible debt	10,228	149	50,288			50,437
Other issuances of ordinary shares	1,043	15	2,731			2,746
Share-based compensation			4,284			4,284
Balance at December 27, 2009	74,001	\$ 968	\$ 344,049	\$ 19,489	\$ (144,718)	\$ 219,788
Net loss					(9,356)	(9,356)
Foreign currency translation adjustments				(5,616)		(5,616)

Edgar Filing: Tornier B.V. - Form S-1/A

Total comprehensive loss							(14,972)
Accretion of non-controlling interest						(679)	(679)
Issuance of ordinary shares related to acquisition of non-controlling interest	3,093	41	23,159				23,200
Issuance of ordinary shares to related parties	40	2	299				301
Issuance of ordinary shares related to stock option exercise	52	1	239				240
Share-based compensation			1,614				1,614
Balance at April 4, 2010 ( <i>Unaudited</i> )	77,186	\$ 1,012	\$ 368,681	\$	13,873	\$ (154,074)	\$ 229,492

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**1. Business Description**

Tornier B.V., or the Company, is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. Tornier refers to these surgeons as extremity specialists. Tornier sells to this extremity specialist customer base a broad line of joint replacement, trauma, sports medicine and orthobiologic products to treat extremity joints. Their motto of "specialists serving specialists" encompasses this focus. In certain international markets, Tornier also offers joint replacement products for the hip and knee. Tornier currently sells over 70 product lines in approximately 35 countries.

Tornier has a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology since its founding approximately 70 years ago in France by René Tornier. Tornier's history includes the introduction of the world's first porous orthopaedic hip implant, the application of the Morse taper, which is a reliable means of joining modular orthopaedic implants and, more recently, the introduction of the reversed shoulder implant in the United States. This track record of innovation over the decades stems from our close collaboration with leading orthopaedic surgeons and thought leaders throughout the world.

The Company was acquired in 2006 by an investor group led by Warburg Pincus (Bermuda) Private Equity IX, L.P., or WP Bermuda, and medical device investors, including The Vertical Group, L.P., or The Vertical Group, and Split Rock Partners, L.P., and Douglas W. Kohrs, Tornier's Chief Executive Officer.

During 2007, the Company made several acquisitions (see Note 5) that expanded its product offerings within the orthopaedic industry. The consolidated financial statements and accompanying notes present the consolidated results of the Company for each of the fiscal years in the three-year period ended December 27, 2009, December 28, 2008, and December 31, 2007.

The Company's global headquarters are located in Amsterdam, The Netherlands. The Company's U.S. headquarters are in Edina, Minnesota, and its U.S. sales and distribution operations are in Stafford, Texas. The Company has manufacturing, research and development, sales and distribution and administrative activities in Grenoble, France. The Company also has manufacturing operations in Ireland. The Company has other sales and distribution operations in Australia, Germany, Italy, The Netherlands, Spain, the United Kingdom, Scandinavia and Switzerland. The Company also has other research and development and quality and regulatory functions located in Warsaw, Indiana, and Beverly, Massachusetts.

In 2009, the Company consolidated its U.S. operations and closed quality and regulatory and sales and marketing functions in San Diego, California and manufacturing operations in Beverly, Massachusetts. See Note 19 for further details.

In 2008, the Company changed its fiscal reporting periods to 13-week quarters and a 52-week annual period, which ends on the Sunday nearest to and preceding December 31. The 2008 fiscal year began on January 1, 2008 and ended on December 28, 2008. This change did not have a material effect on the consolidated financial statements as compared to the prior years. During the first quarter of 2010 the Company added a 14<sup>th</sup> week to the quarterly reporting period in order to make up for past annual periods that included only 364 days under the 52-week annual period rather than a full 365 day annual period. As a result, the first quarter of 2010 includes an extra week of operations as compared to the first quarter of 2009.



Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies**

**Consolidation**

The consolidated financial statements include the accounts of the Company and all of its wholly and majority owned subsidiaries. Additionally, the Company has consolidated the assets and liabilities of a variable interest entity (VIE), C2M Medical Inc. (C2M), for which the Company is deemed to be the primary beneficiary. In the first quarter of 2010, the Company exercised its option to acquire the outstanding shares of C2M in exchange for Tornier ordinary shares. Upon exercise of the purchase option, a non-controlling interest in C2M no longer existed. The balance of the non-controlling interest was eliminated and the fair value of the shares issued in the acquisition, \$23.2 million, was recorded as a component of shareholders' equity. Refer to Note 16 for further details. In consolidation, all material intercompany accounts and transactions are eliminated.

**Unaudited Interim Financial Information**

The accompanying balance sheet as of April 4, 2010, statements of operations and cash flows for the first quarter ended March 29, 2009, and first quarter ended April 4, 2010, Statement of Shareholders' Equity and Comprehensive Loss and related financial data and other information disclosed in these notes to the financial statements as of April 4, 2010, and for the first quarter ended March 29, 2009, and first quarter ended April 4, 2010, are unaudited. The unaudited interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles. In the opinion of the Company's management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring accruals, necessary for the fair presentation of the Company's financial position, results of operations and cash flows for the first quarter ended March 29, 2009, and first quarter ended April 4, 2010. The results for the first quarter ended April 4, 2010, are not necessarily indicative of the results of operations to be expected for the year ending January 2, 2011.

**Use of Estimates**

The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (GAAP) and include amounts that are based on management's best estimates and judgments. Actual results could differ from those estimates.

**Foreign Currency Translation**

The functional currencies for the Company and all of the Company's wholly owned subsidiaries are their local currencies. The reporting currency of the Company is the U.S. dollar. Accordingly, the consolidated financial statements of the Company and its international subsidiaries are translated into U.S. dollars using current exchange rates for the consolidated balance sheets and average exchange rates for the consolidated statements of operations and cash flows. Unrealized translation gains and losses are included in accumulated other comprehensive income (loss) in shareholders' equity. When a transaction is denominated in a currency other than the subsidiary's functional currency, the Company recognizes a transaction gain or loss in net earnings. Foreign currency transaction gains (losses) included in net earnings were \$(6.5) million, \$0.9 million and \$3.0 million during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, and \$4.1 million and \$(2.3) million for the first quarter ended March 29, 2009 and first quarter ended April 4, 2010, respectively. Included

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies (Continued)**

in the \$3.0 million of foreign currency transaction gain recognized in 2009 is \$3.9 million related to the revaluation of warrants carried as a liability on the consolidated balance sheets, which are denominated in a currency other than Tornier BV's functional currency. The first quarter ended April 4, 2010, also included \$5.7 million of foreign currency transaction loss related to the revaluation of the warrants. See Note 8 for further explanation.

**Revenue Recognition**

The Company derives its revenue from the sale of medical devices that are used by orthopaedic surgeons who treat diseases and disorders of extremity joints including the shoulder, elbow, wrist, hand, ankle and foot. The Company's revenue is generated from sales to two types of customers: healthcare institutions and distributors. Sales to healthcare institutions represent the majority of the Company's revenue. The Company utilizes a network of independent commission-based sales agencies for sales in the United States and a combination of direct sales organizations, independent sales representatives and distributors for sales outside the United States. Revenue from sales to healthcare institutions is recognized at the time of surgical implantation. The Company generally records revenue from sales to its distributors at the time the product is shipped to the distributor. Distributors, who sell the products to their customers, take title to the products and assume all risks of ownership at time of shipment. The Company's distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. In certain circumstances, the Company may accept sales returns from distributors and in certain situations in which the right of return exists, the Company estimates a reserve for sales returns and recognizes the reserve as a reduction of revenue. The Company bases its estimate for sales returns on historical sales and product return information including historical experience and trend information. The Company's reserve for sales returns has historically been immaterial. The Company charges its customers for shipping and handling and recognizes these amounts as part of revenue.

**Shipping and Handling**

Amounts billed to customers for shipping and handling of products are reflected in revenue and are not significant. Costs related to shipping and handling of products are expensed as incurred, are included in sales and marketing expense and were \$3.5 million, \$3.7 million and \$3.4 million for the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively.

**Cash and Cash Equivalents**

Cash equivalents are highly liquid investments with an original maturity of three months or less. The carrying amount reported in the consolidated balance sheets for cash and cash equivalents is cost, which approximates fair value.

**Accounts Receivable**

Accounts receivable consist of trade customer receivables. The Company maintains an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. The Company makes estimates regarding the future ability of its customers to make required payments based on historical credit experience, delinquency and expected future trends. The majority of the

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies (Continued)**

Company's receivables are from health care institutions, many of which are government-funded. The Company's allowance for doubtful accounts was \$2.2 million, \$2.7 million and \$2.4 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively.

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers' credit history before extending credit and by monitoring credit exposure on a regular basis. The allowance for doubtful accounts is established based on factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. As of December 27, 2009, and April 4, 2010, there were no customers that accounted for more than 10% of accounts receivable.

**Advertising**

The Company records advertising expenses as a component of sales and marketing expenses in the period in which they are incurred. The Company incurred \$2.3 million, \$2.6 million and \$1.9 million in advertising costs during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively.

**Royalties**

The Company pays royalties to individuals and companies that have developed and retain the legal rights to the technology or have assisted the Company in the development of technology or new products. These royalties are based on sales and are reflected as a sales and marketing expense in the consolidated statements of operations.

**Inventories**

Inventories, net of reserves for obsolete and slow-moving goods, are stated at the lower of cost or market value. Cost is determined on a first-in, first-out (FIFO) basis. Inventory is held both within the Company and by third-party distributors on a consignment basis. Inventories consist of raw materials, work-in-process and finished goods. Finished goods inventories are held in the United States, Europe and Australia and consist primarily of implants. Manufactured and assembled instruments that have not been completed and placed in service are also included in the inventory balances and are reclassified as instruments, net in the consolidated balance sheets upon being made available for service.

Existing inventory was recorded at fair value at the date of the Company's recapitalization (July 18, 2006). The initial increase in inventory from historical book value to fair value was \$26.8 million. The fair value of the inventory acquired in the Company's 2007 acquisitions also exceeded historical book value by \$1.2 million at the dates of acquisition. Approximately \$16.7 million of this additional value was expensed in cost of goods sold during the year ended December 31, 2007. Sales of stepped-up inventory did not impact cost of goods sold in the fiscal years ended December 28, 2008, or December 27, 2009, or in the first quarter ended April 4, 2010.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****2. Significant Accounting Policies (Continued)**

Inventory balances consist of the following (in thousands):

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Raw materials	\$ 7,387	\$ 7,384	\$ 5,913
Work-in-process	7,372	7,773	7,337
Finished goods	60,243	67,559	69,745
Total	\$ 75,002	\$ 82,716	\$ 82,995

The Company regularly reviews inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incurs charges to write down inventories to their net realizable value. The Company's review of inventory for excess and obsolete quantities is based primarily on the estimated forecast of product demand, production requirements and introduction of new products. The Company recognized \$5.1 million, \$4.3 million and \$7.8 million of expense for excess or obsolete inventory in earnings during the fiscal years ended December 31, 2007, December 28, 2008, and December 29, 2009, respectively, and \$1.9 million and \$1.7 million for the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively. Additionally, the Company had \$12.4 million and \$13.3 million in inventory held on consignment at December 28, 2008, and December 27, 2009, respectively.

**Property, Plant and Equipment**

Property, plant and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method based on estimated useful lives of ten to 39 years for buildings and improvements and two to eight years for machinery and equipment. The cost of maintenance and repairs is expensed as incurred. The Company reviews property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset's carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. No impairment losses were recognized during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, or for the first quarter ended April 4, 2010. See Note 5 for additional detail.

**Instruments**

Instruments are handheld devices used by orthopaedic surgeons during joint replacement and other surgical procedures to facilitate the implantation of the Company's products. Instruments are recognized as long-lived assets once they have been placed in service. Instruments that have not been placed in service are carried at cost, net of allowances for excess and obsolete instruments, and are included in inventories on the consolidated balance sheets. The balances of instruments that have not been placed in service as of December 28, 2008, December 27, 2009 and April 4, 2010 were \$4.5 million, \$4.2 million and \$4.7 million, respectively. Once placed in service, instruments are carried at cost, less accumulated depreciation. Depreciation is computed using the straight-line method based

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****2. Significant Accounting Policies (Continued)**

on average estimated useful lives. Estimated useful lives are determined principally in reference to associated product life cycles, and average five years. The Company reviews instruments for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset's carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. Instruments included in long-term assets on the consolidated balance sheets are as follows (in thousands):

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Instruments	\$ 33,554	\$ 47,376	\$ 47,896
Accumulated depreciation	(11,235)	(21,021)	(22,160)
Instruments, net	\$ 22,319	\$ 26,355	\$ 25,736

The Company provides instruments to surgeons for use in surgeries and retains title to the instruments throughout the implantation process. As instruments are used as tools to assist surgeons, depreciation of instruments is recognized as a sales and marketing expense. Instrument depreciation expense was \$4.0 million, \$6.3 million, and \$9.4 million during the fiscal years ended December 31, 2007, December 28, 2008 and December 27, 2009, respectively, and \$1.9 million and \$2.4 million during the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively.

**Goodwill**

Goodwill is recognized as the excess of the purchase price over the fair value of net assets of businesses acquired. Goodwill is not amortized, but is subject to impairment tests. The Company performs impairment tests annually unless circumstances otherwise dictate. Based on the Company's single business approach to decision-making, planning and resource allocation, management has determined that the Company has only one reporting unit for the purpose of evaluating goodwill for impairment. The Company performs its annual goodwill impairment test as of the first day of the fourth quarter of its fiscal year. Impairment tests are done by comparing the reporting unit's fair value to its carrying amount to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit's goodwill is less than the carrying value of the reporting unit's goodwill. The fair value of the reporting unit and the implied fair value of goodwill are determined based on widely accepted valuation techniques, primarily the income approach, as appropriate. The calculation of the fair value of the reporting unit involves significant management judgment, including the valuation of the Company's shares. The Company's shares are not traded in an active market, and therefore, this assumption is unobservable. No goodwill impairment losses were recorded during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, or for the first quarter ended April 4, 2010 as the fair value of the reporting unit significantly exceeded its carrying value.

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies (Continued)**

**Intangible Assets**

Intangible assets with an indefinite life, including certain trademarks and trade names, are not amortized. The useful lives of indefinite-life intangible assets are assessed annually to determine whether events and circumstances continue to support an indefinite life. Intangible assets with an indefinite life are tested for impairment annually or whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized if the carrying amount exceeds the estimated fair value of the asset. The amount of the impairment loss to be recorded would be determined based on the excess of the asset's carrying value over its fair value. No impairment losses were recorded during the fiscal years ended December 31, 2007, December 28, 2008, or December 27, 2009, or for the first quarter ended April 4, 2010.

Intangible assets with a finite life, including developed technology, customer relationships, and patents and licenses, are amortized on a straight-line basis over their estimated useful lives, ranging from ten to 20 years. Intangible assets with a finite life are tested for impairment whenever events or circumstances indicate that the carrying amount may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset are less than the asset's carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset exceeds its fair value. During the year ended December 27, 2009, an impairment loss of \$3.4 million was recognized when developed technology from acquired entities was abandoned and is included in amortization of intangible assets in the consolidated statements of operations.

**Derivative Financial Instruments**

All of the Company's derivative instruments are recorded in the accompanying consolidated balance sheets as either an asset or liability and are measured at fair value. The changes in the derivative's fair value are recognized in current period earnings.

Changes to the fair value of foreign currency derivative instruments designated as economic hedges resulted in charges of \$0.6 million and \$0.7 million for the fiscal years ended December 31, 2007, and December 28, 2008. These charges were classified as foreign currency transaction loss on the consolidated statements of operations. Any related derivative assets are recorded as other current assets in the consolidated balance sheets. There were no outstanding foreign currency derivative instruments at December 27, 2009, or April 4, 2010.

The Company also issued warrants in 2008 and 2009 for ordinary shares that are recognized as warrant liabilities on the consolidated balance sheets. Changes in the fair value of these warrants resulted in other non-operating income (expense) of (\$28.0) million for the year ended December 27, 2009, and (\$1.9) million and \$0.1 million for the first quarter ended March 29, 2009, and first quarter ended April 4, 2010, respectively. See Note 8 for further information.

**Research and Development**

All research and development costs are expensed as incurred.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****2. Significant Accounting Policies (Continued)****Income Taxes**

Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances for deferred tax assets are recognized if it is more likely than not that some component or all of the benefits of deferred tax assets will not be realized.

The Company adopted the provisions of FASB Accounting Standards Codification (ASC) Topic 740 related to accounting for uncertainty in income taxes on December 29, 2008. As a result of the implementation of these provisions, the Company recognized a \$0.3 million increase in the liability for unrecognized tax benefits, which was accounted for as an increase to the December 29, 2008 balance of accumulated deficit. The Company accrues interest and penalties related to unrecognized tax benefits in the Company's provision for income taxes. At December 27, 2009, and April 4, 2010, accrued interest and penalties were immaterial.

**Other Comprehensive Income (Loss)**

Other comprehensive income (loss) refers to revenues, expenses, gains, and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings, as these amounts are recorded directly as an adjustment to shareholders' equity. Other comprehensive income (loss) is comprised mainly of foreign currency translation adjustments. These amounts are presented in the consolidated statements of shareholders' equity and comprehensive loss.

The reconciliation of net loss to comprehensive loss is as follows:

	<b>First quarter ended</b>	
	<b>March 29, 2009</b>	<b>April 4, 2010</b>
	(\$ in thousands)	
Net loss	\$ (3,097)	\$ (9,356)
Foreign currency translation adjustments	(9,877)	(5,616)
<b>Total Comprehensive Loss</b>	<b>\$ (12,974)</b>	<b>(14,972)</b>

**Share-Based Compensation**

The Company accounts for share-based compensation in accordance with ASC Topic 718, formerly Statement of Financial Accounting Standards (SFAS) No. 123(R), *Share-Based Payments Revised*, which requires share-based compensation cost to be measured at the grant date based on the fair value of the award and recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. The determination of the fair value of share-based payment awards, such as options, on the date of grant using an option-pricing model is affected by the Company's share price, as well as assumptions regarding a number of complex and subjective variables, which include the expected life of the award, the expected share price volatility over the expected life of the awards, expected dividend yield and risk-free interest rate.

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies (Continued)**

**Fair Value of Financial Instruments**

The Company adopted ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC Topic 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company's principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC Topic 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity's own assumptions based on market data and the entity's judgments about the assumptions that that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances.

In October 2008, the FASB clarified ASC Topic 820 when an active market does not exist, stating that it may be appropriate to use unobservable inputs to determine fair value. The carrying value of the Company's cash and cash equivalents, accounts receivable and accounts payable approximates the fair value of these financial instruments at December 28, 2008, December 27, 2009, and April 4, 2010. Assets and liabilities measured at fair value are done so on a recurring basis. U.S. GAAP requires fair value measurements to be classified and disclosed in one of the following three categories:

*Level 1* Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.

*Level 2* Assets and liabilities determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

*Level 3* Assets and liabilities that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the asset or liability. The prices are determined using significant unobservable inputs or valuation techniques.

As of December 27, 2009, the Company has warrants that are classified as warrant liabilities that have a fair value of \$85.2 million. The fair value of the Company's share price is a significant input into this valuation, which is unobservable in the market. Therefore, these warrants are considered Level 3 instruments. See Note 8 for further information.

**Recent Accounting Pronouncements**

The Company adopted the FASB's ASC Topic 105 as the single official source of authoritative, non-governmental U.S. GAAP in the United States. On the effective date, all then-existing non-SEC accounting literature and reporting standards were superseded and deemed non-authoritative. The adoption of this pronouncement did not have a material impact on the Company's consolidated financial statements; however, ASC Topic 105 affected the way that the Company references authoritative guidance in the notes to the consolidated financial statements.



Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies (Continued)**

In December 2007, the FASB issued ASC Topic 805, formerly SFAS No. 141(R), *Business Combinations*. ASC Topic 805 establishes principles and requirements for how an acquirer in a business combination recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed and any controlling interest; recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. ASC Topic 805 is to be applied prospectively to business combinations for which the acquisition date is during or after fiscal year 2009. Additionally, ASC Topic 805 requires that changes to tax accounting related to acquisitions prior to the effective date of this guidance be recorded in the consolidated statements of operations rather than goodwill. The adoption of this guidance did not have a material impact on the Company's current consolidated financial statements or results of operations.

In December 2007, the FASB also issued ASC Topic 810, formerly SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB 51*. ASC Topic 810 changes the accounting and reporting for minority interests, which are recharacterized as non-controlling interests and classified as a component of equity. ASC Topic 810 required retroactive adoption of the presentation and disclosure requirements for existing minority interests. The guidance became effective for fiscal years beginning on or after December 15, 2008, and interim periods within those fiscal years. The impact of adoption changed the presentation of non-controlling interests on the consolidated financial statements but did not have a material effect on the consolidated balance sheets, the consolidated statements of operations or the consolidated statements of cash flows.

In March 2008, the FASB issued ASC Topic 815, formerly SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities, An amendment of SFAS No. 133*. ASC Topic 815 requires increased disclosure of the Company's derivative instruments and hedging activities, including how derivative instruments and hedging activities affect the consolidated statements of operations, balance sheets and cash flows. The guidance was effective for fiscal years beginning on or after December 15, 2008, and interim periods within those fiscal years. The adoption of this guidance did not have any impact on the Company's financial position or results of operations.

ASC Topic 740 includes certain provisions that clarify the accounting for uncertainty in income taxes recognized in a company's financial statements by defining the criteria that an individual tax position must meet in order to be recognized in the financial statements. These provisions require that the tax effects of a position be recognized only if it is more likely than not to be sustained based solely on the technical merits as of the reporting date. These provisions further require that interest to be paid on the underpayment of taxes should be accrued on the difference between the amount claimed or expected to be claimed on the return and the tax benefit recognized in the financial statements. These provisions also require additional disclosures of unrecognized tax benefits, including a reconciliation of the beginning and ending balance. On December 30, 2008, the FASB further delayed the effective date of this guidance for certain non-public enterprises until annual financial statements for fiscal years beginning after December 15, 2008. The Company adopted the provisions of ASC Topic 740 in 2009. As a result of the implementation of these provisions, the Company recognized a \$0.3 million increase in the liability for unrecognized tax benefit, which was accounted for as an increase to the December 29, 2008, balance of accumulated deficit. Refer to Note 11 for details regarding the impact of adoption.

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**2. Significant Accounting Policies (Continued)**

In June 2008, the Emerging Issues Task Force (EITF) issued ASC Topic 815-40-15, formerly EITF Issue 07-5, *Determining Whether an Instrument (or an Embedded Feature) Is Indexed to an Entity's Own Stock*. ASC Topic 815-40-15 addresses how an entity should determine if an instrument (or an embedded feature), such as the warrants issued by the Company in 2008 and 2009, is indexed to its own stock. The EITF reached a consensus that establishes a two-step approach to making this assessment. In the first step, an entity evaluates any contingent exercise provisions. In the second step, an entity will evaluate the instruments' settlement provisions. This guidance became effective for fiscal year 2009 for the Company and is accounted for as a change in accounting principle through prospective application, with the cumulative effect of adoption of \$(0.9) million being recognized at the beginning of the year as a reduction in accumulated deficit. In addition, adoption of this guidance required that warrants issued by the Company in 2008 be reclassified from equity to a liability. These warrants, as well as warrants issued in 2009, are now carried at fair value on the consolidated balance sheets as warrant liabilities. Subsequent to adoption, these liabilities are adjusted to fair value through current period earnings. See Note 8 for further discussion.

ASC Topic 808-10 (issued as EITF Issue 07-1, *Accounting for Collaborative Arrangements*) requires participants in a collaborative arrangement (sometimes referred to as a "virtual joint venture") to present the results of activities for which they act as the principal on a gross basis and to report any payments received from (made to) other collaborators based on other applicable GAAP or, in the absence of other applicable GAAP, based on analogy to authoritative literature or a reasonable, rational and consistently applied accounting policy election. This guidance also requires significant disclosures related to collaborative arrangements. The adoption of this standard did not have material impact on the Company's financial statements.

In May 2009, the FASB issued ASC Topic 855, formerly SFAS No. 165, *Subsequent Events*, on management's assessment of subsequent events. This guidance clarifies that management must evaluate, as of each reporting period, events or transactions that occur for potential recognition or disclosure in the financial statements and the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date. The implementation of ASC Topic 855 did not have a material impact on the Company's financial statements.

**3. Share-Based Compensation**

Share-based awards are granted under the Company's stock option plan. Under this plan, options to purchase ordinary shares are the only type of share-based compensation awards granted. These options generally have graded vesting periods of four years and expire ten years after the grant date. The options are granted with exercise prices equal to the fair value of the Company's shares on the date of grant. The Company recognizes compensation expense for these options on a straight-line basis over the vesting period. Share-based compensation expense is included in cost of goods sold, sales and marketing, research and development, and general and administrative expenses on the consolidated

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****3. Share-Based Compensation (Continued)**

statements of operations. Below is a summary of the allocation of share-based compensation (in thousands):

	December 31, 2007	Year ended December 28, 2008	December 27, 2009
Cost of goods sold	\$ 221	\$ 341	\$ 77
Sales and marketing	794	1,034	1,306
General and administrative	1,608	2,051	2,250
Research and development	213	246	280
<b>Total</b>	<b>\$ 2,836</b>	<b>\$ 3,672</b>	<b>\$ 3,913</b>

The Company recognizes the fair value of an award of equity instruments granted in exchange for employee services as a cost of those services.

The Company estimates the fair value of options using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of estimates, including the expected life of options, expected price volatility, the risk-free interest rate and the expected dividend yield. The Company calculates the expected life of options using the SEC's allowed short-cut method. The expected share price volatility assumption was estimated based upon historical volatility of the ordinary shares of a group of the Company's peers that are publicly traded. The risk-free interest rate was determined using U.S. Treasury rates with terms consistent with the expected life of the options. Expected dividend yield is not considered, as the Company has never paid dividends and has no plans of doing so during the term of the options. The Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data when available to estimate pre-vesting option forfeitures, and records share-based compensation expense only for those awards that are expected to vest. All options are amortized and recognized as compensation expense on a straight-line basis over their respective requisite service periods, which are generally the vesting periods. Total compensation cost included in the consolidated statements of operations for employee share-based payment arrangements was \$2.5 million, \$3.3 million and \$3.4 million during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, and \$0.6 million and \$1.3 million for the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively. Additionally, \$0.4 million and \$0.4 million were included in inventory as a capitalized cost as of December 27, 2009, and April 4, 2010, respectively. Capitalized costs in inventory as of December 28, 2008, was immaterial.

The weighted-average fair value of the Company's options granted to employees was \$2.13, \$2.17 and \$2.41 per share, in 2007, 2008 and 2009, respectively. There were no options granted during the first quarter ended April 4, 2010. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:

As of December 27, 2009, the Company had \$7.2 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted to employees under the stock option plan. That cost is expected to be recognized over a weighted-average service period of 2.2 years. Shares reserved for future compensation grants were \$1.6 million and \$0.4 million at December 28,

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****3. Share-Based Compensation (Continued)**

2008, and December 27, 2009, respectively. Exercise prices for options outstanding at December 27, 2009, ranged from \$4.46 to \$6.00.

	2007	2008	2009
Risk-free interest rate	4.5%	2.5%	1.8%
Expected life in years	6.0	6.0	6.0
Expected volatility	36.8%	35.1%	41.8%
Expected dividend yield	0.0%	0.0%	0.0%

A summary of the Company's employee stock option activity is as follows:

	Shares (in thousands)	Weighted-average exercise price	Weighted-average remaining contractual life (in years)
Outstanding at December 31, 2006	2,599	\$ 4.46	9.6
Granted	2,838	4.78	
Exercised			
Forfeited or expired	(21)	4.63	
Outstanding at December 31, 2007	5,416	4.63	8.9
Granted	1,633	5.66	
Exercised	(26)	4.48	
Forfeited or expired	(185)	4.54	
Outstanding at December 28, 2008	6,838	4.87	8.2
Granted	1,522	5.65	
Exercised	(30)	4.50	
Forfeited or expired	(371)	4.80	
Outstanding at December 27, 2009	7,959	5.02	7.6

During the years ended December 31, 2007, and December 27, 2009, the Company issued 514,000 and 176,500 options, respectively, to non-employees in exchange for consulting services. No options were issued to non-employees during the year ended December 28, 2008. The options issued in 2007 and 2009 had weighted-average exercise prices of \$4.78 and \$5.63, respectively. Approximately 364,000 of these non-employee options were exercisable at December 27, 2009. None of these options were exercised in 2009. These options have vesting periods of either two or four years and expire ten years after the grant date. The measurement date for options granted to non-employees is often after the grant date, which often requires updates to the estimate of fair value until the services are performed. The weighted-average fair value of each non-employee option granted was \$2.54 and \$2.53 in 2007 and 2009, respectively. The amount of expense related to non-employee options was \$0.3 million, \$0.4 million and \$0.5 million for the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively. The amount of expense related to non-employee options was \$0.1 million and \$0.3 million during the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively.



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****4. Acquisitions****Nexa Orthopedics, Inc.**

On February 27, 2007, the Company acquired all of the outstanding stock of Nexa Orthopedics, Inc. (Nexa), a privately held orthopaedics company, for a cash payment of \$72.5 million plus certain transaction costs. Nexa was a California-based company that developed and marketed medical devices for orthopaedic and podiatric surgeons. The acquisition of Nexa increased Tornier's product offerings within the extremities marketplace. The results of operations for Nexa are included in the Company's consolidated statement of operations for the period since February 27, 2007. During 2007, Nexa was merged into the Company's existing U.S. operations.

The purchase agreement also provided for additional payments to be made in cash upon the completion of certain milestones. In 2009, a payment of \$0.3 million was made in accordance with the contract. The purchase price of \$73.3 million includes \$72.5 million cash paid at closing, \$0.3 million for milestone payments from Nexa's previous acquisitions and transaction costs of \$0.5 million. The purchase price has been allocated based on the fair values of the assets acquired and liabilities assumed as follows (in thousands):

Current assets, excluding inventory	\$ 2,428
Inventories	2,948
Acquired in-process research and development	12,300
Instruments	951
Fixed assets	1,284
Identifiable intangible assets:	
Developed technology	\$ 10,500
Customer relationships	14,700
Tradename	300
Total identifiable intangible assets	25,500
Other assets	387
Goodwill (non-deductible)	34,722
Accounts payable and accrued expenses	(4,871)
Capital leases	(277)
Deferred tax liabilities, net	(1,886)
Other liabilities	(173)
	\$ 73,313

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**4. Acquisitions (Continued)**

In connection with the acquisition of Nexa, the Company completed a valuation of the intangible assets acquired. The value assigned to purchased in-process research and development (IPR&D) was \$12.3 million. Accordingly, these amounts were expensed in the period immediately following consummation of the acquisition of Nexa. The allocation of the \$12.3 million charge consisted of \$4.8 million related to Pyrocarbon Radial Head and \$7.5 million related to a new shoulder product. The value was determined by estimating the costs to develop the IPR&D into commercially viable products, estimating the resulting cash flows from such projects and discounting the net cash flows back to their present value. The discount rate utilized in discounting the net cash flows from IPR&D was 15% for Nexa products. This discount rate reflects uncertainties surrounding the successful development of the IPR&D.

In 2009, the Company made an additional milestone payment of \$0.3 million related to Nexa's previous acquisitions, which was recognized as additional goodwill.

**Axya Medical, Inc.**

On February 27, 2007, the Company acquired Axya Medical, Inc. (Axya), a privately held sports medicine company, by issuing approximately 5.8 million ordinary shares of the Company in exchange for all of the outstanding shares of Axya. All previous shareholders of Axya were shareholders of the Company at the time of acquisition. Axya was a Massachusetts-based company that developed knotless fixation systems for shoulder surgeons. The acquisition of Axya further integrated the Company's extremity products into the sports medicine market. The results of operations for Axya are included in the Company's consolidated statement of operations for the period since February 27, 2007. During 2007, Axya was merged into the Company's existing U.S. operations.

Because this transaction was between entities with common shareholders, the determination of the purchase price and allocation thereof was accounted for at partial carry-over basis. The ownership interest in Axya held by the Company's controlling shareholder is recorded at historical basis, and the remaining interests were recognized at fair value because no individual shareholder controlled Axya at the time of the acquisition.

The result of this accounting treatment is a purchase price of approximately \$22.7 million based on a \$9.2 million historical carryover value assigned to shares issued to the Company's controlling shareholder, \$13.4 million for the Company's ordinary shares issued to other owners of Axya at a fair value of \$4.69 per share and transaction costs of \$0.1 million. The fair value of the Company's ordinary shares was based on the price of ordinary shares sold in contemporaneous sales of the Company's ordinary shares to existing shareholders in order to raise working capital.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****4. Acquisitions (Continued)**

The purchase price has been allocated based on a combination of historical cost and the fair values of the assets acquired and liabilities assumed as follows (in thousands):

Current assets, excluding inventory	\$ 761
Inventories	1,128
Acquired IPR&D	2,807
Fixed assets	324
Identifiable intangible assets:	
Developed technology	\$ 8,639
Customer relationships	807
Non-compete agreement	487
Trade name	59
 Total identifiable intangible assets	 9,992
Other assets	24
Goodwill (non-deductible)	8,700
Accounts payable and accrued expenses	(1,066)
	 \$ 22,670

In connection with the acquisition of Axya, the Company completed a valuation of the intangible assets acquired. The value assigned to purchased IPR&D was \$2.8 million of the purchase price for Axya. Accordingly, these amounts were expensed in the period immediately following consummation of the acquisition. The allocation of the \$2.8 million charge consisted of \$1.6 million related to thermal welder technology, \$0.8 million related to mesh technology and \$0.4 million related to suture passer technology. The value was determined by estimating the costs to develop the IPR&D into commercially viable products, estimating the resulting cash flows from such projects and discounting the net cash flows back to their present value. The discount rate utilized in discounting the net cash flows from IPR&D was 22% for Axya products. This discount rate reflects uncertainties surrounding the successful development of the IPR&D.

**DVO Extremity Solutions, LLC**

On March 20, 2007, the Company acquired substantially all of the assets of DVO Extremity Solutions, LLC (DVO), a privately held orthopaedics company based in Warsaw, Indiana, for a cash payment of \$11.6 million plus certain transaction costs. DVO's main products were the DVO Volar Plate, a fixed-angle plate used to repair distal radius fractures, and the Mifx Dorsal IM Plate, used in dorsally displaced unstable distal radius fractures. The acquisition of the assets of DVO continued to expand the Company's orthopaedic extremity product offering. The results of operations for DVO are included in the Company's consolidated statement of operations for the period from March 20, 2007, to December 31, 2007. During 2007, DVO was merged into the Company's existing U.S. operations.

The purchase agreement also provided for additional contingent payments to be made to the former DVO shareholders equal to two times the revenue generated from acquired DVO product offerings during a stipulated 12-month period. The purchase agreement also allowed the former DVO shareholders the option to purchase ordinary shares of the Company with the cash received from these



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****4. Acquisitions (Continued)**

contingent payments at a price equal to the fair value of the Company's ordinary shares at the date of the respective contingent payment. In 2008, the first contingent payment of \$9.1 million was made in accordance with the contract. In 2009, the second contingent payment of \$3.5 million was made. The payments were made in cash, and the additional purchase price was recorded as an increase to goodwill. Subsequent to the payment of the contingent consideration, the previous owners of DVO purchased 168,437 and 910,206 ordinary shares of the Company at \$5.66 per share in 2009 and 2008, respectively. There are no remaining future contingent payments.

The initial purchase price of \$11.8 million includes \$11.6 million paid at closing and transaction costs of \$0.2 million and has been allocated based on the fair values of the assets acquired and liabilities assumed as follows (in thousands):

Current assets, excluding inventory	\$	202
Inventories		4,103
Instruments		326
Fixed assets		186
Identifiable intangible assets:		
Developed technology	\$	3,100
Customer relationships		900
Tradename		500
Total identifiable intangible assets		4,500
Other assets		14
Goodwill (non-deductible)		3,224
Accounts payable and accrued expenses		(782)
	\$	11,773

**5. Property, Plant and Equipment**

Property, plant and equipment balances are as follows (in thousands):

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Land	\$ 2,283	\$ 2,337	\$ 2,210
Building and improvements	7,965	10,630	9,998
Machinery and equipment	16,475	19,604	20,295
Furniture, fixtures and office equipment	12,915	16,092	15,874
Software	3,187	4,035	3,910
Construction in progress		3,079	4,515
	42,825	55,777	56,802
Accumulated depreciation	(14,199)	(20,701)	(20,839)
Property, plant and equipment, net	\$ 28,626	\$ 35,076	\$ 35,963



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****5. Property, Plant and Equipment (Continued)**

In 2009, the Company leased a new manufacturing facility in Ireland. In conjunction with moving into the leased building, the Company made approximately \$2.4 million in leasehold improvements that are included in fixed assets as of December 27, 2009.

Depreciation expense recorded on property, plant and equipment was \$3.8 million, \$5.3 million and \$5.7 million during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively, and \$1.4 million and \$1.5 million for the first quarter ended March 29, 2009 and the first quarter ended April 4, 2010, respectively.

During the fiscal year ended December 27, 2009, the Company's majority-owned subsidiary, SCI Calyx, acquired a combined manufacturing and office facility in Grenoble, France, for approximately \$6.1 million. See Note 17 for additional detail.

**6. Goodwill and Other Intangible Assets**

The following table summarizes the changes in the carrying amount of goodwill (in thousands):

Balance at December 31, 2007	\$ 127,820
Contingent payment on acquisition	9,051
Reversal of acquired valuation allowance	(2,411)
Other	195
Foreign currency translation	(4,023)
 Balance at December 28, 2008	 130,632
Contingent payment on acquisition	3,836
Goodwill from acquisitions	171
Other	76
Foreign currency translation	2,234
 Balance at December 27, 2009	 136,949
Contingent payment on acquisition	636
Foreign currency translation	(5,243)
 Balance at April 4, 2010 ( <i>Unaudited</i> )	 \$ 132,342

The goodwill balance at December 27, 2009, contains \$15.1 million of goodwill that qualifies for future tax deductions.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****6. Goodwill and Other Intangible Assets (Continued)**

The components of identifiable intangible assets are as follows (in thousands):

	Gross value	Accumulated amortization	Net value
<b>Balances at December 28, 2008</b>			
Intangible assets subject to amortization:			
Developed technology	\$ 77,636	\$ (9,692)	\$ 67,944
Customer relationships	64,024	(10,495)	53,529
Other	2,387	(776)	1,611
Intangible assets not subject to amortization:			
Tradename	10,390		10,390
Total	\$ 154,437	\$ (20,963)	\$ 133,474

	Gross value	Accumulated amortization	Net value
<b>Balances at December 27, 2009</b>			
Intangible assets subject to amortization:			
Developed technology	\$ 79,252	\$ (19,134)	\$ 60,118
Customer relationships	65,360	(15,017)	50,343
Licenses	3,780	(470)	3,310
Other	2,172	(1,404)	768
Intangible assets not subject to amortization:			
Tradename	10,682		10,682
Total	\$ 161,246	\$ (36,025)	\$ 125,221

	Gross value (unaudited)	Accumulated amortization (unaudited)	Net value (unaudited)
<b>Balances at April 4, 2010</b>			
Intangible assets subject to amortization:			
Developed technology	\$ 76,735	\$ (19,960)	\$ 56,775
Customer relationships	62,198	(15,312)	46,886
Licenses	3,780	(787)	2,993
Other	2,137	(1,412)	725
Intangible assets not subject to amortization:			

Edgar Filing: Tornier B.V. - Form S-1/A

Tradename	9,992	9,992
Total	\$ 154,842	\$ (37,471) \$ 117,371

All finite-lived intangible assets have been assigned an estimated useful life and are amortized on a straight-line basis over the number of years that approximates the assets' respective useful lives

F-25

---

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****6. Goodwill and Other Intangible Assets (Continued)**

(ranging from 10 to 20 years). The weighted-average amortization periods, by major intangible asset class, are as follows:

	<b>Weighted-average amortization period (in years)</b>
Developed technology	13
Customer relationships	15
Licenses	6

Total amortization expense for finite-lived intangible assets was \$7.9 million, \$11.2 million and \$15.2 million during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, and \$2.6 million and \$3.0 million for the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively. Amortization expense is recorded as amortization of intangible assets in the consolidated statements of operations. Estimated annual amortization expense for fiscal years ending 2010 through 2014 is as follows (in thousands):

	<b>Amortization expense</b>
2010	\$ 11,019
2011	10,459
2012	10,333
2013	10,321
2014	10,279

**7. Accrued Liabilities**

Accrued liabilities at December 27, 2009, December 28, 2008, and April 4, 2010, consisted of the following (in thousands):

	<b>December 28, 2008</b>	<b>December 27, 2009</b>	<b>April 4 2010</b>
			<b>(unaudited)</b>
Accrued payroll	\$ 10,260	\$ 15,578	\$ 12,628
VAT and other non income taxes	2,890	2,997	3,807
Accrued royalties	4,448	5,620	6,247
Other accrued liabilities	10,075	11,385	12,474
	<b>\$ 27,673</b>	<b>\$ 35,580</b>	<b>\$ 35,156</b>

**8. Notes Payable and Warrants to Issue Ordinary Shares**

In April 2009, the Company issued notes payable in the amount of €37 million (approximately \$49.3 million) to a group of investors that included existing shareholders, new investors and management of the Company. The notes carry a fixed interest rate of 8.0% with interest payments accrued in kind semi-annually. The notes mature in March 2014.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****8. Notes Payable and Warrants to Issue Ordinary Shares (Continued)**

These notes payable have a cross default clause in which any event of default under the terms of the Company's other debt arrangements also are defined as an event of default under the terms of these notes payable. In 2009, there were no events of default. Additionally, \$0.2 million of debt issuance costs related to this issuance have been capitalized and are included in other non-current assets on the consolidated balance sheet and are being recognized as additional interest expense over the term of the notes.

In connection with the note agreement, the Company also issued a total of 8.8 million warrants, which are currently exercisable and expire in March 2019, to purchase ordinary shares at an exercise price of \$5.66 per share. These warrants have a strike price in U.S. dollars; however, the functional currency of the parent company issuing the notes is the Euro. As a result, GAAP requires that these warrants be classified as liabilities on the balance sheet and recorded at fair value. The fair value of the warrants at the date of issuance was \$3.29 per warrant, or \$29.1 million, and was determined using a Black-Scholes option pricing model, which takes into account various assumptions such as share price volatility, risk free interest rate and expected term. Share price volatility is determined based on the volatility of various peers of the Company. The fair value of the warrants as of December 27, 2009, and April 4, 2010, was approximately \$4.83 and \$4.81 respectively per warrant. The Company recorded a \$13.5 million loss in other non-operating expense, net related to the change in the fair value of the warrants in 2009. The Company recorded a \$0.2 million gain in other non-operating expense, net related to the change in the fair value of the warrants during the first quarter ended April 4, 2010. The Company recorded a \$2.7 million foreign currency transaction gain in 2009, and a \$2.8 million foreign currency transaction loss during the first quarter ended April 4, 2010. These gains (losses) are related to the change in the exchange rates, and are recorded in foreign currency transaction gain (loss) in the consolidated statements of operations. A summary of the assumptions used to determine the fair value on the date of grant, December 27, 2009, and April 4, 2010 is as follows:

<b>Date of grant</b>	<b>December 27, 2009</b>		<b>April 4, 2010</b>	
			<b>(unaudited)</b>	
Fair value of underlying stock	\$ 5.66	\$ 7.50	\$ 7.50	
Volatility	44.34%	44.43%	43.00%	
Risk-free interest rate	2.78%	3.55%	4.10%	
Expected term (in years)	10	9	9	
Dividend yield	0%	0%	0%	

The Company recorded the warrants as liabilities with an offsetting debt discount recorded as a reduction of the carrying value of the notes. The debt discount will be amortized as additional interest expense over the life of the notes. GAAP requires that the allocation of proceeds be allocated first to the fair value of the warrant liability with the residual allocated to the outstanding debt. The debt discount was \$21.7 million (net of tax of \$7.4 million) on the issuance date. The Company recorded \$4.6 million and \$1.5 million of additional interest expense related to the amortization of discount during the year ended December 27, 2009, and the first quarter ended April 4, 2010, respectively. The Company also recognized \$3.1 million and \$1.2 million of non-cash interest expense related to the stated 8% interest rate on the notes during the year ended December 27, 2009, and the first quarter

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**8. Notes Payable and Warrants to Issue Ordinary Shares (Continued)**

ended April 4, 2010, respectively. Together with the stated interest and amortization of debt discount, the effective interest rate recognized related to the notes payable was approximately 19.7%.

In February 2008, the Company issued notes payable in the amount of €34.5 million (approximately \$52.4 million) to a group of investors that included existing shareholders and management of the Company. The notes carry a fixed interest rate of 8.0% with interest payments accrued in-kind. The notes mature on February 28, 2013. These notes payable also have a cross default clause in which any event of default under the terms of the Company's other debt arrangements also are defined as an event of default under the terms of these notes payable.

Also, in connection with the 2008 note agreement, the Company issued a total of 9.3 million warrants, which are currently exercisable and expire on February 28, 2018, to purchase ordinary shares at a price of \$5.66 per share. At issuance, the Company accounted for the warrants separately from the debt and allocated the proceeds received to the debt and the warrants based on their relative fair values. As a result, the warrants were valued at \$21.8 million (net of tax of \$7.5 million) as an increase to equity with an offsetting discount of \$29.3 million recorded as a reduction of the carrying value of the notes.

Upon the Company's adoption of ASC Topic 815 on December 29, 2008, the Company determined that the warrants no longer qualified to be recognized as equity under ASC Topic 815 as they were determined to not be indexed to the Company's stock as prescribed by ASC Topic 815 due to the fact that the warrants are denominated in a currency other than their functional currency. On December 29, 2008, the warrants, upon adoption of ASC Topic 815, were reclassified from equity to warrant liability at the then fair value of \$28.1 million and marked to market through the consolidated statement of operations subsequent to that date. The value of the warrants decreased by \$1.2 million (\$0.9 million net of tax) from the warrants issuance date to the adoption date of ASC Topic 815 on December 29, 2008. As of December 29, 2008, the cumulative effect of adopting ASC Topic 815 was recognized as a reduction to additional paid-in capital of \$21.8 million (\$29.3 million net of tax of \$7.5 million) to reclassify the warrants from equity to warrant liability and a decrease in accumulated deficit of \$0.9 million recognized as a cumulative effect of a change in accounting principle to reflect the change in the value of the warrants between their issuance date and December 29, 2008.

For the year ended December 27, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, the Company recognized a loss on the change in fair value of the warrant liability of \$14.5 million, \$1.9 million and \$0.0 million, respectively, in non-operating expense, net related to the warrants issued in 2008. Additionally, the Company recognized \$1.2 million and \$1.4 million of foreign currency transaction gains on the warrant liability for the year ended December 27, 2009, and the first quarter ended March 29, 2009, respectively. The Company recognized a \$2.8 million foreign currency transaction loss during the first quarter ended April 4, 2010. Under ASC Topic 815, the warrants will be carried at fair value and adjusted at each reporting period to fair



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****8. Notes Payable and Warrants to Issue Ordinary Shares (Continued)**

value through current period earnings. As of December 27, 2009, the warrant liability had a fair value of \$42.6 million. The impact of adoption is as follows:

	Balance prior to adoption	Impact of adoption	Balance after adoption
Warrant liabilities	\$	\$ (28,119)	\$ (28,119)
Non-current deferred tax assets		7,170	7,170
Additional paid-in capital	(313,311)	21,812	(291,499)
Accumulated deficit	94,473	(863)	93,610

The fair value was determined using the Black-Scholes Option Pricing Model. The following table summarizes the assumptions used to determine fair value on the date of grant, the date of adoption of ASC Topic 815, as of December 27, 2009, and as of April 4, 2010:

	Date of grant	December 29, 2008	December 27, 2009	April 4, 2010 (unaudited)
Fair value of underlying stock	\$ 5.66	\$ 5.66	\$ 7.50	\$ 7.50
Volatility	39.38%	42.35%	43.46%	43.00%
Risk-free interest rate	3.53%	2.46%	3.55%	4.10%
Expected term (in years)	10	9	8	8
Dividend yield	0%	0%	0%	0%

The Company is amortizing the value of the debt discount as additional interest expense over the term of the notes. The Company recorded \$4.7 million, \$5.4 million, \$1.3 million and \$1.3 million of additional interest expense related to the amortization of discount during 2008, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively. The Company also recognized \$3.4 million, \$4.2 million, \$0.9 million and \$1.2 million of interest expense in 2008, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively, related to the stated 8% interest rate on the notes. Together with the stated interest and amortization of debt discount, the effective interest rate recognized related to the notes payable was approximately 19.9%.

Changes in the carrying value of warrants for are as follows:

Warrant value at December 28, 2008	\$ 29,277
Impact of adoption of ASC Topic 815 fair value adjustment	(1,159)
Issuance of 2009 warrants at fair value	29,070
Change in fair value during the year	28,027
Warrant value at December 27, 2009	\$ 85,215
Change in fair value during the period	(147)
Warrant value at April 4, 2010 (Unaudited)	\$ 85,068

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****8. Notes Payable and Warrants to Issue Ordinary Shares (Continued)**

Notes payable outstanding are as follows:

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Gross notes payable	\$ 51,575	\$ 113,793	\$ 108,728
Discount to notes payable	(22,495)	(44,258)	(38,633)
Net notes payable	\$ 29,080	\$ 69,535	\$ 70,095

The fair value of the Company's Notes Payable as of December 28, 2008, and December 27, 2009, was approximately \$26.1 million and \$63.7 million, respectively. The fair value was determined using a discounted cash flow analysis, calculated using management's best estimates of the key assumptions, primarily the discount rate. As a result of various factors, including the Company's financial position, the assumptions used are unobservable in the market place.

**9. Other Long-Term Debt**

The Company's European subsidiaries have established unsecured lines of credit totaling \$19.7 million, \$15.3 million, and \$16.6 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively. Available borrowings under these lines were \$3.5 million, \$7.2 million and \$5.1 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively. Borrowings under these lines have variable interest rates based on the Euro Overnight Index Average plus 0.3% to 1.3% or a three-month Euro plus 1% to 3%.

The Company's U.S.-based subsidiary has established a \$6.0 million secured line of credit at December 28, 2008, December 27, 2009 and April 4, 2010. This line of credit expires in July 2010 and is callable by the bank at any time. Also, the line is secured by working capital and equipment. Available borrowings under the line were \$3.6 million, \$6.0 million and \$4.8 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively. Borrowings under the line of credit bear interest at a 30-day LIBOR plus 2.25%, with a floor interest rate of 6.5%. This line contains customary affirmative and negative covenants and events of default. As of December 27, 2009, the Company's U.S. subsidiary was subject to a covenant to maintain no less than \$39.0 million of tangible net worth. As of December 27, 2009, the Company was also subject to a covenant to maintain a maximum debt to tangible net worth ratio of 1.50. The covenants relate to the U.S. subsidiary's ratios only. The Company was in compliance with all covenants as of December 27, 2009 and April 4, 2010.

The Company has long-term notes payable secured by the Company's U.S. subsidiary's office building in Stafford, Texas, working capital and equipment. These notes had an outstanding amount of \$3.5 million, \$2.6 million and \$2.3 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively. These notes accrue interest based on a fixed rate of 6.70% or a variable rate based on LIBOR plus 2.25%.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****9. Other Long-Term Debt (Continued)**

The Company and its subsidiaries have other long-term secured and unsecured notes totaling \$29.2 million, \$27.3 million and \$25.8 million at December 28, 2008, December 27, 2009, and April 4, 2010, respectively, with initial maturities ranging from three to ten years. A portion of these notes have fixed interest rates that range from 3.7% to 6.2%. The remaining notes carry a variable interest rate based on LIBOR, plus 0.5% to 1.2%, or a three-month Euro, plus 0.3% to 1.5%.

One of the Company's 51%-owned and consolidated subsidiaries borrowed \$1.0 million from a member of the Supervisory Board who is also a 49% owner of the consolidated subsidiary. This loan was used to partially fund the purchase of real estate in Grenoble, France, to be used as a future manufacturing facility. Interest on the debt is variable based on three-month Euro plus 0.5%. The non-controlling interest in this subsidiary is deemed immaterial.

A summary of debt is as follows (in thousands):

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Lines of credit	\$ 18,650	\$ 15,271	\$ 17,785
Mortgages	5,585	7,438	6,884
Other term debt	27,162	22,464	21,208
Shareholder debt	952	1,015	1,738
<b>Total debt</b>	<b>52,349</b>	<b>46,188</b>	<b>47,615</b>
Less current portion	(27,868)	(23,299)	(25,112)
<b>Long-term debt</b>	<b>\$ 24,481</b>	<b>\$ 22,889</b>	<b>\$ 22,503</b>

Aggregate maturities of long-term debt for the next five years are as follows (in thousands):

2010	\$ 23,299
2011	6,288
2012	5,755
2013	3,863
2014	1,969
Thereafter	5,014

The Company was also party to certain mandatorily convertible debt agreements allowing for conversion into 10.2 million ordinary shares at a conversion price of \$4.90 as of July 18, 2009. These instruments were in their legal form debt, and therefore, were recognized as liabilities in the amount of \$47.8 million within the consolidated balance sheet. The agreements contained a beneficial conversion feature as the fixed conversion price of the bonds was less than the fair value of the ordinary shares on the issuance date. The beneficial conversion feature was accreted through interest expense and resulted in additional interest expense of \$1.0 million, \$1.2 million and \$0.6 million for the years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively. The agreement had no payment terms, did not accrue interest, and, in no circumstances other than liquidation, required the Company to cash settle in part or in full.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****9. Other Long-Term Debt (Continued)**

Additionally, in 2007, the Company purchased Axya (as described in Note 4). At the time of the acquisition, the Company's majority shareholder entered into an agreement with another shareholder of the Company to either issue additional mandatorily convertible zero coupon bonds or decrease the conversion price of the zero coupon bonds, in which additional shares would be obtained upon conversion, if the performance of Axya did not meet certain thresholds. The arrangement represented a modification to the conversion terms of the mandatorily convertible bonds, as under either settlement scenario, the result is that the holder could receive more shares than originally entitled upon mandatory conversion. The Company estimated the fair value of the modification and determined that the modification did not constitute an extinguishment of the debt, but rather is recorded as an increase to equity with an offsetting amount recorded as a discount to the carrying value of the mandatorily convertible bonds. This discount is accreted to the bonds' par value over the remaining term of the bonds as interest expense. The fair value of the modification was determined to be \$0.6 million at the date of modification. The Company recognized \$0.2 million, \$0.3 million and \$0.1 million in additional interest expense in 2007, 2008 and 2009, respectively, as a result of this modification.

All of the outstanding mandatorily convertible debt agreements were converted in accordance with the terms of the agreements during 2009.

**10. Retirement and Postretirement Benefit Plans**

The Company's French subsidiary is required by French government regulations to provide certain lump-sum retirement benefits that qualify as a defined benefit. The French regulations do not require funding of this liability in advance and as a result there are no plan assets associated with this defined-benefit plan. The Company has a liability of \$1.1 million and \$1.5 million recorded at December 28, 2008, and December 27, 2009, respectively. The related periodic benefit expense was immaterial in all periods presented.

**11. Income Taxes**

The components of earnings (loss) before taxes for the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, consist of the following (in thousands):

	2007	2008	2009
United States loss	\$ (37,467)	\$ (24,174)	\$ (18,444)
Rest of the world loss	(10,304)	(15,230)	(51,655)
Loss before taxes	\$ (47,771)	\$ (39,404)	\$ (70,099)

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****11. Income Taxes (Continued)**

The income tax benefit (provision) for the fiscal years ended December 31, 2007, December 28, 2008 and December 27, 2009 consists of the following (in thousands):

	2007	2008	2009
Current benefit (provision):			
United States	\$ (889)	\$	\$ 2,884
Rest of the world	(1,755)	(196)	553
Deferred benefit	9,224	5,423	10,976
Total benefit for income taxes	\$ 6,580	\$ 5,227	\$ 14,413

A reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate for the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, is as follows:

	2007	2008	2009
Income tax provision at U.S. statutory rate	34.0%	34.0%	34.0%
Change in valuation allowance	(19.8)	(22.9)	(6.8)
Non-deductible purchased in-process R&D	(11.0)		
Non-taxed interest income on participating loan	6.8	1.0	0.2
Change in tax law	6.6		
State and local taxes	1.7	2.2	0.1
R&D credits		1.3	1.0
Non-deductible interest expense		(1.6)	(1.4)
Additional tax on intercompany transfers	(4.0)		
Impact of foreign income tax rates	(0.6)	(0.2)	(5.1)
Non-deductible expenses			(0.3)
Other	0.1	(0.5)	(1.1)
Total	13.8%	13.3%	20.6%

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established valuation allowances for deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit.

During 2008, the Company reversed \$2.9 million of previously recognized valuation allowance related to accumulated net operating losses of one of its French subsidiaries. Of the \$2.9 million, \$2.4 million was recorded as a reduction of goodwill as it related to valuation allowances recorded as a part of one of the Company's 2007 acquisitions. The Company has \$17.4 million and \$22.8 million of valuation allowance recorded at December 28, 2008, and December 27, 2009, respectively. If any amounts reverse, the reversals would be recognized in the income tax provision in the period of reversal. The Company recognized \$9.3 million, \$9.1 million and \$4.8 million of the valuation allowance as a tax expense during the fiscal years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively.

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****11. Income Taxes (Continued)**

The components of deferred taxes for the fiscal years ended December 28, 2008 and December 27, 2009 consist of the following (in thousands):

	2008	2009
Deferred tax assets:		
Net operating loss carryforwards	\$ 17,382	\$ 19,937
Warrant liabilities		21,730
Intangible assets	6,661	6,303
Transaction costs	2,071	955
Exchange rate changes	1,386	1,235
Stock options	2,603	4,072
Accruals and other provisions	6,742	7,914
<b>Total deferred tax assets</b>	<b>36,845</b>	<b>62,146</b>
Less: valuation allowance	(17,400)	(22,816)
<b>Total deferred tax assets after valuation allowance</b>	<b>19,445</b>	<b>39,330</b>
Deferred tax liabilities:		
Intangible assets	(36,675)	(34,040)
Debt discount	(5,691)	(11,286)
Depreciation	(2,182)	(2,022)
Other	(913)	(149)
<b>Total deferred tax liabilities</b>	<b>(45,461)</b>	<b>(47,497)</b>
<b>Total net deferred tax liabilities</b>	<b>\$ (26,016)</b>	<b>\$ (8,167)</b>

Net operating loss carryforwards totaling approximately \$32 million and \$22 million at December 27, 2009, are available to reduce future taxable earnings of the Company's consolidated U.S. subsidiaries and certain European subsidiaries, respectively. These net operating loss carryforwards include \$17.9 million with no expiration date; the remaining carryforwards have expiration dates between 2010 and 2029.

The Company has experienced historical losses; however, it has recognized a \$14.4 million tax benefit in the current year. In France, the Company recognized a \$3.2 million benefit as there is sufficient future taxable income from existing temporary differences to avoid the need for a valuation allowance. In the United States, the Company recognized a \$2.8 million benefit related to a one-time tax law change allowing existing losses to be carried back to years in which the Company had taxable income. In The Netherlands, the Company recognized a \$9.2 million benefit related to the reversal of the deferred tax liabilities related to the debt discount on the notes payable issued in 2008 and 2009.

During 2006, the Company's French subsidiary had its 1997 through 1999 tax years settled by the taxing authorities, and additional taxes in the amount of \$6.6 million were assessed and were paid during 2007. Also, the Company's French subsidiary had its 2004, 2005 and 2006 tax years audited. However, in conjunction with the acquisition of the Predecessor Companies, the Company entered into an indemnification agreement with the former shareholders of the Predecessor Companies under which the former shareholders indemnified the Company for certain damages resulting from actions of the Predecessor Companies prior to the acquisition date. As a result, the Predecessor Companies' former



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****11. Income Taxes (Continued)**

shareholders are liable for any tax liabilities of the Company for tax years prior to the acquisition of the Company in 2006.

The Company has recorded a long-term liability of approximately \$1.3 million and \$0.3 million at December 28, 2008, and December 27, 2009, respectively, which represents the Company's best estimate of the potential additional tax liability related to certain tax positions from unclosed tax years in certain of its subsidiaries. Because these tax years primarily relate to periods covered by the Company's indemnification agreement with the former shareholders of the Predecessor Companies, there is also a long-term receivable recorded for the majority of this amount with the portion related to the period from July 18, 2006, to December 31, 2006, recorded as additional tax expense. To the extent that the results of any future tax audits differ from the Company's estimate, changes to tax uncertainties outside the measurement period will be reported as adjustments to income tax expense.

The total amount of net unrecognized tax benefits that, if recognized, would affect the tax rate was \$2.7 million at December 27, 2009. Management believes that it is reasonably possible the total amounts of unrecognized tax benefits will decrease between zero and \$0.3 million due to the resolution of certain issues resulting from the expiration of the statute of limitations in foreign jurisdictions within the 12 months subsequent to December 27, 2009. The Company files income tax returns in the U.S. federal jurisdiction and in various U.S. state and foreign jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local or non-U.S. income tax examinations by tax authorities for years before 2007. There are currently no examinations in progress in any jurisdiction.

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows (in thousands):

Gross unrecognized tax benefits at December 29, 2008	\$ 3,240
Increase for tax positions from adoption of new standard	1,056
Increase for tax positions in prior years	
Decrease for tax positions in prior years	(1,355)
Settlements	
Increase for tax positions in current years	
Foreign currency translation	47

Gross unrecognized tax benefits at December 27, 2009	\$ 2,988
--	----------

There was no material adjustments to the balances of unrecognized tax benefits during the first quarter ended March 29, 2009, or the first quarter ended April 4, 2010.

**12. Capital Stock and Earnings Per Share**

The Company had 62.7 million, 74.0 million and 77.2 million ordinary shares issued and outstanding as of December 28, 2008, December 27, 2009, and April 4, 2010, respectively.

The dividend rights of the mandatorily convertible debt and ordinary shares are identical. In addition, the shares issuable under the convertible debt agreement have been included as outstanding



Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****12. Capital Stock and Earnings Per Share (Continued)**

ordinary shares for the purpose of computing basic earnings per share in accordance with GAAP in all years presented.

The Company had 5.9 million, 7.2 million, 8.5 million and 8.3 million options outstanding at December 31, 2007, December 28, 2008, December 27, 2009 and April 4, 2010, respectively. Also outstanding are 9.3 million, 18.1 million and 18.1 million warrants to purchase ordinary shares as of December 28, 2008, December 27, 2009, and April 4, 2010, respectively. All warrants were issued in 2008 and 2009 in relation to long-term debt financing agreements (see Note 8). Outstanding options and warrants representing 5.9 million, 16.5 million, 26.6 million and 26.4 million shares are not included in diluted earnings per share for the fiscal years ended December 31, 2007, December 28, 2008, December 27, 2009, and April 4, 2010, respectively, because the Company recorded a net loss in all periods and, therefore, including these instruments would be anti-dilutive.

**13. Segment and Geographic Data**

The Company has one reportable segment, orthopaedic products, which includes the design, manufacture and marketing of reconstructive joint devices and other related products. The Company's geographic regions consist of the United States and Europe and other areas, which are referred to as International. Long-lived assets are those assets located in each region. Revenue attributed to each region are based on the location in which the products were sold.

Revenue by geographic region are as follows (in thousands):

	Year ended		First quarter ended		
	December 31, 2007	December 28, 2008	December 27, 2009	March 29, 2009	April 4, 2010
	(unaudited)				
Net sales by geographic region:					
United States	\$ 73,701	\$ 92,730	\$ 114,206	\$ 28,809	\$ 34,182
France	37,300	43,206	46,331	12,029	14,688
Other International	34,368	41,434	40,925	10,017	12,973
<b>Total</b>	<b>\$ 145,369</b>	<b>\$ 177,370</b>	<b>\$ 201,462</b>	<b>\$ 50,855</b>	<b>\$ 61,843</b>

Net sales by product category are as follows (in thousands):

	Year ended		First quarter ended		
	December 31, 2007	December 28, 2008	December 27, 2009	March 29, 2009	April 4, 2010
	(unaudited)				
Net sales by product type:					
Upper extremity joints and trauma	\$ 87,724	\$ 108,829	\$ 125,454	\$ 31,540	\$ 36,647
Lower extremity joints and trauma	13,729	18,167	20,417	5,171	6,256
	2,082	2,513	6,593	1,142	3,441

Edgar Filing: Tornier B.V. - Form S-1/A

Sports medicine and orthobiologics					
Large joints and other	41,834	47,861	48,999	13,002	15,499
Total	\$ 145,369	\$ 177,370	\$ 201,462	\$ 50,855	\$ 61,843

F-36

---

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****13. Segment and Geographic Data (Continued)**

Long-lived tangible assets, including instruments, property, plant and equipment, as of December 28, 2008, December 27, 2009, and April 4, 2010 are as follows (in thousands):

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Long-lived assets:			
United States	\$ 15,080	\$ 16,013	\$ 15,384
France	27,213	32,510	33,384
Other International	8,652	12,908	12,931
<b>Total</b>	<b>\$ 50,945</b>	<b>\$ 61,431</b>	<b>\$ 61,699</b>

**14. Leases**

Future minimum rental commitments under non-cancelable operating leases in effect as of December 27, 2009, are as follows (in thousands):

2010	\$ 3,954
2011	4,037
2012	2,584
2013	1,561
2014	1,537
Thereafter	4,485
<b>Total</b>	<b>\$ 18,158</b>

Total rent expense was \$3.4 million and \$3.7 million for the years ended December 28, 2008, and December 27, 2009, respectively.

Future lease payments under capital leases are as follows (in thousands):

2010	\$ 494
2011	455
2012	450
2013	215
2014	26
Thereafter	
<b>Total minimum lease payments</b>	<b>1,640</b>
Less amount representing interest	(157)
<b>Present value of minimum lease payments</b>	<b>1,483</b>
Current portion	(423)
<b>Long-term portion</b>	<b>\$ 1,060</b>



Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**14. Leases (Continued)**

Fixed assets that are recorded as capital lease assets consist of machinery and equipment, and have a carrying value of \$1.5 million (\$1.7 million gross value, less \$0.2 million accumulated depreciation) at December 28, 2008, \$1.8 million (\$2.2 million gross value, less \$0.4 million accumulated depreciation) at December 27, 2009. Amortization of capital lease assets is included in depreciation expense in the consolidated financial statements.

**15. Indemnification Receivable**

In conjunction with the acquisition of the Predecessor Companies, the Company entered into an indemnification agreement with the former shareholders of the Predecessor Companies, under which the former shareholders are required to indemnify the Company for damages resulting from certain contingent liabilities that may have existed at the time of the acquisition of the Predecessor Companies. The Company has also recorded a long-term receivable of \$1.3 million and \$0.2 million as of December 28, 2008, and December 27, 2009, respectively. There are also related liabilities recorded as long-term liabilities in the consolidated balance sheets as discussed further in Note 11.

**16. Non-Controlling Interests**

The Company currently markets the Piton Knotless Anchor, or Piton, an arthroscopic technology for rotator cuff repair. The Piton Knotless Anchor was based on technology developed by Sapphire Medical, Inc., or Sapphire. In April 2007, C2M acquired all the assets related to the Piton technology from Sapphire. C2M was a company founded and owned by certain current shareholders of the Company. The Company had no equity ownership interest in C2M.

Under the terms of the purchase agreement between C2M and Sapphire, C2M paid Sapphire \$7.5 million upon execution of the transaction. C2M also agreed to pay Sapphire a \$5 million milestone payment upon completion of 75 surgeries using the Piton and a separate \$7.5 million milestone payment once the Piton was commercially launched to the sales force. These milestones were paid by C2M during 2008. Additionally, C2M agreed to pay Sapphire an earnout equal to 25% of Piton sales for the first three years after launch.

In January of 2008, the Company began negotiating a licensing agreement with C2M for use of its Piton technology to launch as an anchor product in the Company's newly developed sports medicine product portfolio. In June of 2008, the Company executed an exclusive worldwide license agreement with C2M for use of the Piton technology. The terms of the agreement called for the Company to assume the remaining obligation of C2M under their purchase agreement with Sapphire related to future earnout payments equal to 25% of Piton sales for the three-year period after product launch. C2M had the right to terminate the license agreement at any time after 18 months from the execution of the license. The terms of the license also included an option purchase agreement (the "Option Agreement") that allowed the Company to purchase 100% of the common stock of C2M once cumulative Piton sales reach \$5 million or C2M terminates the license (the "Call Option"). Additionally, the license included a clause, whereby C2M could require the Company to purchase 100% of C2M's common stock if sales of the Piton anchor products exceed \$5 million (the "Put Option"). Under both the Call Option and the Put Option, the purchase price of C2M would be equal to the paid-in capital of C2M and is required to be paid in the Company's ordinary shares. The paid-in capital of C2M as of both December 2008 and 2009 was approximately \$23.2 million, which consisted of the

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**16. Non-Controlling Interests (Continued)**

purchase price paid to Sapphire for the Piton technology, including milestones paid, and an additional amount of capital to fund development activities.

The Company determined that C2M was a variable interest entity ("VIE") as of June 2008. The Option Agreement allows for Tornier to purchase C2M at a fixed price regardless of the actual performance of the Piton products. As a result, C2M does not have the right to receive expected residual returns that would instead be enjoyed by the Company. The Company is considered the primary beneficiary of C2M because it has the obligation to absorb the majority of the expected losses and the right to absorb the majority of the expected returns. As a result, the Company is required to consolidate C2M. This conclusion was reached due to the existence of the Put Option and Call Option to acquire C2M at a price that was fixed upon entry into the license agreement. Accordingly, the financial position and results of operations of C2M have been included in the consolidated financial statements from the date of execution of the license agreement. The liabilities recognized as a result of consolidating C2M consist primarily of the fair value of the obligations C2M had under its purchase agreement with Sapphire. As of December 28, 2008, December 29, 2009, and April 4, 2010 the only material liability recognized relates to the estimated remaining earnout payments due under the original Sapphire purchase agreement. The Company is required to make these earnout payments on behalf of C2M in accordance with the license agreement. The assets of C2M consist of only cash used to fund ongoing operations and the Piton technology intangible asset.

Pursuant to authoritative guidance, the equity interests in C2M not owned by the Company were reported as non-controlling interests on the consolidated balance sheet of the Company. Losses incurred by C2M were charged to the Company and to the non-controlling interest holders based on their ownership percentage. Prior to the acquisition of the non-controlling interest by the Company, the non-controlling interest holders held 100% of the equity interests in C2M, and, therefore, none of the results of operations were allocated to the Company. Therefore the non-controlling interest was accounted for on the consolidated financial statements as a contingently redeemable non-controlling interest that was initially recorded at fair value and classified as mezzanine equity.

However, pursuant to authoritative guidance, if the fair value of the contingently redeemable non-controlling interest is less than the current redemption value, and it is probable that the contingency related to the put option will be met, then the carrying value of the contingently redeemable non-controlling interest must be adjusted to its redemption value through a charge directly to equity. The Company has recognized \$3.8 million, \$1.1 million, \$0.4 million and \$0.7 million in accretion charges in 2008, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively, to reflect the contingently redeemable non-controlling interest at its current redemption value as it is probable the \$5 million sales contingency included in the put option will be met.

In accordance with authoritative guidance, the Company recorded the identifiable assets, liabilities and non-controlling interests in the VIE at their fair value upon initial consolidation. The C2M entity did not constitute a business at the time of consolidation and as a result the consolidation of C2M's related assets and liabilities were accounted for as the acquisition of an asset in accordance with applicable authoritative guidance. The primary asset consolidated consisted of the developed technology intangible asset underlying our Piton products. The fair value of this intangible asset was determined as of the date of consolidation based on the Company's consideration of a valuation

Table of Contents**TORNIER B.V. AND SUBSIDIARIES****Notes to the Consolidated Financial Statements (Continued)****(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)****16. Non-Controlling Interests (Continued)**

performed using a discounted cash flow assessment together with consideration of historical transactions. The Company recognized \$1.2 million, \$1.1 million, \$0.4 million and \$0.7 million in net losses in 2008, 2009, the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, respectively, as a result of the consolidation of C2M. These net losses consist primarily of intangible asset amortization and, as such, the results of consolidation of C2M did not have a significant impact on the consolidated cash flows of the Company. Total assets and liabilities of C2M are as follows (in thousands):

	December 28, 2008	December 27, 2009	April 4, 2010 (unaudited)
Current assets	\$ 812	\$ 697	\$ 88
Intangible asset, net	22,169	20,236	19,752
Deferred tax asset	415	621	535
Current liabilities	57	16	
Contingent liabilities	3,900	3,167	2,743
Non-controlling interests	23,200	23,259	

The intangible asset, net consists of developed technology. In the first quarter of 2010, the Company exercised its option to acquire the outstanding shares of C2M in exchange for Tornier ordinary shares. The transaction represents the acquisition of a non-controlling interest and as a result was accounted for as an equity transaction in accordance with ASC 810-10. Upon exercise of the purchase option, a non-controlling interest in C2M no longer existed. The balance of the non-controlling interest was eliminated and the fair value of the shares issued in the acquisition, \$23.2 million, was recorded as a component of shareholders' equity.

**17. Certain Relationships and Related-Party Transactions**

During 2009, the Company issued 557,093 shares pursuant to an agreement with a current shareholder based on the performance of an entity acquired in 2007 (see Note 9).

The Company leases approximately 55,000 square feet of manufacturing facilities and approximately 52,000 square feet of office space located in Grenoble, France, with a shareholder and current member of the Board of Directors. Annual lease payments to the member of the Board of Directors amounted to \$1.3 million, \$1.6 million and \$1.3 million during the years ended December 31, 2007, December 28, 2008, and December 27, 2009, respectively.

During 2008, the Company formed a real estate holding company (SCI Calyx) together with a shareholder and current member of the Board of Directors. SCI Calyx is owned 51% by the Company and 49% by the shareholder and member of the Board of Directors. SCI Calyx was initially capitalized by a contribution of capital of €10,000 funded 51% by the Company and 49% by the shareholder and member of the Board of Directors. SCI Calyx then acquired a combined manufacturing and office facility in Grenoble, France, for approximately \$6.1 million. This real estate purchase was funded through mortgage borrowings of \$4.1 million and \$2.0 million cash borrowed from the two current shareholders of SCI Calyx. As of December 27, 2009, SCI Calyx had related-party debt outstanding to the shareholder and member of the Board of Directors of \$1.0 million. The SCI Calyx entity is

Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**17. Certain Relationships and Related-Party Transactions (Continued)**

consolidated by Tornier, and the related real estate and liabilities are included in the consolidated balance sheets.

A current member of the Board of Directors and shareholder is also party to a consulting agreement with the Company to provide various consulting services to the Company's management. Amounts owed to this member of the Board of Directors under this agreement were \$0.7 million and \$1.1 million for the years ended December 28, 2008, and December 27, 2009, respectively.

**18. Other Non-Operating Expense**

During the year ended December 31, 2007, the Company recognized \$2.0 million of non-operating expense related to value-added tax expenses incurred, associated with the transfer of certain acquisition-related expenses between legal entities to obtain future income tax deductibility.

During the year ended December 28, 2008, the Company recognized \$1.4 million of non-operating expense related to the disposal of certain non-operating assets acquired in its Axya acquisition.

During the year ended December 27, 2009, the Company recognized approximately \$28.0 million of loss related to fair value adjustments of the warrant liability.

During the first quarter ended March 29, 2009, and the first quarter ended April 4, 2010, the Company recognized approximately \$1.9 million of non-operating expense and \$0.1 million of non-operating income related to the fair value adjustments of the warrant liability.

**19. Special Charges**

During the year ended December 27, 2009, the Company consolidated its U.S. operations and closed quality and regulatory sales and marketing functions in San Diego, California and manufacturing operations in Beverly, Massachusetts. Additionally, the Company opened sales offices in Scandinavia and the United Kingdom in 2009. The Company incurred \$1.9 million in costs related to the consolidation and launching of the sales sites. The operating costs for Scandinavia and the United Kingdom are included in sales and marketing expense. Included in the \$1.9 million of special charges are expenses incurred related to severance, lease termination, and moving costs related to consolidation of the Company's U.S. operations, as well as expenses for travel, consulting and legal costs incurred to launch the sales sites. All expenses were paid in 2009.

During the first quarter ended April 4, 2010, the Company recorded \$0.2 million in special charges related to commissions paid in the United Kingdom related to the termination of the relationship with a former distributor and expenses related to the Company's consolidation of its U.S. operations.

**20. Litigation**

On October 25, 2007, two of our former distributors filed a complaint in the U.S. District Court for the Southern District of Illinois, alleging that we had breached their agency agreements and committed fraudulent and negligent misrepresentations. The plaintiffs, Garry Boyd of Boyd Medical, Inc., and Charles Wetherill of Addison Medical, Inc. claimed that we had intentionally set



Table of Contents

**TORNIER B.V. AND SUBSIDIARIES**

**Notes to the Consolidated Financial Statements (Continued)**

**(unaudited with respect to the quarters ended March 29, 2009 and April 4, 2010)**

**20. Litigation (Continued)**

their 2007 quotas too high, in hopes that Boyd and Wetherill would not meet the quotas so that we could terminate them for cause and install another distributor in their territories. The complaint also included allegations that we had falsely suggested to the plaintiffs that if they dropped all other product lines, we would fill the void with new product lines. The jury rendered a verdict on July 31, 2009, awarding the plaintiffs a total of \$2.6 million in actual damages and \$4 million in punitive damages. While the court struck the award of punitive damages on March 31, 2010, it denied our motion to set aside the verdict or order a new trial. We have filed a notice of appeal with the U.S. Court of Appeals for the Seventh Circuit in respect of the remaining actual damages.

The Company has considered the facts of the case and related case law and, based on this information, we believe that the verdict rendered on July 31, 2009 was inappropriate given the related facts and supporting legal arguments. The Company has been successful in striking the jury awarded punitive damages through a motion filed with the original court. The Company has filed a notice of appeal with the U.S. Court of Appeals for the Seventh Circuit in respect of the remaining actual damages. Based on the arguments made in our appeal, the Company believes a loss is not probable and reasonably estimable at the date these financial statements were completed. The Company has determined that a loss is reasonably possible, and management estimates the range of loss to be between zero and \$6.6 million, the amount of the initial jury verdict. The Company believes it has a strong defense against these claims and is vigorously contesting these allegations. As of December 27, 2009 and April 4, 2010, no accrual was recorded relating to this case.

In addition to the item noted above, the Company is subject to various other legal proceedings, product liability claims and other matters which arise in the ordinary course of business. In the opinion of management, the amount of liability, if any, with respect to these matters, will not materially affect the Company's consolidated results of operations or financial position.

**21. Subsequent Events (Unaudited)**

In May 2010 we completed agreements with 100% of the warrant holders that acquired warrants under the February 2008 and April 2009 note payable and warrant issuances discussed in Note 8. Each warrant holder agreed to exchange their warrants under the February 2008 and April 2009 agreements in exchange for ordinary shares of the Company at an exchange ratio of 0.6133 and 0.6410 respectively. This transaction effectively settled the warrant liability of \$85.1 million included in the consolidated balance sheet at April 4, 2010.

The Company was party to a consulting agreement with Mr. Tornier, pursuant to which, in exchange for his services to the Company as a consultant, his services as a member of the Board of Directors, he is entitled to receive a consulting fee of €16,000 per month. Pursuant to the agreement, Mr. Tornier advised the Company and its executive officers with respect to investments, new opportunities for Company growth and general business matters. The agreement, which had a specified term of one year, was subject to automatic renewal for one-year terms unless either party provides three months' advance notice of their desire not to renew and contained covenants intended to protect against the disclosure of confidential information during and following the term of the agreement. On June 4, 2010, the Company issued 130,900 ordinary shares to KCH Stockholm, a Swedish entity which is wholly owned by Mr. Tornier, to settle the full amount due under the agreement of approximately €0.7 million. Mr. Tornier's consulting agreement was terminated effective as of March 31, 2010.

Table of Contents

Until \_\_\_\_\_, 2010 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade ordinary shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.

---

Table of Contents**PART II****INFORMATION NOT REQUIRED IN PROSPECTUS****ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.**

The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by Tornier B.V. in connection with the sale of ordinary shares being registered. All amounts shown are estimates, except the SEC registration fee, the FINRA filing fee and the NASDAQ application fee.

Item	Amount to be paid
SEC Registration Fee	\$ 14,617
FINRA Filing Fee	\$ 21,000
NASDAQ Fee	\$ 25,000
Blue Sky Fees and Expenses	*
Legal Fees and Expenses	*
Accounting Fees and Expenses	*
Printing Expenses	*
Transfer Agent and Registrar Fees	*
Directors' and Officers' Liability Insurance Premium	*
Miscellaneous	*
Total	*

\*

To be completed by amendment.

Previously paid.

**ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS.**

Under Dutch law, indemnification provisions may be included in the articles of association and accordingly our amended articles of association that will be in effect upon the completion of this offering provide that we shall indemnify any of our directors against all adverse financial effects incurred by such person in connection with any action, suit or proceeding if such person acted in good faith and in a manner that reasonably could be believed to be in or not opposed to our best interests. In addition, upon completion of this offering, we expect to enter into indemnification agreements with our directors and officers.

**ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES.**

During the past three years, we have issued the following securities (including options to acquire our ordinary shares). We believe that each of the following issuances was exempt from registration under the Securities Act pursuant to Section 4(2) of the Securities Act regarding transactions not involving a public offering or in reliance on Regulation S under the Securities Act regarding sales by an issuer in offshore transactions. The proceeds from each transaction were used for general business purposes.

Table of Contents**Options to Purchase Ordinary Shares**

Date of grant	Grantee	Amount	Price
4/10/2007-10/1/2007	Certain employees	269,750	\$ 4.63
10/12/2007	Certain non-employees	50,000	\$ 6.00
10/17/2007	Certain employees	25,000	€ 4.25
12/28/2007	Certain Employees	64,000	\$ 6.00
12/28/2007	Mark Lazarus	15,000	\$ 6.00
4/24/2008-8/1/2009	Certain employees	3,004,750	\$ 5.66
12/8/2008	Richard F. Wallman	150,000	\$ 5.66
1/7/2009-5/1/2009	Certain non-employees	176,500	\$ 5.66
6/3/2010	Kevin O'Boyle	150,000	\$ 7.50
6/3/2010-6/21/2010	Certain employees	2,121,392	\$ 7.50
6/3/2010	Certain non-employees	25,000	\$ 7.50

**Debt Financing (Warrants)**

Date of sale or issuance	Purchaser	Number of warrants	Loan amount	Exercise price
2/29/2008	Robert Anderson	20,678(1) €	77,000	\$ 5.66
2/29/2008	Ralph E. Barisano, Jr.	6,982(1) €	26,000	\$ 5.66
2/29/2008	Diane Doty	44,580(1) €	166,000	\$ 5.66
2/29/2008	James C. Harber	5,102(1) €	19,000	\$ 5.66
2/29/2008	Jean-Marc Idier	2,686(1) €	10,000	\$ 5.66
2/29/2008	KCH Stockholm AB	939,929(1) €	3,500,000	\$ 5.66
2/29/2008	Douglas W. Kohrs	150,926(1) €	562,000	\$ 5.66
2/29/2008	James E. Kwan	1,880(1) €	7,000	\$ 5.66
2/29/2008	Rod Mayer	44,580(1) €	166,000	\$ 5.66
2/29/2008	Jamal D. Rushdy	6,982(1) €	26,000	\$ 5.66
2/29/2008	Split Rock Partners, LP	311,251(1) €	1,159,000	\$ 5.66
2/29/2008	Vertical Fund I, L.P.	846,742(1) €	3,153,000	\$ 5.66
2/29/2008	Vertical Fund II, L.P.	249,484(1) €	929,000	\$ 5.66
2/29/2008	Warburg Pincus (Bermuda) Private Equity IX, L.P.	6,633,216(1) €	24,700,000	\$ 5.66
4/3/2009	Ralph E. Barisano, Jr.	10,733(2) €	45,000	\$ 5.66
4/3/2009	Diane Doty	4,293(2) €	18,000	\$ 5.66
4/3/2009	Stéphan Epinette	7,155(2) €	30,000	\$ 5.66
4/3/2009	KCH Stockholm AB	572,438(2) €	2,400,000	\$ 5.66
4/3/2009	Douglas W. Kohrs	61,537(2) €	258,000	\$ 5.66
4/3/2009	Medtronic Bakken Research Center B.V.	4,412,544(2) €	18,500,000	\$ 5.66
4/3/2009	Kevin Ohashi	13,118(2) €	55,000	\$ 5.66
4/3/2009	PJC Capital LLC	794,258(2) €	3,330,000	\$ 5.66
4/3/2009	PJC Merchant Banking Partners I, LLC	88,251(2) €	370,000	\$ 5.66
4/3/2009	Split Rock Partners, LP	126,413(2) €	530,000	\$ 5.66
4/3/2009	Amy and Richard F. Wallman	62,014(2) €	260,000	\$ 5.66
4/3/2009	Warburg Pincus (Bermuda) Private Equity IX, L.P.	2,672,332(2) €	11,204,000	\$ 5.66

(1)

Represents warrants issued on February 29, 2008 as consideration for a loan to the Company in the amount specified above pursuant to the Warrant Agreement, dated February 29, 2008 by and among the Company, Warburg Pincus, Vertical Fund I, L.P., Vertical Fund II, L.P., Mr. Douglas W. Kohrs, Split Rock Partners, LP ("Split Rock"), KCH Stockholm AB ("KCH"),

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

Rod Mayer, Diane Doty, Robert Anderson, Ralph Barisano, Jamal Rushdy, James C. Harber, Jean-Marc Idier and James Kwan.

(2)

Represents warrants issued on April 3, 2009 as consideration for a loan to the Company in the amount specified above pursuant to the Warrant Agreement, dated April 3, 2009 by and among the Company, Medtronic Bakken Research Center B.V., Warburg Pincus, PJC Capital LLC, PJC Merchant Banking Partners I, LLC, KCH, Split Rock, Amy and Richard F. Wallman, Douglas W. Kohrs, Kevin Ohashi, Ralph Barisano Jr., Stéphan Epinette and Diane Doty.

### Ordinary Shares

Date of sale or issuance	Purchaser	Number of shares	Price per share	Price total
9/24/2007	TMG Partners II LLC	140,339	€ 3.5628	€ 500,000
11/22/2007	Vertical Fund I, L.P.	35,876	€ 3.5628	€ 127,819
11/22/2007	Vertical Fund II, L.P.	54,124	€ 3.5628	€ 192,833
12/13/2007	TMG Partners II LLC	148,190	€ 3.5628	€ 527,972
1/16/2008	TMG Partners II LLC	42,102	€ 3.5628	€ 150,000
8/25/2008	DVO TH, LLC	910,206	\$ 5.66	\$ 5,151,767
10/27/2008	TMG Partners III LLC	636,878	\$ 5.66	\$ 3,604,731
9/10/2009	TMG Partners III LLC	316,779	\$ 5.66	\$ 1,792,969
9/10/2009	DVO TH, LLC	168,437	\$ 5.66	\$ 953,353
9/11/2009	Phil Invest ApS	1,402,391	€ 3.5628	€ 5,000,000
10/1/2009	KCH Stockholm AB	8,824,494(1)	€ 3.3543	€ 29,600,000
10/1/2009	KCH Stockholm AB	557,093	€ 0.01	€ 5,571
3/26/2010	Richard F. Wallman	40,000(2)	\$ 7.50	\$ 300,000
3/26/2010	Fred Dinger	17,676(3)	\$ 7.50	\$ 132,570
3/26/2010	Douglas W. Kohrs	46,400	\$ 7.50	\$ 348,000
3/26/2010	TMG Holdings Coöperatief U.A.	1,514,629	\$ 7.50	\$ 11,359,713
3/26/2010	Vertical Fund I, L.P.	1,200,344	\$ 7.50	\$ 9,002,583
3/26/2010	Vertical Fund II, L.P.	314,284	\$ 7.50	\$ 2,357,131
5/25/2010	Douglas W. Kohrs	132,007(4)	N/A	N/A
5/25/2010	Ralph E. Barisano, Jr.	11,161(4)	N/A	N/A
5/25/2010	Stéphan Epinette	4,586(4)	N/A	N/A
5/25/2010	Jamal D. Rushdy	4,282(4)	N/A	N/A
5/25/2010	James C. Harber	3,129(4)	N/A	N/A
5/25/2010	James E. Kwan	1,153(4)	N/A	N/A
5/25/2010	Amy and Richard F. Wallman	39,750(2),(4)	N/A	N/A
5/25/2010	Vertical Fund I, L.P. and Vertical Fund II, L.P.	672,314(4)	N/A	N/A
5/25/2010	Warburg Pincus (Bermuda) Private Equity IX, L.P.	5,781,115(4)	N/A	N/A
5/25/2010	Medtronic Bakken Research Center B.V.	2,828,440(4)	N/A	N/A
5/25/2010	KCH Stockholm AB	943,390(4)	N/A	N/A
5/25/2010	Jean-Marc Idier	1,647(4)	N/A	N/A
5/25/2010	Split Rock Partners, LP	271,920(4)	N/A	N/A
5/25/2010	Rod Mayer	27,340(4)	N/A	N/A
5/25/2010	Diane Doty	30,091(4)	N/A	N/A
5/25/2010	Robert Anderson	12,681(4)	N/A	N/A
5/25/2010	Kevin Ohashi	8,408(4)	N/A	N/A
5/25/2010	PJC Capital LLC	509,119(4)	N/A	N/A
5/25/2010	PJC Merchant Banking Partners I, LLC	56,568(4)	N/A	N/A
6/4/2010	KCH Stockholm AB	130,900(5)	N/A	N/A

(1)

Issued as part of a debt to equity conversion.



Table of Contents

- (2) Purchased on behalf of Mr. Wallman by Stichting Administratiekantoor Tornier ("STAK"). STAK was established as a foundation under Dutch law to allow the Company's option holders to exercise their options without obtaining legal title in any of the Company's ordinary shares. Upon exercise of an option, STAK acquires the respective ordinary shares in exchange for depository receipts issued to the option holder, who is entitled only to the economic benefits in Tornier's shares.
- (3) Purchased by STAK.
- (4) Represents ordinary shares of the Company issued in exchange for warrants originally issued under the February 29, 2008 and April 3, 2009 warrant agreements at an exchange ratio of 0.6133 for warrants issued February 29, 2008 and 0.6410 for warrants issued April 3, 2009.
- (5) Issued to KCH as an assignment of fees owed to Mr. Tornier in the amount of \$981,751, pursuant to the termination of his consulting agreement. Mr. Tornier assigned fees owed by Tornier to KCH, which elected to receive them in the form of 130,900 of our ordinary shares.

**Exercise of Options to Purchase Ordinary Shares**

All options to purchase ordinary shares indicated below were exercised by STAK on behalf of the indicated option holder.

Date	Option holder	Shares issued	Strike price	Exercise amount
4/17/2008	Mike Kaufman	9,375	\$ 4.46	\$ 41,848
7/9/2008	Jim Hook	13,000	\$ 4.46	\$ 58,029
8/12/2008	Keith Boudreau	1,200	\$ 4.63	\$ 5,556
9/5/2008	Joshua Kitzerow	625	\$ 4.63	\$ 2,894
10/15/2008	Sarah Fisbeck	2,000	\$ 4.46	\$ 8,928
5/20/2009	Greg Sherburn	28,125	\$ 4.46	\$ 125,544
5/14/2009	Sarah Hook	1,405	\$ 4.46	\$ 6,272
7/27/2009	Jordan Myers	784	\$ 4.63	\$ 3,630
3/26/2010	Tanya Fernandez Brice	2,188	\$ 6.00	\$ 13,128
3/26/2010	Michael N. Campbell	1,875	\$ 4.63	\$ 8,681
3/26/2010	Rexford Carrow	16,250	\$ 4.46	\$ 72,537
3/26/2010	Jason Kirsch	5,625	\$ 4.46	\$ 25,109
3/26/2010	Elaine Mattheus	6,094	\$ 4.46	\$ 27,202
3/26/2010	Leo Reubelt	2,500	\$ 4.63	\$ 11,575
3/26/2010	David Vancellette	5,160	\$ 4.63	\$ 23,891
3/26/2010	John Yannone	4,320	\$ 4.63	\$ 20,002
3/29/2010	Michael Phipps	1,875	\$ 4.63	\$ 8,681
3/29/2010	Peter Verrillo	6,250	\$ 4.63	\$ 28,938
5/25/2010	Richard F. Wallman	46,875	\$ 5.66	\$ 265,313

**ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.**

- (a) Exhibits

Exhibit number	Description of document
1.1	Form of Underwriting Agreement.*
3.1	Articles of Association of the Registrant, as currently in effect.***
3.2	Form of Articles of Association of the Registrant, as effective prior to the completion of this offering.*





## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

<b>Exhibit number</b>	<b>Description of document</b>
3.3	Form of Amended Articles of Association of the Registrant, as effective upon the completion of this offering.*
4.1	Registrant's Specimen Certificate for Ordinary Shares.*
4.2	Registration Rights Agreement, by and among the investors on Schedule I thereto, the persons listed on Schedule II thereto and Tornier B.V.*(1)
5.1	Opinion of Stibbe N.V. regarding the validity of the ordinary shares being registered.*
10.1	Employment Agreement, dated July 18, 2006, by and between Tornier, Inc. and Douglas W. Kohrs.***
10.2	Employment Agreement, dated June 21, 2010, by and between Tornier, Inc. and Carmen L. Diersen.**
10.3	Employment Agreement, dated February 5, 2007, by and between Tornier, Inc. and Michael Doty.***
10.4	Employment Agreement, dated April 28, 2008, by and between Tornier Inc. and Andrew Joiner.***
10.5	Employment Agreement, dated August 29, 2008, by and between Tornier, SAS and Stéphan Epinette.***
10.6	Employment Agreement, dated September 5, 2006, by and between Tornier, Inc. and Robert Ball.***
10.7	Separation Agreement, dated February 19, 2010, by and between Tornier, Inc. and Michael Doty.***
10.8	Letter Agreement, dated December 8, 2008, by and between Tornier B.V. and Richard Wallman.***
10.9	Tornier B.V. Stock Option Plan.***
10.10	Form of Option Agreement under the TMG B.V. Stock Option Plan for Directors and Officers.***
10.11	Retraite Supplémentaire maintained by Tornier SAS.***
10.12	Asset Purchase Agreement, dated March 5, 2007, by and between DVO Acquisition, Inc. and Tornier B.V.**
10.13	Merger Agreement, dated January 22, 2007, by and among Nexa Orthopedics, Inc., Tornier US Holdings, Inc. and Nexa Acquisition, Inc.**
10.14	Agreement and Plan of Merger, dated February 27, 2007, by and among Tornier US Holdings, Inc., Axya Acquisition II, Inc. and Axya Holdings, Inc.**
10.15	Contribution Agreement, dated March 26, 2010, by and between Tornier B.V., Vertical Fund I, L.P., Vertical Fund II, L.P., TMG Holdings Coöperatief U.A., Stichting Administratiekantoor Tornier, Fred B. Dinger III and Douglas W. Kohrs.**
10.16	Warrant Agreement, dated February 29, 2008, by and among Tornier B.V. and the former warrant holders party thereto.**
10.17	EUR 34,500,000 Loan Note Instrument, dated February 29, 2008, issued by Tornier B.V. in favor of the lenders thereto.**

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

<b>Exhibit number</b>	<b>Description of document</b>
10.18	Warrant Agreement, dated April 3, 2009, by and among Tornier B.V. and the former warrantholders party thereto.**
10.19	EUR 37,000,000 Loan Note Instrument, dated April 3, 2009, issued by Tornier B.V. in favor of the lenders thereto.**
10.20	Warrant Exchange Agreement (2008), dated May 25, 2010, by and among Tornier B.V. and the former warrantholders party thereto.**
10.21	Warrant Exchange Agreement (2009), dated May 25, 2010, by and among Tornier B.V. and the former warrantholders party thereto.**
10.22	Commercial leases (two), dated May 30, 2006, by and between Alain Tornier and Colette Tornier and Tornier SAS.*
10.23	Commercial lease, dated December 29, 2007, by and between Animus SCI and Tornier SAS.*
10.24	Commercial lease, dated February 6, 2008, by and between Balux SCI and Tornier SAS.*
10.25	Commercial lease, dated April, 2008, by and between Cymaise SCI and Tornier SAS.*
10.26	Commercial lease, dated July, 2008, by and between SCI Calyx and Tornier SAS.*
10.27	Commercial lease, dated December 23, 2008, by and between Seamus Geaney and Tornier Orthopedics Ireland Limited.**
10.28	Securityholders' Agreement, dated July 18, 2006, by and among the parties listed on Schedule I thereto, KCH Stockholm AB, Alain Tornier, Warburg Pincus (Bermuda) Private Equity IX, L.P., TMG B.V. (predecessor to Tornier B.V.).*
10.29	Joinder Agreement, dated March 30, 2007, by and between Tornier B.V. and DVO Extremity Solutions, LLC. *
10.30	Joinder Agreement, dated September 24, 2007, by and between Tornier B.V. and TMG Partners II LLC.*
10.31	Joinder Agreement, dated October 27, 2008, by and between Tornier B.V. and TMG Partners III LLC.*
10.32	Joinder Agreement, dated May 11, 2009, by and between Tornier B.V. and Split Rock Partners, L.P. *
10.33	Joinder Agreement, dated May 11, 2009, by and between Tornier B.V. and Stichting Administratiekantoor Tornier. *
10.34	Joinder Agreement, dated May 25, 2010, by and between Tornier B.V. and Medtronic Bakken Research Center B.V. *
10.35	Quality Assurance Agreement, dated April 1, 1998, by and between CeramTec AG and Tornier SA.*
10.36	Articles of Association of SCI Calyx.*
10.37	Amendment to the Securityholders' Agreement, by and among the securityholders on Schedule I thereto and Tornier B.V.*(2)
21.1	Subsidiaries of the Registrant.***
23.1	Consent of Ernst & Young LLP, an Independent Registered Public Accounting Firm.**

Table of Contents

<b>Exhibit number</b>	<b>Description of document</b>
23.2	Consent of Stibbe N.V. (included in Exhibit 5.1).*
24.1	Powers of Attorney (included on signature page).***

---

(1) We expect to enter into the Registration Rights Agreement shortly after the filing of this Registration Statement.

(2) We expect to amend the Securityholders' Agreement shortly after the filing of this Registration Statement.

\* To be filed by amendment.

\*\* Filed herewith.

\*\*\* Incorporated by reference from exhibit of same number to Registration Statement on Form S-1, filed July 8, 2010.

(b) Financial Statement Schedules

The consolidated financial statement schedule (Schedule II) of the Company and its subsidiaries has been submitted as a separate section of this report following the signature page. All other schedules for which provision is made in the applicable accounting regulation of the U.S. Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.

**ITEM 17. UNDERTAKINGS.**

The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions described in Item 14, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 1 to its registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Edina, MN, on July 15, 2010.

TORNIER B.V.

By: /s/ DOUGLAS W. KOHRS

Name: Douglas W. Kohrs  
 Title: *President and Chief Executive Officer*

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Douglas W. Kohrs and Sean D. Carney as attorneys-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, as amended (the "Securities Act"), and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant (the "Shares"), including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form S-1 (the "Registration Statement") to be filed with the Securities and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
<u>/s/ DOUGLAS W. KOHRS</u> Name: Douglas W. Kohrs	President, Chief Executive Officer and Director (principal executive officer)	July 15, 2010
<u>/s/ CARMEN L. DIERSEN</u> Name: Carmen L. Diersen	Global Chief Financial Officer (principal financial and accounting officer)	July 15, 2010
<u>*</u> Name: Sean D. Carney	Director	July 15, 2010

Edgar Filing: Tornier B.V. - Form S-1/A

Table of Contents

<b>Signature</b>	<b>Title</b>	<b>Date</b>
*		
_____ Name: Richard B. Emmitt	Director	July 15, 2010
*		
_____ Name: Kevin C. O'Boyle	Director	July 15, 2010
*		
_____ Name: Alain Tornier	Director	July 15, 2010
*		
_____ Name: Simon Turton	Director	July 15, 2010
*		
_____ Name: Richard F. Wallman	Director	July 15, 2010
*		
_____ Name: Elizabeth H. Weatherman	Director	July 15, 2010

\*By /s/ Douglas W. Kohrs, authorized under a Power of Attorney filed with Form S-1 (File No. 333-167370), filed with the Securities and Exchange Commission on June 8, 2010.



Table of Contents

**SCHEDULE II Valuation and Qualifying Accounts  
Tornier B.V. and Subsidiaries**

Description	Balance at beginning of period	Additions Charged to costs & expenses	Deductions		Balance at end of period
			Describe(a)	Describe(b)	
<b>DEDUCTED FROM ASSET ACCOUNTS</b>					
Allowance for Doubtful Accounts (in millions):					
Year ended December 27, 2009	\$ (2,169)	\$ (601)	\$ 153	\$ (50)	\$ (2,667)
Year ended December 28, 2008	\$ (1,879)	\$ (434)	\$ 119	\$ 25	\$ (2,169)
Year ended December 31, 2007	\$ (609)	\$ (1,224)	\$ 10	\$ (56)	\$ (1,879)

---

(a) Uncollectible amounts written off, net of recoveries.

(b) Effect of changes in foreign exchange rates.

Table of Contents

**TORNIER B.V.**

**EXHIBIT INDEX**

<b>Exhibit number</b>	<b>Description of document</b>
1.1	Form of Underwriting Agreement.*
3.1	Articles of Association of the Registrant, as currently in effect.***
3.2	Form of Articles of Association of the Registrant, as effective prior to the completion of this offering.*
3.3	Form of Amended Articles of Association of the Registrant, as effective upon the completion of this offering.*
4.1	Registrant's Specimen Certificate for Ordinary Shares.*
4.2	Registration Rights Agreement, by and among the investors on Schedule I thereto, the persons listed on Schedule II thereto and Tornier B.V.*(1)
5.1	Opinion of Stibbe N.V. regarding the validity of the ordinary shares being registered.*
10.1	Employment Agreement, dated July 18, 2006, by and between Tornier, Inc. and Douglas W. Kohrs.***
10.2	Employment Agreement, dated June 21, 2010, by and between Tornier, Inc. and Carmen L. Diersen.**
10.3	Employment Agreement, dated February 5, 2007, by and between Tornier, Inc. and Michael Doty.***
10.4	Employment Agreement, dated April 28, 2008, by and between Tornier, Inc. and Andrew Joiner.***
10.5	Employment Agreement, dated August 29, 2008, by and between Tornier, SAS and Stéphan Epinette.***
10.6	Employment Agreement, dated September 5, 2006, by and between Tornier, Inc. and Robert Ball.***
10.7	Separation Agreement, dated February 19, 2010, by and between Tornier, Inc. and Michael Doty.***
10.8	Letter Agreement, dated December 8, 2008, by and between Tornier B.V. and Richard Wallman.***
10.9	Tornier B.V. Stock Option Plan.***
10.10	Form of Option Agreement under the TMG B.V. Stock Option Plan for Directors and Officers.***
10.11	Retraite Supplémentaire maintained by Tornier SAS.***
10.12	Asset Purchase Agreement, dated March 5, 2007, by and between DVO Acquisition, Inc. and Tornier B.V.**
10.13	Merger Agreement, dated January 22, 2007, by and among Nexa Orthopedics, Inc., Tornier US Holdings, Inc. and Nexa Acquisition, Inc.**
10.14	Agreement and Plan of Merger, dated February 27, 2007, by and among Tornier US Holdings, Inc., Axya Acquisition II, Inc. and Axya Holdings, Inc.**



## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

<b>Exhibit number</b>	<b>Description of document</b>
10.15	Contribution Agreement, dated March 26, 2010, by and between Tornier B.V., Vertical Fund I, L.P., Vertical Fund II, L.P., TMG Holdings Coöperatief U.A., Stichting Administratiekantoor Tornier, Fred B. Dinger III and Douglas W. Kohrs.**
10.16	Warrant Agreement, dated February 29, 2008, by and among Tornier B.V. and the former warrantholders party thereto.**
10.17	EUR 34,500,000 Loan Note Instrument, dated February 29, 2008, issued by Tornier B.V. in favor of the lenders thereto.**
10.18	Warrant Agreement, dated April 3, 2009, by and among Tornier B.V. and the former warrantholders party thereto.**
10.19	EUR 37,000,000 Loan Note Instrument, dated April 3, 2009, issued by Tornier B.V. in favor of the lenders thereto.**
10.20	Warrant Exchange Agreement (2008), dated May 25, 2010, by and among Tornier B.V. and the former warrantholders party thereto.**
10.21	Warrant Exchange Agreement (2009), dated May 25, 2010, by and among Tornier B.V. and the former warrantholders party thereto.**
10.22	Commercial leases (two), dated May 30, 2006, by and between Alain Tornier and Colette Tornier and Tornier SAS.*
10.23	Commercial lease, dated December 29, 2007, by and between Animus SCI and Tornier SAS.*
10.24	Commercial lease, dated February 6, 2008, by and between Balux SCI and Tornier SAS.*
10.25	Commercial lease, dated April, 2008, by and between Cymaise SCI and Tornier SAS.*
10.26	Commercial lease, dated July, 2008, by and between SCI Calyx and Tornier SAS.*
10.27	Commercial lease, dated December 23, 2008, by and between Seamus Geaney and Tornier Orthopedics Ireland Limited.**
10.28	Securityholders' Agreement, dated July 18, 2006, by and among the parties listed on Schedule I thereto, KCH Stockholm AB, Alain Tornier, Warburg Pincus (Bermuda) Private Equity IX, L.P., TMG B.V. (predecessor to Tornier B.V.).*
10.29	Joinder Agreement, dated March 30, 2007, by and between Tornier B.V. and DVO Extremity Solutions, LLC. *
10.30	Joinder Agreement, dated September 24, 2007, by and between Tornier B.V. and TMG Partners II LLC.*
10.31	Joinder Agreement, dated October 27, 2008, by and between Tornier B.V. and TMG Partners III LLC.*
10.32	Joinder Agreement, dated May 11, 2009, by and between Tornier B.V. and Split Rock Partners, L.P. *
10.33	Joinder Agreement, dated May 11, 2009, by and between Tornier B.V. and Stichting Administratiekantoor Tornier. *
10.34	Joinder Agreement, dated May 25, 2010, by and between Tornier B.V. and Medtronic Bakken Research Center B.V. *
10.35	Quality Assurance Agreement, dated April 1, 1998, by and between CeramTec AG and Tornier SA.*
10.36	Articles of Association of SCI Calyx.*

---

## Edgar Filing: Tornier B.V. - Form S-1/A

### Table of Contents

<b>Exhibit number</b>	<b>Description of document</b>
10.37	Amendment to the Securityholders' Agreement, by and among the securityholders on Schedule I thereto and Tornier B.V.* <sup>(2)</sup>
21.1	Subsidiaries of the Registrant.***
23.1	Consent of Ernst & Young LLP, an Independent Registered Public Accounting Firm.**
23.2	Consent of Stibbe N.V. (included in Exhibit 5.1).*
24.1	Powers of Attorney (included on signature page).***

---

(1) We expect to enter into the Registration Rights Agreement shortly after the filing of this Registration Statement.

(2) We expect to amend the Securityholders' Agreement shortly after the filing of this Registration Statement.

\* To be filed by amendment.

\*\* Filed herewith.

\*\*\* Incorporated by reference from exhibit of same number to Registration Statement on Form S-1, filed July 8, 2010.

---